<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title>Dovato, INN-dolutegravir, lamivudine;</title>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
<meta name="generator" content="pdftohtml 0.36"/>
<meta name="author" content="CHMP"/>
<meta name="keywords" content="Dovato, INN-dolutegravir, lamivudine"/>
<meta name="date" content="2022-11-07T17:11:21+00:00"/>
<meta name="subject" content="EPAR"/>
<style type="text/css">
<!--
.xflip {
    -moz-transform: scaleX(-1);
    -webkit-transform: scaleX(-1);
    -o-transform: scaleX(-1);
    transform: scaleX(-1);
    filter: fliph;
}
.yflip {
    -moz-transform: scaleY(-1);
    -webkit-transform: scaleY(-1);
    -o-transform: scaleY(-1);
    transform: scaleY(-1);
    filter: flipv;
}
.xyflip {
    -moz-transform: scaleX(-1) scaleY(-1);
    -webkit-transform: scaleX(-1) scaleY(-1);
    -o-transform: scaleX(-1) scaleY(-1);
    transform: scaleX(-1) scaleY(-1);
    filter: fliph + flipv;
}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<!-- Page 1 -->
<a name="1"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft10{font-size:12px;font-family:FLHGME+ArialMT;color:#000000;}
	.ft11{font-size:17px;font-family:PVDJWK+TimesNewRomanPS;color:#000000;}
	.ft12{font-size:17px;font-family:DTAKKI+TimesNewRomanPSMT;color:#000000;}
	.ft13{font-size:17px;font-family:DTAKKI+TimesNewRomanPSMT;color:#008000;}
-->
</style>
<div id="page1-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1191px;left:439px;white-space:nowrap" class="ft10">1&#160;</p>
<p style="position:absolute;top:83px;left:446px;white-space:nowrap" class="ft11"><b>&#160;</b></p>
<p style="position:absolute;top:103px;left:446px;white-space:nowrap" class="ft11"><b>&#160;</b></p>
<p style="position:absolute;top:122px;left:446px;white-space:nowrap" class="ft11"><b>&#160;</b></p>
<p style="position:absolute;top:142px;left:446px;white-space:nowrap" class="ft11"><b>&#160;</b></p>
<p style="position:absolute;top:161px;left:446px;white-space:nowrap" class="ft11"><b>&#160;</b></p>
<p style="position:absolute;top:181px;left:446px;white-space:nowrap" class="ft11"><b>&#160;</b></p>
<p style="position:absolute;top:200px;left:446px;white-space:nowrap" class="ft11"><b>&#160;</b></p>
<p style="position:absolute;top:220px;left:446px;white-space:nowrap" class="ft11"><b>&#160;</b></p>
<p style="position:absolute;top:239px;left:446px;white-space:nowrap" class="ft11"><b>&#160;</b></p>
<p style="position:absolute;top:259px;left:446px;white-space:nowrap" class="ft11"><b>&#160;</b></p>
<p style="position:absolute;top:278px;left:446px;white-space:nowrap" class="ft11"><b>&#160;</b></p>
<p style="position:absolute;top:298px;left:446px;white-space:nowrap" class="ft11"><b>&#160;</b></p>
<p style="position:absolute;top:317px;left:446px;white-space:nowrap" class="ft11"><b>&#160;</b></p>
<p style="position:absolute;top:337px;left:446px;white-space:nowrap" class="ft11"><b>&#160;</b></p>
<p style="position:absolute;top:356px;left:446px;white-space:nowrap" class="ft11"><b>&#160;</b></p>
<p style="position:absolute;top:376px;left:446px;white-space:nowrap" class="ft11"><b>&#160;</b></p>
<p style="position:absolute;top:395px;left:446px;white-space:nowrap" class="ft11"><b>&#160;</b></p>
<p style="position:absolute;top:415px;left:446px;white-space:nowrap" class="ft11"><b>&#160;</b></p>
<p style="position:absolute;top:434px;left:446px;white-space:nowrap" class="ft11"><b>&#160;</b></p>
<p style="position:absolute;top:454px;left:446px;white-space:nowrap" class="ft11"><b>&#160;</b></p>
<p style="position:absolute;top:473px;left:446px;white-space:nowrap" class="ft11"><b>&#160;</b></p>
<p style="position:absolute;top:493px;left:446px;white-space:nowrap" class="ft11"><b>&#160;</b></p>
<p style="position:absolute;top:512px;left:446px;white-space:nowrap" class="ft11"><b>&#160;</b></p>
<p style="position:absolute;top:532px;left:412px;white-space:nowrap" class="ft11"><b>ANNEX I</b>&#160;</p>
<p style="position:absolute;top:551px;left:446px;white-space:nowrap" class="ft12">&#160;</p>
<p style="position:absolute;top:571px;left:264px;white-space:nowrap" class="ft11"><b>SUMMARY OF&#160;PRODUCT&#160;CHARACTERISTICS&#160;</b></p>
<p style="position:absolute;top:591px;left:446px;white-space:nowrap" class="ft12">&#160;</p>
<p style="position:absolute;top:610px;left:85px;white-space:nowrap" class="ft13">&#160;</p>
<p style="position:absolute;top:610px;left:301px;white-space:nowrap" class="ft12">&#160;</p>
</div>
<!-- Page 2 -->
<a name="2"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft24{font-size:17px;font-family:PGAZWK+TimesNewRomanPS;color:#000000;}
	.ft25{font-size:17px;font-family:ITJJCY+TimesNewRomanPS;color:#000000;}
-->
</style>
<div id="page2-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1191px;left:439px;white-space:nowrap" class="ft20">2&#160;</p>
<p style="position:absolute;top:83px;left:85px;white-space:nowrap" class="ft21"><b>1.&#160;</b></p>
<p style="position:absolute;top:83px;left:127px;white-space:nowrap" class="ft21"><b>NAME&#160;OF&#160;THE&#160;MEDICINAL&#160;PRODUCT</b>&#160;</p>
<p style="position:absolute;top:103px;left:85px;white-space:nowrap" class="ft22">&#160;</p>
<p style="position:absolute;top:122px;left:85px;white-space:nowrap" class="ft22">Dovato&#160;50&#160;mg/300&#160;mg&#160;film-coated&#160;tablets&#160;</p>
<p style="position:absolute;top:142px;left:85px;white-space:nowrap" class="ft22">&#160;</p>
<p style="position:absolute;top:162px;left:85px;white-space:nowrap" class="ft22">&#160;</p>
<p style="position:absolute;top:181px;left:85px;white-space:nowrap" class="ft21"><b>2.&#160;</b></p>
<p style="position:absolute;top:181px;left:127px;white-space:nowrap" class="ft21"><b>QUALITATIVE&#160;AND QUANTITATIVE&#160;COMPOSITION</b>&#160;</p>
<p style="position:absolute;top:200px;left:85px;white-space:nowrap" class="ft22">&#160;</p>
<p style="position:absolute;top:220px;left:85px;white-space:nowrap" class="ft22">Each&#160;film-coated&#160;tablet&#160;contains&#160;dolutegravir&#160;sodium&#160;equivalent&#160;to 50&#160;mg&#160;dolutegravir&#160;and&#160;300&#160;mg&#160;</p>
<p style="position:absolute;top:239px;left:85px;white-space:nowrap" class="ft22">lamivudine.&#160;</p>
<p style="position:absolute;top:259px;left:85px;white-space:nowrap" class="ft22">&#160;</p>
<p style="position:absolute;top:279px;left:85px;white-space:nowrap" class="ft22">For&#160;the&#160;full&#160;list&#160;of&#160;excipients, see&#160;section 6.1.&#160;</p>
<p style="position:absolute;top:298px;left:85px;white-space:nowrap" class="ft22">&#160;</p>
<p style="position:absolute;top:317px;left:85px;white-space:nowrap" class="ft22">&#160;</p>
<p style="position:absolute;top:337px;left:85px;white-space:nowrap" class="ft21"><b>3.&#160;</b></p>
<p style="position:absolute;top:337px;left:127px;white-space:nowrap" class="ft21"><b>PHARMACEUTICAL&#160;FORM</b>&#160;</p>
<p style="position:absolute;top:356px;left:85px;white-space:nowrap" class="ft22">&#160;</p>
<p style="position:absolute;top:376px;left:85px;white-space:nowrap" class="ft22">Film-coated&#160;tablet&#160;(tablet).&#160;</p>
<p style="position:absolute;top:396px;left:85px;white-space:nowrap" class="ft22">&#160;</p>
<p style="position:absolute;top:415px;left:85px;white-space:nowrap" class="ft22">Oval, biconvex, white, film&#160;coated tablet,&#160;approximately 18.5 x 9.5&#160;mm,&#160;debossed&#160;with “SV&#160;137”&#160;on one&#160;face.&#160;</p>
<p style="position:absolute;top:434px;left:85px;white-space:nowrap" class="ft22">&#160;</p>
<p style="position:absolute;top:454px;left:85px;white-space:nowrap" class="ft22">&#160;</p>
<p style="position:absolute;top:473px;left:85px;white-space:nowrap" class="ft21"><b>4.&#160;</b></p>
<p style="position:absolute;top:473px;left:127px;white-space:nowrap" class="ft21"><b>CLINICAL&#160;PARTICULARS</b>&#160;</p>
<p style="position:absolute;top:493px;left:85px;white-space:nowrap" class="ft22">&#160;</p>
<p style="position:absolute;top:512px;left:85px;white-space:nowrap" class="ft21"><b>4.1&#160;&#160;Therapeutic&#160;indications</b>&#160;</p>
<p style="position:absolute;top:532px;left:85px;white-space:nowrap" class="ft22">&#160;</p>
<p style="position:absolute;top:551px;left:85px;white-space:nowrap" class="ft22">Dovato&#160;is&#160;indicated&#160;for&#160;the&#160;treatment&#160;of&#160;Human Immunodeficiency Virus&#160;type&#160;1&#160;(HIV-1)&#160;infection&#160;in&#160;adults&#160;</p>
<p style="position:absolute;top:571px;left:85px;white-space:nowrap" class="ft22">and&#160;adolescents above 12&#160;years&#160;of&#160;age weighing&#160;at&#160;least&#160;40&#160;kg,&#160;with no known or&#160;suspected&#160;resistance&#160;to the&#160;</p>
<p style="position:absolute;top:591px;left:85px;white-space:nowrap" class="ft22">integrase&#160;inhibitor&#160;class, or&#160;lamivudine&#160;(see section&#160;5.1).&#160;</p>
<p style="position:absolute;top:610px;left:85px;white-space:nowrap" class="ft22">&#160;</p>
<p style="position:absolute;top:630px;left:85px;white-space:nowrap" class="ft22">&#160;</p>
<p style="position:absolute;top:649px;left:85px;white-space:nowrap" class="ft21"><b>4.2&#160;&#160;Posology&#160;and&#160;method&#160;of&#160;administration&#160;</b>&#160;</p>
<p style="position:absolute;top:668px;left:85px;white-space:nowrap" class="ft22">&#160;</p>
<p style="position:absolute;top:688px;left:85px;white-space:nowrap" class="ft22">Dovato&#160;should be&#160;prescribed by physicians&#160;experienced in&#160;the&#160;management&#160;of&#160;HIV&#160;infection.&#160;</p>
<p style="position:absolute;top:708px;left:85px;white-space:nowrap" class="ft24"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:727px;left:85px;white-space:nowrap" class="ft22">Posology&#160;</p>
<p style="position:absolute;top:747px;left:85px;white-space:nowrap" class="ft22">&#160;</p>
<p style="position:absolute;top:766px;left:85px;white-space:nowrap" class="ft25"><i>Adults&#160;and adolescents&#160;(above&#160;12&#160;years&#160;of&#160;age&#160;weighing at&#160;least&#160;40</i>&#160;<i>kg).&#160;</i></p>
<p style="position:absolute;top:786px;left:85px;white-space:nowrap" class="ft25"><i>&#160;</i></p>
<p style="position:absolute;top:805px;left:85px;white-space:nowrap" class="ft22">The&#160;recommended dose&#160;of&#160;Dovato&#160;in adults&#160;and adolescents&#160;is&#160;one&#160;50&#160;mg/300&#160;mg&#160;tablet&#160;once&#160;daily.&#160;</p>
<p style="position:absolute;top:824px;left:85px;white-space:nowrap" class="ft22">&#160;</p>
<p style="position:absolute;top:844px;left:85px;white-space:nowrap" class="ft25"><i>Dose&#160;adjustments&#160;</i></p>
<p style="position:absolute;top:864px;left:85px;white-space:nowrap" class="ft22">A&#160;separate preparation&#160;of&#160;dolutegravir&#160;is available where a dose&#160;adjustment&#160;is&#160;indicated&#160;due&#160;to&#160;drug-drug&#160;</p>
<p style="position:absolute;top:883px;left:85px;white-space:nowrap" class="ft22">interactions&#160;(e.g.&#160;rifampicin,&#160;carbamazepine,&#160;oxcarbazepine, phenytoin, phenobarbital, St. John’s&#160;wort,&#160;</p>
<p style="position:absolute;top:902px;left:85px;white-space:nowrap" class="ft22">etravirine&#160;(without&#160;boosted&#160;protease&#160;inhibitors), efavirenz, nevirapine, or&#160;tipranavir/ritonavir,&#160;see&#160;sections&#160;4.4&#160;</p>
<p style="position:absolute;top:922px;left:85px;white-space:nowrap" class="ft22">and&#160;4.5). In these&#160;cases&#160;the&#160;physician should&#160;refer&#160;to&#160;the&#160;individual&#160;product&#160;information&#160;for&#160;dolutegravir.&#160;</p>
<p style="position:absolute;top:941px;left:85px;white-space:nowrap" class="ft22">&#160;</p>
<p style="position:absolute;top:961px;left:85px;white-space:nowrap" class="ft25"><i>Missed doses&#160;</i></p>
<p style="position:absolute;top:981px;left:85px;white-space:nowrap" class="ft22">If&#160;the patient&#160;misses&#160;a dose&#160;of&#160;Dovato,&#160;the patient&#160;should&#160;take&#160;Dovato&#160;as&#160;soon&#160;as&#160;possible,&#160;providing the&#160;next&#160;</p>
<p style="position:absolute;top:1000px;left:85px;white-space:nowrap" class="ft22">dose&#160;is&#160;not&#160;due&#160;within&#160;4&#160;hours.&#160;If&#160;the&#160;next&#160;dose&#160;is&#160;due&#160;within&#160;4&#160;hours,&#160;the&#160;patient&#160;should not&#160;take&#160;the&#160;missed&#160;</p>
<p style="position:absolute;top:1019px;left:85px;white-space:nowrap" class="ft22">dose&#160;and simply&#160;resume&#160;the&#160;usual&#160;dosing&#160;schedule.&#160;</p>
<p style="position:absolute;top:1039px;left:85px;white-space:nowrap" class="ft22">&#160;</p>
<p style="position:absolute;top:1059px;left:85px;white-space:nowrap" class="ft25"><i>Elderly&#160;</i></p>
<p style="position:absolute;top:1078px;left:85px;white-space:nowrap" class="ft22">There&#160;are&#160;limited&#160;data&#160;available&#160;on&#160;the use of&#160;Dovato&#160;in patients&#160;aged 65&#160;years&#160;and&#160;over.&#160;No dose&#160;adjustment&#160;</p>
<p style="position:absolute;top:1098px;left:85px;white-space:nowrap" class="ft22">is necessary&#160;(see section&#160;5.2).&#160;</p>
<p style="position:absolute;top:1117px;left:85px;white-space:nowrap" class="ft25"><i>&#160;</i></p>
<p style="position:absolute;top:1137px;left:85px;white-space:nowrap" class="ft25"><i>Renal&#160;impairment&#160;</i></p>
</div>
<!-- Page 3 -->
<a name="3"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft36{font-size:18px;font-family:DTAKKI+TimesNewRomanPSMT;color:#000000;}
-->
</style>
<div id="page3-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1191px;left:439px;white-space:nowrap" class="ft30">3&#160;</p>
<p style="position:absolute;top:83px;left:85px;white-space:nowrap" class="ft32">Dovato&#160;is not&#160;recommended&#160;for&#160;use&#160;in&#160;patients with&#160;a&#160;creatinine clearance &lt;&#160;30&#160;mL/min (see&#160;section 5.2).&#160;No&#160;</p>
<p style="position:absolute;top:103px;left:85px;white-space:nowrap" class="ft32">dose adjustment&#160;is required&#160;in&#160;patients&#160;with&#160;mild&#160;or&#160;moderate&#160;renal&#160;impairment.&#160;However, the&#160;lamivudine&#160;</p>
<p style="position:absolute;top:122px;left:85px;white-space:nowrap" class="ft32">exposure&#160;is significantly&#160;increased&#160;in&#160;patients with&#160;a&#160;creatinine clearance &lt;&#160;50&#160;mL/min&#160;(see&#160;section&#160;4.4).&#160;</p>
<p style="position:absolute;top:142px;left:85px;white-space:nowrap" class="ft35"><i>&#160;</i></p>
<p style="position:absolute;top:162px;left:85px;white-space:nowrap" class="ft35"><i>Hepatic&#160;impairment&#160;</i></p>
<p style="position:absolute;top:181px;left:85px;white-space:nowrap" class="ft32">No dosage&#160;adjustment&#160;is&#160;required in patients&#160;with&#160;mild&#160;or&#160;moderate&#160;hepatic&#160;impairment&#160;(Child-Pugh&#160;grade&#160;A&#160;</p>
<p style="position:absolute;top:200px;left:85px;white-space:nowrap" class="ft32">or&#160;B).&#160;No&#160;data are available&#160;in&#160;patients with&#160;severe hepatic impairment&#160;(Child-Pugh grade&#160;C);&#160;therefore&#160;</p>
<p style="position:absolute;top:220px;left:85px;white-space:nowrap" class="ft32">Dovato&#160;should be&#160;used with caution&#160;in&#160;these&#160;patients&#160;(see&#160;section&#160;5.2).&#160;</p>
<p style="position:absolute;top:239px;left:85px;white-space:nowrap" class="ft32">&#160;</p>
<p style="position:absolute;top:259px;left:85px;white-space:nowrap" class="ft35"><i>Paediatric&#160;population<b>&#160;</b></i></p>
<p style="position:absolute;top:279px;left:85px;white-space:nowrap" class="ft32">The&#160;safety and&#160;efficacy&#160;of&#160;Dovato&#160;in children aged less&#160;than 12&#160;years or&#160;weighing&#160;less than&#160;40&#160;kg&#160;have&#160;not&#160;</p>
<p style="position:absolute;top:298px;left:85px;white-space:nowrap" class="ft32">been&#160;established.&#160;No&#160;data&#160;are available.&#160;</p>
<p style="position:absolute;top:317px;left:85px;white-space:nowrap" class="ft32">&#160;</p>
<p style="position:absolute;top:337px;left:85px;white-space:nowrap" class="ft32">Method&#160;of&#160;administration&#160;</p>
<p style="position:absolute;top:356px;left:85px;white-space:nowrap" class="ft32">&#160;</p>
<p style="position:absolute;top:376px;left:85px;white-space:nowrap" class="ft32">Oral&#160;use.&#160;&#160;</p>
<p style="position:absolute;top:396px;left:85px;white-space:nowrap" class="ft32">Dovato&#160;can be&#160;taken with or&#160;without&#160;food&#160;(see&#160;section&#160;5.2).&#160;</p>
<p style="position:absolute;top:415px;left:85px;white-space:nowrap" class="ft32">&#160;</p>
<p style="position:absolute;top:434px;left:85px;white-space:nowrap" class="ft32">&#160;</p>
<p style="position:absolute;top:454px;left:85px;white-space:nowrap" class="ft31"><b>4.3&#160;&#160;Contraindications</b>&#160;</p>
<p style="position:absolute;top:473px;left:85px;white-space:nowrap" class="ft32">&#160;</p>
<p style="position:absolute;top:493px;left:85px;white-space:nowrap" class="ft32">Hypersensitivity to&#160;the active substances&#160;or&#160;to any of&#160;the&#160;excipients&#160;listed&#160;in&#160;section&#160;6.1.&#160;</p>
<p style="position:absolute;top:513px;left:85px;white-space:nowrap" class="ft32">&#160;</p>
<p style="position:absolute;top:532px;left:85px;white-space:nowrap" class="ft32">Co-administration&#160;with&#160;medicinal&#160;products&#160;with narrow&#160;therapeutic&#160;windows, that&#160;are substrates of&#160;organic&#160;</p>
<p style="position:absolute;top:551px;left:85px;white-space:nowrap" class="ft32">cation transporter&#160;(OCT) 2,&#160;including but&#160;not&#160;limited&#160;to&#160;fampridine&#160;(also known as&#160;dalfampridine;&#160;see section&#160;</p>
<p style="position:absolute;top:571px;left:85px;white-space:nowrap" class="ft32">4.5).&#160;</p>
<p style="position:absolute;top:590px;left:85px;white-space:nowrap" class="ft32">&#160;</p>
<p style="position:absolute;top:610px;left:85px;white-space:nowrap" class="ft32">&#160;</p>
<p style="position:absolute;top:629px;left:85px;white-space:nowrap" class="ft31"><b>4.4&#160;&#160;Special&#160;warnings&#160;and&#160;precautions&#160;for&#160;use&#160;</b></p>
<p style="position:absolute;top:649px;left:85px;white-space:nowrap" class="ft32">&#160;</p>
<p style="position:absolute;top:668px;left:85px;white-space:nowrap" class="ft32">&#160;</p>
<p style="position:absolute;top:688px;left:85px;white-space:nowrap" class="ft32">Hypersensitivity reactions&#160;</p>
<p style="position:absolute;top:707px;left:85px;white-space:nowrap" class="ft32">&#160;</p>
<p style="position:absolute;top:727px;left:85px;white-space:nowrap" class="ft32">Hypersensitivity reactions&#160;have&#160;been reported&#160;with&#160;dolutegravir,&#160;and&#160;were characterized&#160;by&#160;rash,&#160;</p>
<p style="position:absolute;top:747px;left:85px;white-space:nowrap" class="ft32">constitutional&#160;findings, and&#160;sometimes, organ&#160;dysfunction,&#160;including&#160;severe&#160;liver&#160;reactions.&#160;Dovato&#160;and other&#160;</p>
<p style="position:absolute;top:766px;left:85px;white-space:nowrap" class="ft32">suspect&#160;medicinal&#160;products&#160;should be&#160;discontinued&#160;immediately&#160;if&#160;signs&#160;or&#160;symptoms&#160;of&#160;hypersensitivity&#160;</p>
<p style="position:absolute;top:785px;left:85px;white-space:nowrap" class="ft32">reactions&#160;develop (including,&#160;but&#160;not&#160;limited&#160;to, severe&#160;rash or&#160;rash&#160;accompanied by&#160;raised liver&#160;enzymes,&#160;</p>
<p style="position:absolute;top:805px;left:85px;white-space:nowrap" class="ft32">fever,&#160;general&#160;malaise,&#160;fatigue,&#160;muscle&#160;or&#160;joint aches,&#160;blisters,&#160;oral lesions,&#160;conjunctivitis,&#160;facial&#160;oedema,&#160;</p>
<p style="position:absolute;top:824px;left:85px;white-space:nowrap" class="ft32">eosinophilia, angioedema).&#160;Clinical&#160;status&#160;including liver&#160;aminotransferases&#160;and bilirubin&#160;should be&#160;</p>
<p style="position:absolute;top:844px;left:85px;white-space:nowrap" class="ft32">monitored.&#160;Delay&#160;in&#160;stopping&#160;treatment with&#160;Dovato&#160;or&#160;other&#160;suspect&#160;active substances&#160;after&#160;the onset&#160;of&#160;</p>
<p style="position:absolute;top:864px;left:85px;white-space:nowrap" class="ft32">hypersensitivity&#160;may&#160;result in&#160;a&#160;life-threatening&#160;allergic&#160;reaction.</p>
<p style="position:absolute;top:862px;left:513px;white-space:nowrap" class="ft36">&#160;</p>
<p style="position:absolute;top:883px;left:85px;white-space:nowrap" class="ft32">&#160;</p>
<p style="position:absolute;top:902px;left:85px;white-space:nowrap" class="ft32">Weight and&#160;metabolic&#160;parameters&#160;</p>
<p style="position:absolute;top:922px;left:85px;white-space:nowrap" class="ft32">&#160;</p>
<p style="position:absolute;top:941px;left:85px;white-space:nowrap" class="ft32">An increase&#160;in weight&#160;and in levels&#160;of&#160;blood&#160;lipids&#160;and&#160;glucose&#160;may occur&#160;during&#160;antiretroviral&#160;therapy.&#160;Such&#160;</p>
<p style="position:absolute;top:961px;left:85px;white-space:nowrap" class="ft32">changes&#160;may&#160;in part&#160;be&#160;linked to disease&#160;control&#160;and lifestyle. For&#160;lipids&#160;and weight,&#160;there&#160;is&#160;in&#160;some cases&#160;</p>
<p style="position:absolute;top:981px;left:85px;white-space:nowrap" class="ft32">evidence&#160;for&#160;a treatment&#160;effect.&#160;For&#160;monitoring of&#160;blood lipids&#160;and glucose&#160;reference&#160;is&#160;made&#160;to established&#160;</p>
<p style="position:absolute;top:1000px;left:85px;white-space:nowrap" class="ft32">HIV&#160;treatment&#160;guidelines. Lipid disorders&#160;should&#160;be&#160;managed&#160;as&#160;clinically appropriate.</p>
<p style="position:absolute;top:998px;left:660px;white-space:nowrap" class="ft36">&#160;</p>
<p style="position:absolute;top:1019px;left:85px;white-space:nowrap" class="ft32">&#160;</p>
<p style="position:absolute;top:1039px;left:85px;white-space:nowrap" class="ft32">Liver&#160;disease&#160;</p>
<p style="position:absolute;top:1058px;left:85px;white-space:nowrap" class="ft32">&#160;</p>
<p style="position:absolute;top:1078px;left:85px;white-space:nowrap" class="ft32">Patients with&#160;chronic hepatitis B&#160;or&#160;C&#160;and&#160;treated&#160;with&#160;combination&#160;antiretroviral&#160;therapy&#160;are at&#160;an&#160;increased&#160;</p>
<p style="position:absolute;top:1098px;left:85px;white-space:nowrap" class="ft32">risk&#160;of&#160;severe and&#160;potentially&#160;fatal&#160;hepatic adverse reactions.&#160;In&#160;case&#160;of&#160;concomitant&#160;antiviral&#160;therapy&#160;for&#160;</p>
<p style="position:absolute;top:1117px;left:85px;white-space:nowrap" class="ft32">hepatitis B&#160;or&#160;C,&#160;please&#160;refer&#160;also&#160;to&#160;the relevant&#160;product&#160;information for&#160;these&#160;medicinal&#160;products.&#160;</p>
<p style="position:absolute;top:1136px;left:85px;white-space:nowrap" class="ft32">&#160;</p>
</div>
<!-- Page 4 -->
<a name="4"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page4-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1191px;left:439px;white-space:nowrap" class="ft40">4&#160;</p>
<p style="position:absolute;top:83px;left:85px;white-space:nowrap" class="ft42">Dovato&#160;includes&#160;lamivudine,&#160;which&#160;is&#160;active&#160;against hepatitis&#160;B.&#160;Dolutegravir&#160;lacks&#160;such activity.&#160;</p>
<p style="position:absolute;top:103px;left:85px;white-space:nowrap" class="ft42">Lamivudine&#160;monotherapy&#160;is&#160;generally&#160;not&#160;considered&#160;an adequate&#160;treatment&#160;for&#160;hepatitis&#160;B, since&#160;the&#160;risk&#160;for&#160;</p>
<p style="position:absolute;top:122px;left:85px;white-space:nowrap" class="ft42">hepatitis B&#160;resistance development&#160;is high.&#160;If&#160;Dovato&#160;is used&#160;in&#160;patients co-infected with&#160;hepatitis&#160;B&#160;an&#160;</p>
<p style="position:absolute;top:142px;left:85px;white-space:nowrap" class="ft42">additional&#160;antiviral&#160;is therefore&#160;generally&#160;needed.&#160;Reference should&#160;be&#160;made to&#160;treatment&#160;guidelines.&#160;</p>
<p style="position:absolute;top:162px;left:85px;white-space:nowrap" class="ft42">&#160;</p>
<p style="position:absolute;top:181px;left:85px;white-space:nowrap" class="ft42">If&#160;Dovato&#160;is&#160;discontinued in patients&#160;co-infected&#160;with hepatitis&#160;B&#160;virus,&#160;periodic&#160;monitoring&#160;of&#160;both liver&#160;</p>
<p style="position:absolute;top:200px;left:85px;white-space:nowrap" class="ft42">function&#160;tests&#160;and markers&#160;of&#160;HBV&#160;replication is&#160;recommended,&#160;as&#160;withdrawal of&#160;lamivudine&#160;may&#160;result&#160;in&#160;</p>
<p style="position:absolute;top:220px;left:85px;white-space:nowrap" class="ft42">an&#160;acute&#160;exacerbation&#160;of&#160;hepatitis.</p>
<p style="position:absolute;top:219px;left:310px;white-space:nowrap" class="ft46">&#160;</p>
<p style="position:absolute;top:239px;left:85px;white-space:nowrap" class="ft42">&#160;</p>
<p style="position:absolute;top:259px;left:85px;white-space:nowrap" class="ft42">Patients&#160;with&#160;pre-existing&#160;liver&#160;dysfunction,&#160;including&#160;chronic&#160;active&#160;hepatitis&#160;have&#160;an increased frequency&#160;of&#160;</p>
<p style="position:absolute;top:279px;left:85px;white-space:nowrap" class="ft42">liver&#160;function abnormalities&#160;during&#160;combination antiretroviral&#160;therapy, and should&#160;be&#160;monitored according&#160;to&#160;</p>
<p style="position:absolute;top:298px;left:85px;white-space:nowrap" class="ft42">standard&#160;practice. If&#160;there&#160;is&#160;evidence&#160;of&#160;worsening&#160;liver&#160;disease&#160;in such patients, interruption or&#160;</p>
<p style="position:absolute;top:317px;left:85px;white-space:nowrap" class="ft42">discontinuation of&#160;treatment&#160;must&#160;be&#160;considered.</p>
<p style="position:absolute;top:316px;left:407px;white-space:nowrap" class="ft46">&#160;</p>
<p style="position:absolute;top:337px;left:85px;white-space:nowrap" class="ft42">&#160;</p>
<p style="position:absolute;top:356px;left:85px;white-space:nowrap" class="ft42">Immune&#160;Reactivation Syndrome&#160;</p>
<p style="position:absolute;top:376px;left:85px;white-space:nowrap" class="ft42">&#160;</p>
<p style="position:absolute;top:396px;left:85px;white-space:nowrap" class="ft42">In&#160;HIV-infected&#160;patients&#160;with&#160;severe&#160;immune&#160;deficiency&#160;at&#160;the&#160;time&#160;of&#160;institution of&#160;combination&#160;</p>
<p style="position:absolute;top:415px;left:85px;white-space:nowrap" class="ft42">antiretroviral&#160;therapy (CART), an&#160;inflammatory&#160;reaction to asymptomatic&#160;or&#160;residual&#160;opportunistic&#160;</p>
<p style="position:absolute;top:434px;left:85px;white-space:nowrap" class="ft42">pathogens&#160;may arise&#160;and&#160;cause&#160;serious&#160;clinical&#160;conditions, or&#160;aggravation&#160;of&#160;symptoms.&#160;Typically, such&#160;</p>
<p style="position:absolute;top:454px;left:85px;white-space:nowrap" class="ft42">reactions&#160;have&#160;been observed within&#160;the&#160;first&#160;few&#160;weeks&#160;or&#160;months&#160;of&#160;initiation of&#160;CART. Relevant&#160;examples&#160;</p>
<p style="position:absolute;top:473px;left:85px;white-space:nowrap" class="ft42">are&#160;<i>Cytomegalovirus&#160;retinitis</i>, generalised and/or&#160;focal&#160;mycobacterial&#160;infections,&#160;and&#160;<i>Pneumocystis&#160;jirovecii</i>&#160;</p>
<p style="position:absolute;top:493px;left:85px;white-space:nowrap" class="ft42">pneumonia&#160;(often&#160;referred&#160;to&#160;as PCP). Any inflammatory symptoms&#160;should&#160;be&#160;evaluated and treatment&#160;</p>
<p style="position:absolute;top:513px;left:85px;white-space:nowrap" class="ft42">instituted&#160;when necessary.&#160;Autoimmune disorders&#160;(such&#160;as Graves’&#160;disease&#160;and autoimmune&#160;hepatitis)&#160;have&#160;</p>
<p style="position:absolute;top:532px;left:85px;white-space:nowrap" class="ft42">also been reported to&#160;occur&#160;in&#160;the&#160;setting of&#160;immune&#160;reactivation;&#160;however, the&#160;reported time&#160;to onset&#160;is&#160;more&#160;</p>
<p style="position:absolute;top:551px;left:85px;white-space:nowrap" class="ft42">variable and&#160;these&#160;events&#160;can&#160;occur&#160;many&#160;months&#160;after&#160;initiation&#160;of&#160;treatment.&#160;</p>
<p style="position:absolute;top:571px;left:85px;white-space:nowrap" class="ft42">&#160;</p>
<p style="position:absolute;top:590px;left:85px;white-space:nowrap" class="ft42">Liver&#160;chemistry elevations&#160;consistent&#160;with&#160;immune&#160;reconstitution syndrome&#160;were&#160;observed&#160;in some&#160;hepatitis&#160;</p>
<p style="position:absolute;top:610px;left:85px;white-space:nowrap" class="ft42">B and/or&#160;C co-infected&#160;patients at&#160;the start&#160;of&#160;dolutegravir&#160;therapy.&#160;Monitoring&#160;of&#160;liver&#160;chemistries is&#160;</p>
<p style="position:absolute;top:630px;left:85px;white-space:nowrap" class="ft42">recommended&#160;in&#160;patients&#160;with&#160;hepatitis&#160;B&#160;and/or&#160;C&#160;co-infection. (See&#160;‘Liver&#160;disease’&#160;earlier&#160;in&#160;this&#160;section&#160;</p>
<p style="position:absolute;top:649px;left:85px;white-space:nowrap" class="ft42">and also see&#160;section&#160;4.8).</p>
<p style="position:absolute;top:647px;left:250px;white-space:nowrap" class="ft46">&#160;</p>
<p style="position:absolute;top:668px;left:85px;white-space:nowrap" class="ft42">&#160;</p>
<p style="position:absolute;top:688px;left:85px;white-space:nowrap" class="ft42">Mitochondrial&#160;dysfunction&#160;following exposure&#160;<i>in&#160;utero&#160;</i></p>
<p style="position:absolute;top:707px;left:85px;white-space:nowrap" class="ft42">&#160;</p>
<p style="position:absolute;top:727px;left:85px;white-space:nowrap" class="ft42">Nucleoside&#160;and nucleotide&#160;analogues&#160;may&#160;impact&#160;mitochondrial&#160;function to a&#160;variable&#160;degree,&#160;which&#160;is&#160;most&#160;</p>
<p style="position:absolute;top:747px;left:85px;white-space:nowrap" class="ft42">pronounced with&#160;stavudine,&#160;didanosine&#160;and zidovudine. There&#160;have&#160;been&#160;reports&#160;of&#160;mitochondrial&#160;</p>
<p style="position:absolute;top:766px;left:85px;white-space:nowrap" class="ft42">dysfunction in&#160;HIV-negative infants exposed&#160;<i>in utero</i>&#160;and/or&#160;post-natally to nucleoside&#160;analogues,&#160;these&#160;have&#160;</p>
<p style="position:absolute;top:785px;left:85px;white-space:nowrap" class="ft42">predominantly&#160;concerned treatment&#160;with&#160;regimens&#160;containing zidovudine. The&#160;main&#160;adverse&#160;reactions&#160;</p>
<p style="position:absolute;top:805px;left:85px;white-space:nowrap" class="ft42">reported&#160;are haematological&#160;disorders&#160;(anaemia,&#160;neutropenia),&#160;and metabolic&#160;disorders&#160;(hyperlactatemia,&#160;</p>
<p style="position:absolute;top:824px;left:85px;white-space:nowrap" class="ft42">hyperlipasemia).&#160;These reactions have often&#160;been&#160;transitory.&#160;Some&#160;late-onset&#160;neurological&#160;disorders&#160;have&#160;</p>
<p style="position:absolute;top:844px;left:85px;white-space:nowrap" class="ft42">been&#160;reported rarely&#160;(hypertonia, convulsion, abnormal&#160;behaviour).&#160;Whether&#160;such&#160;neurological&#160;disorders are&#160;</p>
<p style="position:absolute;top:864px;left:85px;white-space:nowrap" class="ft42">transient&#160;or&#160;permanent&#160;is&#160;currently unknown. These&#160;findings&#160;should be&#160;considered&#160;for&#160;any child exposed&#160;<i>in&#160;</i></p>
<p style="position:absolute;top:883px;left:85px;white-space:nowrap" class="ft45"><i>utero</i>&#160;to&#160;nucleoside&#160;and nucleotide&#160;analogues, who&#160;presents&#160;with&#160;severe&#160;clinical&#160;findings&#160;of&#160;unknown&#160;</p>
<p style="position:absolute;top:902px;left:85px;white-space:nowrap" class="ft42">aetiology, particularly neurologic&#160;findings. These&#160;findings&#160;do not&#160;affect&#160;current&#160;national&#160;recommendations&#160;to&#160;</p>
<p style="position:absolute;top:922px;left:85px;white-space:nowrap" class="ft42">use&#160;antiretroviral&#160;therapy in&#160;pregnant&#160;women to&#160;prevent&#160;vertical&#160;transmission&#160;of&#160;HIV.&#160;</p>
<p style="position:absolute;top:941px;left:85px;white-space:nowrap" class="ft42">&#160;</p>
<p style="position:absolute;top:961px;left:85px;white-space:nowrap" class="ft42">Osteonecrosis&#160;</p>
<p style="position:absolute;top:981px;left:85px;white-space:nowrap" class="ft42">&#160;</p>
<p style="position:absolute;top:1000px;left:85px;white-space:nowrap" class="ft42">Although the&#160;aetiology is&#160;considered to&#160;be&#160;multifactorial&#160;(including&#160;corticosteroid&#160;use, biphosphonates,&#160;</p>
<p style="position:absolute;top:1019px;left:85px;white-space:nowrap" class="ft42">alcohol&#160;consumption, severe&#160;immunosuppression, higher&#160;body mass&#160;index),&#160;cases&#160;of&#160;osteonecrosis&#160;have&#160;been&#160;</p>
<p style="position:absolute;top:1039px;left:85px;white-space:nowrap" class="ft42">reported&#160;in&#160;patients with&#160;advanced&#160;HIV-disease&#160;and/or&#160;long-term&#160;exposure to&#160;CART.&#160;Patients should&#160;be&#160;</p>
<p style="position:absolute;top:1058px;left:85px;white-space:nowrap" class="ft42">advised&#160;to&#160;seek&#160;medical&#160;advice&#160;if&#160;they&#160;experience joint&#160;aches and&#160;pain,&#160;joint&#160;stiffness or&#160;difficulty&#160;in&#160;</p>
<p style="position:absolute;top:1078px;left:85px;white-space:nowrap" class="ft42">movement.&#160;</p>
<p style="position:absolute;top:1098px;left:85px;white-space:nowrap" class="ft42">&#160;</p>
<p style="position:absolute;top:1117px;left:85px;white-space:nowrap" class="ft42">Opportunistic&#160;infections&#160;</p>
<p style="position:absolute;top:1136px;left:85px;white-space:nowrap" class="ft42">&#160;</p>
</div>
<!-- Page 5 -->
<a name="5"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft57{font-size:17px;font-family:FOBBME+TimesNewRomanPSMT;color:#000000;}
-->
</style>
<div id="page5-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1191px;left:439px;white-space:nowrap" class="ft50">5&#160;</p>
<p style="position:absolute;top:83px;left:85px;white-space:nowrap" class="ft52">Patients&#160;should be&#160;advised that&#160;dolutegravir,&#160;lamivudine&#160;or&#160;any other&#160;antiretroviral&#160;therapy does&#160;not&#160;cure&#160;</p>
<p style="position:absolute;top:103px;left:85px;white-space:nowrap" class="ft52">HIV&#160;infection&#160;and&#160;that&#160;they&#160;may&#160;still&#160;develop opportunistic&#160;infections&#160;and other&#160;complications&#160;of&#160;HIV&#160;</p>
<p style="position:absolute;top:122px;left:85px;white-space:nowrap" class="ft52">infection. Therefore, patients&#160;should&#160;remain under&#160;close&#160;clinical&#160;observation by&#160;physicians&#160;experienced&#160;in&#160;the&#160;</p>
<p style="position:absolute;top:142px;left:85px;white-space:nowrap" class="ft52">treatment&#160;of&#160;these&#160;associated&#160;HIV&#160;diseases.&#160;</p>
<p style="position:absolute;top:162px;left:85px;white-space:nowrap" class="ft52">&#160;</p>
<p style="position:absolute;top:181px;left:85px;white-space:nowrap" class="ft52">Administration&#160;in&#160;subjects&#160;with&#160;moderate&#160;renal impairment&#160;</p>
<p style="position:absolute;top:200px;left:85px;white-space:nowrap" class="ft52">&#160;</p>
<p style="position:absolute;top:220px;left:85px;white-space:nowrap" class="ft52">Patients&#160;with a&#160;creatinine&#160;clearance&#160;between 30&#160;and 49&#160;mL/min receiving Dovato&#160;may experience&#160;a&#160;1.6-to&#160;</p>
<p style="position:absolute;top:239px;left:85px;white-space:nowrap" class="ft52">3.3-fold higher&#160;lamivudine&#160;exposure&#160;(AUC)&#160;than patients&#160;with&#160;a&#160;creatinine&#160;clearance&#160;≥50&#160;mL/min. There&#160;are&#160;</p>
<p style="position:absolute;top:259px;left:85px;white-space:nowrap" class="ft52">no&#160;safety&#160;data from&#160;randomized,&#160;controlled&#160;trials comparing&#160;Dovato&#160;to the&#160;individual&#160;components&#160;in patients&#160;</p>
<p style="position:absolute;top:279px;left:85px;white-space:nowrap" class="ft52">with&#160;a creatinine&#160;clearance&#160;between 30 and 49&#160;mL/min&#160;who received dose-adjusted lamivudine. In the&#160;</p>
<p style="position:absolute;top:298px;left:85px;white-space:nowrap" class="ft52">original lamivudine&#160;registrational&#160;trials&#160;in&#160;combination&#160;with&#160;zidovudine,&#160;higher&#160;lamivudine&#160;exposures&#160;were&#160;</p>
<p style="position:absolute;top:317px;left:85px;white-space:nowrap" class="ft52">associated with&#160;higher&#160;rates&#160;of&#160;haematologic toxicities (neutropenia and&#160;anaemia), although&#160;discontinuations&#160;</p>
<p style="position:absolute;top:337px;left:85px;white-space:nowrap" class="ft52">due&#160;to&#160;neutropenia&#160;or&#160;anaemia&#160;each occurred&#160;in &lt;1%&#160;of&#160;subjects.&#160;Other&#160;lamivudine-related&#160;adverse events&#160;</p>
<p style="position:absolute;top:356px;left:85px;white-space:nowrap" class="ft52">(such&#160;as gastro-intestinal&#160;and hepatic&#160;disorders)&#160;may&#160;occur.&#160;</p>
<p style="position:absolute;top:376px;left:85px;white-space:nowrap" class="ft52">&#160;</p>
<p style="position:absolute;top:396px;left:85px;white-space:nowrap" class="ft52">Patients with&#160;a&#160;sustained&#160;creatinine clearance between&#160;30 and 49&#160;mL/min who&#160;receive&#160;Dovato&#160;should be&#160;</p>
<p style="position:absolute;top:415px;left:85px;white-space:nowrap" class="ft52">monitored for&#160;lamivudine-related adverse&#160;events, notably&#160;haematologic&#160;toxicities.&#160;If&#160;new&#160;or&#160;worsening&#160;</p>
<p style="position:absolute;top:434px;left:85px;white-space:nowrap" class="ft52">neutropenia&#160;or&#160;anaemia&#160;develop,&#160;a&#160;dose&#160;adjustment&#160;of&#160;lamivudine, per&#160;lamivudine&#160;prescribing information, is&#160;</p>
<p style="position:absolute;top:454px;left:85px;white-space:nowrap" class="ft52">indicated, which&#160;cannot&#160;be&#160;achieved with Dovato. Dovato&#160;should be&#160;discontinued&#160;and the&#160;individual&#160;</p>
<p style="position:absolute;top:473px;left:85px;white-space:nowrap" class="ft52">components&#160;should be&#160;used&#160;to construct&#160;the&#160;treatment&#160;regimen.&#160;</p>
<p style="position:absolute;top:493px;left:85px;white-space:nowrap" class="ft52">&#160;</p>
<p style="position:absolute;top:513px;left:85px;white-space:nowrap" class="ft52">Drug&#160;interactions&#160;</p>
<p style="position:absolute;top:532px;left:85px;white-space:nowrap" class="ft52">&#160;</p>
<p style="position:absolute;top:551px;left:85px;white-space:nowrap" class="ft52">The&#160;recommended dose&#160;of&#160;dolutegravir&#160;is&#160;50&#160;mg twice&#160;daily&#160;when co-administered&#160;with&#160;rifampicin,&#160;</p>
<p style="position:absolute;top:571px;left:85px;white-space:nowrap" class="ft52">carbamazepine,&#160;oxcarbazepine,&#160;phenytoin, phenobarbital, St. John’s&#160;wort,&#160;etravirine&#160;(without&#160;boosted&#160;</p>
<p style="position:absolute;top:590px;left:85px;white-space:nowrap" class="ft52">protease&#160;inhibitors), efavirenz, nevirapine, or&#160;tipranavir/ritonavir&#160;(see section&#160;4.5).&#160;</p>
<p style="position:absolute;top:610px;left:85px;white-space:nowrap" class="ft52">&#160;</p>
<p style="position:absolute;top:630px;left:85px;white-space:nowrap" class="ft52">Dovato&#160;should not&#160;be&#160;co-administered&#160;with&#160;polyvalent&#160;cation-containing&#160;antacids. Polyvalent&#160;cation-</p>
<p style="position:absolute;top:649px;left:85px;white-space:nowrap" class="ft52">containing antacids&#160;are&#160;recommended to&#160;be&#160;taken 2&#160;hours&#160;after or 6&#160;hours&#160;before&#160;Dovato&#160;(see&#160;section 4.5).&#160;</p>
<p style="position:absolute;top:668px;left:85px;white-space:nowrap" class="ft52">&#160;</p>
<p style="position:absolute;top:688px;left:85px;white-space:nowrap" class="ft52">When&#160;taken with food,&#160;Dovato&#160;and&#160;supplements&#160;or&#160;multivitamins&#160;containing calcium,&#160;iron&#160;or&#160;magnesium&#160;can&#160;</p>
<p style="position:absolute;top:707px;left:85px;white-space:nowrap" class="ft52">be&#160;taken&#160;at&#160;the same time.&#160;If&#160;Dovato&#160;is&#160;administered&#160;under&#160;fasting&#160;conditions,&#160;supplements&#160;or&#160;multivitamins&#160;</p>
<p style="position:absolute;top:727px;left:85px;white-space:nowrap" class="ft52">containing&#160;calcium, iron&#160;or&#160;magnesium&#160;are recommended&#160;to&#160;be taken&#160;2&#160;hours&#160;after&#160;or 6&#160;hours&#160;before&#160;Dovato&#160;</p>
<p style="position:absolute;top:747px;left:85px;white-space:nowrap" class="ft52">(see section&#160;4.5).&#160;</p>
<p style="position:absolute;top:766px;left:85px;white-space:nowrap" class="ft52">&#160;</p>
<p style="position:absolute;top:785px;left:85px;white-space:nowrap" class="ft52">Dolutegravir&#160;increased metformin&#160;concentrations. A&#160;dose&#160;adjustment&#160;of&#160;metformin should be&#160;considered&#160;</p>
<p style="position:absolute;top:805px;left:85px;white-space:nowrap" class="ft52">when starting and&#160;stopping&#160;coadministration of&#160;Dovato&#160;with&#160;metformin,&#160;to&#160;maintain&#160;glycaemic&#160;control (see&#160;</p>
<p style="position:absolute;top:824px;left:85px;white-space:nowrap" class="ft52">section 4.5). Metformin is eliminated&#160;renally&#160;and,&#160;therefore,&#160;it&#160;is&#160;of&#160;importance&#160;to&#160;monitor&#160;renal&#160;function&#160;</p>
<p style="position:absolute;top:844px;left:85px;white-space:nowrap" class="ft52">when co-treated&#160;with&#160;Dovato.&#160;This combination&#160;may&#160;increase the risk&#160;for&#160;lactic&#160;acidosis&#160;in&#160;patients&#160;with&#160;</p>
<p style="position:absolute;top:864px;left:85px;white-space:nowrap" class="ft52">moderate&#160;renal&#160;impairment&#160;(stage 3a creatinine&#160;clearance 45–&#160;59&#160;mL/min)&#160;and&#160;a&#160;cautious&#160;approach&#160;is&#160;</p>
<p style="position:absolute;top:883px;left:85px;white-space:nowrap" class="ft52">recommended. Reduction of&#160;the&#160;metformin dose&#160;should be&#160;highly considered.&#160;</p>
<p style="position:absolute;top:902px;left:85px;white-space:nowrap" class="ft52">&#160;</p>
<p style="position:absolute;top:922px;left:85px;white-space:nowrap" class="ft52">The&#160;combination of&#160;Dovato&#160;with&#160;cladribine&#160;is&#160;not&#160;recommended&#160;(see&#160;section&#160;4.5).&#160;</p>
<p style="position:absolute;top:942px;left:85px;white-space:nowrap" class="ft52">&#160;</p>
<p style="position:absolute;top:961px;left:85px;white-space:nowrap" class="ft52">Dovato&#160;should not&#160;be&#160;taken&#160;with any other&#160;medicinal&#160;product&#160;containing dolutegravir,&#160;lamivudine&#160;or&#160;</p>
<p style="position:absolute;top:980px;left:85px;white-space:nowrap" class="ft52">emtricitabine,&#160;except&#160;where&#160;a&#160;dose&#160;adjustment&#160;of&#160;dolutegravir&#160;is&#160;indicated&#160;due&#160;to drug-drug&#160;interactions&#160;(see&#160;</p>
<p style="position:absolute;top:999px;left:85px;white-space:nowrap" class="ft52">section 4.5).&#160;</p>
<p style="position:absolute;top:1018px;left:85px;white-space:nowrap" class="ft52">&#160;</p>
<p style="position:absolute;top:1037px;left:85px;white-space:nowrap" class="ft52">&#160;</p>
<p style="position:absolute;top:1057px;left:85px;white-space:nowrap" class="ft51"><b>4.5&#160;&#160;Interaction&#160;with&#160;other medicinal&#160;products&#160;and other&#160;forms&#160;of&#160;interaction&#160;</b>&#160;</p>
<p style="position:absolute;top:1077px;left:85px;white-space:nowrap" class="ft52">&#160;</p>
<p style="position:absolute;top:1096px;left:85px;white-space:nowrap" class="ft52">No&#160;drug interaction studies&#160;have&#160;been&#160;conducted using&#160;Dovato.&#160;Dovato&#160;contains&#160;dolutegravir&#160;and&#160;</p>
<p style="position:absolute;top:1115px;left:85px;white-space:nowrap" class="ft52">lamivudine,&#160;therefore any&#160;interactions identified&#160;for&#160;these&#160;individually&#160;are&#160;relevant&#160;to&#160;Dovato.&#160;No&#160;clinically&#160;</p>
<p style="position:absolute;top:1135px;left:85px;white-space:nowrap" class="ft52">significant&#160;drug&#160;interactions are&#160;expected&#160;between dolutegravir&#160;and lamivudine.&#160;</p>
<p style="position:absolute;top:1154px;left:85px;white-space:nowrap" class="ft52">&#160;</p>
</div>
<!-- Page 6 -->
<a name="6"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft68{font-size:10px;font-family:DTAKKI+TimesNewRomanPSMT;color:#000000;}
-->
</style>
<div id="page6-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1191px;left:439px;white-space:nowrap" class="ft60">6&#160;</p>
<p style="position:absolute;top:83px;left:85px;white-space:nowrap" class="ft62">Effect&#160;of&#160;other&#160;medicinal&#160;products&#160;on&#160;the&#160;pharmacokinetics of&#160;dolutegravir&#160;and&#160;lamivudine&#160;</p>
<p style="position:absolute;top:103px;left:85px;white-space:nowrap" class="ft62">&#160;</p>
<p style="position:absolute;top:122px;left:85px;white-space:nowrap" class="ft62">Dolutegravir&#160;is&#160;eliminated&#160;mainly&#160;through&#160;metabolism&#160;by uridine&#160;diphosphate&#160;glucuronosyl&#160;transferase&#160;</p>
<p style="position:absolute;top:142px;left:85px;white-space:nowrap" class="ft62">(UGT)&#160;1A1. Dolutegravir&#160;is&#160;also a&#160;substrate&#160;of&#160;UGT1A3, UGT1A9, CYP3A4, P-glycoprotein (P-gp), and&#160;</p>
<p style="position:absolute;top:162px;left:85px;white-space:nowrap" class="ft62">breast&#160;cancer&#160;resistance&#160;protein<i><b>&#160;</b></i>(BCRP).&#160;Co-administration&#160;of&#160;Dovato&#160;and other&#160;medicinal products&#160;that&#160;</p>
<p style="position:absolute;top:181px;left:85px;white-space:nowrap" class="ft62">inhibit&#160;UGT1A1, UGT1A3, UGT1A9, CYP3A4, and/or&#160;P-gp may,&#160;therefore,&#160;increase dolutegravir&#160;plasma&#160;</p>
<p style="position:absolute;top:200px;left:85px;white-space:nowrap" class="ft62">concentration.&#160;Medicinal&#160;products&#160;that&#160;induce&#160;those&#160;enzymes&#160;or&#160;transporters&#160;may decrease&#160;dolutegravir&#160;</p>
<p style="position:absolute;top:220px;left:85px;white-space:nowrap" class="ft62">plasma&#160;concentration&#160;and reduce&#160;the&#160;therapeutic&#160;effect&#160;of&#160;dolutegravir.&#160;</p>
<p style="position:absolute;top:239px;left:85px;white-space:nowrap" class="ft62">&#160;</p>
<p style="position:absolute;top:259px;left:85px;white-space:nowrap" class="ft62">The&#160;absorption of&#160;dolutegravir&#160;is&#160;reduced by&#160;certain&#160;metal&#160;cation-containing&#160;anti-acid&#160;substances&#160;and&#160;</p>
<p style="position:absolute;top:279px;left:85px;white-space:nowrap" class="ft62">supplements&#160;(see Table 1).&#160;</p>
<p style="position:absolute;top:298px;left:85px;white-space:nowrap" class="ft62">&#160;</p>
<p style="position:absolute;top:317px;left:85px;white-space:nowrap" class="ft62">Lamivudine&#160;is&#160;cleared&#160;renally.&#160;Active&#160;renal&#160;secretion&#160;of&#160;lamivudine&#160;in&#160;the&#160;urine&#160;is&#160;mediated&#160;through&#160;the&#160;</p>
<p style="position:absolute;top:337px;left:85px;white-space:nowrap" class="ft62">OCT2 and multidrug and toxin extrusion transporters&#160;(MATE1 and&#160;MATE2-K).&#160;Trimethoprim&#160;(an inhibitor&#160;</p>
<p style="position:absolute;top:356px;left:85px;white-space:nowrap" class="ft62">of&#160;these&#160;transporters)&#160;has been&#160;shown&#160;to&#160;increase&#160;lamivudine&#160;plasma concentrations,&#160;however&#160;the&#160;resulting&#160;</p>
<p style="position:absolute;top:376px;left:85px;white-space:nowrap" class="ft62">increase was not&#160;clinically&#160;significant&#160;(see Table 1).&#160;Dolutegravir&#160;is&#160;an OCT2&#160;and&#160;MATE1 inhibitor;&#160;</p>
<p style="position:absolute;top:396px;left:85px;white-space:nowrap" class="ft62">however,&#160;lamivudine&#160;concentrations&#160;were&#160;similar&#160;with&#160;or&#160;without&#160;co-administration of&#160;dolutegravir&#160;based&#160;on&#160;</p>
<p style="position:absolute;top:415px;left:85px;white-space:nowrap" class="ft62">a&#160;cross&#160;study analysis, indicating&#160;that&#160;dolutegravir&#160;has&#160;no&#160;relevant&#160;effect&#160;on lamivudine&#160;exposure&#160;<i>in&#160;vivo</i>.&#160;</p>
<p style="position:absolute;top:434px;left:85px;white-space:nowrap" class="ft62">Lamivudine&#160;is also&#160;substrate of&#160;the hepatic uptake&#160;transporter&#160;OCT1.&#160;As&#160;hepatic elimination&#160;plays a&#160;minor&#160;</p>
<p style="position:absolute;top:454px;left:85px;white-space:nowrap" class="ft62">role&#160;in&#160;the&#160;clearance&#160;of&#160;lamivudine, drug&#160;interactions&#160;due&#160;to&#160;inhibition of&#160;OCT1 are&#160;unlikely&#160;to be&#160;of&#160;clinical&#160;</p>
<p style="position:absolute;top:473px;left:85px;white-space:nowrap" class="ft62">significance.&#160;</p>
<p style="position:absolute;top:493px;left:85px;white-space:nowrap" class="ft62">&#160;</p>
<p style="position:absolute;top:513px;left:85px;white-space:nowrap" class="ft62">Although&#160;lamivudine&#160;is&#160;a&#160;substrate&#160;of&#160;BCRP&#160;and P-gp&#160;<i>in&#160;vitro</i>, given&#160;its&#160;high absolute&#160;bioavailability,&#160;(see&#160;</p>
<p style="position:absolute;top:532px;left:85px;white-space:nowrap" class="ft62">section 5.2), inhibitors&#160;of&#160;these&#160;efflux transporters&#160;are&#160;unlikely to result&#160;in a&#160;clinically relevant&#160;impact&#160;on&#160;</p>
<p style="position:absolute;top:551px;left:85px;white-space:nowrap" class="ft62">lamivudine&#160;concentrations.&#160;</p>
<p style="position:absolute;top:571px;left:85px;white-space:nowrap" class="ft62">&#160;</p>
<p style="position:absolute;top:590px;left:85px;white-space:nowrap" class="ft62">Effect&#160;of&#160;dolutegravir&#160;and&#160;lamivudine&#160;on the&#160;pharmacokinetics of&#160;other&#160;medicinal&#160;products&#160;</p>
<p style="position:absolute;top:610px;left:85px;white-space:nowrap" class="ft62">&#160;</p>
<p style="position:absolute;top:630px;left:85px;white-space:nowrap" class="ft65"><i>In&#160;vivo</i>, dolutegravir&#160;did not&#160;have&#160;an&#160;effect&#160;on&#160;midazolam, a&#160;CYP3A4 probe. Based on&#160;<i>in&#160;vivo</i>&#160;and/or&#160;<i>in&#160;vitro</i>&#160;</p>
<p style="position:absolute;top:649px;left:85px;white-space:nowrap" class="ft62">data, dolutegravir&#160;is&#160;not&#160;expected&#160;to&#160;affect&#160;the&#160;pharmacokinetics&#160;of&#160;medicinal&#160;products&#160;that&#160;are&#160;substrates of&#160;</p>
<p style="position:absolute;top:668px;left:85px;white-space:nowrap" class="ft62">any major&#160;enzyme&#160;or&#160;transporter&#160;such as&#160;CYP3A4, CYP2C9 and P-gp (for&#160;more&#160;information&#160;see&#160;section 5.2).&#160;</p>
<p style="position:absolute;top:688px;left:85px;white-space:nowrap" class="ft62">&#160;</p>
<p style="position:absolute;top:708px;left:85px;white-space:nowrap" class="ft65"><i>In&#160;vitro</i>, dolutegravir&#160;inhibited&#160;the&#160;renal&#160;transporters&#160;OCT2 and MATE1.&#160;<i>In&#160;vivo</i>, a&#160;10-14%&#160;decrease of&#160;</p>
<p style="position:absolute;top:727px;left:85px;white-space:nowrap" class="ft62">creatinine&#160;clearance&#160;(secretory fraction is&#160;dependent&#160;on OCT2 and MATE1&#160;transport)&#160;was&#160;observed&#160;in&#160;</p>
<p style="position:absolute;top:747px;left:85px;white-space:nowrap" class="ft62">patients.&#160;<i>In&#160;vivo</i>,&#160;dolutegravir&#160;may&#160;increase plasma&#160;concentrations&#160;of&#160;medicinal&#160;products&#160;in&#160;which&#160;excretion&#160;</p>
<p style="position:absolute;top:766px;left:85px;white-space:nowrap" class="ft62">is&#160;dependent&#160;upon OCT2 and/or&#160;MATE1&#160;(e.g.&#160;fampridine&#160;[also known&#160;as&#160;dalfampridine],&#160;metformin)&#160;(see&#160;</p>
<p style="position:absolute;top:785px;left:85px;white-space:nowrap" class="ft62">Table&#160;1&#160;and section&#160;4.3).&#160;</p>
<p style="position:absolute;top:805px;left:85px;white-space:nowrap" class="ft62">&#160;</p>
<p style="position:absolute;top:825px;left:85px;white-space:nowrap" class="ft65"><i>In&#160;vitro</i>, dolutegravir&#160;inhibited&#160;the&#160;renal&#160;uptake&#160;organic&#160;anion&#160;transporters&#160;(OAT)1&#160;and OAT3. Based&#160;on the&#160;</p>
<p style="position:absolute;top:844px;left:85px;white-space:nowrap" class="ft62">lack of&#160;effect&#160;on the&#160;<i>in&#160;vivo</i>&#160;pharmacokinetics&#160;of&#160;the&#160;OAT&#160;substrate&#160;tenofovir,&#160;<i>in&#160;vivo</i>&#160;inhibition&#160;of&#160;OAT1&#160;is&#160;</p>
<p style="position:absolute;top:864px;left:85px;white-space:nowrap" class="ft62">unlikely. Inhibition of&#160;OAT3 has&#160;not&#160;been studied&#160;<i>in&#160;vivo</i>.&#160;Dolutegravir&#160;may&#160;increase&#160;plasma concentrations&#160;</p>
<p style="position:absolute;top:883px;left:85px;white-space:nowrap" class="ft62">of&#160;medicinal&#160;products&#160;in which&#160;excretion&#160;is&#160;dependent&#160;upon OAT3.&#160;</p>
<p style="position:absolute;top:902px;left:85px;white-space:nowrap" class="ft62">&#160;</p>
<p style="position:absolute;top:922px;left:85px;white-space:nowrap" class="ft65"><i>In&#160;vitro,</i>&#160;lamivudine&#160;was&#160;an&#160;inhibitor&#160;of&#160;OCT1 and OCT2;&#160;the&#160;clinical&#160;consequences&#160;are&#160;not&#160;known.&#160;</p>
<p style="position:absolute;top:941px;left:85px;white-space:nowrap" class="ft62">&#160;</p>
<p style="position:absolute;top:961px;left:85px;white-space:nowrap" class="ft62">Established&#160;and&#160;theoretical&#160;interactions&#160;with&#160;selected&#160;antiretrovirals&#160;and&#160;non-antiretroviral medicinal&#160;</p>
<p style="position:absolute;top:981px;left:85px;white-space:nowrap" class="ft62">products are&#160;listed&#160;in&#160;Table 1.&#160;</p>
<p style="position:absolute;top:1000px;left:85px;white-space:nowrap" class="ft62">&#160;</p>
<p style="position:absolute;top:1019px;left:85px;white-space:nowrap" class="ft62">Interaction&#160;table&#160;</p>
<p style="position:absolute;top:1039px;left:85px;white-space:nowrap" class="ft62">&#160;</p>
<p style="position:absolute;top:1058px;left:85px;white-space:nowrap" class="ft62">Interactions&#160;between dolutegravir,&#160;lamivudine&#160;and co-administered&#160;medical products&#160;are&#160;listed&#160;in&#160;Table&#160;1&#160;</p>
<p style="position:absolute;top:1078px;left:85px;white-space:nowrap" class="ft62">(increase&#160;is&#160;indicated&#160;as&#160;“↑”,&#160;decrease&#160;as&#160;“↓”,&#160;no&#160;change&#160;as&#160;“↔”,&#160;area&#160;under&#160;the&#160;concentration versus&#160;time&#160;</p>
<p style="position:absolute;top:1098px;left:85px;white-space:nowrap" class="ft62">curve&#160;as&#160;“AUC”,&#160;maximum&#160;observed concentration as&#160;“Cmax”,&#160;concentration&#160;at&#160;end of&#160;dosing&#160;interval&#160;as&#160;</p>
<p style="position:absolute;top:1117px;left:85px;white-space:nowrap" class="ft67">“Cτ”).&#160;The table should&#160;not&#160;be considered&#160;exhaustive but&#160;is representative of&#160;the&#160;classes studied.&#160;</p>
<p style="position:absolute;top:1136px;left:85px;white-space:nowrap" class="ft62">&#160;</p>
<p style="position:absolute;top:1156px;left:85px;white-space:nowrap" class="ft61"><b>Table&#160;1:&#160;</b></p>
<p style="position:absolute;top:1156px;left:193px;white-space:nowrap" class="ft61"><b>Drug&#160;Interactions&#160;</b></p>
</div>
<!-- Page 7 -->
<a name="7"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft79{font-size:17px;font-family:LIVBSS+SymbolMT;color:#000000;}
-->
</style>
<div id="page7-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1191px;left:439px;white-space:nowrap" class="ft70">7&#160;</p>
<p style="position:absolute;top:83px;left:85px;white-space:nowrap" class="ft72">&#160;</p>
<p style="position:absolute;top:104px;left:94px;white-space:nowrap" class="ft71"><b>Medicinal&#160;products by&#160;</b></p>
<p style="position:absolute;top:123px;left:94px;white-space:nowrap" class="ft71"><b>therapeutic areas</b>&#160;</p>
<p style="position:absolute;top:103px;left:325px;white-space:nowrap" class="ft71"><b>Interaction&#160;geometric&#160;</b></p>
<p style="position:absolute;top:122px;left:325px;white-space:nowrap" class="ft71"><b>mean change&#160;(%)&#160;&#160;</b></p>
<p style="position:absolute;top:104px;left:516px;white-space:nowrap" class="ft71"><b>Recommendations concerning&#160;co-</b></p>
<p style="position:absolute;top:123px;left:516px;white-space:nowrap" class="ft71"><b>administration</b>&#160;</p>
<p style="position:absolute;top:143px;left:94px;white-space:nowrap" class="ft71"><b>Antiretroviral&#160;medicinal&#160;products</b>&#160;</p>
<p style="position:absolute;top:164px;left:94px;white-space:nowrap" class="ft75"><i>Non-nucleoside&#160;reverse transcriptase inhibitors&#160;</i></p>
<p style="position:absolute;top:184px;left:94px;white-space:nowrap" class="ft72">Etravirine&#160;without&#160;boosted&#160;</p>
<p style="position:absolute;top:203px;left:94px;white-space:nowrap" class="ft72">protease&#160;inhibitors&#160;/&#160;</p>
<p style="position:absolute;top:223px;left:94px;white-space:nowrap" class="ft72">Dolutegravir<i>&#160;</i></p>
<p style="position:absolute;top:184px;left:325px;white-space:nowrap" class="ft72">Dolutegravir&#160;↓&#160;</p>
<p style="position:absolute;top:203px;left:325px;white-space:nowrap" class="ft72">&#160; &#160;AUC&#160;↓&#160;71%&#160;</p>
<p style="position:absolute;top:223px;left:325px;white-space:nowrap" class="ft72">&#160; &#160;Cmax&#160;↓&#160;52%&#160;</p>
<p style="position:absolute;top:243px;left:325px;white-space:nowrap" class="ft72">&#160; &#160;Cτ&#160;↓&#160;88%&#160;</p>
<p style="position:absolute;top:262px;left:325px;white-space:nowrap" class="ft72">&#160;</p>
<p style="position:absolute;top:281px;left:325px;white-space:nowrap" class="ft72">Etravirine&#160;↔&#160;</p>
<p style="position:absolute;top:301px;left:325px;white-space:nowrap" class="ft72">(induction of&#160;UGT1A1&#160;</p>
<p style="position:absolute;top:320px;left:325px;white-space:nowrap" class="ft72">and CYP3A&#160;enzymes)&#160;</p>
<p style="position:absolute;top:184px;left:516px;white-space:nowrap" class="ft72">Etravirine&#160;without&#160;boosted&#160;protease&#160;</p>
<p style="position:absolute;top:203px;left:516px;white-space:nowrap" class="ft72">inhibitors&#160;decreased&#160;plasma&#160;dolutegravir&#160;</p>
<p style="position:absolute;top:223px;left:516px;white-space:nowrap" class="ft72">concentration.&#160;The recommended&#160;dose&#160;</p>
<p style="position:absolute;top:243px;left:516px;white-space:nowrap" class="ft72">of&#160;dolutegravir&#160;is&#160;50&#160;mg&#160;twice&#160;daily&#160;for&#160;</p>
<p style="position:absolute;top:262px;left:516px;white-space:nowrap" class="ft72">patients&#160;taking etravirine&#160;without&#160;</p>
<p style="position:absolute;top:281px;left:516px;white-space:nowrap" class="ft72">boosted&#160;protease&#160;inhibitors.&#160;As&#160;Dovato&#160;</p>
<p style="position:absolute;top:301px;left:516px;white-space:nowrap" class="ft72">is&#160;a fixed-dose&#160;tablet, an&#160;additional&#160;</p>
<p style="position:absolute;top:320px;left:516px;white-space:nowrap" class="ft72">50&#160;mg&#160;tablet&#160;of&#160;dolutegravir&#160;should be&#160;</p>
<p style="position:absolute;top:340px;left:516px;white-space:nowrap" class="ft72">administered, approximately 12&#160;hours&#160;</p>
<p style="position:absolute;top:360px;left:516px;white-space:nowrap" class="ft72">after&#160;Dovato&#160;for&#160;the&#160;duration of&#160;the&#160;</p>
<p style="position:absolute;top:379px;left:516px;white-space:nowrap" class="ft72">etravirine&#160;without&#160;boosted&#160;protease&#160;</p>
<p style="position:absolute;top:398px;left:516px;white-space:nowrap" class="ft72">inhibitor&#160;co-administration&#160;(a&#160;separate&#160;</p>
<p style="position:absolute;top:418px;left:516px;white-space:nowrap" class="ft72">formulation of&#160;dolutegravir&#160;is available&#160;</p>
<p style="position:absolute;top:437px;left:516px;white-space:nowrap" class="ft72">for&#160;this&#160;dose&#160;adjustment, see&#160;section&#160;</p>
<p style="position:absolute;top:457px;left:516px;white-space:nowrap" class="ft72">4.2).&#160;&#160;</p>
<p style="position:absolute;top:477px;left:94px;white-space:nowrap" class="ft72">Lopinavir+ritonavir+etravirine/&#160;</p>
<p style="position:absolute;top:497px;left:94px;white-space:nowrap" class="ft72">Dolutegravir&#160;</p>
<p style="position:absolute;top:477px;left:325px;white-space:nowrap" class="ft72">Dolutegravir&#160;↔&#160;</p>
<p style="position:absolute;top:497px;left:325px;white-space:nowrap" class="ft72">&#160; &#160;AUC&#160;↑&#160;11%&#160;</p>
<p style="position:absolute;top:516px;left:325px;white-space:nowrap" class="ft72">&#160; &#160;Cmax&#160;↑&#160;7%&#160;</p>
<p style="position:absolute;top:536px;left:325px;white-space:nowrap" class="ft72">&#160; &#160;Cτ&#160;↑&#160;28%&#160;</p>
<p style="position:absolute;top:555px;left:325px;white-space:nowrap" class="ft72">&#160;</p>
<p style="position:absolute;top:574px;left:325px;white-space:nowrap" class="ft72">Lopinavir&#160;↔&#160;</p>
<p style="position:absolute;top:594px;left:325px;white-space:nowrap" class="ft72">Ritonavir&#160;↔&#160;</p>
<p style="position:absolute;top:613px;left:325px;white-space:nowrap" class="ft72">Etravirine&#160;↔&#160;</p>
<p style="position:absolute;top:477px;left:516px;white-space:nowrap" class="ft72">No&#160;dose adjustment&#160;is necessary.&#160;</p>
<p style="position:absolute;top:633px;left:94px;white-space:nowrap" class="ft72">Darunavir+ritonavir+etravirine/&#160;</p>
<p style="position:absolute;top:653px;left:94px;white-space:nowrap" class="ft72">Dolutegravir&#160;</p>
<p style="position:absolute;top:633px;left:325px;white-space:nowrap" class="ft72">Dolutegravir&#160;↓&#160;</p>
<p style="position:absolute;top:653px;left:325px;white-space:nowrap" class="ft72">&#160; &#160;AUC&#160;↓&#160;25%&#160;</p>
<p style="position:absolute;top:673px;left:325px;white-space:nowrap" class="ft72">&#160; &#160;Cmax&#160;↓&#160;12%&#160;</p>
<p style="position:absolute;top:692px;left:325px;white-space:nowrap" class="ft72">&#160; &#160;Cτ&#160;↓&#160;36%&#160;</p>
<p style="position:absolute;top:711px;left:325px;white-space:nowrap" class="ft72">&#160;</p>
<p style="position:absolute;top:730px;left:325px;white-space:nowrap" class="ft72">Darunavir&#160;↔&#160;</p>
<p style="position:absolute;top:750px;left:325px;white-space:nowrap" class="ft72">Ritonavir&#160;↔&#160;</p>
<p style="position:absolute;top:769px;left:325px;white-space:nowrap" class="ft72">Etravirine&#160;↔&#160;</p>
<p style="position:absolute;top:633px;left:516px;white-space:nowrap" class="ft72">No&#160;dose adjustment&#160;is&#160;necessary.&#160;</p>
<p style="position:absolute;top:790px;left:94px;white-space:nowrap" class="ft72">Efavirenz/Dolutegravir&#160;</p>
<p style="position:absolute;top:791px;left:325px;white-space:nowrap" class="ft72">Dolutegravir&#160;↓&#160;</p>
<p style="position:absolute;top:811px;left:325px;white-space:nowrap" class="ft72">&#160; &#160;AUC&#160;↓&#160;57%&#160;</p>
<p style="position:absolute;top:831px;left:325px;white-space:nowrap" class="ft72">&#160; &#160;Cmax&#160;↓&#160;39%&#160;</p>
<p style="position:absolute;top:851px;left:325px;white-space:nowrap" class="ft72">&#160; &#160;Cτ&#160;↓&#160;75%&#160;</p>
<p style="position:absolute;top:870px;left:325px;white-space:nowrap" class="ft72">&#160;</p>
<p style="position:absolute;top:889px;left:325px;white-space:nowrap" class="ft72">Efavirenz&#160;↔&#160;(historical&#160;</p>
<p style="position:absolute;top:909px;left:325px;white-space:nowrap" class="ft72">controls)&#160;</p>
<p style="position:absolute;top:929px;left:325px;white-space:nowrap" class="ft72">(induction of&#160;UGT1A1&#160;</p>
<p style="position:absolute;top:948px;left:325px;white-space:nowrap" class="ft72">and CYP3A&#160;enzymes)&#160;</p>
<p style="position:absolute;top:790px;left:516px;white-space:nowrap" class="ft72">The&#160;recommended dose&#160;of&#160;dolutegravir&#160;</p>
<p style="position:absolute;top:809px;left:516px;white-space:nowrap" class="ft72">is&#160;50&#160;mg&#160;twice&#160;daily when&#160;</p>
<p style="position:absolute;top:829px;left:516px;white-space:nowrap" class="ft72">co-administered&#160;with&#160;efavirenz.&#160;As&#160;</p>
<p style="position:absolute;top:848px;left:516px;white-space:nowrap" class="ft72">Dovato&#160;is a&#160;fixed-dose&#160;tablet, an&#160;</p>
<p style="position:absolute;top:868px;left:516px;white-space:nowrap" class="ft72">additional&#160;50&#160;mg tablet&#160;of&#160;dolutegravir&#160;</p>
<p style="position:absolute;top:887px;left:516px;white-space:nowrap" class="ft72">should be&#160;administered, approximately&#160;</p>
<p style="position:absolute;top:907px;left:516px;white-space:nowrap" class="ft72">12&#160;hours&#160;after&#160;Dovato&#160;for&#160;the&#160;duration of&#160;</p>
<p style="position:absolute;top:926px;left:516px;white-space:nowrap" class="ft72">the&#160;efavirenz&#160;co-administration (a&#160;</p>
<p style="position:absolute;top:946px;left:516px;white-space:nowrap" class="ft72">separate formulation&#160;of&#160;dolutegravir&#160;is&#160;</p>
<p style="position:absolute;top:965px;left:516px;white-space:nowrap" class="ft72">available for&#160;this&#160;dose&#160;adjustment,&#160;see&#160;</p>
<p style="position:absolute;top:985px;left:516px;white-space:nowrap" class="ft72">section 4.2).&#160;&#160;</p>
<p style="position:absolute;top:1005px;left:94px;white-space:nowrap" class="ft72">Nevirapine/Dolutegravir&#160;</p>
<p style="position:absolute;top:1005px;left:325px;white-space:nowrap" class="ft72">Dolutegravir&#160;↓&#160;</p>
<p style="position:absolute;top:1024px;left:325px;white-space:nowrap" class="ft72">(Not studied,&#160;a&#160;similar&#160;</p>
<p style="position:absolute;top:1044px;left:325px;white-space:nowrap" class="ft72">reduction in exposure&#160;as&#160;</p>
<p style="position:absolute;top:1064px;left:325px;white-space:nowrap" class="ft72">observed&#160;with efavirenz&#160;is&#160;</p>
<p style="position:absolute;top:1083px;left:325px;white-space:nowrap" class="ft72">expected, due&#160;to&#160;</p>
<p style="position:absolute;top:1102px;left:325px;white-space:nowrap" class="ft72">induction)&#160;</p>
<p style="position:absolute;top:1005px;left:516px;white-space:nowrap" class="ft72">The&#160;recommended dose&#160;of&#160;dolutegravir&#160;</p>
<p style="position:absolute;top:1024px;left:516px;white-space:nowrap" class="ft72">is&#160;50&#160;mg&#160;twice&#160;daily when&#160;</p>
<p style="position:absolute;top:1044px;left:516px;white-space:nowrap" class="ft72">co-administered&#160;with nevirapine. As&#160;</p>
<p style="position:absolute;top:1064px;left:516px;white-space:nowrap" class="ft72">Dovato&#160;is a&#160;fixed-dose&#160;tablet, an&#160;</p>
<p style="position:absolute;top:1083px;left:516px;white-space:nowrap" class="ft72">additional&#160;50&#160;mg tablet&#160;of&#160;dolutegravir&#160;</p>
<p style="position:absolute;top:1102px;left:516px;white-space:nowrap" class="ft72">should be&#160;administered, approximately&#160;</p>
<p style="position:absolute;top:1122px;left:516px;white-space:nowrap" class="ft72">12&#160;hours&#160;after&#160;Dovato&#160;for&#160;the&#160;duration of&#160;</p>
<p style="position:absolute;top:1141px;left:516px;white-space:nowrap" class="ft72">the&#160;nevirapine&#160;co-administration (a&#160;</p>
</div>
<!-- Page 8 -->
<a name="8"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft810{font-size:18px;font-family:LIVBSS+SymbolMT;color:#000000;}
-->
</style>
<div id="page8-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1191px;left:439px;white-space:nowrap" class="ft80">8&#160;</p>
<p style="position:absolute;top:84px;left:516px;white-space:nowrap" class="ft82">separate formulation of&#160;dolutegravir&#160;is&#160;</p>
<p style="position:absolute;top:104px;left:516px;white-space:nowrap" class="ft82">available for&#160;this&#160;dose&#160;adjustment,&#160;see&#160;</p>
<p style="position:absolute;top:123px;left:516px;white-space:nowrap" class="ft82">section 4.2).&#160;&#160;</p>
<p style="position:absolute;top:144px;left:94px;white-space:nowrap" class="ft82">Rilpivirine/Dolutegravir&#160;</p>
<p style="position:absolute;top:144px;left:325px;white-space:nowrap" class="ft82">Dolutegravir&#160;↔&#160;</p>
<p style="position:absolute;top:163px;left:325px;white-space:nowrap" class="ft82">&#160; &#160;AUC&#160;↑&#160;12%&#160;</p>
<p style="position:absolute;top:182px;left:325px;white-space:nowrap" class="ft82">&#160; &#160;Cmax&#160;↑&#160;13%&#160;</p>
<p style="position:absolute;top:202px;left:325px;white-space:nowrap" class="ft82">&#160; &#160;Cτ&#160;↑&#160;22%&#160;</p>
<p style="position:absolute;top:221px;left:325px;white-space:nowrap" class="ft82">Rilpivirine&#160;↔&#160;</p>
<p style="position:absolute;top:144px;left:516px;white-space:nowrap" class="ft82">No&#160;dose adjustment&#160;is necessary.&#160;</p>
<p style="position:absolute;top:242px;left:94px;white-space:nowrap" class="ft85"><i>Nucleoside&#160;reverse transcriptase&#160;inhibitors (NRTIs)&#160;</i></p>
<p style="position:absolute;top:262px;left:94px;white-space:nowrap" class="ft82">Tenofovir&#160;disoproxil&#160;&#160;</p>
<p style="position:absolute;top:281px;left:94px;white-space:nowrap" class="ft82">&#160;</p>
<p style="position:absolute;top:301px;left:94px;white-space:nowrap" class="ft82">&#160;</p>
<p style="position:absolute;top:320px;left:94px;white-space:nowrap" class="ft82">&#160;</p>
<p style="position:absolute;top:340px;left:94px;white-space:nowrap" class="ft82">&#160;</p>
<p style="position:absolute;top:360px;left:94px;white-space:nowrap" class="ft82">&#160;</p>
<p style="position:absolute;top:379px;left:94px;white-space:nowrap" class="ft82">&#160;</p>
<p style="position:absolute;top:398px;left:94px;white-space:nowrap" class="ft82">Emtricitabine, didanosine,&#160;</p>
<p style="position:absolute;top:418px;left:94px;white-space:nowrap" class="ft82">stavudine,&#160;tenofovir&#160;</p>
<p style="position:absolute;top:437px;left:94px;white-space:nowrap" class="ft82">alafenamide,&#160;zidovudine&#160;</p>
<p style="position:absolute;top:262px;left:325px;white-space:nowrap" class="ft82">Dolutegravir&#160;↔&#160;</p>
<p style="position:absolute;top:281px;left:325px;white-space:nowrap" class="ft82">&#160; &#160;AUC&#160;↑&#160;1%&#160;</p>
<p style="position:absolute;top:301px;left:325px;white-space:nowrap" class="ft82">&#160; &#160;Cmax&#160;↓&#160;3%&#160;</p>
<p style="position:absolute;top:320px;left:325px;white-space:nowrap" class="ft82">&#160; &#160;Cτ&#160;↓&#160;8%&#160;</p>
<p style="position:absolute;top:340px;left:325px;white-space:nowrap" class="ft82">Tenofovir&#160;↔&#160;</p>
<p style="position:absolute;top:360px;left:325px;white-space:nowrap" class="ft82">&#160;</p>
<p style="position:absolute;top:379px;left:325px;white-space:nowrap" class="ft82">&#160;</p>
<p style="position:absolute;top:398px;left:325px;white-space:nowrap" class="ft82">Interaction not&#160;studied&#160;</p>
<p style="position:absolute;top:418px;left:325px;white-space:nowrap" class="ft82">&#160;</p>
<p style="position:absolute;top:262px;left:516px;white-space:nowrap" class="ft82">No&#160;dose adjustment&#160;is necessary&#160;when&#160;</p>
<p style="position:absolute;top:281px;left:516px;white-space:nowrap" class="ft82">Dovato&#160;is&#160;combined with&#160;tenofovir,&#160;</p>
<p style="position:absolute;top:301px;left:516px;white-space:nowrap" class="ft82">didanosine, stavudine&#160;or&#160;zidovudine.&#160;</p>
<p style="position:absolute;top:320px;left:516px;white-space:nowrap" class="ft82">&#160;</p>
<p style="position:absolute;top:340px;left:516px;white-space:nowrap" class="ft82">Dovato&#160;is&#160;not&#160;recommended&#160;for&#160;use&#160;in&#160;</p>
<p style="position:absolute;top:360px;left:516px;white-space:nowrap" class="ft82">combination with emtricitabine&#160;</p>
<p style="position:absolute;top:379px;left:516px;white-space:nowrap" class="ft82">containing products,&#160;since&#160;both&#160;</p>
<p style="position:absolute;top:398px;left:516px;white-space:nowrap" class="ft82">lamivudine&#160;(in&#160;Dovato)&#160;and&#160;</p>
<p style="position:absolute;top:418px;left:516px;white-space:nowrap" class="ft82">emtricitabine are&#160;cytidine&#160;analogues&#160;(i.e.&#160;</p>
<p style="position:absolute;top:437px;left:516px;white-space:nowrap" class="ft82">risk&#160;for&#160;intracellular&#160;interactions),&#160;see&#160;</p>
<p style="position:absolute;top:457px;left:516px;white-space:nowrap" class="ft82">section 4.4.&#160;</p>
<p style="position:absolute;top:478px;left:94px;white-space:nowrap" class="ft85"><i>Protease&#160;inhibitors&#160;</i></p>
<p style="position:absolute;top:497px;left:94px;white-space:nowrap" class="ft82">Atazanavir/Dolutegravir&#160;</p>
<p style="position:absolute;top:498px;left:325px;white-space:nowrap" class="ft82">Dolutegravir&#160;↑&#160;</p>
<p style="position:absolute;top:519px;left:325px;white-space:nowrap" class="ft82">&#160; &#160;AUC&#160;↑&#160;91%&#160;</p>
<p style="position:absolute;top:539px;left:325px;white-space:nowrap" class="ft82">&#160; &#160;Cmax&#160;↑&#160;50%&#160;</p>
<p style="position:absolute;top:559px;left:325px;white-space:nowrap" class="ft82">&#160; &#160;Cτ&#160;↑&#160;180%&#160;</p>
<p style="position:absolute;top:578px;left:325px;white-space:nowrap" class="ft82">&#160;</p>
<p style="position:absolute;top:598px;left:325px;white-space:nowrap" class="ft82">Atazanavir&#160;↔&#160;(historical&#160;</p>
<p style="position:absolute;top:617px;left:325px;white-space:nowrap" class="ft82">controls)&#160;</p>
<p style="position:absolute;top:636px;left:325px;white-space:nowrap" class="ft82">(inhibition of&#160;UGT1A1&#160;</p>
<p style="position:absolute;top:655px;left:325px;white-space:nowrap" class="ft82">and CYP3A&#160;enzymes)&#160;</p>
<p style="position:absolute;top:497px;left:516px;white-space:nowrap" class="ft82">No&#160;dose adjustment&#160;is necessary.&#160;</p>
<p style="position:absolute;top:675px;left:94px;white-space:nowrap" class="ft82">Atazanavir+&#160;ritonavir/&#160;</p>
<p style="position:absolute;top:694px;left:94px;white-space:nowrap" class="ft82">Dolutegravir&#160;</p>
<p style="position:absolute;top:675px;left:325px;white-space:nowrap" class="ft82">Dolutegravir&#160;↑&#160;</p>
<p style="position:absolute;top:695px;left:325px;white-space:nowrap" class="ft82">&#160; &#160;AUC&#160;↑&#160;62%&#160;</p>
<p style="position:absolute;top:714px;left:325px;white-space:nowrap" class="ft82">&#160; &#160;Cmax&#160;↑&#160;34%&#160;</p>
<p style="position:absolute;top:734px;left:325px;white-space:nowrap" class="ft82">&#160; &#160;Cτ&#160;↑&#160;121%&#160;</p>
<p style="position:absolute;top:753px;left:325px;white-space:nowrap" class="ft82">&#160;</p>
<p style="position:absolute;top:774px;left:325px;white-space:nowrap" class="ft82">Atazanavir&#160;↔&#160;</p>
<p style="position:absolute;top:794px;left:325px;white-space:nowrap" class="ft82">Ritonavir&#160;↔&#160;</p>
<p style="position:absolute;top:675px;left:516px;white-space:nowrap" class="ft82">No&#160;dose adjustment&#160;is necessary.&#160;</p>
<p style="position:absolute;top:813px;left:94px;white-space:nowrap" class="ft82">Tipranavir+ritonavir/&#160;</p>
<p style="position:absolute;top:833px;left:94px;white-space:nowrap" class="ft82">Dolutegravir&#160;</p>
<p style="position:absolute;top:815px;left:325px;white-space:nowrap" class="ft82">Dolutegravir&#160;↓&#160;</p>
<p style="position:absolute;top:835px;left:325px;white-space:nowrap" class="ft82">&#160; &#160;AUC&#160;↓&#160;59%&#160;</p>
<p style="position:absolute;top:855px;left:325px;white-space:nowrap" class="ft82">&#160; &#160;Cmax&#160;↓&#160;47%&#160;</p>
<p style="position:absolute;top:877px;left:325px;white-space:nowrap" class="ft82">&#160; &#160;Cτ&#160;↓&#160;76%&#160;</p>
<p style="position:absolute;top:896px;left:325px;white-space:nowrap" class="ft82">&#160;</p>
<p style="position:absolute;top:916px;left:325px;white-space:nowrap" class="ft82">Tipranavir&#160;↔&#160;</p>
<p style="position:absolute;top:937px;left:325px;white-space:nowrap" class="ft82">Ritonavir&#160;↔&#160;</p>
<p style="position:absolute;top:956px;left:325px;white-space:nowrap" class="ft82">(induction of&#160;UGT1A1&#160;</p>
<p style="position:absolute;top:975px;left:325px;white-space:nowrap" class="ft82">and CYP3A&#160;enzymes)&#160;</p>
<p style="position:absolute;top:814px;left:516px;white-space:nowrap" class="ft82">The&#160;recommended dose&#160;of&#160;dolutegravir&#160;</p>
<p style="position:absolute;top:833px;left:516px;white-space:nowrap" class="ft82">is&#160;50&#160;mg&#160;twice&#160;daily when&#160;</p>
<p style="position:absolute;top:853px;left:516px;white-space:nowrap" class="ft82">co&#160;administered&#160;with&#160;</p>
<p style="position:absolute;top:872px;left:516px;white-space:nowrap" class="ft82">tipranavir/ritonavir. As&#160;Dovato&#160;is&#160;a&#160;</p>
<p style="position:absolute;top:892px;left:516px;white-space:nowrap" class="ft82">fixed-dose&#160;tablet,&#160;an additional&#160;50&#160;mg&#160;</p>
<p style="position:absolute;top:911px;left:516px;white-space:nowrap" class="ft82">tablet&#160;of&#160;dolutegravir&#160;should&#160;be&#160;</p>
<p style="position:absolute;top:931px;left:516px;white-space:nowrap" class="ft82">administered, approximately 12&#160;hours&#160;</p>
<p style="position:absolute;top:950px;left:516px;white-space:nowrap" class="ft82">after&#160;Dovato&#160;for&#160;the&#160;duration of&#160;the&#160;</p>
<p style="position:absolute;top:970px;left:516px;white-space:nowrap" class="ft82">tipranavir/ritonavir&#160;co-administration (a&#160;</p>
<p style="position:absolute;top:989px;left:516px;white-space:nowrap" class="ft82">separate formulation of&#160;dolutegravir&#160;is&#160;</p>
<p style="position:absolute;top:1009px;left:516px;white-space:nowrap" class="ft82">available for&#160;this&#160;dose&#160;adjustment,&#160;see&#160;</p>
<p style="position:absolute;top:1028px;left:516px;white-space:nowrap" class="ft82">section 4.2).&#160;&#160;</p>
<p style="position:absolute;top:1048px;left:94px;white-space:nowrap" class="ft82">Fosamprenavir+ritonavir/&#160;</p>
<p style="position:absolute;top:1067px;left:94px;white-space:nowrap" class="ft82">Dolutegravir&#160;</p>
<p style="position:absolute;top:1049px;left:325px;white-space:nowrap" class="ft82">Dolutegravir↓&#160;</p>
<p style="position:absolute;top:1070px;left:325px;white-space:nowrap" class="ft82">&#160; &#160;AUC&#160;↓&#160;35%&#160;</p>
<p style="position:absolute;top:1090px;left:325px;white-space:nowrap" class="ft82">&#160; &#160;Cmax&#160;↓&#160;24%&#160;</p>
<p style="position:absolute;top:1110px;left:325px;white-space:nowrap" class="ft82">&#160; &#160;Cτ&#160;↓&#160;49%&#160;</p>
<p style="position:absolute;top:1129px;left:325px;white-space:nowrap" class="ft82">&#160;</p>
<p style="position:absolute;top:1149px;left:325px;white-space:nowrap" class="ft82">Fosamprenavir↔&#160;</p>
<p style="position:absolute;top:1049px;left:516px;white-space:nowrap" class="ft82">Fosamprenavir/ritonavir&#160;decreases&#160;</p>
<p style="position:absolute;top:1068px;left:516px;white-space:nowrap" class="ft82">dolutegravir&#160;concentrations, but&#160;based&#160;</p>
<p style="position:absolute;top:1088px;left:516px;white-space:nowrap" class="ft82">on limited data, did not&#160;result&#160;in&#160;</p>
<p style="position:absolute;top:1107px;left:516px;white-space:nowrap" class="ft82">decreased&#160;efficacy&#160;in&#160;Phase&#160;III&#160;studies.&#160;</p>
<p style="position:absolute;top:1127px;left:516px;white-space:nowrap" class="ft82">No&#160;dose adjustment&#160;is necessary.&#160;&#160;</p>
</div>
<!-- Page 9 -->
<a name="9"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page9-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1191px;left:439px;white-space:nowrap" class="ft90">9&#160;</p>
<p style="position:absolute;top:85px;left:325px;white-space:nowrap" class="ft92">Ritonavir&#160;↔&#160;</p>
<p style="position:absolute;top:104px;left:325px;white-space:nowrap" class="ft92">(induction of&#160;UGT1A1&#160;</p>
<p style="position:absolute;top:123px;left:325px;white-space:nowrap" class="ft92">and CYP3A&#160;enzymes)&#160;</p>
<p style="position:absolute;top:143px;left:94px;white-space:nowrap" class="ft92">Lopinavir+ritonavir/&#160;</p>
<p style="position:absolute;top:162px;left:94px;white-space:nowrap" class="ft92">Dolutegravir&#160;</p>
<p style="position:absolute;top:143px;left:325px;white-space:nowrap" class="ft92">Dolutegravir&#160;↔&#160;</p>
<p style="position:absolute;top:163px;left:325px;white-space:nowrap" class="ft92">&#160; &#160;AUC&#160;↓&#160;4%&#160;</p>
<p style="position:absolute;top:182px;left:325px;white-space:nowrap" class="ft92">&#160; &#160;Cmax&#160;↔&#160;0%&#160;</p>
<p style="position:absolute;top:202px;left:325px;white-space:nowrap" class="ft92">&#160; &#160;C24&#160;↓&#160;6%&#160;</p>
<p style="position:absolute;top:221px;left:325px;white-space:nowrap" class="ft92">&#160;</p>
<p style="position:absolute;top:241px;left:325px;white-space:nowrap" class="ft92">Lopinavir&#160;↔&#160;</p>
<p style="position:absolute;top:261px;left:325px;white-space:nowrap" class="ft92">Ritonavir&#160;↔&#160;</p>
<p style="position:absolute;top:143px;left:516px;white-space:nowrap" class="ft92">No&#160;dose adjustment&#160;is necessary.&#160;</p>
<p style="position:absolute;top:281px;left:94px;white-space:nowrap" class="ft92">Darunavir+ritonavir/&#160;</p>
<p style="position:absolute;top:300px;left:94px;white-space:nowrap" class="ft92">Dolutegravir&#160;</p>
<p style="position:absolute;top:281px;left:325px;white-space:nowrap" class="ft92">Dolutegravir&#160;↓&#160;</p>
<p style="position:absolute;top:301px;left:325px;white-space:nowrap" class="ft92">&#160; &#160;AUC&#160;↓&#160;22%&#160;&#160;</p>
<p style="position:absolute;top:320px;left:325px;white-space:nowrap" class="ft92">&#160; &#160;Cmax&#160;↓&#160;11%&#160;</p>
<p style="position:absolute;top:340px;left:325px;white-space:nowrap" class="ft92">&#160; &#160;Cτ&#160;↓&#160;38%&#160;</p>
<p style="position:absolute;top:359px;left:325px;white-space:nowrap" class="ft92">&#160;</p>
<p style="position:absolute;top:379px;left:325px;white-space:nowrap" class="ft92">Darunavir&#160;↔&#160;</p>
<p style="position:absolute;top:399px;left:325px;white-space:nowrap" class="ft92">Ritonavir&#160;↔&#160;</p>
<p style="position:absolute;top:418px;left:325px;white-space:nowrap" class="ft92">(induction of&#160;UGT1A1&#160;</p>
<p style="position:absolute;top:437px;left:325px;white-space:nowrap" class="ft92">and CYP3A&#160;enzymes)&#160;</p>
<p style="position:absolute;top:281px;left:516px;white-space:nowrap" class="ft92">No&#160;dose adjustment&#160;is&#160;necessary.&#160;</p>
<p style="position:absolute;top:457px;left:94px;white-space:nowrap" class="ft91"><b>Other antiviral&#160;active substances&#160;</b></p>
<p style="position:absolute;top:478px;left:94px;white-space:nowrap" class="ft92">Daclatasvir/Dolutegravir&#160;</p>
<p style="position:absolute;top:478px;left:325px;white-space:nowrap" class="ft92">Dolutegravir&#160;↔&#160;</p>
<p style="position:absolute;top:499px;left:325px;white-space:nowrap" class="ft92">&#160; &#160;AUC&#160;↑&#160;33%&#160;&#160;</p>
<p style="position:absolute;top:519px;left:325px;white-space:nowrap" class="ft92">&#160; &#160;Cmax&#160;↑&#160;29%&#160;</p>
<p style="position:absolute;top:539px;left:325px;white-space:nowrap" class="ft92">&#160; &#160;Cτ&#160;↑&#160;45%&#160;</p>
<p style="position:absolute;top:559px;left:325px;white-space:nowrap" class="ft92">Daclatasvir&#160;↔&#160;</p>
<p style="position:absolute;top:478px;left:516px;white-space:nowrap" class="ft92">Daclatasvir&#160;did not&#160;change&#160;dolutegravir&#160;</p>
<p style="position:absolute;top:497px;left:516px;white-space:nowrap" class="ft92">plasma&#160;concentration&#160;to&#160;a&#160;clinically&#160;</p>
<p style="position:absolute;top:517px;left:516px;white-space:nowrap" class="ft92">relevant&#160;extent.&#160;Dolutegravir&#160;did&#160;not&#160;</p>
<p style="position:absolute;top:536px;left:516px;white-space:nowrap" class="ft92">change&#160;daclatasvir&#160;plasma&#160;concentration.&#160;</p>
<p style="position:absolute;top:556px;left:516px;white-space:nowrap" class="ft92">No&#160;dose adjustment&#160;is necessary.&#160;</p>
<p style="position:absolute;top:579px;left:94px;white-space:nowrap" class="ft92">Ledipasvir/Sofosbuvir/&#160;</p>
<p style="position:absolute;top:599px;left:94px;white-space:nowrap" class="ft92">Lamivudine&#160;(with&#160;abacavir)&#160;</p>
<p style="position:absolute;top:580px;left:325px;white-space:nowrap" class="ft92">Lamivudine&#160;↔&#160;</p>
<p style="position:absolute;top:601px;left:325px;white-space:nowrap" class="ft92">Ledipasvir&#160;↔&#160;</p>
<p style="position:absolute;top:621px;left:325px;white-space:nowrap" class="ft92">Sofosbuvir&#160;↔&#160;</p>
<p style="position:absolute;top:579px;left:516px;white-space:nowrap" class="ft92">No&#160;dosage&#160;adjustment&#160;necessary.&#160;</p>
<p style="position:absolute;top:641px;left:94px;white-space:nowrap" class="ft92">Sofosbuvir/&#160;</p>
<p style="position:absolute;top:660px;left:94px;white-space:nowrap" class="ft92">Velpatasvir/Dolutegravir&#160;</p>
<p style="position:absolute;top:642px;left:325px;white-space:nowrap" class="ft92">Dolutegravir&#160;↔&#160;</p>
<p style="position:absolute;top:662px;left:325px;white-space:nowrap" class="ft92">Sofosbuvir&#160;↔&#160;</p>
<p style="position:absolute;top:682px;left:325px;white-space:nowrap" class="ft92">Velpatasvir↔&#160;</p>
<p style="position:absolute;top:641px;left:516px;white-space:nowrap" class="ft92">No&#160;dosage&#160;adjustment&#160;necessary.&#160;</p>
<p style="position:absolute;top:702px;left:94px;white-space:nowrap" class="ft92">Ribavirin&#160;</p>
<p style="position:absolute;top:702px;left:325px;white-space:nowrap" class="ft92">Interaction not&#160;studied.&#160;</p>
<p style="position:absolute;top:721px;left:325px;white-space:nowrap" class="ft92">&#160;</p>
<p style="position:absolute;top:740px;left:325px;white-space:nowrap" class="ft92">Clinically&#160;significant&#160;</p>
<p style="position:absolute;top:759px;left:325px;white-space:nowrap" class="ft92">interaction unlikely.&#160;</p>
<p style="position:absolute;top:702px;left:516px;white-space:nowrap" class="ft92">No&#160;dosage&#160;adjustment&#160;necessary.&#160;</p>
<p style="position:absolute;top:779px;left:94px;white-space:nowrap" class="ft91"><b>Anti-infective products</b>&#160;</p>
<p style="position:absolute;top:799px;left:94px;white-space:nowrap" class="ft92">Trimethoprim/sulfamethoxazole&#160;</p>
<p style="position:absolute;top:818px;left:94px;white-space:nowrap" class="ft92">(Co-trimoxazole)/Lamivudine&#160;</p>
<p style="position:absolute;top:837px;left:94px;white-space:nowrap" class="ft92">(160&#160;mg/800&#160;mg once&#160;daily&#160;for&#160;</p>
<p style="position:absolute;top:857px;left:94px;white-space:nowrap" class="ft92">5&#160;days/300&#160;mg single&#160;dose)&#160;</p>
<p style="position:absolute;top:799px;left:325px;white-space:nowrap" class="ft92">Lamivudine:&#160;&#160;</p>
<p style="position:absolute;top:819px;left:325px;white-space:nowrap" class="ft92">&#160; &#160;AUC&#160;↑&#160;43%&#160;</p>
<p style="position:absolute;top:839px;left:325px;white-space:nowrap" class="ft92">&#160; &#160;Cmax&#160;↑&#160;7%&#160;</p>
<p style="position:absolute;top:858px;left:325px;white-space:nowrap" class="ft92">&#160;</p>
<p style="position:absolute;top:877px;left:325px;white-space:nowrap" class="ft92">Trimethoprim:&#160;&#160;</p>
<p style="position:absolute;top:897px;left:325px;white-space:nowrap" class="ft92">&#160; &#160;AUC&#160;↔&#160;</p>
<p style="position:absolute;top:916px;left:325px;white-space:nowrap" class="ft92">&#160;</p>
<p style="position:absolute;top:935px;left:325px;white-space:nowrap" class="ft92">Sulfamethoxazole:&#160;&#160;</p>
<p style="position:absolute;top:955px;left:325px;white-space:nowrap" class="ft92">&#160; &#160;AUC&#160;↔&#160;</p>
<p style="position:absolute;top:975px;left:325px;white-space:nowrap" class="ft92">&#160;</p>
<p style="position:absolute;top:994px;left:325px;white-space:nowrap" class="ft92">(organic&#160;cation transporter&#160;</p>
<p style="position:absolute;top:1013px;left:325px;white-space:nowrap" class="ft92">inhibition)&#160;</p>
<p style="position:absolute;top:799px;left:516px;white-space:nowrap" class="ft92">No&#160;dosage&#160;adjustment&#160;necessary.&#160;</p>
<p style="position:absolute;top:1044px;left:94px;white-space:nowrap" class="ft91"><b>Antimycobacterials</b>&#160;</p>
<p style="position:absolute;top:1064px;left:94px;white-space:nowrap" class="ft92">Rifampicin/Dolutegravir&#160;</p>
<p style="position:absolute;top:1064px;left:325px;white-space:nowrap" class="ft92">Dolutegravir&#160;↓&#160;</p>
<p style="position:absolute;top:1083px;left:325px;white-space:nowrap" class="ft92">&#160; &#160;AUC&#160;↓&#160;54%&#160;</p>
<p style="position:absolute;top:1103px;left:325px;white-space:nowrap" class="ft92">&#160; &#160;Cmax&#160;↓&#160;43%&#160;</p>
<p style="position:absolute;top:1123px;left:325px;white-space:nowrap" class="ft92">&#160; &#160;Cτ&#160;↓&#160;72%&#160;</p>
<p style="position:absolute;top:1064px;left:516px;white-space:nowrap" class="ft92">The&#160;recommended dose&#160;of&#160;dolutegravir&#160;</p>
<p style="position:absolute;top:1083px;left:516px;white-space:nowrap" class="ft92">is&#160;50&#160;mg&#160;twice&#160;daily when&#160;</p>
<p style="position:absolute;top:1103px;left:516px;white-space:nowrap" class="ft92">co-administered&#160;with rifampicin. As&#160;</p>
<p style="position:absolute;top:1123px;left:516px;white-space:nowrap" class="ft92">Dovato&#160;is&#160;a&#160;fixed-dose&#160;tablet, an&#160;</p>
<p style="position:absolute;top:1142px;left:516px;white-space:nowrap" class="ft92">additional&#160;50&#160;mg tablet&#160;of&#160;dolutegravir&#160;</p>
</div>
<!-- Page 10 -->
<a name="10"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page10-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1191px;left:436px;white-space:nowrap" class="ft100">10&#160;</p>
<p style="position:absolute;top:84px;left:325px;white-space:nowrap" class="ft102">(induction of&#160;UGT1A1&#160;</p>
<p style="position:absolute;top:103px;left:325px;white-space:nowrap" class="ft102">and CYP3A&#160;enzymes)&#160;</p>
<p style="position:absolute;top:84px;left:516px;white-space:nowrap" class="ft102">should be&#160;administered, approximately&#160;</p>
<p style="position:absolute;top:104px;left:516px;white-space:nowrap" class="ft102">12&#160;hours&#160;after&#160;Dovato&#160;for&#160;the&#160;duration of&#160;</p>
<p style="position:absolute;top:123px;left:516px;white-space:nowrap" class="ft102">the&#160;rifampicin&#160;co-administration (a&#160;</p>
<p style="position:absolute;top:143px;left:516px;white-space:nowrap" class="ft102">separate&#160;formulation of&#160;dolutegravir&#160;is&#160;</p>
<p style="position:absolute;top:162px;left:516px;white-space:nowrap" class="ft102">available for&#160;this&#160;dose&#160;adjustment,&#160;see&#160;</p>
<p style="position:absolute;top:182px;left:516px;white-space:nowrap" class="ft102">section 4.2).&#160;&#160;</p>
<p style="position:absolute;top:202px;left:94px;white-space:nowrap" class="ft102">Rifabutin/Dolutegravir&#160;</p>
<p style="position:absolute;top:203px;left:325px;white-space:nowrap" class="ft102">Dolutegravir&#160;↔&#160;</p>
<p style="position:absolute;top:223px;left:325px;white-space:nowrap" class="ft102">&#160; &#160;AUC&#160;↓&#160;5%&#160;</p>
<p style="position:absolute;top:243px;left:325px;white-space:nowrap" class="ft102">&#160; &#160;Cmax&#160;↑&#160;16%&#160;</p>
<p style="position:absolute;top:264px;left:325px;white-space:nowrap" class="ft102">&#160; &#160;Cτ&#160;↓&#160;30%&#160;</p>
<p style="position:absolute;top:282px;left:325px;white-space:nowrap" class="ft102">(induction of&#160;UGT1A1&#160;</p>
<p style="position:absolute;top:301px;left:325px;white-space:nowrap" class="ft102">and CYP3A&#160;enzymes)&#160;</p>
<p style="position:absolute;top:202px;left:516px;white-space:nowrap" class="ft102">No&#160;dose adjustment&#160;is necessary.&#160;</p>
<p style="position:absolute;top:321px;left:94px;white-space:nowrap" class="ft101"><b>Anticonvulsants</b>&#160;</p>
<p style="position:absolute;top:342px;left:94px;white-space:nowrap" class="ft102">Carbamazepine/Dolutegravir&#160;</p>
<p style="position:absolute;top:342px;left:325px;white-space:nowrap" class="ft102">Dolutegravir&#160;↓&#160;</p>
<p style="position:absolute;top:361px;left:325px;white-space:nowrap" class="ft102">&#160; &#160;AUC&#160;↓&#160;49%&#160;</p>
<p style="position:absolute;top:381px;left:325px;white-space:nowrap" class="ft102">&#160; &#160;Cmax&#160;↓&#160;33%&#160;</p>
<p style="position:absolute;top:400px;left:325px;white-space:nowrap" class="ft102">&#160; &#160;Cτ&#160;↓&#160;73%&#160;</p>
<p style="position:absolute;top:420px;left:325px;white-space:nowrap" class="ft102">&#160;</p>
<p style="position:absolute;top:342px;left:516px;white-space:nowrap" class="ft102">The&#160;recommended dose&#160;of&#160;dolutegravir&#160;</p>
<p style="position:absolute;top:361px;left:516px;white-space:nowrap" class="ft102">is&#160;50&#160;mg&#160;twice&#160;daily when&#160;</p>
<p style="position:absolute;top:381px;left:516px;white-space:nowrap" class="ft102">co-administered&#160;with&#160;these&#160;metabolic&#160;</p>
<p style="position:absolute;top:400px;left:516px;white-space:nowrap" class="ft102">inducers. As&#160;Dovato&#160;is&#160;a fixed-dose&#160;</p>
<p style="position:absolute;top:420px;left:516px;white-space:nowrap" class="ft102">tablet,&#160;an additional&#160;50&#160;mg&#160;tablet&#160;of&#160;</p>
<p style="position:absolute;top:439px;left:516px;white-space:nowrap" class="ft102">dolutegravir&#160;should be&#160;administered,&#160;</p>
<p style="position:absolute;top:459px;left:516px;white-space:nowrap" class="ft102">approximately 12&#160;hours&#160;after&#160;Dovato&#160;for&#160;</p>
<p style="position:absolute;top:478px;left:516px;white-space:nowrap" class="ft102">the&#160;duration&#160;of&#160;the&#160;co-administration&#160;</p>
<p style="position:absolute;top:498px;left:516px;white-space:nowrap" class="ft102">with&#160;these metabolic inducers (a&#160;separate&#160;</p>
<p style="position:absolute;top:517px;left:516px;white-space:nowrap" class="ft102">formulation of&#160;dolutegravir&#160;is available&#160;</p>
<p style="position:absolute;top:537px;left:516px;white-space:nowrap" class="ft102">for&#160;this dose adjustment,&#160;see section&#160;</p>
<p style="position:absolute;top:556px;left:516px;white-space:nowrap" class="ft102">4.2).&#160;&#160;</p>
<p style="position:absolute;top:440px;left:94px;white-space:nowrap" class="ft102">Phenobarbital/Dolutegravir&#160;</p>
<p style="position:absolute;top:460px;left:94px;white-space:nowrap" class="ft102">Phenytoin/Dolutegravir&#160;</p>
<p style="position:absolute;top:479px;left:94px;white-space:nowrap" class="ft102">Oxcarbazepine/Dolutegravir&#160;</p>
<p style="position:absolute;top:498px;left:94px;white-space:nowrap" class="ft102">&#160;</p>
<p style="position:absolute;top:440px;left:325px;white-space:nowrap" class="ft102">Dolutegravir&#160;↓&#160;</p>
<p style="position:absolute;top:460px;left:325px;white-space:nowrap" class="ft102">(Not&#160;studied, decrease&#160;</p>
<p style="position:absolute;top:479px;left:325px;white-space:nowrap" class="ft102">expected due&#160;to&#160;induction&#160;</p>
<p style="position:absolute;top:498px;left:325px;white-space:nowrap" class="ft102">of&#160;UGT1A1 and CYP3A&#160;</p>
<p style="position:absolute;top:518px;left:325px;white-space:nowrap" class="ft102">enzymes,&#160;a&#160;similar&#160;</p>
<p style="position:absolute;top:538px;left:325px;white-space:nowrap" class="ft102">reduction in exposure&#160;as&#160;</p>
<p style="position:absolute;top:557px;left:325px;white-space:nowrap" class="ft102">observed with&#160;</p>
<p style="position:absolute;top:577px;left:325px;white-space:nowrap" class="ft102">carbamazepine&#160;is&#160;</p>
<p style="position:absolute;top:596px;left:325px;white-space:nowrap" class="ft102">expected).&#160;</p>
<p style="position:absolute;top:616px;left:94px;white-space:nowrap" class="ft101"><b>Antihistamines (histamine&#160;H2&#160;receptor&#160;antagonists)</b>&#160;</p>
<p style="position:absolute;top:637px;left:94px;white-space:nowrap" class="ft102">Ranitidine&#160;</p>
<p style="position:absolute;top:636px;left:325px;white-space:nowrap" class="ft102">Interaction not&#160;studied.&#160;</p>
<p style="position:absolute;top:655px;left:325px;white-space:nowrap" class="ft102">&#160;</p>
<p style="position:absolute;top:675px;left:325px;white-space:nowrap" class="ft102">Clinically&#160;significant&#160;</p>
<p style="position:absolute;top:694px;left:325px;white-space:nowrap" class="ft102">interaction unlikely.&#160;</p>
<p style="position:absolute;top:637px;left:516px;white-space:nowrap" class="ft102">No&#160;dosage&#160;adjustment&#160;necessary.&#160;</p>
<p style="position:absolute;top:714px;left:94px;white-space:nowrap" class="ft102">Cimetidine&#160;</p>
<p style="position:absolute;top:714px;left:325px;white-space:nowrap" class="ft102">Interaction not&#160;studied.&#160;</p>
<p style="position:absolute;top:733px;left:325px;white-space:nowrap" class="ft102">&#160;</p>
<p style="position:absolute;top:752px;left:325px;white-space:nowrap" class="ft102">Clinically&#160;significant&#160;</p>
<p style="position:absolute;top:772px;left:325px;white-space:nowrap" class="ft102">interaction unlikely.&#160;</p>
<p style="position:absolute;top:714px;left:516px;white-space:nowrap" class="ft102">No&#160;dosage&#160;adjustment&#160;necessary.&#160;</p>
<p style="position:absolute;top:792px;left:94px;white-space:nowrap" class="ft101"><b>Cytotoxics</b>&#160;</p>
<p style="position:absolute;top:812px;left:94px;white-space:nowrap" class="ft102">Cladribine/Lamivudine&#160;</p>
<p style="position:absolute;top:812px;left:325px;white-space:nowrap" class="ft102">Interaction not&#160;studied.&#160;&#160;</p>
<p style="position:absolute;top:831px;left:325px;white-space:nowrap" class="ft102">&#160;</p>
<p style="position:absolute;top:850px;left:325px;white-space:nowrap" class="ft105"><i>In&#160;vitro</i>&#160;lamivudine&#160;</p>
<p style="position:absolute;top:869px;left:325px;white-space:nowrap" class="ft102">inhibits&#160;the&#160;intracellular&#160;</p>
<p style="position:absolute;top:888px;left:325px;white-space:nowrap" class="ft102">phosphorylation of&#160;</p>
<p style="position:absolute;top:907px;left:325px;white-space:nowrap" class="ft102">cladribine&#160;leading to a&#160;</p>
<p style="position:absolute;top:926px;left:325px;white-space:nowrap" class="ft102">potential&#160;risk&#160;of&#160;cladribine&#160;</p>
<p style="position:absolute;top:945px;left:325px;white-space:nowrap" class="ft102">loss&#160;of&#160;efficacy&#160;in&#160;case of&#160;</p>
<p style="position:absolute;top:964px;left:325px;white-space:nowrap" class="ft102">combination&#160;in&#160;the&#160;</p>
<p style="position:absolute;top:982px;left:325px;white-space:nowrap" class="ft102">clinical&#160;setting.&#160;Some&#160;</p>
<p style="position:absolute;top:1002px;left:325px;white-space:nowrap" class="ft102">clinical findings&#160;also&#160;</p>
<p style="position:absolute;top:1020px;left:325px;white-space:nowrap" class="ft102">support&#160;a&#160;possible&#160;</p>
<p style="position:absolute;top:1040px;left:325px;white-space:nowrap" class="ft102">interaction between&#160;</p>
<p style="position:absolute;top:1058px;left:325px;white-space:nowrap" class="ft102">lamivudine&#160;and&#160;</p>
<p style="position:absolute;top:1078px;left:325px;white-space:nowrap" class="ft102">cladribine.&#160;</p>
<p style="position:absolute;top:812px;left:516px;white-space:nowrap" class="ft102">Concomitant&#160;use&#160;of&#160;Dovato&#160;with&#160;</p>
<p style="position:absolute;top:832px;left:516px;white-space:nowrap" class="ft102">cladribine&#160;is&#160;not&#160;recommended&#160;(see&#160;</p>
<p style="position:absolute;top:851px;left:516px;white-space:nowrap" class="ft102">section 4.4).&#160;</p>
<p style="position:absolute;top:1097px;left:94px;white-space:nowrap" class="ft101"><b>Miscellaneous</b>&#160;</p>
<p style="position:absolute;top:1118px;left:94px;white-space:nowrap" class="ft105"><i>Sorbitol&#160;</i></p>
</div>
<!-- Page 11 -->
<a name="11"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft1111{font-size:18px;font-family:FZYRME+ArialNarrow;color:#000000;}
	.ft1112{font-size:18px;font-family:FOBBME+TimesNewRomanPSMT;color:#000000;}
	.ft1113{font-size:17px;line-height:28px;font-family:DTAKKI+TimesNewRomanPSMT;color:#000000;}
	.ft1114{font-size:17px;line-height:29px;font-family:DTAKKI+TimesNewRomanPSMT;color:#000000;}
-->
</style>
<div id="page11-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1191px;left:436px;white-space:nowrap" class="ft110">11&#160;</p>
<p style="position:absolute;top:85px;left:94px;white-space:nowrap" class="ft112">Sorbitol&#160;solution (3.2</p>
<p style="position:absolute;top:84px;left:235px;white-space:nowrap" class="ft1111">&#160;g, 10.2&#160;g,&#160;</p>
<p style="position:absolute;top:106px;left:94px;white-space:nowrap" class="ft112">13.4</p>
<p style="position:absolute;top:104px;left:123px;white-space:nowrap" class="ft1111">&#160;g)/Lamivudine&#160;</p>
<p style="position:absolute;top:84px;left:325px;white-space:nowrap" class="ft112">Single&#160;dose&#160;lamivudine&#160;</p>
<p style="position:absolute;top:104px;left:325px;white-space:nowrap" class="ft1114">oral&#160;solution 300&#160;mg.&#160;&#160;<br/>Lamivudine:&#160;<br/>AUC&#160;↓&#160;14%;&#160;32%;&#160;36%&#160;&#160;<br/>Cmax&#160;↓&#160;28%;&#160;52%, 55%.&#160;</p>
<p style="position:absolute;top:84px;left:516px;white-space:nowrap" class="ft112">When possible, avoid&#160;chronic&#160;</p>
<p style="position:absolute;top:104px;left:516px;white-space:nowrap" class="ft112">coadministration&#160;of&#160;Dovato&#160;with&#160;</p>
<p style="position:absolute;top:123px;left:516px;white-space:nowrap" class="ft112">medicinal&#160;products&#160;containing sorbitol&#160;</p>
<p style="position:absolute;top:143px;left:516px;white-space:nowrap" class="ft112">or&#160;other&#160;osmotic&#160;acting&#160;poly-alcohols or&#160;</p>
<p style="position:absolute;top:162px;left:516px;white-space:nowrap" class="ft112">monosaccharide&#160;alcohols&#160;(eg:&#160;xylitol,&#160;</p>
<p style="position:absolute;top:182px;left:516px;white-space:nowrap" class="ft112">mannitol,&#160;lactitol,&#160;maltitol).&#160;Consider&#160;</p>
<p style="position:absolute;top:201px;left:516px;white-space:nowrap" class="ft112">more&#160;frequent&#160;monitoring of&#160;HIV-1 viral&#160;</p>
<p style="position:absolute;top:221px;left:516px;white-space:nowrap" class="ft112">load&#160;when&#160;chronic&#160;coadministration&#160;</p>
<p style="position:absolute;top:240px;left:516px;white-space:nowrap" class="ft112">cannot&#160;be&#160;avoided.&#160;</p>
<p style="position:absolute;top:261px;left:94px;white-space:nowrap" class="ft115"><i>Potassium&#160;channel&#160;blockers</i>&#160;</p>
<p style="position:absolute;top:280px;left:94px;white-space:nowrap" class="ft112">Fampridine&#160;(also known as&#160;</p>
<p style="position:absolute;top:299px;left:94px;white-space:nowrap" class="ft112">dalfampridine)/Dolutegravir&#160;</p>
<p style="position:absolute;top:281px;left:325px;white-space:nowrap" class="ft112">Fampridine&#160;↑&#160;</p>
<p style="position:absolute;top:300px;left:325px;white-space:nowrap" class="ft112">&#160;</p>
<p style="position:absolute;top:281px;left:516px;white-space:nowrap" class="ft112">Co-administration&#160;of&#160;dolutegravir&#160;has&#160;</p>
<p style="position:absolute;top:300px;left:516px;white-space:nowrap" class="ft112">the potential&#160;to&#160;cause seizures due&#160;to&#160;</p>
<p style="position:absolute;top:320px;left:516px;white-space:nowrap" class="ft112">increased&#160;fampridine plasma&#160;</p>
<p style="position:absolute;top:339px;left:516px;white-space:nowrap" class="ft112">concentration via&#160;inhibition&#160;of&#160;OCT2&#160;</p>
<p style="position:absolute;top:359px;left:516px;white-space:nowrap" class="ft112">transporter;&#160;co-administration&#160;has&#160;not&#160;</p>
<p style="position:absolute;top:378px;left:516px;white-space:nowrap" class="ft112">been studied. Fampridine&#160;co-</p>
<p style="position:absolute;top:398px;left:516px;white-space:nowrap" class="ft112">administration with&#160;Dovato&#160;is&#160;</p>
<p style="position:absolute;top:417px;left:516px;white-space:nowrap" class="ft112">contraindicated&#160;(see&#160;section&#160;4.3).&#160;&#160;</p>
<p style="position:absolute;top:438px;left:94px;white-space:nowrap" class="ft115"><i>Antacids&#160;and supplements&#160;</i></p>
<p style="position:absolute;top:457px;left:94px;white-space:nowrap" class="ft112">Magnesium/&#160;</p>
<p style="position:absolute;top:476px;left:94px;white-space:nowrap" class="ft112">aluminium-containing&#160;</p>
<p style="position:absolute;top:495px;left:94px;white-space:nowrap" class="ft112">antacids/Dolutegravir&#160;</p>
<p style="position:absolute;top:459px;left:325px;white-space:nowrap" class="ft112">Dolutegravir&#160;↓&#160;</p>
<p style="position:absolute;top:479px;left:325px;white-space:nowrap" class="ft112">AUC&#160;↓&#160;74%&#160;&#160;</p>
<p style="position:absolute;top:499px;left:325px;white-space:nowrap" class="ft112">Cmax&#160;↓&#160;72%&#160;</p>
<p style="position:absolute;top:518px;left:325px;white-space:nowrap" class="ft112">&#160;</p>
<p style="position:absolute;top:537px;left:325px;white-space:nowrap" class="ft112">(Complex binding to&#160;</p>
<p style="position:absolute;top:556px;left:325px;white-space:nowrap" class="ft112">polyvalent&#160;ions)&#160;</p>
<p style="position:absolute;top:458px;left:516px;white-space:nowrap" class="ft112">Magnesium/ aluminium-containing&#160;</p>
<p style="position:absolute;top:477px;left:516px;white-space:nowrap" class="ft112">antacids should&#160;be taken&#160;well&#160;separated&#160;</p>
<p style="position:absolute;top:497px;left:516px;white-space:nowrap" class="ft112">in&#160;time&#160;from the&#160;administration&#160;of&#160;</p>
<p style="position:absolute;top:516px;left:516px;white-space:nowrap" class="ft112">Dovato&#160;(minimum&#160;2&#160;hours&#160;after&#160;or&#160;</p>
<p style="position:absolute;top:536px;left:516px;white-space:nowrap" class="ft112">6&#160;hours&#160;before).&#160;</p>
<p style="position:absolute;top:576px;left:94px;white-space:nowrap" class="ft112">Calcium&#160;</p>
<p style="position:absolute;top:595px;left:94px;white-space:nowrap" class="ft112">supplements/Dolutegravir&#160;</p>
<p style="position:absolute;top:614px;left:94px;white-space:nowrap" class="ft112">(fasted&#160;intake)&#160;</p>
<p style="position:absolute;top:577px;left:325px;white-space:nowrap" class="ft112">Dolutegravir&#160;↓&#160;</p>
<p style="position:absolute;top:597px;left:325px;white-space:nowrap" class="ft112">&#160; &#160;AUC&#160;↓&#160;39%&#160;&#160;</p>
<p style="position:absolute;top:617px;left:325px;white-space:nowrap" class="ft112">&#160; &#160;Cmax&#160;↓&#160;37%&#160;</p>
<p style="position:absolute;top:638px;left:325px;white-space:nowrap" class="ft112">&#160; &#160;C24&#160;↓&#160;39%&#160;</p>
<p style="position:absolute;top:657px;left:325px;white-space:nowrap" class="ft112">(Complex binding to&#160;</p>
<p style="position:absolute;top:676px;left:325px;white-space:nowrap" class="ft112">polyvalent&#160;ions)&#160;</p>
<p style="position:absolute;top:576px;left:516px;white-space:nowrap" class="ft112">-&#160;When taken with&#160;food, Dovato&#160;and&#160;</p>
<p style="position:absolute;top:595px;left:516px;white-space:nowrap" class="ft112">supplements&#160;or&#160;multivitamins&#160;containing&#160;</p>
<p style="position:absolute;top:615px;left:516px;white-space:nowrap" class="ft112">calcium,&#160;iron&#160;or&#160;magnesium&#160;can&#160;be taken&#160;</p>
<p style="position:absolute;top:635px;left:516px;white-space:nowrap" class="ft112">at&#160;the same time.&#160;&#160;</p>
<p style="position:absolute;top:654px;left:516px;white-space:nowrap" class="ft112">-&#160;If&#160;Dovato is&#160;taken&#160;in&#160;a&#160;fasted&#160;state,&#160;</p>
<p style="position:absolute;top:674px;left:516px;white-space:nowrap" class="ft112">such&#160;supplements&#160;should be&#160;taken&#160;a&#160;</p>
<p style="position:absolute;top:693px;left:516px;white-space:nowrap" class="ft112">minimum&#160;2&#160;hours&#160;after or 6&#160;hours&#160;before&#160;</p>
<p style="position:absolute;top:713px;left:516px;white-space:nowrap" class="ft112">the&#160;intake&#160;of&#160;Dovato.&#160;</p>
<p style="position:absolute;top:732px;left:516px;white-space:nowrap" class="ft112">&#160;</p>
<p style="position:absolute;top:752px;left:516px;white-space:nowrap" class="ft112">The&#160;stated reductions&#160;in dolutegravir&#160;</p>
<p style="position:absolute;top:771px;left:516px;white-space:nowrap" class="ft112">exposure&#160;were&#160;observed with the&#160;intake&#160;</p>
<p style="position:absolute;top:791px;left:516px;white-space:nowrap" class="ft112">of&#160;dolutegravir&#160;and these&#160;supplements&#160;</p>
<p style="position:absolute;top:810px;left:516px;white-space:nowrap" class="ft112">during fasted conditions. In&#160;fed state,&#160;the&#160;</p>
<p style="position:absolute;top:830px;left:516px;white-space:nowrap" class="ft112">changes&#160;in exposure&#160;following intake&#160;</p>
<p style="position:absolute;top:849px;left:516px;white-space:nowrap" class="ft112">together&#160;with&#160;calcium or&#160;iron&#160;</p>
<p style="position:absolute;top:869px;left:516px;white-space:nowrap" class="ft112">supplements&#160;were&#160;modified&#160;by the&#160;food&#160;</p>
<p style="position:absolute;top:888px;left:516px;white-space:nowrap" class="ft112">effect,&#160;resulting in an exposure&#160;similar&#160;to&#160;</p>
<p style="position:absolute;top:908px;left:516px;white-space:nowrap" class="ft112">that&#160;obtained with dolutegravir&#160;</p>
<p style="position:absolute;top:927px;left:516px;white-space:nowrap" class="ft112">administered&#160;in&#160;the fasted&#160;state.&#160;</p>
<p style="position:absolute;top:695px;left:94px;white-space:nowrap" class="ft112">Iron&#160;supplements/Dolutegravir&#160;</p>
<p style="position:absolute;top:714px;left:94px;white-space:nowrap" class="ft112">(fasted&#160;intake)&#160;</p>
<p style="position:absolute;top:696px;left:325px;white-space:nowrap" class="ft112">Dolutegravir&#160;↓&#160;</p>
<p style="position:absolute;top:717px;left:325px;white-space:nowrap" class="ft112">&#160; &#160;AUC&#160;↓&#160;54%&#160;&#160;</p>
<p style="position:absolute;top:737px;left:325px;white-space:nowrap" class="ft112">&#160; &#160;Cmax&#160;↓&#160;57%&#160;</p>
<p style="position:absolute;top:757px;left:325px;white-space:nowrap" class="ft112">&#160; &#160;C24&#160;↓&#160;56%&#160;</p>
<p style="position:absolute;top:776px;left:325px;white-space:nowrap" class="ft112">(Complex binding to&#160;</p>
<p style="position:absolute;top:795px;left:325px;white-space:nowrap" class="ft112">polyvalent&#160;ions)&#160;</p>
<p style="position:absolute;top:815px;left:94px;white-space:nowrap" class="ft112">Multivitamins&#160;(containing&#160;</p>
<p style="position:absolute;top:834px;left:94px;white-space:nowrap" class="ft112">calcium,&#160;iron&#160;and&#160;magnesium)&#160;</p>
<p style="position:absolute;top:853px;left:94px;white-space:nowrap" class="ft112">/Dolutegravir&#160;</p>
<p style="position:absolute;top:872px;left:94px;white-space:nowrap" class="ft112">(fasted&#160;intake)&#160;</p>
<p style="position:absolute;top:815px;left:325px;white-space:nowrap" class="ft112">Dolutegravir&#160;↓&#160;</p>
<p style="position:absolute;top:835px;left:325px;white-space:nowrap" class="ft112">&#160; &#160;AUC&#160;↓&#160;33%&#160;&#160;</p>
<p style="position:absolute;top:854px;left:325px;white-space:nowrap" class="ft112">&#160; &#160;Cmax&#160;↓&#160;35%&#160;</p>
<p style="position:absolute;top:874px;left:325px;white-space:nowrap" class="ft112">&#160; &#160;C24&#160;↓&#160;32%&#160;</p>
<p style="position:absolute;top:894px;left:325px;white-space:nowrap" class="ft112">(Complex binding to&#160;</p>
<p style="position:absolute;top:912px;left:325px;white-space:nowrap" class="ft112">polyvalent&#160;ions)&#160;</p>
<p style="position:absolute;top:947px;left:94px;white-space:nowrap" class="ft115"><i>Proton pump&#160;inhibitors&#160;</i></p>
<p style="position:absolute;top:968px;left:94px;white-space:nowrap" class="ft112">Omeprazole&#160;</p>
<p style="position:absolute;top:968px;left:325px;white-space:nowrap" class="ft112">Dolutegravir&#160;↔&#160;</p>
<p style="position:absolute;top:968px;left:516px;white-space:nowrap" class="ft112">No&#160;dosage&#160;adjustment&#160;necessary.&#160;</p>
<p style="position:absolute;top:989px;left:94px;white-space:nowrap" class="ft115"><i>Corticosteroids&#160;</i></p>
<p style="position:absolute;top:1008px;left:94px;white-space:nowrap" class="ft112">Prednisone/Dolutegravir&#160;</p>
<p style="position:absolute;top:1010px;left:325px;white-space:nowrap" class="ft112">Dolutegravir&#160;↔&#160;</p>
<p style="position:absolute;top:1029px;left:325px;white-space:nowrap" class="ft112">&#160; &#160;AUC&#160;↑&#160;11%&#160;</p>
<p style="position:absolute;top:1049px;left:325px;white-space:nowrap" class="ft112">&#160; &#160;Cmax&#160;↑&#160;6%&#160;</p>
<p style="position:absolute;top:1069px;left:325px;white-space:nowrap" class="ft1111">&#160; &#160;Cτ&#160;↑&#160;17%&#160;</p>
<p style="position:absolute;top:1009px;left:516px;white-space:nowrap" class="ft112">No&#160;dose adjustment&#160;is necessary.&#160;</p>
<p style="position:absolute;top:1091px;left:94px;white-space:nowrap" class="ft115"><i>Antidiabetics&#160;</i></p>
<p style="position:absolute;top:1111px;left:94px;white-space:nowrap" class="ft112">Metformin/Dolutegravir&#160;</p>
<p style="position:absolute;top:1112px;left:325px;white-space:nowrap" class="ft112">Metformin&#160;↑&#160;</p>
<p style="position:absolute;top:1132px;left:325px;white-space:nowrap" class="ft112">Dolutegravir&#160;↔&#160;</p>
<p style="position:absolute;top:1111px;left:516px;white-space:nowrap" class="ft112">A&#160;dose&#160;adjustment&#160;of&#160;metformin should&#160;</p>
<p style="position:absolute;top:1130px;left:516px;white-space:nowrap" class="ft112">be&#160;considered&#160;when starting and&#160;</p>
<p style="position:absolute;top:1150px;left:516px;white-space:nowrap" class="ft112">stopping coadministration of&#160;Dovato&#160;</p>
</div>
<!-- Page 12 -->
<a name="12"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page12-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1191px;left:436px;white-space:nowrap" class="ft120">12&#160;</p>
<p style="position:absolute;top:84px;left:325px;white-space:nowrap" class="ft122">When&#160;co-administered&#160;</p>
<p style="position:absolute;top:103px;left:325px;white-space:nowrap" class="ft122">with&#160;dolutegravir&#160;50&#160;mg&#160;</p>
<p style="position:absolute;top:122px;left:325px;white-space:nowrap" class="ft122">QD:&#160;</p>
<p style="position:absolute;top:141px;left:325px;white-space:nowrap" class="ft122">Metformin&#160;</p>
<p style="position:absolute;top:161px;left:325px;white-space:nowrap" class="ft122">&#160; &#160;AUC&#160;↑&#160;79%&#160;&#160;</p>
<p style="position:absolute;top:181px;left:325px;white-space:nowrap" class="ft122">&#160; &#160;Cmax&#160;↑&#160;66%&#160;</p>
<p style="position:absolute;top:200px;left:325px;white-space:nowrap" class="ft122">When&#160;co-administered&#160;</p>
<p style="position:absolute;top:219px;left:325px;white-space:nowrap" class="ft122">with&#160;dolutegravir&#160;50&#160;mg&#160;</p>
<p style="position:absolute;top:238px;left:325px;white-space:nowrap" class="ft122">BID:&#160;&#160;</p>
<p style="position:absolute;top:257px;left:325px;white-space:nowrap" class="ft122">&#160; &#160;Metformin&#160;</p>
<p style="position:absolute;top:277px;left:325px;white-space:nowrap" class="ft122">&#160; &#160;AUC&#160;↑&#160;145 %&#160;&#160;</p>
<p style="position:absolute;top:298px;left:325px;white-space:nowrap" class="ft122">&#160; &#160;Cmax&#160;↑&#160;111%&#160;</p>
<p style="position:absolute;top:84px;left:516px;white-space:nowrap" class="ft122">with&#160;metformin,&#160;to&#160;maintain&#160;glycaemic&#160;</p>
<p style="position:absolute;top:104px;left:516px;white-space:nowrap" class="ft122">control.&#160;In&#160;patients&#160;with&#160;moderate renal&#160;</p>
<p style="position:absolute;top:123px;left:516px;white-space:nowrap" class="ft122">impairment&#160;a dose adjustment&#160;of&#160;</p>
<p style="position:absolute;top:143px;left:516px;white-space:nowrap" class="ft122">metformin should be&#160;considered&#160;when&#160;</p>
<p style="position:absolute;top:162px;left:516px;white-space:nowrap" class="ft122">coadministered&#160;with&#160;Dovato,&#160;because of&#160;</p>
<p style="position:absolute;top:182px;left:516px;white-space:nowrap" class="ft122">the increased&#160;risk&#160;for&#160;lactic acidosis&#160;in&#160;</p>
<p style="position:absolute;top:201px;left:516px;white-space:nowrap" class="ft122">patients&#160;with&#160;moderate&#160;renal&#160;impairment&#160;</p>
<p style="position:absolute;top:221px;left:516px;white-space:nowrap" class="ft122">due&#160;to increased metformin&#160;</p>
<p style="position:absolute;top:240px;left:516px;white-space:nowrap" class="ft122">concentration (section&#160;4.4).&#160;</p>
<p style="position:absolute;top:317px;left:94px;white-space:nowrap" class="ft125"><i>Herbal&#160;products&#160;</i></p>
<p style="position:absolute;top:317px;left:325px;white-space:nowrap" class="ft122">&#160;</p>
<p style="position:absolute;top:318px;left:516px;white-space:nowrap" class="ft122">&#160;</p>
<p style="position:absolute;top:338px;left:94px;white-space:nowrap" class="ft122">St. John’s&#160;wort/Dolutegravir&#160;</p>
<p style="position:absolute;top:357px;left:94px;white-space:nowrap" class="ft122">&#160;</p>
<p style="position:absolute;top:339px;left:325px;white-space:nowrap" class="ft122">Dolutegravir&#160;↓&#160;</p>
<p style="position:absolute;top:358px;left:325px;white-space:nowrap" class="ft122">(Not&#160;studied,&#160;decrease&#160;</p>
<p style="position:absolute;top:377px;left:325px;white-space:nowrap" class="ft122">expected due&#160;to&#160;induction&#160;</p>
<p style="position:absolute;top:396px;left:325px;white-space:nowrap" class="ft122">of&#160;UGT1A1 and CYP3A&#160;</p>
<p style="position:absolute;top:415px;left:325px;white-space:nowrap" class="ft122">enzymes,&#160;a&#160;similar&#160;</p>
<p style="position:absolute;top:434px;left:325px;white-space:nowrap" class="ft122">reduction in exposure&#160;as&#160;</p>
<p style="position:absolute;top:453px;left:325px;white-space:nowrap" class="ft122">observed with&#160;</p>
<p style="position:absolute;top:472px;left:325px;white-space:nowrap" class="ft122">carbamazepine is&#160;</p>
<p style="position:absolute;top:491px;left:325px;white-space:nowrap" class="ft122">expected).&#160;</p>
<p style="position:absolute;top:338px;left:516px;white-space:nowrap" class="ft122">The&#160;recommended dose&#160;of&#160;dolutegravir&#160;</p>
<p style="position:absolute;top:357px;left:516px;white-space:nowrap" class="ft122">is&#160;50&#160;mg twice&#160;daily&#160;when co-</p>
<p style="position:absolute;top:377px;left:516px;white-space:nowrap" class="ft122">administered with St.&#160;John’s&#160;wort.&#160;As&#160;</p>
<p style="position:absolute;top:396px;left:516px;white-space:nowrap" class="ft122">Dovato&#160;is&#160;a&#160;fixed-dose&#160;tablet, an&#160;</p>
<p style="position:absolute;top:416px;left:516px;white-space:nowrap" class="ft122">additional&#160;50&#160;mg tablet&#160;of&#160;dolutegravir&#160;</p>
<p style="position:absolute;top:435px;left:516px;white-space:nowrap" class="ft122">should be&#160;administered, approximately&#160;</p>
<p style="position:absolute;top:455px;left:516px;white-space:nowrap" class="ft122">12&#160;hours&#160;after&#160;Dovato&#160;for&#160;the&#160;duration of&#160;</p>
<p style="position:absolute;top:474px;left:516px;white-space:nowrap" class="ft122">the&#160;St. John’s&#160;wort&#160;co-administration (a&#160;</p>
<p style="position:absolute;top:494px;left:516px;white-space:nowrap" class="ft122">separate formulation&#160;of&#160;dolutegravir&#160;is&#160;</p>
<p style="position:absolute;top:513px;left:516px;white-space:nowrap" class="ft122">available for&#160;this&#160;dose&#160;adjustment,&#160;see&#160;</p>
<p style="position:absolute;top:533px;left:516px;white-space:nowrap" class="ft122">section 4.2).&#160;&#160;</p>
<p style="position:absolute;top:553px;left:94px;white-space:nowrap" class="ft125"><i>Oral&#160;contraceptives&#160;</i></p>
<p style="position:absolute;top:573px;left:94px;white-space:nowrap" class="ft122">Ethinyl&#160;estradiol&#160;(EE)&#160;and&#160;</p>
<p style="position:absolute;top:593px;left:94px;white-space:nowrap" class="ft122">Norgestromin&#160;</p>
<p style="position:absolute;top:612px;left:94px;white-space:nowrap" class="ft122">(NGMN)/Dolutegravir&#160;</p>
<p style="position:absolute;top:573px;left:325px;white-space:nowrap" class="ft122">Effect&#160;of&#160;dolutegravir:&#160;</p>
<p style="position:absolute;top:593px;left:325px;white-space:nowrap" class="ft122">EE&#160;↔&#160;</p>
<p style="position:absolute;top:612px;left:325px;white-space:nowrap" class="ft122">&#160; &#160;AUC&#160;↑&#160;3%&#160;&#160;</p>
<p style="position:absolute;top:632px;left:325px;white-space:nowrap" class="ft122">&#160; &#160;Cmax&#160;↓&#160;1%&#160;</p>
<p style="position:absolute;top:651px;left:325px;white-space:nowrap" class="ft122">&#160;</p>
<p style="position:absolute;top:671px;left:325px;white-space:nowrap" class="ft122">Effect&#160;of&#160;dolutegravir:&#160;</p>
<p style="position:absolute;top:691px;left:325px;white-space:nowrap" class="ft122">NGMN&#160;↔&#160;</p>
<p style="position:absolute;top:711px;left:325px;white-space:nowrap" class="ft122">&#160; &#160;AUC&#160;↓&#160;2%&#160;&#160;</p>
<p style="position:absolute;top:732px;left:325px;white-space:nowrap" class="ft122">&#160; &#160;Cmax&#160;↓&#160;11%&#160;</p>
<p style="position:absolute;top:573px;left:516px;white-space:nowrap" class="ft122">Dolutegravir&#160;had&#160;no pharmacodynamic&#160;</p>
<p style="position:absolute;top:593px;left:516px;white-space:nowrap" class="ft122">effect&#160;on Luteinizing Hormone&#160;(LH),&#160;</p>
<p style="position:absolute;top:612px;left:516px;white-space:nowrap" class="ft122">Follicle&#160;Stimulating Hormone&#160;(FSH)&#160;and&#160;</p>
<p style="position:absolute;top:632px;left:516px;white-space:nowrap" class="ft122">progesterone. No dose&#160;adjustment&#160;of&#160;</p>
<p style="position:absolute;top:651px;left:516px;white-space:nowrap" class="ft122">oral&#160;contraceptives&#160;is necessary&#160;when&#160;</p>
<p style="position:absolute;top:671px;left:516px;white-space:nowrap" class="ft122">co-administered&#160;with&#160;Dovato.&#160;</p>
<p style="position:absolute;top:752px;left:85px;white-space:nowrap" class="ft122">&#160;</p>
<p style="position:absolute;top:771px;left:85px;white-space:nowrap" class="ft122">Paediatric&#160;population&#160;</p>
<p style="position:absolute;top:791px;left:85px;white-space:nowrap" class="ft122">&#160;</p>
<p style="position:absolute;top:810px;left:85px;white-space:nowrap" class="ft122">Interaction&#160;studies&#160;have&#160;only&#160;been&#160;performed&#160;in adults.&#160;</p>
<p style="position:absolute;top:830px;left:85px;white-space:nowrap" class="ft122">&#160;</p>
<p style="position:absolute;top:849px;left:85px;white-space:nowrap" class="ft121"><b>4.6&#160;&#160;Fertility, pregnancy and&#160;lactation&#160;</b></p>
<p style="position:absolute;top:869px;left:85px;white-space:nowrap" class="ft122">&#160;</p>
<p style="position:absolute;top:888px;left:85px;white-space:nowrap" class="ft122">Women of&#160;childbearing&#160;potential&#160;</p>
<p style="position:absolute;top:908px;left:85px;white-space:nowrap" class="ft122">&#160;</p>
<p style="position:absolute;top:927px;left:85px;white-space:nowrap" class="ft122">Women&#160;of&#160;childbearing potential&#160;(WOCBP)&#160;should&#160;be&#160;counselled about&#160;the&#160;potential&#160;risk of&#160;neural&#160;tube&#160;</p>
<p style="position:absolute;top:947px;left:85px;white-space:nowrap" class="ft122">defects&#160;with dolutegravir&#160;(a&#160;component&#160;of&#160;Dovato,&#160;see&#160;below),&#160;including consideration of&#160;effective&#160;</p>
<p style="position:absolute;top:966px;left:85px;white-space:nowrap" class="ft122">contraceptive measures.&#160;</p>
<p style="position:absolute;top:986px;left:85px;white-space:nowrap" class="ft122">&#160;</p>
<p style="position:absolute;top:1005px;left:85px;white-space:nowrap" class="ft122">If&#160;a&#160;woman plans&#160;pregnancy, the&#160;benefits&#160;and&#160;the&#160;risks&#160;of&#160;continuing treatment&#160;with Dovato&#160;should be&#160;</p>
<p style="position:absolute;top:1025px;left:85px;white-space:nowrap" class="ft122">discussed&#160;with&#160;the patient.&#160;</p>
<p style="position:absolute;top:1044px;left:85px;white-space:nowrap" class="ft122">&#160;</p>
<p style="position:absolute;top:1064px;left:85px;white-space:nowrap" class="ft122">Pregnancy&#160;</p>
<p style="position:absolute;top:1083px;left:85px;white-space:nowrap" class="ft122">&#160;</p>
<p style="position:absolute;top:1103px;left:85px;white-space:nowrap" class="ft122">The&#160;safety and&#160;efficacy&#160;of&#160;a&#160;dual&#160;regimen&#160;has not&#160;been&#160;studied&#160;in&#160;pregnancy.&#160;</p>
<p style="position:absolute;top:1122px;left:85px;white-space:nowrap" class="ft122">&#160;</p>
</div>
<!-- Page 13 -->
<a name="13"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page13-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1191px;left:436px;white-space:nowrap" class="ft130">13&#160;</p>
<p style="position:absolute;top:83px;left:85px;white-space:nowrap" class="ft132">Human&#160;experience&#160;from&#160;a birth&#160;outcome&#160;surveillance&#160;study&#160;in&#160;Botswana shows a small&#160;increase of&#160;neural&#160;</p>
<p style="position:absolute;top:103px;left:85px;white-space:nowrap" class="ft132">tube&#160;defects;&#160;7&#160;cases&#160;in 3,591 deliveries&#160;(0.19%;&#160;95%&#160;CI&#160;0.09%, 0.40%)&#160;to&#160;mothers&#160;taking dolutegravir-</p>
<p style="position:absolute;top:122px;left:85px;white-space:nowrap" class="ft132">containing regimens&#160;at&#160;the&#160;time&#160;of&#160;conception compared&#160;to&#160;21 cases&#160;in&#160;19,361&#160;deliveries&#160;(0.11%:&#160;95%&#160;CI&#160;</p>
<p style="position:absolute;top:142px;left:85px;white-space:nowrap" class="ft132">0.07%, 0.17%)&#160;to&#160;women exposed&#160;to non-dolutegravir&#160;regimens at&#160;the&#160;time of&#160;conception.&#160;</p>
<p style="position:absolute;top:162px;left:85px;white-space:nowrap" class="ft132">&#160;</p>
<p style="position:absolute;top:181px;left:85px;white-space:nowrap" class="ft132">The incidence&#160;of&#160;neural&#160;tube defects in&#160;the general&#160;population ranges&#160;from&#160;0.5-1 case&#160;per&#160;1,000 live&#160;births&#160;</p>
<p style="position:absolute;top:200px;left:85px;white-space:nowrap" class="ft132">(0.05-0.1%).&#160;Most&#160;neural&#160;tube defects occur&#160;within&#160;the&#160;first&#160;4&#160;weeks of&#160;embryonic&#160;development&#160;after&#160;</p>
<p style="position:absolute;top:220px;left:85px;white-space:nowrap" class="ft132">conception&#160;(approximately 6&#160;weeks&#160;after&#160;the&#160;last&#160;menstrual&#160;period).&#160;If&#160;a&#160;pregnancy&#160;is&#160;confirmed in the&#160;first&#160;</p>
<p style="position:absolute;top:239px;left:85px;white-space:nowrap" class="ft132">trimester&#160;while&#160;on Dovato,&#160;the&#160;benefits&#160;and risks&#160;of&#160;continuing Dovato versus&#160;switching to another&#160;</p>
<p style="position:absolute;top:259px;left:85px;white-space:nowrap" class="ft132">antiretroviral&#160;regimen&#160;should&#160;be discussed&#160;with&#160;the patient&#160;taking&#160;the gestational&#160;age and&#160;the&#160;critical&#160;time&#160;</p>
<p style="position:absolute;top:279px;left:85px;white-space:nowrap" class="ft132">period of&#160;neural&#160;tube&#160;defect&#160;development&#160;into account.&#160;</p>
<p style="position:absolute;top:298px;left:85px;white-space:nowrap" class="ft132">&#160;</p>
<p style="position:absolute;top:317px;left:85px;white-space:nowrap" class="ft132">Data&#160;analysed&#160;from&#160;the&#160;Antiretroviral&#160;Pregnancy Registry do not&#160;indicate&#160;an&#160;increased&#160;risk of&#160;major&#160;birth&#160;</p>
<p style="position:absolute;top:337px;left:85px;white-space:nowrap" class="ft132">defects in&#160;over&#160;600&#160;women&#160;exposed to&#160;dolutegravir&#160;during pregnancy but&#160;are&#160;currently&#160;insufficient&#160;to address&#160;</p>
<p style="position:absolute;top:356px;left:85px;white-space:nowrap" class="ft132">the&#160;risk&#160;of&#160;neural&#160;tube&#160;defects.&#160;&#160;</p>
<p style="position:absolute;top:376px;left:85px;white-space:nowrap" class="ft132">&#160;</p>
<p style="position:absolute;top:396px;left:85px;white-space:nowrap" class="ft132">In animal&#160;reproductive&#160;toxicology&#160;studies&#160;with dolutegravir, no&#160;adverse&#160;development&#160;outcomes, including&#160;</p>
<p style="position:absolute;top:415px;left:85px;white-space:nowrap" class="ft132">neural&#160;tube defects,&#160;were identified&#160;(see section&#160;5.3).&#160;&#160;</p>
<p style="position:absolute;top:434px;left:85px;white-space:nowrap" class="ft132">&#160;</p>
<p style="position:absolute;top:454px;left:85px;white-space:nowrap" class="ft132">More&#160;than&#160;1000 outcomes&#160;from&#160;exposure&#160;to dolutegravir&#160;during&#160;second and third trimester&#160;pregnancy&#160;</p>
<p style="position:absolute;top:474px;left:85px;white-space:nowrap" class="ft132">indicate no&#160;evidence of&#160;increased&#160;risk&#160;of&#160;foetal/neonatal&#160;toxicity.&#160;Dovato&#160;may&#160;be&#160;used&#160;during&#160;the&#160;second and&#160;</p>
<p style="position:absolute;top:493px;left:85px;white-space:nowrap" class="ft132">third&#160;trimester&#160;of&#160;pregnancy&#160;when&#160;the expected&#160;benefit&#160;justifies&#160;the&#160;potential risk&#160;to&#160;the&#160;foetus.&#160;</p>
<p style="position:absolute;top:513px;left:85px;white-space:nowrap" class="ft132">&#160;</p>
<p style="position:absolute;top:532px;left:85px;white-space:nowrap" class="ft132">Dolutegravir&#160;crosses&#160;the&#160;placenta&#160;in humans. In pregnant&#160;women&#160;living&#160;with&#160;HIV,&#160;the&#160;median&#160;foetal&#160;</p>
<p style="position:absolute;top:551px;left:85px;white-space:nowrap" class="ft132">umbilical&#160;cord concentration of&#160;dolutegravir&#160;was&#160;approximately&#160;1.3-fold greater&#160;compared with&#160;the&#160;maternal&#160;</p>
<p style="position:absolute;top:571px;left:85px;white-space:nowrap" class="ft132">peripheral&#160;plasma&#160;concentration.&#160;</p>
<p style="position:absolute;top:591px;left:85px;white-space:nowrap" class="ft132">&#160;</p>
<p style="position:absolute;top:610px;left:85px;white-space:nowrap" class="ft132">There&#160;is&#160;insufficient&#160;information on&#160;the&#160;effects&#160;of&#160;dolutegravir&#160;on neonates.&#160;</p>
<p style="position:absolute;top:630px;left:85px;white-space:nowrap" class="ft132">&#160;</p>
<p style="position:absolute;top:649px;left:85px;white-space:nowrap" class="ft132">A&#160;large&#160;amount&#160;of&#160;data&#160;on the&#160;use&#160;of&#160;lamivudine&#160;in&#160;pregnant&#160;women&#160;(more&#160;than&#160;5200&#160;outcomes&#160;from&#160;first&#160;</p>
<p style="position:absolute;top:668px;left:85px;white-space:nowrap" class="ft132">trimester)&#160;indicates&#160;no&#160;malformative&#160;toxicity.&#160;&#160;</p>
<p style="position:absolute;top:688px;left:85px;white-space:nowrap" class="ft132">&#160;</p>
<p style="position:absolute;top:708px;left:85px;white-space:nowrap" class="ft132">Animal studies&#160;showed&#160;lamivudine&#160;may&#160;inhibit&#160;cellular&#160;DNA&#160;replication (see&#160;section 5.3). The&#160;clinical&#160;</p>
<p style="position:absolute;top:727px;left:85px;white-space:nowrap" class="ft132">relevance of&#160;these&#160;findings&#160;is unknown.&#160;</p>
<p style="position:absolute;top:747px;left:85px;white-space:nowrap" class="ft132">&#160;</p>
<p style="position:absolute;top:766px;left:85px;white-space:nowrap" class="ft135"><i>Mitochondrial&#160;dysfunction</i>&#160;&#160;</p>
<p style="position:absolute;top:785px;left:85px;white-space:nowrap" class="ft132">Nucleoside and&#160;nucleotide&#160;analogues&#160;have&#160;been&#160;demonstrated&#160;<i>in&#160;vitro</i>&#160;and&#160;<i>in&#160;vivo</i>&#160;to&#160;cause&#160;a variable degree&#160;</p>
<p style="position:absolute;top:805px;left:85px;white-space:nowrap" class="ft132">of&#160;mitochondrial&#160;damage. There&#160;have&#160;been&#160;reports&#160;of&#160;mitochondrial&#160;dysfunction&#160;in&#160;HIV-negative&#160;infants&#160;</p>
<p style="position:absolute;top:825px;left:85px;white-space:nowrap" class="ft132">exposed&#160;<i>in utero</i>&#160;and/or&#160;post-natally&#160;to nucleoside&#160;analogues&#160;(see&#160;section&#160;4.4).&#160;</p>
<p style="position:absolute;top:844px;left:85px;white-space:nowrap" class="ft132">&#160;</p>
<p style="position:absolute;top:864px;left:85px;white-space:nowrap" class="ft132">Breast-feeding&#160;&#160;</p>
<p style="position:absolute;top:883px;left:85px;white-space:nowrap" class="ft132">&#160;</p>
<p style="position:absolute;top:902px;left:85px;white-space:nowrap" class="ft132">Dolutegravir&#160;is&#160;excreted&#160;in&#160;human&#160;milk&#160;in&#160;small&#160;amounts&#160;(a median&#160;dolutegravir&#160;breast milk&#160;to&#160;maternal&#160;</p>
<p style="position:absolute;top:922px;left:85px;white-space:nowrap" class="ft132">plasma&#160;ratio&#160;of&#160;0.033&#160;has been&#160;shown).&#160;There&#160;is&#160;insufficient&#160;information&#160;on the&#160;effects&#160;of&#160;dolutegravir&#160;in&#160;</p>
<p style="position:absolute;top:941px;left:85px;white-space:nowrap" class="ft132">neonates/infants.&#160;&#160;</p>
<p style="position:absolute;top:961px;left:85px;white-space:nowrap" class="ft132">&#160;</p>
<p style="position:absolute;top:981px;left:85px;white-space:nowrap" class="ft132">Based&#160;on more&#160;than 200 mother/child&#160;pairs&#160;treated&#160;for&#160;HIV,&#160;serum&#160;concentrations&#160;of&#160;lamivudine&#160;in&#160;breastfed&#160;</p>
<p style="position:absolute;top:1000px;left:85px;white-space:nowrap" class="ft132">infants&#160;of&#160;mothers&#160;treated for&#160;HIV&#160;are&#160;very&#160;low&#160;(&lt;&#160;4%&#160;of&#160;maternal&#160;serum&#160;concentrations)&#160;and progressively&#160;</p>
<p style="position:absolute;top:1019px;left:85px;white-space:nowrap" class="ft132">decrease to&#160;undetectable&#160;levels when&#160;breastfed&#160;infants&#160;reach&#160;24&#160;weeks of&#160;age.&#160;There&#160;are&#160;no&#160;data&#160;available on&#160;</p>
<p style="position:absolute;top:1039px;left:85px;white-space:nowrap" class="ft132">the&#160;safety&#160;of&#160;lamivudine&#160;when&#160;administered&#160;to&#160;babies&#160;less&#160;than&#160;three&#160;months&#160;old.&#160;</p>
<p style="position:absolute;top:1058px;left:85px;white-space:nowrap" class="ft132">&#160;</p>
<p style="position:absolute;top:1078px;left:85px;white-space:nowrap" class="ft132">It&#160;is recommended&#160;that&#160;women&#160;living&#160;with&#160;HIV&#160;do not&#160;breast-feed&#160;their&#160;infants&#160;in order&#160;to avoid&#160;transmission&#160;</p>
<p style="position:absolute;top:1098px;left:85px;white-space:nowrap" class="ft132">of&#160;HIV.&#160;</p>
<p style="position:absolute;top:1117px;left:85px;white-space:nowrap" class="ft132">&#160;</p>
<p style="position:absolute;top:1136px;left:85px;white-space:nowrap" class="ft132">Fertility&#160;&#160;</p>
</div>
<!-- Page 14 -->
<a name="14"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft1415{font-size:17px;line-height:29px;font-family:ITJJCY+TimesNewRomanPS;color:#000000;}
	.ft1416{font-size:17px;line-height:28px;font-family:ITJJCY+TimesNewRomanPS;color:#000000;}
	.ft1417{font-size:17px;line-height:23px;font-family:DTAKKI+TimesNewRomanPSMT;color:#000000;}
-->
</style>
<div id="page14-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1191px;left:436px;white-space:nowrap" class="ft140">14&#160;</p>
<p style="position:absolute;top:83px;left:85px;white-space:nowrap" class="ft142">&#160;</p>
<p style="position:absolute;top:103px;left:85px;white-space:nowrap" class="ft142">There&#160;are&#160;no&#160;data on&#160;the effects&#160;of&#160;dolutegravir&#160;or&#160;lamivudine&#160;on&#160;human&#160;male&#160;or&#160;female&#160;fertility.&#160;Animal&#160;</p>
<p style="position:absolute;top:122px;left:85px;white-space:nowrap" class="ft142">studies indicate no&#160;effects&#160;of&#160;dolutegravir&#160;or&#160;lamivudine&#160;on male&#160;or&#160;female&#160;fertility&#160;(see&#160;section 5.3).&#160;&#160;</p>
<p style="position:absolute;top:142px;left:85px;white-space:nowrap" class="ft145"><i>&#160;</i></p>
<p style="position:absolute;top:161px;left:85px;white-space:nowrap" class="ft141"><b>4.7&#160;&#160;Effects&#160;on&#160;ability&#160;to drive&#160;and&#160;use&#160;machines&#160;</b>&#160;</p>
<p style="position:absolute;top:181px;left:85px;white-space:nowrap" class="ft142">&#160;</p>
<p style="position:absolute;top:200px;left:85px;white-space:nowrap" class="ft142">Dovato has&#160;no&#160;or&#160;negligible&#160;influence&#160;on&#160;the&#160;ability&#160;to&#160;drive&#160;and&#160;use&#160;machines.&#160;Patients&#160;should&#160;be&#160;informed&#160;</p>
<p style="position:absolute;top:220px;left:85px;white-space:nowrap" class="ft142">that&#160;dizziness&#160;and somnolence&#160;has&#160;been reported&#160;during treatment&#160;with&#160;dolutegravir.&#160;The&#160;clinical status&#160;of&#160;</p>
<p style="position:absolute;top:239px;left:85px;white-space:nowrap" class="ft142">the&#160;patient&#160;and&#160;the&#160;adverse&#160;reaction profile&#160;of&#160;Dovato&#160;should be&#160;borne&#160;in&#160;mind&#160;when considering the&#160;patient’s&#160;</p>
<p style="position:absolute;top:259px;left:85px;white-space:nowrap" class="ft142">ability to drive&#160;or&#160;operate&#160;machinery.&#160;&#160;</p>
<p style="position:absolute;top:279px;left:85px;white-space:nowrap" class="ft142">&#160;</p>
<p style="position:absolute;top:297px;left:85px;white-space:nowrap" class="ft141"><b>4.8&#160;&#160;Undesirable effects&#160;&#160;</b></p>
<p style="position:absolute;top:317px;left:85px;white-space:nowrap" class="ft142">&#160;</p>
<p style="position:absolute;top:336px;left:85px;white-space:nowrap" class="ft142">Summary&#160;of&#160;the&#160;safety&#160;profile&#160;</p>
<p style="position:absolute;top:356px;left:85px;white-space:nowrap" class="ft142">&#160;</p>
<p style="position:absolute;top:376px;left:85px;white-space:nowrap" class="ft142">The most&#160;frequently&#160;reported&#160;adverse reactions&#160;are&#160;headache (3%),&#160;diarrhoea&#160;(2%),&#160;nausea (2%)&#160;and&#160;</p>
<p style="position:absolute;top:395px;left:85px;white-space:nowrap" class="ft142">insomnia&#160;(2%).&#160;&#160;</p>
<p style="position:absolute;top:414px;left:85px;white-space:nowrap" class="ft142">&#160;</p>
<p style="position:absolute;top:434px;left:85px;white-space:nowrap" class="ft142">The&#160;most&#160;severe adverse&#160;reaction&#160;reported&#160;with dolutegravir&#160;was&#160;a&#160;hypersensitivity reaction&#160;that&#160;included&#160;</p>
<p style="position:absolute;top:453px;left:85px;white-space:nowrap" class="ft142">rash&#160;and&#160;severe&#160;liver&#160;effects&#160;(see&#160;section 4.4).&#160;</p>
<p style="position:absolute;top:473px;left:85px;white-space:nowrap" class="ft142">&#160;</p>
<p style="position:absolute;top:493px;left:85px;white-space:nowrap" class="ft142">Tabulated&#160;list&#160;of&#160;adverse reactions&#160;</p>
<p style="position:absolute;top:512px;left:85px;white-space:nowrap" class="ft142">&#160;</p>
<p style="position:absolute;top:531px;left:85px;white-space:nowrap" class="ft142">The&#160;adverse&#160;reactions&#160;from&#160;clinical&#160;study and&#160;post-marketing&#160;experience are&#160;listed&#160;in&#160;Table&#160;2&#160;by body&#160;</p>
<p style="position:absolute;top:551px;left:85px;white-space:nowrap" class="ft142">system,&#160;organ&#160;class and&#160;absolute frequency.&#160;Frequencies are defined&#160;as&#160;very&#160;common (≥1/10), common&#160;</p>
<p style="position:absolute;top:570px;left:85px;white-space:nowrap" class="ft142">(≥1/100&#160;to &lt;1/10), uncommon (≥1/1,000&#160;to &lt;1/100), rare&#160;(≥1/10,000&#160;to &lt;1/1,000), very rare&#160;(&lt;1/10,000),&#160;not&#160;</p>
<p style="position:absolute;top:590px;left:85px;white-space:nowrap" class="ft142">known (cannot&#160;be&#160;estimated from&#160;the available data).&#160;</p>
<p style="position:absolute;top:610px;left:85px;white-space:nowrap" class="ft142">&#160;</p>
<p style="position:absolute;top:629px;left:85px;white-space:nowrap" class="ft141"><b>Table&#160;2:&#160;</b></p>
<p style="position:absolute;top:629px;left:193px;white-space:nowrap" class="ft141"><b>Tabulated&#160;summary&#160;of&#160;adverse&#160;reactions to&#160;Dovato&#160;based on clinical&#160;study&#160;and post-</b></p>
<p style="position:absolute;top:648px;left:193px;white-space:nowrap" class="ft141"><b>marketing&#160;experience with&#160;Dovato&#160;and&#160;its&#160;individual&#160;components&#160;&#160;</b></p>
<p style="position:absolute;top:673px;left:153px;white-space:nowrap" class="ft141"><b>Frequency&#160;</b></p>
<p style="position:absolute;top:673px;left:332px;white-space:nowrap" class="ft141"><b>Adverse reaction&#160;</b></p>
<p style="position:absolute;top:703px;left:154px;white-space:nowrap" class="ft1415"><i>Blood and lymphatic&#160;systems&#160;disorders:&#160;<br/></i>Uncommon:&#160;</p>
<p style="position:absolute;top:732px;left:332px;white-space:nowrap" class="ft142">neutropenia, anaemia, thrombocytopenia<i>&#160;</i></p>
<p style="position:absolute;top:761px;left:154px;white-space:nowrap" class="ft142">Very&#160;rare:&#160;</p>
<p style="position:absolute;top:761px;left:332px;white-space:nowrap" class="ft142">pure red&#160;cell&#160;aplasia&#160;</p>
<p style="position:absolute;top:791px;left:154px;white-space:nowrap" class="ft1416"><i>Immune system&#160;disorders:&#160;<br/></i>Uncommon:&#160;</p>
<p style="position:absolute;top:819px;left:332px;white-space:nowrap" class="ft142">hypersensitivity&#160;(see&#160;section 4.4),&#160;immune&#160;reconstitution&#160;</p>
<p style="position:absolute;top:839px;left:332px;white-space:nowrap" class="ft142">syndrome&#160;(see&#160;section&#160;4.4)<i>&#160;</i></p>
<p style="position:absolute;top:868px;left:154px;white-space:nowrap" class="ft1415"><i>Metabolism&#160;and nutrition disorders:&#160;<br/></i>Very&#160;rare:&#160;</p>
<p style="position:absolute;top:898px;left:332px;white-space:nowrap" class="ft142">lactic&#160;acidosis&#160;</p>
<p style="position:absolute;top:927px;left:154px;white-space:nowrap" class="ft1415"><i>Psychiatric&#160;disorders:&#160;&#160;<br/></i>Common:&#160;</p>
<p style="position:absolute;top:956px;left:332px;white-space:nowrap" class="ft142">depression, anxiety,&#160;insomnia, abnormal&#160;dreams&#160;</p>
<p style="position:absolute;top:985px;left:154px;white-space:nowrap" class="ft142">Uncommon:&#160;</p>
<p style="position:absolute;top:985px;left:332px;white-space:nowrap" class="ft142">suicidal ideation*,&#160;suicide&#160;attempt*,&#160;panic attack&#160;</p>
<p style="position:absolute;top:1005px;left:332px;white-space:nowrap" class="ft142">&#160;</p>
<p style="position:absolute;top:1024px;left:332px;white-space:nowrap" class="ft142">*particularly&#160;in&#160;patients&#160;with&#160;a&#160;pre-existing history of&#160;</p>
<p style="position:absolute;top:1044px;left:332px;white-space:nowrap" class="ft142">depression&#160;or&#160;psychiatric illness.&#160;</p>
<p style="position:absolute;top:1073px;left:154px;white-space:nowrap" class="ft142">Rare:&#160;</p>
<p style="position:absolute;top:1073px;left:332px;white-space:nowrap" class="ft1417">completed&#160;suicide*&#160;<br/>&#160;<br/>*particularly&#160;in&#160;patients&#160;with&#160;a&#160;pre-existing history of&#160;</p>
<p style="position:absolute;top:1141px;left:332px;white-space:nowrap" class="ft142">depression&#160;or&#160;psychiatric illness.&#160;</p>
</div>
<!-- Page 15 -->
<a name="15"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft1518{font-size:17px;line-height:24px;font-family:DTAKKI+TimesNewRomanPSMT;color:#000000;}
-->
</style>
<div id="page15-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1191px;left:436px;white-space:nowrap" class="ft150">15&#160;</p>
<p style="position:absolute;top:89px;left:154px;white-space:nowrap" class="ft1516"><i>Nervous&#160;system&#160;disorders:&#160;&#160;<br/></i>Very&#160;common:&#160;</p>
<p style="position:absolute;top:118px;left:332px;white-space:nowrap" class="ft152">headache<i>&#160;</i></p>
<p style="position:absolute;top:147px;left:154px;white-space:nowrap" class="ft152">Common:&#160;</p>
<p style="position:absolute;top:147px;left:332px;white-space:nowrap" class="ft152">dizziness, somnolence<i>&#160;</i></p>
<p style="position:absolute;top:176px;left:154px;white-space:nowrap" class="ft152">Very&#160;rare:&#160;</p>
<p style="position:absolute;top:176px;left:332px;white-space:nowrap" class="ft152">peripheral&#160;neuropathy,&#160;paraesthesia&#160;</p>
<p style="position:absolute;top:206px;left:154px;white-space:nowrap" class="ft1516"><i>Gastrointestinal&#160;disorders:&#160;&#160;<br/></i>Very&#160;common:&#160;</p>
<p style="position:absolute;top:235px;left:332px;white-space:nowrap" class="ft152">nausea, diarrhoea<i>&#160;</i></p>
<p style="position:absolute;top:264px;left:154px;white-space:nowrap" class="ft152">Common:&#160;</p>
<p style="position:absolute;top:264px;left:332px;white-space:nowrap" class="ft152">vomiting,&#160;flatulence,&#160;abdominal pain/&#160;discomfort<i>&#160;</i></p>
<p style="position:absolute;top:293px;left:154px;white-space:nowrap" class="ft152">Rare:&#160;</p>
<p style="position:absolute;top:293px;left:332px;white-space:nowrap" class="ft152">pancreatitis<i>&#160;</i></p>
<p style="position:absolute;top:323px;left:154px;white-space:nowrap" class="ft1516"><i>Hepatobiliary&#160;disorders:&#160;<br/></i>Common:&#160;</p>
<p style="position:absolute;top:352px;left:332px;white-space:nowrap" class="ft152">alanine aminotransferase (ALT)&#160;and/or&#160;aspartate&#160;</p>
<p style="position:absolute;top:371px;left:332px;white-space:nowrap" class="ft152">aminotransferase (AST)&#160;elevations&#160;</p>
<p style="position:absolute;top:401px;left:154px;white-space:nowrap" class="ft152">Uncommon:&#160;</p>
<p style="position:absolute;top:401px;left:332px;white-space:nowrap" class="ft152">hepatitis<i>&#160;</i></p>
<p style="position:absolute;top:430px;left:154px;white-space:nowrap" class="ft152">Rare:&#160;</p>
<p style="position:absolute;top:430px;left:332px;white-space:nowrap" class="ft152">acute&#160;hepatic failure1, increased bilirubin2&#160;</p>
<p style="position:absolute;top:460px;left:154px;white-space:nowrap" class="ft1516"><i>Skin and subcutaneous&#160;tissue&#160;disorders:&#160;&#160;<br/></i>Common:&#160;</p>
<p style="position:absolute;top:488px;left:332px;white-space:nowrap" class="ft152">rash, pruritus, alopecia<i>&#160;</i></p>
<p style="position:absolute;top:518px;left:154px;white-space:nowrap" class="ft152">Rare:&#160;</p>
<p style="position:absolute;top:518px;left:332px;white-space:nowrap" class="ft152">angioedema&#160;</p>
<p style="position:absolute;top:547px;left:154px;white-space:nowrap" class="ft1515"><i>Musculoskeletal&#160;and&#160;connective&#160;tissue&#160;disorders:&#160;<br/></i>Common:&#160;</p>
<p style="position:absolute;top:576px;left:332px;white-space:nowrap" class="ft152">arthralgia, muscle&#160;disorders&#160;(including&#160;myalgia)<i>&#160;</i></p>
<p style="position:absolute;top:605px;left:154px;white-space:nowrap" class="ft152">Rare:&#160;</p>
<p style="position:absolute;top:605px;left:332px;white-space:nowrap" class="ft152">rhabdomyolysis<i>&#160;</i></p>
<p style="position:absolute;top:635px;left:154px;white-space:nowrap" class="ft1516"><i>General&#160;disorders&#160;and administration site&#160;conditions:&#160;&#160;<br/></i>Common:&#160;</p>
<p style="position:absolute;top:664px;left:332px;white-space:nowrap" class="ft152">fatigue<i><b>&#160;</b></i></p>
<p style="position:absolute;top:694px;left:154px;white-space:nowrap" class="ft1516"><i>Investigations:&#160;<br/></i>Common:&#160;</p>
<p style="position:absolute;top:722px;left:332px;white-space:nowrap" class="ft152">creatine&#160;phosphokinase&#160;(CPK)&#160;elevations,&#160;weight&#160;increased<i>&#160;</i></p>
<p style="position:absolute;top:752px;left:154px;white-space:nowrap" class="ft152">Rare:&#160;</p>
<p style="position:absolute;top:752px;left:332px;white-space:nowrap" class="ft152">amylase elevations&#160;</p>
<p style="position:absolute;top:781px;left:154px;white-space:nowrap" class="ft158">1</p>
<p style="position:absolute;top:781px;left:159px;white-space:nowrap" class="ft152">&#160;This&#160;adverse&#160;reaction was&#160;identified through post-marketing surveillance&#160;for&#160;</p>
<p style="position:absolute;top:801px;left:154px;white-space:nowrap" class="ft152">dolutegravir&#160;in combination&#160;with other&#160;ARVs. The&#160;frequency&#160;category of&#160;rare&#160;was&#160;</p>
<p style="position:absolute;top:820px;left:154px;white-space:nowrap" class="ft1518">estimated based on&#160;post-marketing reports.&#160;<br/>2</p>
<p style="position:absolute;top:844px;left:159px;white-space:nowrap" class="ft152">&#160;In combination with&#160;increased&#160;transaminases.&#160;</p>
<p style="position:absolute;top:869px;left:85px;white-space:nowrap" class="ft152">&#160;</p>
<p style="position:absolute;top:888px;left:85px;white-space:nowrap" class="ft152">Description&#160;of&#160;selected&#160;adverse reactions&#160;</p>
<p style="position:absolute;top:908px;left:85px;white-space:nowrap" class="ft152">&#160;</p>
<p style="position:absolute;top:928px;left:85px;white-space:nowrap" class="ft155"><i>Changes&#160;in laboratory&#160;biochemistries&#160;</i></p>
<p style="position:absolute;top:947px;left:85px;white-space:nowrap" class="ft152">Dolutegravir&#160;has&#160;been&#160;associated&#160;with&#160;an&#160;increase in&#160;serum&#160;creatinine&#160;occuring&#160;in&#160;the&#160;first&#160;week&#160;of&#160;treatment&#160;</p>
<p style="position:absolute;top:966px;left:85px;white-space:nowrap" class="ft152">when&#160;administered&#160;with&#160;other&#160;antiretroviral&#160;medicinal&#160;products.&#160;Increases&#160;in&#160;serum&#160;creatinine occurred&#160;</p>
<p style="position:absolute;top:986px;left:85px;white-space:nowrap" class="ft152">within&#160;the&#160;first&#160;four&#160;weeks&#160;of&#160;treatment&#160;with dolutegravir&#160;plus&#160;lamivudine&#160;and remained&#160;stable&#160;through&#160;</p>
<p style="position:absolute;top:1005px;left:85px;white-space:nowrap" class="ft152">48&#160;weeks.&#160;In the&#160;pooled&#160;GEMINI studies&#160;a&#160;mean change&#160;from&#160;baseline&#160;of&#160;10.3&#160;µmol/L&#160;(range:&#160;-36.3&#160;µmol/L&#160;</p>
<p style="position:absolute;top:1025px;left:85px;white-space:nowrap" class="ft152">to 55.7&#160;µmol/L)&#160;was&#160;observed after&#160;48&#160;weeks of&#160;treatment.&#160;These&#160;changes are&#160;linked&#160;to the&#160;inhibiting&#160;effect&#160;</p>
<p style="position:absolute;top:1044px;left:85px;white-space:nowrap" class="ft152">of&#160;dolutegravir&#160;on&#160;renal&#160;tubular&#160;transporters&#160;of&#160;creatinine.&#160;The&#160;changes are&#160;not considered&#160;to&#160;be&#160;clinically&#160;</p>
<p style="position:absolute;top:1064px;left:85px;white-space:nowrap" class="ft152">relevant&#160;and&#160;do&#160;not&#160;reflect&#160;a change in&#160;glomerular&#160;filtration&#160;rate.&#160;</p>
<p style="position:absolute;top:1083px;left:85px;white-space:nowrap" class="ft152">&#160;</p>
<p style="position:absolute;top:1103px;left:85px;white-space:nowrap" class="ft155"><i>Co-infection with Hepatitis&#160;B&#160;or&#160;C&#160;</i></p>
<p style="position:absolute;top:1122px;left:85px;white-space:nowrap" class="ft152">In the&#160;Phase&#160;III&#160;studies&#160;for&#160;the&#160;dolutegravir&#160;single&#160;agent, patients&#160;with hepatitis&#160;B&#160;and/or&#160;C&#160;co-infection&#160;were&#160;</p>
<p style="position:absolute;top:1142px;left:85px;white-space:nowrap" class="ft152">permitted to&#160;enrol&#160;provided&#160;that&#160;baseline&#160;liver&#160;chemistry tests&#160;did not&#160;exceed 5&#160;times&#160;the&#160;upper&#160;limit&#160;of&#160;</p>
</div>
<!-- Page 16 -->
<a name="16"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft1619{font-size:17px;font-family:DTAKKI+TimesNewRomanPSMT;color:#0000ff;}
-->
</style>
<div id="page16-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1191px;left:436px;white-space:nowrap" class="ft160">16&#160;</p>
<p style="position:absolute;top:83px;left:85px;white-space:nowrap" class="ft162">normal&#160;(ULN). Overall,&#160;the&#160;safety profile&#160;in patients&#160;co-infected&#160;with&#160;hepatitis&#160;B&#160;and/or&#160;C&#160;was&#160;similar&#160;to&#160;that&#160;</p>
<p style="position:absolute;top:103px;left:85px;white-space:nowrap" class="ft162">observed&#160;in patients&#160;without&#160;hepatitis&#160;B&#160;or&#160;C&#160;co-infection,&#160;although the&#160;rates&#160;of&#160;AST&#160;and ALT&#160;abnormalities&#160;</p>
<p style="position:absolute;top:122px;left:85px;white-space:nowrap" class="ft162">were&#160;higher&#160;in the&#160;subgroup with&#160;hepatitis&#160;B&#160;and/or&#160;C&#160;co-infection&#160;for&#160;all&#160;treatment&#160;groups. Liver&#160;chemistry&#160;</p>
<p style="position:absolute;top:142px;left:85px;white-space:nowrap" class="ft162">elevations&#160;consistent&#160;with&#160;immune&#160;reconstitution&#160;syndrome were observed&#160;in&#160;some subjects with&#160;hepatitis B&#160;</p>
<p style="position:absolute;top:162px;left:85px;white-space:nowrap" class="ft162">and/or&#160;C&#160;co-infection at&#160;the&#160;start&#160;of&#160;dolutegravir&#160;therapy, particularly in those&#160;whose&#160;anti-hepatitis&#160;B&#160;therapy&#160;</p>
<p style="position:absolute;top:181px;left:85px;white-space:nowrap" class="ft162">was withdrawn&#160;(see section&#160;4.4).&#160;</p>
<p style="position:absolute;top:200px;left:85px;white-space:nowrap" class="ft162">&#160;</p>
<p style="position:absolute;top:220px;left:85px;white-space:nowrap" class="ft165"><i>Metabolic&#160;parameters&#160;&#160;</i></p>
<p style="position:absolute;top:239px;left:85px;white-space:nowrap" class="ft162">Weight&#160;and levels&#160;of&#160;blood lipids&#160;and&#160;glucose&#160;may increase&#160;during&#160;antiretroviral&#160;therapy&#160;(see&#160;section 4.4).&#160;</p>
<p style="position:absolute;top:259px;left:85px;white-space:nowrap" class="ft165"><i>&#160;</i></p>
<p style="position:absolute;top:279px;left:85px;white-space:nowrap" class="ft165"><i>Osteonecrosis&#160;&#160;</i></p>
<p style="position:absolute;top:298px;left:85px;white-space:nowrap" class="ft162">Cases of&#160;osteonecrosis have been&#160;reported,&#160;particularly in patients&#160;with generally&#160;acknowledged risk&#160;factors,&#160;</p>
<p style="position:absolute;top:317px;left:85px;white-space:nowrap" class="ft162">advanced&#160;HIV&#160;disease&#160;or&#160;long-term&#160;exposure&#160;to CART. The&#160;frequency of&#160;this&#160;is&#160;unknown (see&#160;section 4.4).&#160;</p>
<p style="position:absolute;top:337px;left:85px;white-space:nowrap" class="ft165"><i>&#160;</i></p>
<p style="position:absolute;top:357px;left:85px;white-space:nowrap" class="ft165"><i>Immune&#160;response&#160;syndrome&#160;</i></p>
<p style="position:absolute;top:376px;left:85px;white-space:nowrap" class="ft162">In&#160;HIV-infected&#160;patients with&#160;severe immune&#160;deficiency&#160;at&#160;the&#160;time&#160;of&#160;initiation&#160;of&#160;combination&#160;antiretroviral&#160;</p>
<p style="position:absolute;top:396px;left:85px;white-space:nowrap" class="ft162">therapy (CART),&#160;an inflammatory reaction to&#160;asymptomatic&#160;or&#160;residual&#160;opportunistic&#160;infections&#160;may&#160;arise.&#160;</p>
<p style="position:absolute;top:415px;left:85px;white-space:nowrap" class="ft162">Autoimmune disorders&#160;(such&#160;as Graves’&#160;disease&#160;and autoimmune&#160;hepatitis)&#160;have&#160;also been reported;&#160;</p>
<p style="position:absolute;top:434px;left:85px;white-space:nowrap" class="ft162">however,&#160;the&#160;reported&#160;time&#160;to onset&#160;is&#160;more&#160;variable&#160;and these&#160;events&#160;can occur&#160;many months&#160;after&#160;initiation&#160;</p>
<p style="position:absolute;top:454px;left:85px;white-space:nowrap" class="ft162">of&#160;treatment&#160;(see section&#160;4.4).&#160;</p>
<p style="position:absolute;top:474px;left:85px;white-space:nowrap" class="ft162">&#160;</p>
<p style="position:absolute;top:493px;left:85px;white-space:nowrap" class="ft162">Paediatric&#160;population&#160;</p>
<p style="position:absolute;top:513px;left:85px;white-space:nowrap" class="ft162">&#160;</p>
<p style="position:absolute;top:532px;left:85px;white-space:nowrap" class="ft162">There&#160;are&#160;no&#160;clinical&#160;study&#160;data&#160;on&#160;the effects of&#160;Dovato&#160;in&#160;the&#160;paediatric&#160;population. Individual&#160;components&#160;</p>
<p style="position:absolute;top:551px;left:85px;white-space:nowrap" class="ft162">have&#160;been investigated in&#160;adolescents&#160;(12 to&#160;17&#160;years).&#160;</p>
<p style="position:absolute;top:571px;left:85px;white-space:nowrap" class="ft162">&#160;</p>
<p style="position:absolute;top:590px;left:85px;white-space:nowrap" class="ft162">Based on&#160;limited available&#160;data&#160;with&#160;the&#160;dolutegravir&#160;single&#160;entity&#160;or&#160;lamivudine&#160;single&#160;entity&#160;used in&#160;</p>
<p style="position:absolute;top:610px;left:85px;white-space:nowrap" class="ft162">combination with other&#160;antiretroviral&#160;agents&#160;to treat&#160;adolescents&#160;(12 to 17 years),&#160;there&#160;were&#160;no additional&#160;</p>
<p style="position:absolute;top:630px;left:85px;white-space:nowrap" class="ft162">types&#160;of&#160;adverse&#160;reactions&#160;beyond&#160;those&#160;observed in&#160;the&#160;adult&#160;population.&#160;</p>
<p style="position:absolute;top:649px;left:85px;white-space:nowrap" class="ft162">&#160;</p>
<p style="position:absolute;top:668px;left:85px;white-space:nowrap" class="ft162">Reporting of&#160;suspected&#160;adverse&#160;reactions&#160;</p>
<p style="position:absolute;top:688px;left:85px;white-space:nowrap" class="ft162">&#160;</p>
<p style="position:absolute;top:707px;left:85px;white-space:nowrap" class="ft162">Reporting&#160;suspected adverse&#160;reactions&#160;after&#160;authorisation of&#160;the&#160;medicinal&#160;product&#160;is&#160;important. It&#160;allows&#160;</p>
<p style="position:absolute;top:727px;left:85px;white-space:nowrap" class="ft162">continued&#160;monitoring of&#160;the&#160;benefit/risk balance&#160;of&#160;the&#160;medicinal&#160;product. Healthcare&#160;professionals&#160;are&#160;asked&#160;</p>
<p style="position:absolute;top:747px;left:85px;white-space:nowrap" class="ft162">to&#160;report&#160;any&#160;suspected&#160;adverse&#160;reactions via&#160;the national&#160;reporting&#160;system&#160;listed&#160;in<a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">&#160;Appendix V.</a>&#160;</p>
<p style="position:absolute;top:766px;left:85px;white-space:nowrap" class="ft162">&#160;</p>
<p style="position:absolute;top:785px;left:85px;white-space:nowrap" class="ft162">&#160;</p>
<p style="position:absolute;top:805px;left:85px;white-space:nowrap" class="ft161"><b>4.9&#160;&#160;Overdose&#160;</b>&#160;</p>
<p style="position:absolute;top:824px;left:85px;white-space:nowrap" class="ft162">&#160;</p>
<p style="position:absolute;top:844px;left:85px;white-space:nowrap" class="ft162">No&#160;specific symptoms or&#160;signs have been&#160;identified&#160;following&#160;acute overdose with&#160;dolutegravir&#160;or&#160;</p>
<p style="position:absolute;top:864px;left:85px;white-space:nowrap" class="ft162">lamivudine,&#160;apart&#160;from&#160;those listed&#160;as&#160;adverse reactions.&#160;</p>
<p style="position:absolute;top:883px;left:85px;white-space:nowrap" class="ft162">&#160;</p>
<p style="position:absolute;top:902px;left:85px;white-space:nowrap" class="ft162">There&#160;is&#160;no specific&#160;treatment&#160;for&#160;an&#160;overdose&#160;of&#160;Dovato. If&#160;overdose&#160;occurs,&#160;the&#160;patient&#160;should be&#160;treated&#160;</p>
<p style="position:absolute;top:922px;left:85px;white-space:nowrap" class="ft162">supportively with appropriate&#160;monitoring, as&#160;necessary.&#160;Since&#160;lamivudine&#160;is&#160;dialysable, continuous&#160;</p>
<p style="position:absolute;top:941px;left:85px;white-space:nowrap" class="ft162">haemodialysis&#160;could be&#160;used in&#160;the&#160;treatment&#160;of&#160;overdose, although&#160;this&#160;has&#160;not&#160;been studied. As&#160;dolutegravir&#160;</p>
<p style="position:absolute;top:961px;left:85px;white-space:nowrap" class="ft162">is&#160;highly&#160;bound&#160;to&#160;plasma&#160;proteins,&#160;it is&#160;unlikely&#160;that&#160;it&#160;will&#160;be&#160;significantly&#160;removed&#160;by&#160;dialysis.&#160;</p>
<p style="position:absolute;top:981px;left:85px;white-space:nowrap" class="ft162">&#160;</p>
<p style="position:absolute;top:1000px;left:85px;white-space:nowrap" class="ft162">&#160;</p>
<p style="position:absolute;top:1019px;left:85px;white-space:nowrap" class="ft161"><b>5.&#160;</b></p>
<p style="position:absolute;top:1019px;left:127px;white-space:nowrap" class="ft161"><b>PHARMACOLOGICAL&#160;PROPERTIES</b>&#160;</p>
<p style="position:absolute;top:1039px;left:85px;white-space:nowrap" class="ft162">&#160;</p>
<p style="position:absolute;top:1058px;left:85px;white-space:nowrap" class="ft161"><b>5.1&#160;&#160;&#160;Pharmacodynamic&#160;properties&#160;</b>&#160;</p>
<p style="position:absolute;top:1078px;left:85px;white-space:nowrap" class="ft162">&#160;</p>
<p style="position:absolute;top:1098px;left:85px;white-space:nowrap" class="ft162">Pharmacotherapeutic&#160;group:&#160;Antivirals&#160;for&#160;systemic&#160;use, antivirals&#160;for&#160;treatment&#160;of&#160;HIV&#160;infections,&#160;</p>
<p style="position:absolute;top:1117px;left:85px;white-space:nowrap" class="ft162">combinations. ATC&#160;code:&#160;J05AR25&#160;</p>
<p style="position:absolute;top:1137px;left:85px;white-space:nowrap" class="ft165"><i>&#160;</i></p>
<p style="position:absolute;top:1156px;left:85px;white-space:nowrap" class="ft162">Mechanism&#160;of&#160;action&#160;</p>
</div>
<!-- Page 17 -->
<a name="17"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page17-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1191px;left:436px;white-space:nowrap" class="ft170">17&#160;</p>
<p style="position:absolute;top:83px;left:85px;white-space:nowrap" class="ft172">&#160;</p>
<p style="position:absolute;top:103px;left:85px;white-space:nowrap" class="ft172">Dolutegravir&#160;inhibits&#160;HIV&#160;integrase&#160;by binding&#160;to the&#160;integrase&#160;active&#160;site&#160;and&#160;blocking&#160;the&#160;strand&#160;transfer&#160;</p>
<p style="position:absolute;top:122px;left:85px;white-space:nowrap" class="ft172">step&#160;of&#160;retroviral&#160;Deoxyribonucleic&#160;acid&#160;(DNA)&#160;integration&#160;which&#160;is essential&#160;for&#160;the HIV&#160;replication&#160;cycle.&#160;</p>
<p style="position:absolute;top:142px;left:85px;white-space:nowrap" class="ft172">&#160;</p>
<p style="position:absolute;top:162px;left:85px;white-space:nowrap" class="ft172">Lamivudine,&#160;via&#160;its&#160;active&#160;metabolite&#160;5'-triphosphates&#160;(TP)&#160;(an&#160;analogue&#160;for&#160;cytidine),&#160;inhibits&#160;reverse&#160;</p>
<p style="position:absolute;top:181px;left:85px;white-space:nowrap" class="ft172">transcriptase of&#160;HIV-1 and HIV-2 through incorporation of&#160;the&#160;monophosphate&#160;form&#160;into&#160;the&#160;viral&#160;DNA&#160;</p>
<p style="position:absolute;top:200px;left:85px;white-space:nowrap" class="ft172">chain, resulting in chain&#160;termination.&#160;Lamivudine&#160;triphosphate&#160;shows&#160;significantly&#160;less&#160;affinity&#160;for&#160;host&#160;cell&#160;</p>
<p style="position:absolute;top:220px;left:85px;white-space:nowrap" class="ft172">DNA polymerases.&#160;</p>
<p style="position:absolute;top:239px;left:85px;white-space:nowrap" class="ft172">&#160;</p>
<p style="position:absolute;top:259px;left:85px;white-space:nowrap" class="ft172">Pharmacodynamic effects&#160;</p>
<p style="position:absolute;top:279px;left:85px;white-space:nowrap" class="ft175"><i>&#160;</i></p>
<p style="position:absolute;top:298px;left:85px;white-space:nowrap" class="ft175"><i>Antiviral&#160;activity in&#160;cell&#160;culture&#160;&#160;</i></p>
<p style="position:absolute;top:317px;left:85px;white-space:nowrap" class="ft172">Dolutegravir&#160;and lamivudine&#160;have&#160;been shown to&#160;inhibit&#160;replication&#160;of&#160;lab-strains&#160;and&#160;clinical isolates of&#160;</p>
<p style="position:absolute;top:337px;left:85px;white-space:nowrap" class="ft172">HIV&#160;in a&#160;number&#160;of&#160;cell&#160;types, including transformed T&#160;cell&#160;lines,&#160;monocyte/macrophage&#160;derived&#160;lines&#160;and&#160;</p>
<p style="position:absolute;top:356px;left:85px;white-space:nowrap" class="ft172">primary cultures&#160;of&#160;activated peripheral&#160;blood&#160;mononuclear&#160;cells (PMBCs)&#160;and monocyte/macrophages.&#160;The&#160;</p>
<p style="position:absolute;top:376px;left:85px;white-space:nowrap" class="ft172">concentration of&#160;active substance&#160;necessary to&#160;effect&#160;viral&#160;replication by&#160;50%&#160;(IC50&#160;-&#160;half&#160;maximal inhibitory&#160;</p>
<p style="position:absolute;top:396px;left:85px;white-space:nowrap" class="ft172">concentration)&#160;varied according&#160;to virus&#160;and host&#160;cell&#160;type.&#160;</p>
<p style="position:absolute;top:415px;left:85px;white-space:nowrap" class="ft172">&#160;</p>
<p style="position:absolute;top:434px;left:85px;white-space:nowrap" class="ft172">The&#160;IC50&#160;for&#160;dolutegravir&#160;in&#160;various&#160;lab-strains&#160;using PBMC&#160;was&#160;0.5&#160;nM, and when using MT-4&#160;cells&#160;it&#160;</p>
<p style="position:absolute;top:454px;left:85px;white-space:nowrap" class="ft172">ranged from&#160;0.7-2&#160;nM.&#160;Similar&#160;IC50s were&#160;seen&#160;for&#160;clinical&#160;isolates without&#160;any&#160;major&#160;difference between&#160;</p>
<p style="position:absolute;top:473px;left:85px;white-space:nowrap" class="ft172">subtypes;&#160;in&#160;a&#160;panel&#160;of&#160;24&#160;HIV-1 isolates&#160;of&#160;clades&#160;A,&#160;B, C, D, E, F&#160;and G&#160;and&#160;group O&#160;the&#160;mean IC50&#160;value&#160;</p>
<p style="position:absolute;top:493px;left:85px;white-space:nowrap" class="ft172">was&#160;0.2&#160;nM&#160;(range&#160;0.02-2.14). The&#160;mean IC50&#160;for&#160;3 HIV-2&#160;isolates was 0.18&#160;nM&#160;(range&#160;0.09-0.61).&#160;</p>
<p style="position:absolute;top:513px;left:85px;white-space:nowrap" class="ft172">&#160;</p>
<p style="position:absolute;top:532px;left:85px;white-space:nowrap" class="ft172">The&#160;median or&#160;mean IC50&#160;values&#160;for&#160;lamivudine&#160;against&#160;lab-strains&#160;of HIV-1 ranged from&#160;0.007 to 2.3&#160;µM.&#160;</p>
<p style="position:absolute;top:551px;left:85px;white-space:nowrap" class="ft172">The mean&#160;IC50&#160;against&#160;lab-strains&#160;of&#160;HIV-2&#160;(LAV2&#160;and&#160;EHO)&#160;ranged&#160;from&#160;0.16 to 0.51&#160;µM&#160;for&#160;lamivudine.&#160;</p>
<p style="position:absolute;top:571px;left:85px;white-space:nowrap" class="ft172">The&#160;IC50&#160;values&#160;of&#160;lamivudine&#160;against&#160;HIV-1&#160;subtypes&#160;(A-G)&#160;ranged from&#160;0.001&#160;to&#160;0.170&#160;µM, against&#160;Group&#160;</p>
<p style="position:absolute;top:590px;left:85px;white-space:nowrap" class="ft172">O&#160;from&#160;0.030&#160;to&#160;0.160&#160;µM&#160;and&#160;against&#160;HIV-2 isolates&#160;from&#160;0.002 to&#160;0.120&#160;µM&#160;in peripheral&#160;blood&#160;</p>
<p style="position:absolute;top:610px;left:85px;white-space:nowrap" class="ft172">mononuclear&#160;cells.&#160;</p>
<p style="position:absolute;top:630px;left:85px;white-space:nowrap" class="ft172">&#160;</p>
<p style="position:absolute;top:649px;left:85px;white-space:nowrap" class="ft172">HIV-1 isolates&#160;(CRF01_AE,&#160;n=12;&#160;CRF02_AG, n=12;&#160;and Subtype&#160;C&#160;or&#160;CRF_AC, n=13)&#160;from&#160;37 untreated&#160;</p>
<p style="position:absolute;top:668px;left:85px;white-space:nowrap" class="ft172">patients in&#160;Africa and&#160;Asia&#160;were susceptible to&#160;lamivudine&#160;(IC50&#160;fold changes&#160;&lt;&#160;3.0). Group O&#160;isolates&#160;from&#160;</p>
<p style="position:absolute;top:688px;left:85px;white-space:nowrap" class="ft172">antiviral naïve&#160;patients&#160;tested&#160;for&#160;lamivudine&#160;activity&#160;were&#160;highly&#160;sensitive.&#160;</p>
<p style="position:absolute;top:707px;left:85px;white-space:nowrap" class="ft172">&#160;</p>
<p style="position:absolute;top:727px;left:85px;white-space:nowrap" class="ft175"><i>Effect&#160;of&#160;human serum&#160;&#160;</i></p>
<p style="position:absolute;top:747px;left:85px;white-space:nowrap" class="ft172">In 100%&#160;human&#160;serum, the&#160;mean&#160;fold shift&#160;for&#160;dolutegravir&#160;activity was&#160;75&#160;fold, resulting in&#160;protein&#160;adjusted&#160;</p>
<p style="position:absolute;top:766px;left:85px;white-space:nowrap" class="ft172">IC90&#160;of&#160;0.064&#160;µg/mL.&#160;Lamivudine&#160;exhibits&#160;linear&#160;pharmacokinetics&#160;over&#160;the&#160;therapeutic&#160;dose&#160;range&#160;and&#160;</p>
<p style="position:absolute;top:785px;left:85px;white-space:nowrap" class="ft172">displays&#160;low&#160;plasma&#160;protein binding&#160;(less&#160;than&#160;36%).<i>&#160;</i>&#160;</p>
<p style="position:absolute;top:805px;left:85px;white-space:nowrap" class="ft172">&#160;</p>
<p style="position:absolute;top:824px;left:85px;white-space:nowrap" class="ft172">Resistance&#160;</p>
<p style="position:absolute;top:844px;left:85px;white-space:nowrap" class="ft172">&#160;</p>
<p style="position:absolute;top:864px;left:85px;white-space:nowrap" class="ft172">Dovato&#160;is indicated&#160;in&#160;the&#160;absence&#160;of&#160;documented&#160;or&#160;suspected&#160;resistance&#160;to&#160;the&#160;integrase inhibitor&#160;class&#160;and&#160;</p>
<p style="position:absolute;top:883px;left:85px;white-space:nowrap" class="ft172">to lamivudine&#160;(see&#160;section&#160;4.1). For&#160;information around in vitro resistance, and&#160;cross&#160;resistance&#160;to other&#160;</p>
<p style="position:absolute;top:902px;left:85px;white-space:nowrap" class="ft172">agents of&#160;the integrase-&#160;and&#160;NRTI&#160;class,&#160;please&#160;refer&#160;to&#160;the SmPCs of&#160;dolutegravir&#160;and&#160;lamivudine.&#160;&#160;</p>
<p style="position:absolute;top:922px;left:85px;white-space:nowrap" class="ft172">&#160;</p>
<p style="position:absolute;top:941px;left:85px;white-space:nowrap" class="ft172">None&#160;of&#160;the&#160;twelve&#160;subjects&#160;in the&#160;dolutegravir&#160;plus&#160;lamivudine&#160;group or&#160;the&#160;nine&#160;subjects in&#160;the&#160;dolutegravir&#160;</p>
<p style="position:absolute;top:961px;left:85px;white-space:nowrap" class="ft172">plus&#160;tenofovir&#160;disoproxil/emtricitabine&#160;FDC&#160;group&#160;that met virological withdrawal criteria&#160;through&#160;Week&#160;</p>
<p style="position:absolute;top:981px;left:85px;white-space:nowrap" class="ft172">144&#160;across&#160;the GEMINI-1 (204861)&#160;and GEMINI-2 (205543)&#160;studies&#160;had&#160;treatment&#160;emergent&#160;integrase&#160;</p>
<p style="position:absolute;top:1000px;left:85px;white-space:nowrap" class="ft172">inhibitor&#160;or&#160;NRTI&#160;class&#160;resistance.&#160;</p>
<p style="position:absolute;top:1019px;left:85px;white-space:nowrap" class="ft172">&#160;</p>
<p style="position:absolute;top:1039px;left:85px;white-space:nowrap" class="ft172">In previously untreated patients&#160;receiving&#160;dolutegravir&#160;+&#160;2 NRTIs&#160;in Phase&#160;IIb and&#160;Phase&#160;III, no development&#160;</p>
<p style="position:absolute;top:1058px;left:85px;white-space:nowrap" class="ft172">of&#160;resistance to&#160;the integrase&#160;inhibitor&#160;class, or&#160;to&#160;the&#160;NRTI&#160;class&#160;was&#160;seen (n=1118 follow-up of&#160;</p>
<p style="position:absolute;top:1078px;left:85px;white-space:nowrap" class="ft172">48-96&#160;weeks).&#160;&#160;</p>
<p style="position:absolute;top:1098px;left:85px;white-space:nowrap" class="ft172">&#160;</p>
<p style="position:absolute;top:1117px;left:85px;white-space:nowrap" class="ft172">Effects on&#160;electrocardiogram&#160;</p>
<p style="position:absolute;top:1136px;left:85px;white-space:nowrap" class="ft172">&#160;</p>
</div>
<!-- Page 18 -->
<a name="18"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page18-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1191px;left:436px;white-space:nowrap" class="ft180">18&#160;</p>
<p style="position:absolute;top:83px;left:85px;white-space:nowrap" class="ft182">No&#160;relevant&#160;effects were seen&#160;with&#160;dolutegravir&#160;on&#160;the&#160;QTc interval,&#160;with&#160;doses&#160;exceeding&#160;the&#160;clinical&#160;dose&#160;</p>
<p style="position:absolute;top:103px;left:85px;white-space:nowrap" class="ft182">by approximately&#160;three&#160;fold.&#160;A&#160;similar&#160;study&#160;was&#160;not&#160;conducted&#160;with lamivudine.&#160;</p>
<p style="position:absolute;top:122px;left:85px;white-space:nowrap" class="ft182">&#160;</p>
<p style="position:absolute;top:142px;left:85px;white-space:nowrap" class="ft182">Clinical&#160;efficacy&#160;and&#160;safety</p>
<p style="position:absolute;top:142px;left:266px;white-space:nowrap" class="ft181"><b>&#160;&#160;</b></p>
<p style="position:absolute;top:171px;left:85px;white-space:nowrap" class="ft1813"><i>Antiretroviral&#160;naïve subjects</i>&#160;&#160;<br/>The efficacy&#160;of&#160;Dovato&#160;is&#160;supported by data&#160;from&#160;2&#160;identical&#160;148-week,&#160;Phase&#160;III,&#160;randomised, double-blind,&#160;</p>
<p style="position:absolute;top:218px;left:85px;white-space:nowrap" class="ft182">multicentre,&#160;parallel-group,&#160;non-inferiority&#160;controlled&#160;trials&#160;GEMINI-1 (204861)&#160;and&#160;GEMINI-2 (205543).&#160;A&#160;</p>
<p style="position:absolute;top:238px;left:85px;white-space:nowrap" class="ft182">total&#160;of&#160;1433 HIV-1 infected antiretroviral&#160;treatment-naïve&#160;adult&#160;subjects received&#160;treatment&#160;in&#160;the trials.&#160;</p>
<p style="position:absolute;top:257px;left:85px;white-space:nowrap" class="ft182">Subjects were&#160;enrolled&#160;with&#160;a screening&#160;plasma HIV-1&#160;RNA&#160;of&#160;1000&#160;c/mL&#160;to&#160;≤500,000&#160;c/mL.&#160;Subjects were&#160;</p>
<p style="position:absolute;top:277px;left:85px;white-space:nowrap" class="ft182">randomised&#160;to a&#160;two-drug&#160;regimen of&#160;dolutegravir&#160;50&#160;mg&#160;plus&#160;lamivudine&#160;300&#160;mg&#160;once daily or&#160;dolutegravir&#160;</p>
<p style="position:absolute;top:297px;left:85px;white-space:nowrap" class="ft182">50&#160;mg&#160;plus&#160;tenofovir&#160;disoproxil/emtricitabine&#160;245/200&#160;mg&#160;once&#160;daily. The&#160;primary&#160;efficacy endpoint&#160;for&#160;</p>
<p style="position:absolute;top:316px;left:85px;white-space:nowrap" class="ft182">each&#160;GEMINI&#160;trial&#160;was&#160;the&#160;proportion&#160;of&#160;subjects&#160;with&#160;plasma HIV-1&#160;RNA &lt;50&#160;copies/mL&#160;at&#160;Week&#160;48&#160;</p>
<p style="position:absolute;top:335px;left:85px;white-space:nowrap" class="ft182">(Snapshot&#160;algorithm&#160;for&#160;the&#160;ITT-E&#160;population).&#160;Double&#160;blind therapy &#160;continued&#160;up to week 96,&#160;followed&#160;by&#160;</p>
<p style="position:absolute;top:355px;left:85px;white-space:nowrap" class="ft182">open label&#160;therapy up&#160;to week 148.&#160;</p>
<p style="position:absolute;top:374px;left:85px;white-space:nowrap" class="ft182">&#160;</p>
<p style="position:absolute;top:394px;left:85px;white-space:nowrap" class="ft182">At&#160;baseline,&#160;in&#160;the pooled&#160;analysis,&#160;the median&#160;age of&#160;subjects was 33&#160;years,&#160;15%&#160;were female,&#160;69%&#160;were&#160;</p>
<p style="position:absolute;top:414px;left:85px;white-space:nowrap" class="ft182">white,&#160;9%&#160;were&#160;CDC&#160;Stage&#160;3 (AIDS), 20%&#160;had&#160;HIV-1 RNA&#160;&gt;100,000&#160;copies/mL,&#160;and 8%&#160;had CD4+&#160;cell&#160;</p>
<p style="position:absolute;top:433px;left:85px;white-space:nowrap" class="ft182">count&#160;less&#160;than&#160;200&#160;cells&#160;per&#160;mm3;&#160;these characteristics&#160;were similar&#160;between&#160;studies and&#160;treatment&#160;arms.&#160;&#160;</p>
<p style="position:absolute;top:452px;left:85px;white-space:nowrap" class="ft182">&#160;</p>
<p style="position:absolute;top:472px;left:85px;white-space:nowrap" class="ft182">In the&#160;primary week&#160;48 analysis,&#160;dolutegravir&#160;plus&#160;lamivudine&#160;was&#160;non-inferior&#160;to&#160;dolutegravir&#160;plus&#160;tenofovir&#160;</p>
<p style="position:absolute;top:491px;left:85px;white-space:nowrap" class="ft182">disoproxil/emtricitabine&#160;FDC&#160;in&#160;GEMINI-1 and GEMINI-2 studies. This&#160;was&#160;supported by&#160;the&#160;pooled&#160;</p>
<p style="position:absolute;top:511px;left:85px;white-space:nowrap" class="ft182">analysis,&#160;see&#160;Table&#160;3.&#160;</p>
</div>
<!-- Page 19 -->
<a name="19"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft1920{font-size:10px;font-family:PVDJWK+TimesNewRomanPS;color:#000000;}
	.ft1921{font-size:15px;font-family:DTAKKI+TimesNewRomanPSMT;color:#000000;}
	.ft1922{font-size:15px;font-family:FOBBME+TimesNewRomanPSMT;color:#000000;}
	.ft1923{font-size:15px;font-family:FZYRME+ArialNarrow;color:#000000;}
-->
</style>
<div id="page19-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1191px;left:436px;white-space:nowrap" class="ft190">19&#160;</p>
<p style="position:absolute;top:83px;left:85px;white-space:nowrap" class="ft191"><b>Table&#160;3&#160;</b></p>
<p style="position:absolute;top:83px;left:193px;white-space:nowrap" class="ft191"><b>Virologic&#160;Outcomes of&#160;Randomised&#160;Treatment&#160;of&#160;GEMINI&#160;at&#160;Week&#160;48 (Snapshot&#160;</b></p>
<p style="position:absolute;top:103px;left:193px;white-space:nowrap" class="ft191"><b>algorithm)&#160;</b></p>
<p style="position:absolute;top:123px;left:94px;white-space:nowrap" class="ft192">&#160;</p>
<p style="position:absolute;top:123px;left:472px;white-space:nowrap" class="ft191"><b>GEMINI-1&#160;and GEMINI-2&#160;Pooled&#160;</b></p>
<p style="position:absolute;top:143px;left:572px;white-space:nowrap" class="ft191"><b>Data</b>*<b>&#160;</b></p>
<p style="position:absolute;top:163px;left:480px;white-space:nowrap" class="ft191"><b>DTG&#160;+ 3TC&#160;</b></p>
<p style="position:absolute;top:182px;left:499px;white-space:nowrap" class="ft191"><b>N=716&#160;</b></p>
<p style="position:absolute;top:163px;left:602px;white-space:nowrap" class="ft191"><b>DTG&#160;+ TDF/FTC&#160;</b></p>
<p style="position:absolute;top:182px;left:641px;white-space:nowrap" class="ft191"><b>N=717&#160;</b></p>
<p style="position:absolute;top:203px;left:94px;white-space:nowrap" class="ft191"><b>HIV-1&#160;RNA &lt;50&#160;copies/mL</b>&#160;</p>
<p style="position:absolute;top:203px;left:507px;white-space:nowrap" class="ft192">91%&#160;</p>
<p style="position:absolute;top:203px;left:649px;white-space:nowrap" class="ft192">93%&#160;</p>
<p style="position:absolute;top:223px;left:94px;white-space:nowrap" class="ft191"><b>&#160;Treatment&#160;Difference</b>†&#160;(95%&#160;confidence intervals)<b>&#160;</b></p>
<p style="position:absolute;top:223px;left:545px;white-space:nowrap" class="ft192">-1.7 (-4.4, 1.1)&#160;</p>
<p style="position:absolute;top:243px;left:94px;white-space:nowrap" class="ft191"><b>Virologic&#160;non response</b>&#160;</p>
<p style="position:absolute;top:243px;left:511px;white-space:nowrap" class="ft192">3%&#160;</p>
<p style="position:absolute;top:243px;left:653px;white-space:nowrap" class="ft192">2%&#160;</p>
<p style="position:absolute;top:263px;left:94px;white-space:nowrap" class="ft192">Reasons</p>
<p style="position:absolute;top:263px;left:149px;white-space:nowrap" class="ft191"><b>&#160;</b></p>
<p style="position:absolute;top:263px;left:522px;white-space:nowrap" class="ft192">&#160;</p>
<p style="position:absolute;top:263px;left:664px;white-space:nowrap" class="ft192">&#160;</p>
<p style="position:absolute;top:282px;left:104px;white-space:nowrap" class="ft197">Data&#160;in window&#160;and&#160;≥50&#160;copies/mL&#160;&#160;</p>
<p style="position:absolute;top:282px;left:511px;white-space:nowrap" class="ft192">1%&#160;</p>
<p style="position:absolute;top:282px;left:648px;white-space:nowrap" class="ft192">&lt;1%&#160;</p>
<p style="position:absolute;top:302px;left:104px;white-space:nowrap" class="ft192">Discontinued for&#160;lack&#160;of&#160;efficacy&#160;</p>
<p style="position:absolute;top:302px;left:506px;white-space:nowrap" class="ft192">&lt;1%&#160;</p>
<p style="position:absolute;top:302px;left:648px;white-space:nowrap" class="ft192">&lt;1%&#160;</p>
<p style="position:absolute;top:321px;left:104px;white-space:nowrap" class="ft197">Discontinued&#160;for&#160;other&#160;reasons&#160;and&#160;≥50&#160;copies/mL&#160;</p>
<p style="position:absolute;top:321px;left:506px;white-space:nowrap" class="ft192">&lt;1%&#160;</p>
<p style="position:absolute;top:321px;left:648px;white-space:nowrap" class="ft192">&lt;1%&#160;</p>
<p style="position:absolute;top:341px;left:104px;white-space:nowrap" class="ft192">Change&#160;in&#160;ART&#160;</p>
<p style="position:absolute;top:341px;left:506px;white-space:nowrap" class="ft192">&lt;1%&#160;</p>
<p style="position:absolute;top:341px;left:648px;white-space:nowrap" class="ft192">&lt;1%&#160;</p>
<p style="position:absolute;top:361px;left:94px;white-space:nowrap" class="ft191"><b>No virologic&#160;data at&#160;Week&#160;48 window&#160;</b></p>
<p style="position:absolute;top:361px;left:511px;white-space:nowrap" class="ft192">6%&#160;</p>
<p style="position:absolute;top:361px;left:653px;white-space:nowrap" class="ft192">5%&#160;&#160;</p>
<p style="position:absolute;top:380px;left:94px;white-space:nowrap" class="ft192">Reasons</p>
<p style="position:absolute;top:380px;left:149px;white-space:nowrap" class="ft191"><b>&#160;</b></p>
<p style="position:absolute;top:380px;left:522px;white-space:nowrap" class="ft192">&#160;</p>
<p style="position:absolute;top:380px;left:664px;white-space:nowrap" class="ft192">&#160;</p>
<p style="position:absolute;top:400px;left:107px;white-space:nowrap" class="ft192">Discontinued study&#160;due&#160;to adverse&#160;event&#160;or&#160;death&#160;&#160;</p>
<p style="position:absolute;top:400px;left:511px;white-space:nowrap" class="ft192">1%&#160;</p>
<p style="position:absolute;top:400px;left:653px;white-space:nowrap" class="ft192">2%&#160;</p>
<p style="position:absolute;top:419px;left:107px;white-space:nowrap" class="ft192">Discontinued&#160;study for&#160;other&#160;reasons&#160;</p>
<p style="position:absolute;top:419px;left:511px;white-space:nowrap" class="ft192">4%&#160;</p>
<p style="position:absolute;top:419px;left:653px;white-space:nowrap" class="ft192">3%&#160;&#160;</p>
<p style="position:absolute;top:439px;left:107px;white-space:nowrap" class="ft192">Missing data&#160;during window&#160;but&#160;on&#160;study&#160;</p>
<p style="position:absolute;top:439px;left:506px;white-space:nowrap" class="ft192">&lt;1%&#160;</p>
<p style="position:absolute;top:439px;left:653px;white-space:nowrap" class="ft192">0%&#160;</p>
<p style="position:absolute;top:459px;left:377px;white-space:nowrap" class="ft191"><b>HIV-1&#160;RNA &lt;50&#160;copies/mL&#160;by&#160;baseline&#160;covariates</b>&#160;</p>
<p style="position:absolute;top:479px;left:94px;white-space:nowrap" class="ft191"><b>&#160;</b></p>
<p style="position:absolute;top:479px;left:495px;white-space:nowrap" class="ft192">n/N&#160;(%)&#160;</p>
<p style="position:absolute;top:479px;left:637px;white-space:nowrap" class="ft192">n/N&#160;(%)&#160;</p>
<p style="position:absolute;top:499px;left:94px;white-space:nowrap" class="ft191"><b>Baseline&#160;Plasma&#160;Viral&#160;Load&#160;(copies/mL)&#160;</b></p>
<p style="position:absolute;top:518px;left:94px;white-space:nowrap" class="ft197">≤100,000&#160;</p>
<p style="position:absolute;top:538px;left:94px;white-space:nowrap" class="ft192">&gt;100,000&#160;</p>
<p style="position:absolute;top:499px;left:522px;white-space:nowrap" class="ft192">&#160;</p>
<p style="position:absolute;top:518px;left:468px;white-space:nowrap" class="ft192">526 /&#160;576 (91%)&#160;</p>
<p style="position:absolute;top:538px;left:468px;white-space:nowrap" class="ft192">129 /&#160;140 (92%)&#160;</p>
<p style="position:absolute;top:499px;left:664px;white-space:nowrap" class="ft192">&#160;</p>
<p style="position:absolute;top:518px;left:610px;white-space:nowrap" class="ft192">531 /&#160;564 (94%)&#160;</p>
<p style="position:absolute;top:538px;left:610px;white-space:nowrap" class="ft192">138 /&#160;153 (90%)&#160;</p>
<p style="position:absolute;top:558px;left:94px;white-space:nowrap" class="ft191"><b>Baseline CD4+&#160;(cells/&#160;mm3)&#160;</b></p>
<p style="position:absolute;top:558px;left:522px;white-space:nowrap" class="ft192">&#160;</p>
<p style="position:absolute;top:558px;left:664px;white-space:nowrap" class="ft192">&#160;</p>
<p style="position:absolute;top:578px;left:94px;white-space:nowrap" class="ft197">≤200&#160;&#160;</p>
<p style="position:absolute;top:578px;left:476px;white-space:nowrap" class="ft192">50 /&#160;63&#160;(79%)&#160;</p>
<p style="position:absolute;top:578px;left:618px;white-space:nowrap" class="ft192">51 /&#160;55&#160;(93%)&#160;</p>
<p style="position:absolute;top:597px;left:94px;white-space:nowrap" class="ft192">&#160;&gt;200&#160;</p>
<p style="position:absolute;top:597px;left:468px;white-space:nowrap" class="ft192">605 /&#160;653 (93%)&#160;</p>
<p style="position:absolute;top:597px;left:610px;white-space:nowrap" class="ft192">618 /&#160;662 (93%)&#160;</p>
<p style="position:absolute;top:617px;left:94px;white-space:nowrap" class="ft191"><b>HIV-1&#160;subtype&#160;</b></p>
<p style="position:absolute;top:617px;left:522px;white-space:nowrap" class="ft192">&#160;</p>
<p style="position:absolute;top:617px;left:664px;white-space:nowrap" class="ft192">&#160;</p>
<p style="position:absolute;top:637px;left:94px;white-space:nowrap" class="ft192">&#160;B&#160;</p>
<p style="position:absolute;top:637px;left:468px;white-space:nowrap" class="ft192">424 /&#160;467 (91%)&#160;</p>
<p style="position:absolute;top:637px;left:610px;white-space:nowrap" class="ft192">452 /&#160;488&#160;(93%)&#160;</p>
<p style="position:absolute;top:657px;left:94px;white-space:nowrap" class="ft192">&#160;A&#160;</p>
<p style="position:absolute;top:657px;left:476px;white-space:nowrap" class="ft192">84 /&#160;86&#160;(98%)&#160;</p>
<p style="position:absolute;top:657px;left:618px;white-space:nowrap" class="ft192">74 /&#160;78&#160;(95%)&#160;</p>
<p style="position:absolute;top:676px;left:94px;white-space:nowrap" class="ft192">&#160;Other&#160;</p>
<p style="position:absolute;top:676px;left:468px;white-space:nowrap" class="ft192">147&#160;/&#160;163 (90%)&#160;</p>
<p style="position:absolute;top:676px;left:610px;white-space:nowrap" class="ft192">143&#160;/&#160;151 (95%)&#160;</p>
<p style="position:absolute;top:696px;left:94px;white-space:nowrap" class="ft191"><b>Gender&#160;</b></p>
<p style="position:absolute;top:696px;left:522px;white-space:nowrap" class="ft192">&#160;</p>
<p style="position:absolute;top:696px;left:601px;white-space:nowrap" class="ft192">&#160;</p>
<p style="position:absolute;top:716px;left:94px;white-space:nowrap" class="ft192">&#160;Male&#160;</p>
<p style="position:absolute;top:716px;left:136px;white-space:nowrap" class="ft191"><b>&#160;</b></p>
<p style="position:absolute;top:716px;left:468px;white-space:nowrap" class="ft192">555 /&#160;603 (92%)&#160;</p>
<p style="position:absolute;top:716px;left:610px;white-space:nowrap" class="ft192">580 /&#160;619 (94%)&#160;</p>
<p style="position:absolute;top:735px;left:94px;white-space:nowrap" class="ft192">&#160;Female&#160;</p>
<p style="position:absolute;top:735px;left:150px;white-space:nowrap" class="ft191"><b>&#160;</b></p>
<p style="position:absolute;top:735px;left:468px;white-space:nowrap" class="ft192">100 /&#160;113 (88%)&#160;</p>
<p style="position:absolute;top:735px;left:618px;white-space:nowrap" class="ft192">89 /&#160;98&#160;(91%)&#160;</p>
<p style="position:absolute;top:755px;left:94px;white-space:nowrap" class="ft191"><b>Race&#160;&#160;</b></p>
<p style="position:absolute;top:756px;left:522px;white-space:nowrap" class="ft192">&#160;</p>
<p style="position:absolute;top:756px;left:664px;white-space:nowrap" class="ft192">&#160;</p>
<p style="position:absolute;top:775px;left:94px;white-space:nowrap" class="ft192">&#160;White&#160;</p>
<p style="position:absolute;top:775px;left:142px;white-space:nowrap" class="ft191"><b>&#160;</b></p>
<p style="position:absolute;top:775px;left:468px;white-space:nowrap" class="ft192">451&#160;/&#160;484&#160;(93%)&#160;</p>
<p style="position:absolute;top:775px;left:610px;white-space:nowrap" class="ft192">473&#160;/&#160;499&#160;(95%)&#160;</p>
<p style="position:absolute;top:794px;left:94px;white-space:nowrap" class="ft192">&#160;African-American/African&#160;Heritage/Other&#160;</p>
<p style="position:absolute;top:794px;left:468px;white-space:nowrap" class="ft192">204&#160;/&#160;232&#160;(88%)&#160;</p>
<p style="position:absolute;top:794px;left:610px;white-space:nowrap" class="ft192">196&#160;/ 218&#160;(90%)&#160;</p>
<p style="position:absolute;top:815px;left:94px;white-space:nowrap" class="ft1921">*&#160;The&#160;results&#160;of&#160;the&#160;pooled analysis&#160;are&#160;in line&#160;with those&#160;of&#160;the&#160;individual&#160;studies,&#160;for&#160;which the&#160;primary&#160;</p>
<p style="position:absolute;top:833px;left:94px;white-space:nowrap" class="ft1921">endpoint&#160;(difference&#160;in&#160;proportion &lt;50</p>
<p style="position:absolute;top:832px;left:326px;white-space:nowrap" class="ft192">&#160;copies/mL&#160;plasma&#160;HIV-1 RNA&#160;at&#160;Week 48 based on the&#160;</p>
<p style="position:absolute;top:851px;left:94px;white-space:nowrap" class="ft1921">Snapshot&#160;algorithm&#160;for&#160;dolutegravir&#160;plus&#160;lamivudine&#160;versus&#160;dolutegravir&#160;plus&#160;tenofovir</p>
<p style="position:absolute;top:849px;left:616px;white-space:nowrap" class="ft192">&#160;disoproxil&#160;</p>
<p style="position:absolute;top:868px;left:94px;white-space:nowrap" class="ft1921">/emtricitabine FDC)&#160;was&#160;met.&#160;The adjusted&#160;difference was&#160;-2.6 (95%&#160;CI:&#160;-6.7;&#160;1.5)&#160;for&#160;GEMINI-1 and&#160;-</p>
<p style="position:absolute;top:886px;left:94px;white-space:nowrap" class="ft1921">0.7 (95%&#160;CI:&#160;-4.3;&#160;2.9)&#160;for&#160;GEMINI-2&#160;with&#160;a prespecified&#160;non-inferiority margin of&#160;10%.&#160;</p>
<p style="position:absolute;top:903px;left:94px;white-space:nowrap" class="ft1921">†&#160;Based&#160;on&#160;CMH-stratified&#160;analysis&#160;adjusting&#160;for&#160;the&#160;following&#160;baseline&#160;stratification&#160;factors: Plasma&#160;</p>
<p style="position:absolute;top:920px;left:94px;white-space:nowrap" class="ft1921">HIV-1&#160;RNA&#160;(≤100,000&#160;c/mL&#160;vs.&#160;&gt;100,000&#160;c/mL)&#160;and&#160;CD4+ cell&#160;count&#160;</p>
<p style="position:absolute;top:938px;left:94px;white-space:nowrap" class="ft1922">(≤200</p>
<p style="position:absolute;top:937px;left:129px;white-space:nowrap" class="ft192">&#160;cells/mm3&#160;vs.&#160;&gt;200&#160;cells/mm3).&#160;Pooled&#160;analysis&#160;also stratified by study.&#160;Assessed using a&#160;</p>
<p style="position:absolute;top:956px;left:94px;white-space:nowrap" class="ft1921">non-inferiority&#160;margin&#160;of&#160;10%.&#160;</p>
<p style="position:absolute;top:973px;left:94px;white-space:nowrap" class="ft1921">N&#160;= Number&#160;of&#160;subjects&#160;in&#160;each&#160;treatment&#160;group&#160;</p>
<p style="position:absolute;top:991px;left:85px;white-space:nowrap" class="ft192">&#160;</p>
<p style="position:absolute;top:1010px;left:85px;white-space:nowrap" class="ft192">At&#160;96 weeks&#160;and&#160;at&#160;144 weeks&#160;in the&#160;GEMINI&#160;studies,&#160;the&#160;lower&#160;bound&#160;of&#160;the&#160;95%&#160;confidence&#160;interval&#160;for&#160;</p>
<p style="position:absolute;top:1030px;left:85px;white-space:nowrap" class="ft192">the adjusted&#160;treatment&#160;difference&#160;of&#160;proportion&#160;of&#160;subjects&#160;with HIV-1 RNA&#160;&lt;50 copies/mL&#160;(Snapshot)&#160;was&#160;</p>
<p style="position:absolute;top:1049px;left:85px;white-space:nowrap" class="ft192">greater&#160;than the&#160;non-inferiority&#160;margin&#160;of&#160;-10%,&#160;for&#160;the&#160;individual&#160;studies as&#160;well&#160;as pooled&#160;analysis,&#160;see&#160;</p>
<p style="position:absolute;top:1069px;left:85px;white-space:nowrap" class="ft192">Table&#160;4.&#160;</p>
<p style="position:absolute;top:1088px;left:85px;white-space:nowrap" class="ft192">&#160;</p>
</div>
<!-- Page 20 -->
<a name="20"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft2024{font-size:17px;font-family:FLHGME+ArialMT;color:#000000;}
-->
</style>
<div id="page20-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1191px;left:436px;white-space:nowrap" class="ft200">20&#160;</p>
<p style="position:absolute;top:83px;left:85px;white-space:nowrap" class="ft201"><b>Table&#160;4</b>&#160;</p>
<p style="position:absolute;top:83px;left:193px;white-space:nowrap" class="ft201"><b>Virologic&#160;Outcomes of&#160;Randomised&#160;Treatment&#160;of&#160;GEMINI at&#160;Weeks&#160;96 and&#160;144&#160;</b></p>
<p style="position:absolute;top:103px;left:193px;white-space:nowrap" class="ft201"><b>(Snapshot&#160;algorithm)&#160;</b></p>
<p style="position:absolute;top:123px;left:94px;white-space:nowrap" class="ft202">&#160;</p>
<p style="position:absolute;top:123px;left:429px;white-space:nowrap" class="ft201"><b>GEMINI-1&#160;and GEMINI-2 Pooled&#160;Data</b>*<b>&#160;</b></p>
<p style="position:absolute;top:143px;left:414px;white-space:nowrap" class="ft201"><b>DTG&#160;+&#160;</b></p>
<p style="position:absolute;top:163px;left:423px;white-space:nowrap" class="ft201"><b>3TC&#160;</b></p>
<p style="position:absolute;top:182px;left:415px;white-space:nowrap" class="ft201"><b>N=716&#160;</b></p>
<p style="position:absolute;top:143px;left:504px;white-space:nowrap" class="ft201"><b>DTG&#160;+&#160;</b></p>
<p style="position:absolute;top:163px;left:494px;white-space:nowrap" class="ft201"><b>TDF/FTC&#160;</b></p>
<p style="position:absolute;top:182px;left:506px;white-space:nowrap" class="ft201"><b>N=717&#160;</b></p>
<p style="position:absolute;top:143px;left:595px;white-space:nowrap" class="ft201"><b>DTG&#160;+&#160;</b></p>
<p style="position:absolute;top:163px;left:604px;white-space:nowrap" class="ft201"><b>3TC&#160;</b></p>
<p style="position:absolute;top:182px;left:596px;white-space:nowrap" class="ft201"><b>N=716&#160;</b></p>
<p style="position:absolute;top:143px;left:685px;white-space:nowrap" class="ft201"><b>DTG&#160;+&#160;</b></p>
<p style="position:absolute;top:163px;left:674px;white-space:nowrap" class="ft201"><b>TDF/FTC&#160;</b></p>
<p style="position:absolute;top:182px;left:687px;white-space:nowrap" class="ft201"><b>N=717&#160;</b></p>
<p style="position:absolute;top:203px;left:94px;white-space:nowrap" class="ft201"><b>&#160;</b></p>
<p style="position:absolute;top:203px;left:454px;white-space:nowrap" class="ft202">Week&#160;96&#160;</p>
<p style="position:absolute;top:203px;left:631px;white-space:nowrap" class="ft202">Week 144&#160;</p>
<p style="position:absolute;top:223px;left:94px;white-space:nowrap" class="ft201"><b>HIV-1&#160;RNA &lt;50&#160;copies/mL</b>&#160;</p>
<p style="position:absolute;top:223px;left:423px;white-space:nowrap" class="ft202">86%&#160;</p>
<p style="position:absolute;top:223px;left:514px;white-space:nowrap" class="ft202">90%&#160;</p>
<p style="position:absolute;top:223px;left:604px;white-space:nowrap" class="ft202">82%&#160;</p>
<p style="position:absolute;top:223px;left:695px;white-space:nowrap" class="ft202">84%&#160;</p>
<p style="position:absolute;top:243px;left:94px;white-space:nowrap" class="ft201"><b>&#160;Treatment&#160;Difference</b>†&#160;&#160;</p>
<p style="position:absolute;top:263px;left:94px;white-space:nowrap" class="ft202">(95%&#160;confidence&#160;intervals)</p>
<p style="position:absolute;top:263px;left:271px;white-space:nowrap" class="ft201"><b>&#160;</b></p>
<p style="position:absolute;top:253px;left:429px;white-space:nowrap" class="ft202">-3.4%&#160;(-6.7, 0.0)&#160;</p>
<p style="position:absolute;top:253px;left:609px;white-space:nowrap" class="ft202">-1.8%&#160;(-5.8;&#160;2.1)&#160;</p>
<p style="position:absolute;top:283px;left:94px;white-space:nowrap" class="ft201"><b>Virologic&#160;non response</b>&#160;</p>
<p style="position:absolute;top:283px;left:428px;white-space:nowrap" class="ft202">3%&#160;</p>
<p style="position:absolute;top:283px;left:518px;white-space:nowrap" class="ft202">2%&#160;</p>
<p style="position:absolute;top:283px;left:608px;white-space:nowrap" class="ft202">3%&#160;</p>
<p style="position:absolute;top:283px;left:699px;white-space:nowrap" class="ft202">3%&#160;</p>
<p style="position:absolute;top:302px;left:94px;white-space:nowrap" class="ft202">Reasons</p>
<p style="position:absolute;top:302px;left:149px;white-space:nowrap" class="ft201"><b>&#160;</b></p>
<p style="position:absolute;top:302px;left:438px;white-space:nowrap" class="ft202">&#160;</p>
<p style="position:absolute;top:302px;left:529px;white-space:nowrap" class="ft202">&#160;</p>
<p style="position:absolute;top:302px;left:619px;white-space:nowrap" class="ft202">&#160;</p>
<p style="position:absolute;top:302px;left:710px;white-space:nowrap" class="ft202">&#160;</p>
<p style="position:absolute;top:322px;left:104px;white-space:nowrap" class="ft207">Data&#160;in window, ≥50&#160;cps/mL&#160;&#160;</p>
<p style="position:absolute;top:322px;left:423px;white-space:nowrap" class="ft202">&lt;1%&#160;</p>
<p style="position:absolute;top:322px;left:513px;white-space:nowrap" class="ft202">&lt;1%&#160;</p>
<p style="position:absolute;top:322px;left:604px;white-space:nowrap" class="ft202">&lt;1%&#160;</p>
<p style="position:absolute;top:322px;left:694px;white-space:nowrap" class="ft202">&lt;1%&#160;</p>
<p style="position:absolute;top:342px;left:104px;white-space:nowrap" class="ft202">Discontinued, lack&#160;of&#160;efficacy&#160;</p>
<p style="position:absolute;top:342px;left:428px;white-space:nowrap" class="ft202">1%&#160;</p>
<p style="position:absolute;top:342px;left:513px;white-space:nowrap" class="ft202">&lt;1%&#160;</p>
<p style="position:absolute;top:342px;left:608px;white-space:nowrap" class="ft202">1%&#160;</p>
<p style="position:absolute;top:342px;left:694px;white-space:nowrap" class="ft202">&lt;1%&#160;</p>
<p style="position:absolute;top:361px;left:104px;white-space:nowrap" class="ft202">Discontinued, other&#160;reasons, ≥50&#160;cps/mL&#160;</p>
<p style="position:absolute;top:361px;left:423px;white-space:nowrap" class="ft202">&lt;1%&#160;</p>
<p style="position:absolute;top:361px;left:513px;white-space:nowrap" class="ft202">&lt;1%&#160;</p>
<p style="position:absolute;top:361px;left:604px;white-space:nowrap" class="ft202">&lt;1%&#160;</p>
<p style="position:absolute;top:361px;left:699px;white-space:nowrap" class="ft202">2%&#160;</p>
<p style="position:absolute;top:380px;left:104px;white-space:nowrap" class="ft202">Change&#160;in&#160;ART&#160;</p>
<p style="position:absolute;top:380px;left:423px;white-space:nowrap" class="ft202">&lt;1%&#160;</p>
<p style="position:absolute;top:380px;left:513px;white-space:nowrap" class="ft202">&lt;1%&#160;</p>
<p style="position:absolute;top:380px;left:604px;white-space:nowrap" class="ft202">&lt;1%&#160;</p>
<p style="position:absolute;top:380px;left:694px;white-space:nowrap" class="ft202">&lt;1%&#160;</p>
<p style="position:absolute;top:401px;left:94px;white-space:nowrap" class="ft201"><b>No virologic&#160;data at&#160;Week&#160;96/Week&#160;144&#160;</b></p>
<p style="position:absolute;top:420px;left:94px;white-space:nowrap" class="ft201"><b>window&#160;</b></p>
<p style="position:absolute;top:440px;left:94px;white-space:nowrap" class="ft202">Reasons</p>
<p style="position:absolute;top:440px;left:149px;white-space:nowrap" class="ft201"><b>&#160;</b></p>
<p style="position:absolute;top:459px;left:104px;white-space:nowrap" class="ft202">Discontinued study&#160;due&#160;to AE&#160;or&#160;death&#160;&#160;</p>
<p style="position:absolute;top:479px;left:104px;white-space:nowrap" class="ft202">Discontinued&#160;study for&#160;other&#160;reasons&#160;</p>
<p style="position:absolute;top:498px;left:123px;white-space:nowrap" class="ft202">Loss&#160;to follow-up&#160;</p>
<p style="position:absolute;top:518px;left:123px;white-space:nowrap" class="ft202">Withdrew&#160;consent&#160;</p>
<p style="position:absolute;top:537px;left:123px;white-space:nowrap" class="ft202">Protocol&#160;deviations&#160;</p>
<p style="position:absolute;top:557px;left:123px;white-space:nowrap" class="ft202">Physicians&#160;decision&#160;</p>
<p style="position:absolute;top:576px;left:104px;white-space:nowrap" class="ft202">Missing data&#160;in window, on&#160;study</p>
<p style="position:absolute;top:576px;left:328px;white-space:nowrap" class="ft201"><b>&#160;</b></p>
<p style="position:absolute;top:401px;left:423px;white-space:nowrap" class="ft202">11%&#160;</p>
<p style="position:absolute;top:420px;left:438px;white-space:nowrap" class="ft202">&#160;</p>
<p style="position:absolute;top:440px;left:438px;white-space:nowrap" class="ft202">&#160;</p>
<p style="position:absolute;top:459px;left:428px;white-space:nowrap" class="ft202">3%&#160;</p>
<p style="position:absolute;top:479px;left:428px;white-space:nowrap" class="ft202">8%&#160;</p>
<p style="position:absolute;top:498px;left:428px;white-space:nowrap" class="ft202">3%&#160;</p>
<p style="position:absolute;top:518px;left:428px;white-space:nowrap" class="ft202">3%&#160;</p>
<p style="position:absolute;top:537px;left:428px;white-space:nowrap" class="ft202">1%&#160;</p>
<p style="position:absolute;top:557px;left:428px;white-space:nowrap" class="ft202">1%&#160;</p>
<p style="position:absolute;top:576px;left:428px;white-space:nowrap" class="ft202">0%&#160;</p>
<p style="position:absolute;top:401px;left:518px;white-space:nowrap" class="ft202">9%&#160;</p>
<p style="position:absolute;top:420px;left:529px;white-space:nowrap" class="ft202">&#160;</p>
<p style="position:absolute;top:440px;left:529px;white-space:nowrap" class="ft202">&#160;</p>
<p style="position:absolute;top:459px;left:518px;white-space:nowrap" class="ft202">3%&#160;</p>
<p style="position:absolute;top:479px;left:518px;white-space:nowrap" class="ft202">5%&#160;</p>
<p style="position:absolute;top:498px;left:518px;white-space:nowrap" class="ft202">1%&#160;</p>
<p style="position:absolute;top:518px;left:518px;white-space:nowrap" class="ft202">2%&#160;</p>
<p style="position:absolute;top:537px;left:518px;white-space:nowrap" class="ft202">1%&#160;</p>
<p style="position:absolute;top:557px;left:513px;white-space:nowrap" class="ft202">&lt;1%&#160;</p>
<p style="position:absolute;top:576px;left:513px;white-space:nowrap" class="ft202">&lt;1%&#160;</p>
<p style="position:absolute;top:401px;left:604px;white-space:nowrap" class="ft202">15%&#160;</p>
<p style="position:absolute;top:420px;left:619px;white-space:nowrap" class="ft202">&#160;</p>
<p style="position:absolute;top:440px;left:619px;white-space:nowrap" class="ft202">&#160;</p>
<p style="position:absolute;top:459px;left:608px;white-space:nowrap" class="ft202">4%&#160;</p>
<p style="position:absolute;top:479px;left:604px;white-space:nowrap" class="ft202">11%&#160;</p>
<p style="position:absolute;top:498px;left:608px;white-space:nowrap" class="ft202">3%&#160;</p>
<p style="position:absolute;top:518px;left:608px;white-space:nowrap" class="ft202">4%&#160;</p>
<p style="position:absolute;top:537px;left:608px;white-space:nowrap" class="ft202">2%&#160;</p>
<p style="position:absolute;top:557px;left:608px;white-space:nowrap" class="ft202">2%&#160;</p>
<p style="position:absolute;top:576px;left:604px;white-space:nowrap" class="ft202">&lt;1%&#160;</p>
<p style="position:absolute;top:401px;left:695px;white-space:nowrap" class="ft202">14%&#160;</p>
<p style="position:absolute;top:420px;left:710px;white-space:nowrap" class="ft202">&#160;</p>
<p style="position:absolute;top:440px;left:710px;white-space:nowrap" class="ft202">&#160;</p>
<p style="position:absolute;top:459px;left:699px;white-space:nowrap" class="ft202">4%&#160;</p>
<p style="position:absolute;top:479px;left:699px;white-space:nowrap" class="ft202">9%&#160;</p>
<p style="position:absolute;top:498px;left:699px;white-space:nowrap" class="ft202">3%&#160;</p>
<p style="position:absolute;top:518px;left:699px;white-space:nowrap" class="ft202">3%&#160;</p>
<p style="position:absolute;top:537px;left:699px;white-space:nowrap" class="ft202">1%&#160;</p>
<p style="position:absolute;top:557px;left:699px;white-space:nowrap" class="ft202">1%&#160;</p>
<p style="position:absolute;top:576px;left:694px;white-space:nowrap" class="ft202">&lt;1%&#160;</p>
<p style="position:absolute;top:607px;left:85px;white-space:nowrap" class="ft2021">*</p>
<p style="position:absolute;top:606px;left:92px;white-space:nowrap" class="ft205"><i>&#160;</i>The&#160;results&#160;of&#160;the&#160;pooled analysis&#160;are&#160;in line&#160;with those&#160;of&#160;the&#160;individual studies.&#160;</p>
<p style="position:absolute;top:624px;left:85px;white-space:nowrap" class="ft2021">† Based on CMH-stratified&#160;analysis&#160;adjusting&#160;for&#160;the&#160;following&#160;baseline&#160;stratification&#160;factors: Plasma&#160;HIV-1&#160;RNA&#160;</p>
<p style="position:absolute;top:643px;left:85px;white-space:nowrap" class="ft2022">(≤100,000&#160;c/mL&#160;vs.&#160;&gt;100,000&#160;c/mL)&#160;and&#160;CD4+&#160;cell&#160;count&#160;(≤200</p>
<p style="position:absolute;top:641px;left:473px;white-space:nowrap" class="ft202">&#160;cells/mm3&#160;vs.&#160;&gt;200&#160;cells/mm3).&#160;Pooled&#160;analysis&#160;also&#160;</p>
<p style="position:absolute;top:661px;left:85px;white-space:nowrap" class="ft2021">stratified&#160;by study.&#160;Assessed using a&#160;non-inferiority margin&#160;of&#160;10%.&#160;</p>
<p style="position:absolute;top:678px;left:85px;white-space:nowrap" class="ft2021">N&#160;= Number&#160;of&#160;subjects&#160;in&#160;each&#160;treatment&#160;group</p>
<p style="position:absolute;top:676px;left:375px;white-space:nowrap" class="ft2024">&#160;</p>
<p style="position:absolute;top:713px;left:85px;white-space:nowrap" class="ft202">The mean&#160;increase in&#160;CD4+&#160;T-cell&#160;counts&#160;through week 144&#160;was&#160;302&#160;cells/mm3&#160;in the&#160;dolutegravir&#160;plus&#160;</p>
<p style="position:absolute;top:732px;left:85px;white-space:nowrap" class="ft202">lamivudine&#160;arm&#160;and&#160;300&#160;cells/mm3&#160;in the&#160;dolutegravir&#160;plus&#160;tenofovir/emtricitabine&#160;arm.&#160;&#160;</p>
<p style="position:absolute;top:752px;left:85px;white-space:nowrap" class="ft202">&#160;</p>
<p style="position:absolute;top:771px;left:85px;white-space:nowrap" class="ft205"><i>Virologically suppressed&#160;subjects</i>&#160;</p>
<p style="position:absolute;top:791px;left:85px;white-space:nowrap" class="ft202">&#160;</p>
<p style="position:absolute;top:810px;left:85px;white-space:nowrap" class="ft202">The efficacy&#160;of&#160;dolutegravir/lamivudine&#160;in&#160;virologically suppressed subjects&#160;is&#160;supported by&#160;data&#160;from&#160;a&#160;</p>
<p style="position:absolute;top:830px;left:85px;white-space:nowrap" class="ft202">randomised, open-label, trial&#160;(TANGO&#160;[204862]).&#160;A&#160;total&#160;of&#160;741 adult&#160;HIV-1 infected subjects,&#160;without&#160;any&#160;</p>
<p style="position:absolute;top:849px;left:85px;white-space:nowrap" class="ft202">evidence&#160;of&#160;resistance to&#160;the NRTI&#160;or&#160;integrase&#160;inhibitor&#160;(INSTI)&#160;class&#160;and&#160;who&#160;were on&#160;a stable&#160;suppressive&#160;</p>
<p style="position:absolute;top:869px;left:85px;white-space:nowrap" class="ft202">tenofovir&#160;alafenamide&#160;based&#160;regimen&#160;(TBR)&#160;received&#160;treatment&#160;in&#160;the studies.&#160;Subjects&#160;were randomised&#160;in&#160;a&#160;</p>
<p style="position:absolute;top:888px;left:85px;white-space:nowrap" class="ft202">1:1 ratio&#160;to receive&#160;dolutegravir/lamivudine&#160;FDC&#160;or&#160;continue&#160;with TBR&#160;for&#160;up&#160;to&#160;200 weeks. Randomisation&#160;</p>
<p style="position:absolute;top:908px;left:85px;white-space:nowrap" class="ft202">was stratified&#160;by&#160;baseline core agent&#160;class&#160;(protease inhibitor&#160;[PI],&#160;INSTI,&#160;or&#160;non-nucleoside reverse&#160;</p>
<p style="position:absolute;top:927px;left:85px;white-space:nowrap" class="ft202">transcriptase&#160;inhibitor&#160;[NNRTI]).&#160;The&#160;primary&#160;efficacy endpoint&#160;was&#160;the&#160;proportion of&#160;subjects&#160;with plasma&#160;</p>
<p style="position:absolute;top:947px;left:85px;white-space:nowrap" class="ft202">HIV-1 RNA&#160;≥50 c/mL&#160;(virologic&#160;non-response)&#160;as&#160;per&#160;the FDA&#160;Snapshot&#160;category&#160;at&#160;Week&#160;48&#160;(adjusted for&#160;</p>
<p style="position:absolute;top:966px;left:85px;white-space:nowrap" class="ft202">randomisation&#160;stratification&#160;factor).&#160;</p>
<p style="position:absolute;top:986px;left:85px;white-space:nowrap" class="ft202">&#160;</p>
<p style="position:absolute;top:1005px;left:85px;white-space:nowrap" class="ft202">At&#160;baseline&#160;the&#160;median&#160;age&#160;of&#160;subjects was 39&#160;years,&#160;8%&#160;were&#160;female&#160;and 21%&#160;non-white,&#160;5%&#160;were&#160;CDC&#160;</p>
<p style="position:absolute;top:1025px;left:85px;white-space:nowrap" class="ft207">Class&#160;C&#160;(AIDS)&#160;and 98%&#160;subjects&#160;had Baseline&#160;CD4+&#160;cell&#160;count&#160;≥200&#160;cells/mm3;&#160;these characteristics were&#160;</p>
<p style="position:absolute;top:1044px;left:85px;white-space:nowrap" class="ft202">similar&#160;between&#160;treatment&#160;arms. Subjects&#160;had been on&#160;ART&#160;for&#160;a&#160;median&#160;of&#160;around 3 years&#160;prior&#160;to Day 1&#160;</p>
<p style="position:absolute;top:1064px;left:85px;white-space:nowrap" class="ft202">Around&#160;80%&#160;were&#160;on INSTI-based&#160;TBR&#160;(mainly&#160;elvitegravir/c)&#160;at&#160;baseline.&#160;</p>
<p style="position:absolute;top:1083px;left:85px;white-space:nowrap" class="ft202">&#160;</p>
<p style="position:absolute;top:1103px;left:85px;white-space:nowrap" class="ft202">In&#160;the&#160;primary&#160;48 week&#160;analysis,&#160;dolutegravir/lamivudine&#160;was&#160;non-inferior&#160;to TBR, with&#160;&lt;1%&#160;of&#160;subjects&#160;in&#160;</p>
<p style="position:absolute;top:1122px;left:85px;white-space:nowrap" class="ft202">both arms&#160;experiencing virologic&#160;failure&#160;(HIV-1 RNA&#160;≥50 c/mL)&#160;(Table&#160;5).&#160;</p>
<p style="position:absolute;top:1142px;left:85px;white-space:nowrap" class="ft202">&#160;</p>
</div>
<!-- Page 21 -->
<a name="21"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page21-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1191px;left:436px;white-space:nowrap" class="ft210">21&#160;</p>
<p style="position:absolute;top:83px;left:85px;white-space:nowrap" class="ft211"><b>Table&#160;5&#160;</b></p>
<p style="position:absolute;top:83px;left:193px;white-space:nowrap" class="ft211"><b>Virologic&#160;Outcomes of&#160;Randomised&#160;Treatment&#160;of&#160;TANGO&#160;at&#160;Week&#160;48 (Snapshot&#160;</b></p>
<p style="position:absolute;top:103px;left:193px;white-space:nowrap" class="ft211"><b>algorithm)&#160;</b></p>
<p style="position:absolute;top:123px;left:94px;white-space:nowrap" class="ft212">&#160;</p>
<p style="position:absolute;top:123px;left:486px;white-space:nowrap" class="ft211"><b>DTG/3TC&#160;</b></p>
<p style="position:absolute;top:143px;left:499px;white-space:nowrap" class="ft211"><b>N=369&#160;</b></p>
<p style="position:absolute;top:123px;left:647px;white-space:nowrap" class="ft211"><b>TBR&#160;</b></p>
<p style="position:absolute;top:143px;left:641px;white-space:nowrap" class="ft211"><b>N=372&#160;</b></p>
<p style="position:absolute;top:163px;left:94px;white-space:nowrap" class="ft211"><b>HIV-1&#160;RNA &lt;50&#160;copies/mL*</b>&#160;</p>
<p style="position:absolute;top:163px;left:507px;white-space:nowrap" class="ft212">93%&#160;</p>
<p style="position:absolute;top:163px;left:649px;white-space:nowrap" class="ft212">93%&#160;</p>
<p style="position:absolute;top:183px;left:94px;white-space:nowrap" class="ft211"><b>Virologic&#160;non response&#160;</b>(≥50 copies/mL)<b>**&#160;</b></p>
<p style="position:absolute;top:183px;left:506px;white-space:nowrap" class="ft212">&lt;1%&#160;</p>
<p style="position:absolute;top:183px;left:648px;white-space:nowrap" class="ft212">&lt;1%&#160;</p>
<p style="position:absolute;top:203px;left:94px;white-space:nowrap" class="ft211"><b>Treatment&#160;Difference</b>†&#160;(95%&#160;confidence intervals)<b>&#160;</b></p>
<p style="position:absolute;top:203px;left:545px;white-space:nowrap" class="ft212">-0.3 (-1.2, 0.7)&#160;</p>
<p style="position:absolute;top:224px;left:94px;white-space:nowrap" class="ft212">Reasons&#160;for&#160;virologic&#160;non&#160;response:</p>
<p style="position:absolute;top:224px;left:331px;white-space:nowrap" class="ft211"><b>&#160;</b></p>
<p style="position:absolute;top:224px;left:522px;white-space:nowrap" class="ft212">&#160;</p>
<p style="position:absolute;top:224px;left:664px;white-space:nowrap" class="ft212">&#160;</p>
<p style="position:absolute;top:243px;left:104px;white-space:nowrap" class="ft217">Data&#160;in window&#160;and&#160;≥50&#160;copies/mL&#160;&#160;</p>
<p style="position:absolute;top:243px;left:511px;white-space:nowrap" class="ft212">0%&#160;</p>
<p style="position:absolute;top:243px;left:653px;white-space:nowrap" class="ft212">0%&#160;</p>
<p style="position:absolute;top:263px;left:104px;white-space:nowrap" class="ft212">Discontinued for&#160;lack&#160;of&#160;efficacy&#160;</p>
<p style="position:absolute;top:263px;left:511px;white-space:nowrap" class="ft212">0%&#160;</p>
<p style="position:absolute;top:263px;left:648px;white-space:nowrap" class="ft212">&lt;1%&#160;</p>
<p style="position:absolute;top:282px;left:104px;white-space:nowrap" class="ft217">Discontinued&#160;for&#160;other&#160;reasons&#160;and&#160;≥50&#160;copies/mL&#160;</p>
<p style="position:absolute;top:282px;left:506px;white-space:nowrap" class="ft212">&lt;1%&#160;</p>
<p style="position:absolute;top:282px;left:653px;white-space:nowrap" class="ft212">0%&#160;</p>
<p style="position:absolute;top:302px;left:104px;white-space:nowrap" class="ft212">Change&#160;in&#160;ART&#160;</p>
<p style="position:absolute;top:302px;left:511px;white-space:nowrap" class="ft212">0%&#160;</p>
<p style="position:absolute;top:302px;left:653px;white-space:nowrap" class="ft212">0%&#160;</p>
<p style="position:absolute;top:322px;left:94px;white-space:nowrap" class="ft211"><b>No virologic&#160;data at&#160;Week&#160;48 window&#160;</b></p>
<p style="position:absolute;top:322px;left:511px;white-space:nowrap" class="ft212">7%&#160;</p>
<p style="position:absolute;top:322px;left:653px;white-space:nowrap" class="ft212">6%&#160;&#160;</p>
<p style="position:absolute;top:342px;left:94px;white-space:nowrap" class="ft212">Reasons</p>
<p style="position:absolute;top:341px;left:149px;white-space:nowrap" class="ft211"><b>&#160;</b></p>
<p style="position:absolute;top:342px;left:522px;white-space:nowrap" class="ft212">&#160;</p>
<p style="position:absolute;top:342px;left:664px;white-space:nowrap" class="ft212">&#160;</p>
<p style="position:absolute;top:361px;left:107px;white-space:nowrap" class="ft212">Discontinued study&#160;due&#160;to adverse&#160;event&#160;or&#160;death&#160;&#160;</p>
<p style="position:absolute;top:361px;left:511px;white-space:nowrap" class="ft212">3%&#160;</p>
<p style="position:absolute;top:361px;left:648px;white-space:nowrap" class="ft212">&lt;1%&#160;</p>
<p style="position:absolute;top:380px;left:107px;white-space:nowrap" class="ft212">Discontinued&#160;study for&#160;other&#160;reasons&#160;</p>
<p style="position:absolute;top:380px;left:511px;white-space:nowrap" class="ft212">3%&#160;</p>
<p style="position:absolute;top:380px;left:653px;white-space:nowrap" class="ft212">6%&#160;&#160;</p>
<p style="position:absolute;top:400px;left:107px;white-space:nowrap" class="ft212">Missing&#160;data&#160;during window&#160;but&#160;on&#160;study&#160;</p>
<p style="position:absolute;top:400px;left:511px;white-space:nowrap" class="ft212">0%&#160;</p>
<p style="position:absolute;top:400px;left:648px;white-space:nowrap" class="ft212">&lt;1%&#160;</p>
<p style="position:absolute;top:422px;left:94px;white-space:nowrap" class="ft2123">*Based on an&#160;8%&#160;non-inferiority&#160;margin,&#160;DTG/3TC&#160;is&#160;non-inferior&#160;to&#160;TBR&#160;at&#160;Week 48 in the&#160;secondary&#160;</p>
<p style="position:absolute;top:441px;left:94px;white-space:nowrap" class="ft2121">analysis&#160;(proportion&#160;of&#160;subjects&#160;achieving &lt;50 copies/mL&#160;plasma&#160;HIV-1&#160;RNA).&#160;</p>
<p style="position:absolute;top:461px;left:94px;white-space:nowrap" class="ft2121">**Based on a&#160;4%&#160;non-inferiority&#160;margin,&#160;DTG/3TC&#160;is&#160;non-inferior&#160;to TBR&#160;at&#160;Week 48 in&#160;the&#160;primary&#160;</p>
<p style="position:absolute;top:480px;left:94px;white-space:nowrap" class="ft2121">analysis&#160;(proportion&#160;of&#160;subjects&#160;with plasma&#160;HIV-1&#160;RNA&#160;≥50&#160;c/mL).&#160;&#160;</p>
<p style="position:absolute;top:500px;left:94px;white-space:nowrap" class="ft2121">†Based&#160;on&#160;CMH-stratified&#160;analysis&#160;adjusting&#160;for&#160;Baseline&#160;third&#160;agent class&#160;(PI,&#160;NNRTI,&#160;INSTI).&#160;&#160;</p>
<p style="position:absolute;top:519px;left:94px;white-space:nowrap" class="ft2121">N&#160;= Number&#160;of&#160;subjects&#160;in&#160;each&#160;treatment&#160;group;&#160;TBR&#160;= tenofovir&#160;alafenamide&#160;based&#160;regimen.&#160;&#160;</p>
<p style="position:absolute;top:539px;left:94px;white-space:nowrap" class="ft2123">&#160;</p>
<p style="position:absolute;top:557px;left:85px;white-space:nowrap" class="ft212">Treatment&#160;outcomes between&#160;treatment&#160;arms&#160;at&#160;week&#160;48&#160;were&#160;similar&#160;across the stratification&#160;factor,&#160;baseline&#160;</p>
<p style="position:absolute;top:576px;left:85px;white-space:nowrap" class="ft212">third&#160;agent&#160;class&#160;and across&#160;subgroups&#160;by age, sex,&#160;race, baseline&#160;CD4+&#160;cell&#160;count, CDC&#160;HIV&#160;disease stage,&#160;</p>
<p style="position:absolute;top:596px;left:85px;white-space:nowrap" class="ft212">and countries. The&#160;median&#160;change&#160;from&#160;baseline&#160;in CD4+&#160;count&#160;at&#160;Week 48 was&#160;22.5 cells&#160;per&#160;mm3&#160;in&#160;</p>
<p style="position:absolute;top:615px;left:85px;white-space:nowrap" class="ft212">subjects&#160;who switched&#160;to&#160;dolutegravir/lamivudine&#160;and&#160;11.0 cells&#160;per&#160;mm3&#160;in subjects&#160;who&#160;stayed on TBR.&#160;&#160;</p>
<p style="position:absolute;top:635px;left:85px;white-space:nowrap" class="ft212">&#160;</p>
<p style="position:absolute;top:654px;left:85px;white-space:nowrap" class="ft212">At&#160;96&#160;weeks&#160;in&#160;the&#160;TANGO&#160;study,&#160;the&#160;proportion&#160;of&#160;subjects&#160;with&#160;HIV-1&#160;RNA&#160;≥50 c/mL&#160;(Snapshot)&#160;was&#160;</p>
<p style="position:absolute;top:674px;left:85px;white-space:nowrap" class="ft212">0.3%&#160;and 1.1%&#160;in the&#160;dolutegravir/lamivudine&#160;and TBR&#160;groups,&#160;respectively.&#160;Based on a&#160;non-inferiority&#160;</p>
<p style="position:absolute;top:693px;left:85px;white-space:nowrap" class="ft212">margin of&#160;4%,&#160;dolutegravir/lamivudine&#160;remained non-inferior&#160;to TBR,&#160;as&#160;the&#160;upper&#160;bound of&#160;the&#160;95% CI&#160;for&#160;</p>
<p style="position:absolute;top:713px;left:85px;white-space:nowrap" class="ft212">the adjusted&#160;treatment&#160;difference (-2.0%;&#160;0.4%)&#160;was&#160;less&#160;than 4%&#160;for&#160;the&#160;ITT&#160;E&#160;Population.&#160;&#160;</p>
<p style="position:absolute;top:732px;left:85px;white-space:nowrap" class="ft212">&#160;</p>
<p style="position:absolute;top:752px;left:85px;white-space:nowrap" class="ft212">The&#160;median change&#160;from&#160;baseline&#160;in CD4+&#160;T-cell&#160;counts at&#160;week&#160;96&#160;was&#160;61&#160;cells/mm3&#160;in the&#160;</p>
<p style="position:absolute;top:771px;left:85px;white-space:nowrap" class="ft212">dolutegravir/lamivudine&#160;arm&#160;and&#160;45&#160;cells/mm3&#160;in the&#160;TBR&#160;arm.&#160;</p>
<p style="position:absolute;top:791px;left:85px;white-space:nowrap" class="ft212">&#160;</p>
<p style="position:absolute;top:810px;left:85px;white-space:nowrap" class="ft212">At&#160;144&#160;weeks,&#160;the&#160;proportion of&#160;subjects&#160;with&#160;HIV-1&#160;RNA&#160;≥50&#160;c/mL&#160;(Snapshot)&#160;was&#160;0.3%&#160;and 1.3%&#160;in the&#160;</p>
<p style="position:absolute;top:830px;left:85px;white-space:nowrap" class="ft212">dolutegravir/lamivudine&#160;and TBR&#160;groups,&#160;respectively.&#160;Based on a&#160;non-inferiority&#160;margin&#160;of&#160;4%,&#160;</p>
<p style="position:absolute;top:849px;left:85px;white-space:nowrap" class="ft212">dolutegravir/lamivudine&#160;remained non-inferior&#160;to&#160;TBR,&#160;as&#160;the&#160;upper&#160;bound of&#160;the&#160;95%&#160;CI&#160;for&#160;the&#160;adjusted&#160;</p>
<p style="position:absolute;top:869px;left:85px;white-space:nowrap" class="ft212">treatment&#160;difference&#160;(-2.4%, 0.2%)&#160;was&#160;less&#160;than 4%&#160;for&#160;the&#160;ITT&#160;E&#160;Population.&#160;&#160;</p>
<p style="position:absolute;top:888px;left:85px;white-space:nowrap" class="ft212">&#160;</p>
<p style="position:absolute;top:908px;left:85px;white-space:nowrap" class="ft212">The&#160;median change&#160;from&#160;baseline&#160;in CD4+&#160;T-cell&#160;counts at&#160;Week&#160;144&#160;was&#160;36&#160;cells/mm3&#160;in&#160;the&#160;</p>
<p style="position:absolute;top:927px;left:85px;white-space:nowrap" class="ft212">dolutegravir/lamivudine&#160;arm&#160;and&#160;35&#160;cells/mm3&#160;in the&#160;TBR&#160;arm.&#160;</p>
<p style="position:absolute;top:947px;left:85px;white-space:nowrap" class="ft212">&#160;</p>
<p style="position:absolute;top:966px;left:85px;white-space:nowrap" class="ft212">Paediatric&#160;population&#160;</p>
<p style="position:absolute;top:986px;left:85px;white-space:nowrap" class="ft212">The efficacy&#160;of&#160;Dovato,&#160;or&#160;the&#160;dual&#160;combination&#160;of&#160;dolutegravir&#160;plus&#160;lamivudine&#160;(as single entities)&#160;has&#160;not&#160;</p>
<p style="position:absolute;top:1005px;left:85px;white-space:nowrap" class="ft212">been studied&#160;in children&#160;or&#160;adolescents.&#160;</p>
<p style="position:absolute;top:1025px;left:85px;white-space:nowrap" class="ft212">&#160;</p>
<p style="position:absolute;top:1044px;left:85px;white-space:nowrap" class="ft212">The&#160;European&#160;Medicines&#160;Agency has&#160;deferred the&#160;obligation to submit&#160;the&#160;results&#160;of&#160;studies&#160;with&#160;Dovato&#160;in&#160;</p>
<p style="position:absolute;top:1064px;left:85px;white-space:nowrap" class="ft212">one&#160;or&#160;more&#160;subsets&#160;of&#160;the&#160;paediatric&#160;population in&#160;the&#160;treatment&#160;of&#160;HIV&#160;infection.&#160;</p>
<p style="position:absolute;top:1083px;left:85px;white-space:nowrap" class="ft212">&#160;</p>
<p style="position:absolute;top:1103px;left:85px;white-space:nowrap" class="ft212">&#160;</p>
<p style="position:absolute;top:1122px;left:85px;white-space:nowrap" class="ft211"><b>5.2&#160;&#160;Pharmacokinetic properties&#160;&#160;</b></p>
<p style="position:absolute;top:1142px;left:85px;white-space:nowrap" class="ft211"><b>&#160;</b></p>
</div>
<!-- Page 22 -->
<a name="22"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft2225{font-size:10px;font-family:LIVBSS+SymbolMT;color:#000000;}
	.ft2226{font-size:17px;font-family:DTAKKI+TimesNewRomanPSMT;color:#30849b;}
-->
</style>
<div id="page22-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1191px;left:436px;white-space:nowrap" class="ft220">22&#160;</p>
<p style="position:absolute;top:83px;left:85px;white-space:nowrap" class="ft222">When&#160;administered&#160;in&#160;fasted&#160;state,&#160;bioequivalence&#160;regarding&#160;Cmax&#160;was achieved&#160;for&#160;dolutegravir,&#160;when&#160;</p>
<p style="position:absolute;top:103px;left:85px;white-space:nowrap" class="ft222">comparing&#160;Dovato&#160;to dolutegravir&#160;50&#160;mg co-administered with&#160;lamivudine&#160;300&#160;mg.&#160;Dolutegravir&#160;AUC0-t&#160;was&#160;</p>
<p style="position:absolute;top:122px;left:85px;white-space:nowrap" class="ft222">16%&#160;higher&#160;for&#160;Dovato&#160;than for&#160;dolutegravir&#160;50&#160;mg co-administered&#160;with&#160;lamivudine&#160;300&#160;mg.&#160;This increase&#160;</p>
<p style="position:absolute;top:142px;left:85px;white-space:nowrap" class="ft222">is not&#160;considered&#160;clinically&#160;relevant.&#160;</p>
<p style="position:absolute;top:162px;left:85px;white-space:nowrap" class="ft222">&#160;</p>
<p style="position:absolute;top:181px;left:85px;white-space:nowrap" class="ft222">When&#160;administered&#160;in&#160;fasted state,&#160;bioequivalence&#160;was&#160;achieved&#160;for&#160;lamivudine&#160;AUC, when comparing&#160;</p>
<p style="position:absolute;top:200px;left:85px;white-space:nowrap" class="ft222">Dovato&#160;to lamivudine&#160;300&#160;mg co-administered with&#160;dolutegravir&#160;50&#160;mg. Lamivudine&#160;Cmax&#160;for&#160;Dovato&#160;was&#160;</p>
<p style="position:absolute;top:220px;left:85px;white-space:nowrap" class="ft222">32%&#160;higher&#160;than&#160;lamivudine&#160;300&#160;mg co-administered&#160;with&#160;dolutegravir&#160;50&#160;mg.&#160;The&#160;higher&#160;lamivudine&#160;Cmax,&#160;</p>
<p style="position:absolute;top:239px;left:85px;white-space:nowrap" class="ft222">is not&#160;considered&#160;clinically&#160;relevant.&#160;</p>
<p style="position:absolute;top:259px;left:85px;white-space:nowrap" class="ft221"><b>&#160;</b></p>
<p style="position:absolute;top:279px;left:85px;white-space:nowrap" class="ft222">Absorption&#160;&#160;</p>
<p style="position:absolute;top:298px;left:85px;white-space:nowrap" class="ft222">&#160;</p>
<p style="position:absolute;top:317px;left:85px;white-space:nowrap" class="ft222">Dolutegravir&#160;and&#160;lamivudine&#160;are&#160;rapidly absorbed&#160;following oral&#160;administration. The&#160;absolute&#160;bioavailability&#160;</p>
<p style="position:absolute;top:337px;left:85px;white-space:nowrap" class="ft222">of&#160;dolutegravir&#160;has&#160;not&#160;been established.&#160;The&#160;absolute&#160;bioavailability&#160;of&#160;oral lamivudine&#160;in&#160;adults&#160;is&#160;</p>
<p style="position:absolute;top:356px;left:85px;white-space:nowrap" class="ft222">approximately 80-85%.&#160;For&#160;Dovato, the&#160;median&#160;time&#160;to&#160;maximal&#160;plasma&#160;concentration (tmax)&#160;is&#160;2.5&#160;hours&#160;for&#160;</p>
<p style="position:absolute;top:376px;left:85px;white-space:nowrap" class="ft222">dolutegravir&#160;and&#160;1.0&#160;hour&#160;for&#160;lamivudine,&#160;when&#160;dosed under&#160;fasted&#160;conditions.&#160;&#160;</p>
<p style="position:absolute;top:396px;left:85px;white-space:nowrap" class="ft222">&#160;</p>
<p style="position:absolute;top:415px;left:85px;white-space:nowrap" class="ft222">Exposure&#160;to dolutegravir&#160;was&#160;generally&#160;similar&#160;between&#160;healthy&#160;subjects&#160;and HIV-1–infected&#160;subjects. In&#160;</p>
<p style="position:absolute;top:434px;left:85px;white-space:nowrap" class="ft222">HIV-1–infected&#160;adult&#160;subjects&#160;following dolutegravir&#160;50&#160;mg once&#160;daily,&#160;the&#160;steady-state&#160;pharmacokinetic&#160;</p>
<p style="position:absolute;top:454px;left:85px;white-space:nowrap" class="ft222">parameters&#160;(geometric&#160;mean [%CV])&#160;based&#160;on population pharmacokinetic&#160;analyses were&#160;</p>
<p style="position:absolute;top:473px;left:85px;white-space:nowrap" class="ft222">AUC(0-24)&#160;=&#160;53.6&#160;(27)&#160;µg.h/mL, Cmax&#160;=&#160;3.67 (20)&#160;µg/mL, and Cmin&#160;=&#160;1.11 (46)&#160;µg/mL.&#160;Following&#160;multiple-</p>
<p style="position:absolute;top:493px;left:85px;white-space:nowrap" class="ft222">dose&#160;oral administration&#160;of&#160;lamivudine&#160;300&#160;mg once&#160;daily&#160;for&#160;seven days,&#160;the&#160;mean (CV)&#160;steady-state Cmax&#160;is&#160;</p>
<p style="position:absolute;top:513px;left:85px;white-space:nowrap" class="ft222">2.04&#160;µg/mL&#160;(26%) and&#160;the&#160;mean&#160;(CV)&#160;AUC(0-24)&#160;is&#160;8.87&#160;µg.h/mL&#160;(21%).&#160;</p>
<p style="position:absolute;top:532px;left:85px;white-space:nowrap" class="ft222">&#160;</p>
<p style="position:absolute;top:551px;left:85px;white-space:nowrap" class="ft222">Administration&#160;of&#160;a&#160;single&#160;Dovato&#160;tablet with&#160;a&#160;high&#160;fat&#160;meal&#160;increased dolutegravir&#160;AUC(0-∞)&#160;and Cmax&#160;by&#160;</p>
<p style="position:absolute;top:571px;left:85px;white-space:nowrap" class="ft222">33%&#160;and 21%, respectively, and decreased the&#160;lamivudine&#160;Cmax&#160;by 30%&#160;compared&#160;to fasted conditions. The&#160;</p>
<p style="position:absolute;top:590px;left:85px;white-space:nowrap" class="ft222">lamivudine&#160;AUC(0-∞)&#160;was&#160;not&#160;affected by a&#160;high fat&#160;meal. These&#160;changes&#160;are&#160;not&#160;clinically significant.&#160;Dovato&#160;</p>
<p style="position:absolute;top:610px;left:85px;white-space:nowrap" class="ft222">may be&#160;administered with&#160;or&#160;without&#160;food.&#160;</p>
<p style="position:absolute;top:630px;left:85px;white-space:nowrap" class="ft222">&#160;</p>
<p style="position:absolute;top:649px;left:85px;white-space:nowrap" class="ft222">Distribution&#160;&#160;</p>
<p style="position:absolute;top:668px;left:85px;white-space:nowrap" class="ft222">&#160;</p>
<p style="position:absolute;top:688px;left:85px;white-space:nowrap" class="ft222">The&#160;apparent volume&#160;of&#160;distribution&#160;of&#160;dolutegravir&#160;(Vd/F)&#160;is&#160;17-20&#160;L.&#160;Intravenous&#160;studies&#160;with lamivudine&#160;</p>
<p style="position:absolute;top:707px;left:85px;white-space:nowrap" class="ft222">showed that&#160;the&#160;mean apparent&#160;volume&#160;of&#160;distribution&#160;is&#160;1.3&#160;L/kg.&#160;</p>
<p style="position:absolute;top:727px;left:85px;white-space:nowrap" class="ft222">&#160;</p>
<p style="position:absolute;top:747px;left:85px;white-space:nowrap" class="ft222">Dolutegravir&#160;is&#160;highly&#160;bound (&gt;&#160;99%)&#160;to&#160;human plasma&#160;proteins&#160;based on&#160;<i>in&#160;vitro</i>&#160;data. Binding of&#160;</p>
<p style="position:absolute;top:766px;left:85px;white-space:nowrap" class="ft222">dolutegravir&#160;to plasma&#160;proteins&#160;is&#160;independent&#160;of&#160;dolutegravir&#160;concentration. Total&#160;blood&#160;and plasma&#160;drug-</p>
<p style="position:absolute;top:785px;left:85px;white-space:nowrap" class="ft222">related radioactivity&#160;concentration ratios&#160;averaged&#160;between 0.441 to&#160;0.535,&#160;indicating minimal&#160;association of&#160;</p>
<p style="position:absolute;top:805px;left:85px;white-space:nowrap" class="ft222">radioactivity&#160;with&#160;blood cellular&#160;components. The&#160;unbound fraction of&#160;dolutegravir&#160;in&#160;plasma is increased&#160;at&#160;</p>
<p style="position:absolute;top:824px;left:85px;white-space:nowrap" class="ft222">low&#160;levels&#160;of&#160;serum&#160;albumin (&lt;35&#160;g/L)&#160;as seen&#160;in&#160;subjects&#160;with&#160;moderate hepatic&#160;impairment.&#160;Lamivudine&#160;</p>
<p style="position:absolute;top:844px;left:85px;white-space:nowrap" class="ft222">exhibits linear&#160;pharmacokinetics over&#160;the&#160;therapeutic dose range&#160;and displays&#160;limited plasma&#160;protein&#160;binding&#160;</p>
<p style="position:absolute;top:864px;left:85px;white-space:nowrap" class="ft225"><i>in&#160;vitro</i>&#160;(&lt;&#160;16%-&#160;36%&#160;to&#160;serum albumin).&#160;</p>
<p style="position:absolute;top:883px;left:85px;white-space:nowrap" class="ft222">&#160;</p>
<p style="position:absolute;top:902px;left:85px;white-space:nowrap" class="ft222">Dolutegravir&#160;and&#160;lamivudine&#160;are&#160;present&#160;in cerebrospinal&#160;fluid (CSF). In 13&#160;treatment-naïve&#160;subjects&#160;on a&#160;</p>
<p style="position:absolute;top:922px;left:85px;white-space:nowrap" class="ft222">stable&#160;dolutegravir&#160;plus&#160;abacavir/lamivudine&#160;regimen,&#160;dolutegravir&#160;concentration in&#160;CSF&#160;averaged 18&#160;ng/mL&#160;</p>
<p style="position:absolute;top:941px;left:85px;white-space:nowrap" class="ft222">(comparable&#160;to unbound plasma&#160;concentration, and above&#160;the&#160;IC50).&#160;The&#160;mean&#160;ratio&#160;of&#160;CSF/serum&#160;</p>
<p style="position:absolute;top:961px;left:85px;white-space:nowrap" class="ft222">lamivudine&#160;concentrations&#160;2-4&#160;hours&#160;after&#160;oral&#160;administration&#160;was&#160;approximately 12%.&#160;The&#160;true&#160;extent&#160;of&#160;</p>
<p style="position:absolute;top:981px;left:85px;white-space:nowrap" class="ft222">CNS&#160;penetration of&#160;lamivudine&#160;and its&#160;relationship with any clinical&#160;efficacy&#160;is&#160;unknown.&#160;</p>
<p style="position:absolute;top:1000px;left:85px;white-space:nowrap" class="ft222">&#160;</p>
<p style="position:absolute;top:1019px;left:85px;white-space:nowrap" class="ft222">Dolutegravir&#160;is&#160;present&#160;in the&#160;female&#160;and&#160;male&#160;genital&#160;tract. AUC&#160;in cervicovaginal&#160;fluid, cervical&#160;tissue&#160;and&#160;</p>
<p style="position:absolute;top:1039px;left:85px;white-space:nowrap" class="ft222">vaginal&#160;tissue&#160;were 6-10%&#160;of&#160;those&#160;in corresponding plasma&#160;at&#160;steady state. AUC&#160;in semen was&#160;7%&#160;and 17%&#160;</p>
<p style="position:absolute;top:1058px;left:85px;white-space:nowrap" class="ft222">in&#160;rectal&#160;tissue of&#160;those in&#160;corresponding&#160;plasma at&#160;steady&#160;state.&#160;</p>
<p style="position:absolute;top:1078px;left:85px;white-space:nowrap" class="ft222">&#160;</p>
<p style="position:absolute;top:1098px;left:85px;white-space:nowrap" class="ft222">Biotransformation&#160;</p>
<p style="position:absolute;top:1117px;left:85px;white-space:nowrap" class="ft222">&#160;</p>
<p style="position:absolute;top:1136px;left:85px;white-space:nowrap" class="ft222">Dolutegravir&#160;is&#160;primarily&#160;metabolized&#160;via&#160;UGT1A1 with a&#160;minor&#160;CYP3A&#160;component&#160;(9.7%&#160;of&#160;total&#160;dose&#160;</p>
<p style="position:absolute;top:1156px;left:85px;white-space:nowrap" class="ft222">administered in&#160;a&#160;human&#160;mass&#160;balance&#160;study). Dolutegravir&#160;is&#160;the&#160;predominant&#160;circulating compound in&#160;</p>
</div>
<!-- Page 23 -->
<a name="23"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page23-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1191px;left:436px;white-space:nowrap" class="ft230">23&#160;</p>
<p style="position:absolute;top:83px;left:85px;white-space:nowrap" class="ft232">plasma;&#160;renal&#160;elimination&#160;of&#160;unchanged&#160;active substance is&#160;low&#160;(&lt;&#160;1% of the&#160;dose).&#160;Fifty-three percent&#160;of&#160;</p>
<p style="position:absolute;top:103px;left:85px;white-space:nowrap" class="ft232">total&#160;oral&#160;dose&#160;is&#160;excreted unchanged in the&#160;faeces. It&#160;is&#160;unknown if&#160;all&#160;or&#160;part&#160;of&#160;this&#160;is&#160;due&#160;to&#160;unabsorbed&#160;</p>
<p style="position:absolute;top:122px;left:85px;white-space:nowrap" class="ft232">active&#160;substance&#160;or&#160;biliary&#160;excretion of&#160;the&#160;glucuronidate&#160;conjugate, which&#160;can be&#160;further&#160;degraded to form&#160;</p>
<p style="position:absolute;top:142px;left:85px;white-space:nowrap" class="ft232">the&#160;parent&#160;compound&#160;in the&#160;gut&#160;lumen. Thirty-two percent&#160;of&#160;the&#160;total&#160;oral&#160;dose&#160;is&#160;excreted in&#160;the&#160;urine,&#160;</p>
<p style="position:absolute;top:162px;left:85px;white-space:nowrap" class="ft232">represented by ether&#160;glucuronide&#160;of&#160;dolutegravir&#160;(18.9%&#160;of&#160;total&#160;dose), N-dealkylation metabolite&#160;(3.6%&#160;of&#160;</p>
<p style="position:absolute;top:181px;left:85px;white-space:nowrap" class="ft232">total&#160;dose),&#160;and&#160;a&#160;metabolite formed by oxidation at&#160;the&#160;benzylic&#160;carbon (3.0%&#160;of&#160;total&#160;dose).&#160;</p>
<p style="position:absolute;top:200px;left:85px;white-space:nowrap" class="ft232">&#160;</p>
<p style="position:absolute;top:220px;left:85px;white-space:nowrap" class="ft232">Metabolism&#160;of&#160;lamivudine&#160;is&#160;a&#160;minor&#160;route&#160;of&#160;elimination. Lamivudine&#160;is&#160;predominately cleared&#160;by renal&#160;</p>
<p style="position:absolute;top:239px;left:85px;white-space:nowrap" class="ft232">excretion of&#160;unchanged lamivudine. The&#160;likelihood of&#160;metabolic&#160;drug interactions&#160;with&#160;lamivudine&#160;is&#160;low&#160;</p>
<p style="position:absolute;top:259px;left:85px;white-space:nowrap" class="ft232">due&#160;to&#160;the&#160;small extent of&#160;hepatic&#160;metabolism&#160;(5-10%).&#160;</p>
<p style="position:absolute;top:279px;left:85px;white-space:nowrap" class="ft232">&#160;</p>
<p style="position:absolute;top:298px;left:85px;white-space:nowrap" class="ft232">Drug interactions&#160;</p>
<p style="position:absolute;top:318px;left:85px;white-space:nowrap" class="ft235"><i>&#160;</i></p>
<p style="position:absolute;top:337px;left:85px;white-space:nowrap" class="ft235"><i>In&#160;vitro</i>, dolutegravir&#160;demonstrated no direct, or&#160;weak&#160;inhibition (IC50&gt;50&#160;μM)&#160;of&#160;the&#160;enzymes&#160;cytochrome&#160;</p>
<p style="position:absolute;top:356px;left:85px;white-space:nowrap" class="ft232">P450&#160;(CYP)1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 CYP3A,&#160;UGT1A1 or&#160;</p>
<p style="position:absolute;top:376px;left:85px;white-space:nowrap" class="ft232">UGT2B7, or&#160;the&#160;transporters&#160;Pgp, BCRP, BSEP,&#160;organic&#160;anion transporting polypeptide&#160;(OATP)&#160;1B1,&#160;</p>
<p style="position:absolute;top:396px;left:85px;white-space:nowrap" class="ft232">OATP1B3,&#160;OCT1,&#160;MATE2-K,&#160;multidrug resistance-associated protein&#160;(MRP)&#160;2 or&#160;MRP4.&#160;<i>In&#160;vitro</i>,&#160;</p>
<p style="position:absolute;top:415px;left:85px;white-space:nowrap" class="ft232">dolutegravir&#160;did not&#160;induce&#160;CYP1A2, CYP2B6 or&#160;CYP3A4. Based on this&#160;data, dolutegravir&#160;is&#160;not&#160;expected&#160;</p>
<p style="position:absolute;top:434px;left:85px;white-space:nowrap" class="ft232">to&#160;affect&#160;the&#160;pharmacokinetics&#160;of&#160;medicinal products&#160;that are&#160;substrates&#160;of&#160;major&#160;enzymes or&#160;transporters&#160;(see&#160;</p>
<p style="position:absolute;top:454px;left:85px;white-space:nowrap" class="ft232">section 4.5).&#160;</p>
<p style="position:absolute;top:474px;left:85px;white-space:nowrap" class="ft235"><i>&#160;</i></p>
<p style="position:absolute;top:493px;left:85px;white-space:nowrap" class="ft235"><i>In&#160;vitro</i>, dolutegravir&#160;was&#160;not&#160;a&#160;substrate&#160;of&#160;human OATP&#160;1B1, OATP&#160;1B3 or&#160;OCT&#160;1.&#160;</p>
<p style="position:absolute;top:513px;left:85px;white-space:nowrap" class="ft232">&#160;</p>
<p style="position:absolute;top:532px;left:85px;white-space:nowrap" class="ft235"><i>In&#160;vitro,</i>&#160;lamivudine&#160;did&#160;not&#160;inhibit&#160;or&#160;induce&#160;CYP&#160;enzymes&#160;(such as&#160;CYP3A4, CYP2C9 or&#160;CYP2D6)&#160;and&#160;</p>
<p style="position:absolute;top:551px;left:85px;white-space:nowrap" class="ft232">demonstrated&#160;no or&#160;weak&#160;inhibition of&#160;OATP1B1, OAT1B3,&#160;OCT3,&#160;BCRP,&#160;P-gp, MATE1 or&#160;MATE2-K.&#160;</p>
<p style="position:absolute;top:571px;left:85px;white-space:nowrap" class="ft232">Lamivudine&#160;is&#160;therefore not&#160;expected&#160;to&#160;affect&#160;the plasma concentrations of&#160;medicinal products&#160;that&#160;are&#160;</p>
<p style="position:absolute;top:590px;left:85px;white-space:nowrap" class="ft232">substrates&#160;of&#160;these enzymes&#160;or&#160;transporters.&#160;</p>
<p style="position:absolute;top:610px;left:85px;white-space:nowrap" class="ft232">&#160;</p>
<p style="position:absolute;top:630px;left:85px;white-space:nowrap" class="ft232">Lamivudine&#160;was&#160;not&#160;significantly&#160;metabolised by&#160;CYP&#160;enzymes.&#160;</p>
<p style="position:absolute;top:649px;left:85px;white-space:nowrap" class="ft231"><b>&#160;</b></p>
<p style="position:absolute;top:668px;left:85px;white-space:nowrap" class="ft232">Elimination&#160;&#160;</p>
<p style="position:absolute;top:688px;left:85px;white-space:nowrap" class="ft232">&#160;</p>
<p style="position:absolute;top:707px;left:85px;white-space:nowrap" class="ft232">Dolutegravir&#160;has&#160;a&#160;terminal&#160;half-life&#160;of ~14&#160;hours. The&#160;apparent&#160;oral&#160;clearance&#160;(CL/F)&#160;is&#160;approximately&#160;</p>
<p style="position:absolute;top:727px;left:85px;white-space:nowrap" class="ft232">1&#160;L/hr&#160;in&#160;HIV-infected patients&#160;based on a&#160;population&#160;pharmacokinetic&#160;analysis.&#160;&#160;</p>
<p style="position:absolute;top:747px;left:85px;white-space:nowrap" class="ft232">&#160;</p>
<p style="position:absolute;top:766px;left:85px;white-space:nowrap" class="ft232">The&#160;observed lamivudine&#160;half-life&#160;of&#160;elimination&#160;is&#160;18&#160;to&#160;19&#160;hours.&#160;For&#160;patients&#160;receiving lamivudine&#160;300&#160;mg&#160;</p>
<p style="position:absolute;top:785px;left:85px;white-space:nowrap" class="ft232">once daily,&#160;the&#160;terminal&#160;intracellular&#160;half-life&#160;of&#160;lamivudine-TP was&#160;16 to&#160;19&#160;hours.&#160;The&#160;mean&#160;systemic&#160;</p>
<p style="position:absolute;top:805px;left:85px;white-space:nowrap" class="ft232">clearance of&#160;lamivudine&#160;is&#160;approximately&#160;0.32&#160;L/h/kg,&#160;predominantly&#160;by renal&#160;clearance&#160;(&gt;&#160;70%)&#160;via&#160;the&#160;</p>
<p style="position:absolute;top:824px;left:85px;white-space:nowrap" class="ft232">organic&#160;cationic&#160;transport system.&#160;Studies&#160;in&#160;patients&#160;with&#160;renal&#160;impairment show&#160;lamivudine&#160;elimination&#160;is&#160;</p>
<p style="position:absolute;top:844px;left:85px;white-space:nowrap" class="ft232">affected&#160;by&#160;renal&#160;dysfunction. Dose&#160;reduction&#160;is&#160;required for&#160;patients&#160;with creatinine&#160;clearance&#160;&lt;&#160;30&#160;mL/min&#160;</p>
<p style="position:absolute;top:864px;left:85px;white-space:nowrap" class="ft232">(see section&#160;4.2).&#160;</p>
<p style="position:absolute;top:883px;left:85px;white-space:nowrap" class="ft232">&#160;</p>
<p style="position:absolute;top:902px;left:85px;white-space:nowrap" class="ft232">Pharmacokinetic/pharmacodynamic&#160;relationship(s)&#160;</p>
<p style="position:absolute;top:922px;left:85px;white-space:nowrap" class="ft232">&#160;</p>
<p style="position:absolute;top:941px;left:85px;white-space:nowrap" class="ft232">In a&#160;randomized,&#160;dose-ranging&#160;trial,&#160;HIV-1–infected&#160;subjects&#160;treated&#160;with&#160;dolutegravir&#160;monotherapy&#160;</p>
<p style="position:absolute;top:961px;left:85px;white-space:nowrap" class="ft232">(ING111521)&#160;demonstrated&#160;rapid&#160;and&#160;dose-dependent&#160;antiviral&#160;activity,&#160;with mean&#160;decline&#160;in&#160;HIV-1&#160;RNA of&#160;</p>
<p style="position:absolute;top:981px;left:85px;white-space:nowrap" class="ft232">2.5&#160;log10&#160;at&#160;day 11&#160;for&#160;50&#160;mg dose. This&#160;antiviral&#160;response&#160;was&#160;maintained&#160;for&#160;3&#160;to&#160;4&#160;days&#160;after&#160;the last&#160;dose&#160;</p>
<p style="position:absolute;top:1000px;left:85px;white-space:nowrap" class="ft232">in the&#160;50&#160;mg group.&#160;</p>
<p style="position:absolute;top:1019px;left:85px;white-space:nowrap" class="ft232">&#160;</p>
<p style="position:absolute;top:1038px;left:85px;white-space:nowrap" class="ft232">Special&#160;patient&#160;populations&#160;</p>
<p style="position:absolute;top:1058px;left:85px;white-space:nowrap" class="ft232">&#160;</p>
<p style="position:absolute;top:1078px;left:85px;white-space:nowrap" class="ft235"><i>Children&#160;</i></p>
<p style="position:absolute;top:1097px;left:85px;white-space:nowrap" class="ft232">The&#160;pharmacokinetics&#160;of&#160;dolutegravir&#160;in 10 antiretroviral&#160;treatment-experienced&#160;HIV-1&#160;infected&#160;adolescents&#160;</p>
<p style="position:absolute;top:1116px;left:85px;white-space:nowrap" class="ft232">(12 to 17&#160;years)&#160;showed&#160;that&#160;dolutegravir&#160;50&#160;mg once&#160;daily dosage&#160;resulted&#160;in dolutegravir&#160;exposure&#160;</p>
<p style="position:absolute;top:1136px;left:85px;white-space:nowrap" class="ft232">comparable&#160;to that</p>
<p style="position:absolute;top:1135px;left:208px;white-space:nowrap" class="ft236">&#160;observed in adults&#160;who&#160;received&#160;dolutegravir&#160;50&#160;mg&#160;once&#160;daily.&#160;&#160;</p>
<p style="position:absolute;top:1155px;left:85px;white-space:nowrap" class="ft232">&#160;</p>
</div>
<!-- Page 24 -->
<a name="24"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page24-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1191px;left:436px;white-space:nowrap" class="ft240">24&#160;</p>
<p style="position:absolute;top:83px;left:85px;white-space:nowrap" class="ft242">Limited data&#160;are&#160;available&#160;in adolescents&#160;receiving a&#160;daily dose&#160;of&#160;300&#160;mg of&#160;lamivudine.&#160;Pharmacokinetic&#160;</p>
<p style="position:absolute;top:103px;left:85px;white-space:nowrap" class="ft242">parameters are comparable&#160;to&#160;those&#160;reported&#160;in&#160;adults.&#160;</p>
<p style="position:absolute;top:122px;left:85px;white-space:nowrap" class="ft242">&#160;</p>
<p style="position:absolute;top:142px;left:85px;white-space:nowrap" class="ft245"><i>Elderly&#160;</i></p>
<p style="position:absolute;top:162px;left:85px;white-space:nowrap" class="ft242">Population pharmacokinetic&#160;analysis&#160;of&#160;dolutegravir&#160;using data&#160;in HIV-1 infected&#160;adults&#160;showed&#160;that&#160;there&#160;</p>
<p style="position:absolute;top:181px;left:85px;white-space:nowrap" class="ft242">was no&#160;clinically&#160;relevant&#160;effect&#160;of&#160;age on&#160;dolutegravir&#160;exposure.&#160;</p>
<p style="position:absolute;top:200px;left:85px;white-space:nowrap" class="ft242">&#160;</p>
<p style="position:absolute;top:220px;left:85px;white-space:nowrap" class="ft242">Pharmacokinetic data&#160;for&#160;dolutegravir&#160;and&#160;lamivudine&#160;in subjects&#160;&gt;65 years&#160;of&#160;age&#160;are&#160;limited.&#160;</p>
<p style="position:absolute;top:239px;left:85px;white-space:nowrap" class="ft242">&#160;</p>
<p style="position:absolute;top:259px;left:85px;white-space:nowrap" class="ft245"><i>Renal&#160;impairment&#160;</i></p>
<p style="position:absolute;top:279px;left:85px;white-space:nowrap" class="ft242">Pharmacokinetic&#160;data&#160;have&#160;been&#160;obtained for&#160;dolutegravir&#160;and&#160;lamivudine separately.<i>&#160;</i></p>
<p style="position:absolute;top:298px;left:85px;white-space:nowrap" class="ft242">&#160;</p>
<p style="position:absolute;top:317px;left:85px;white-space:nowrap" class="ft242">Renal&#160;clearance&#160;of&#160;unchanged&#160;active substance&#160;is&#160;a minor&#160;pathway of&#160;elimination&#160;for&#160;dolutegravir. A&#160;study&#160;</p>
<p style="position:absolute;top:337px;left:85px;white-space:nowrap" class="ft242">of&#160;the pharmacokinetics of&#160;dolutegravir&#160;was&#160;performed&#160;in&#160;subjects with&#160;severe renal&#160;impairment&#160;</p>
<p style="position:absolute;top:356px;left:85px;white-space:nowrap" class="ft242">(CLcr&#160;&lt;30&#160;mL/min). No clinically important&#160;pharmacokinetic&#160;differences&#160;between&#160;subjects&#160;with severe&#160;renal&#160;</p>
<p style="position:absolute;top:376px;left:85px;white-space:nowrap" class="ft242">impairment&#160;(CLcr&#160;&lt;30&#160;mL/min)&#160;and matching healthy&#160;subjects&#160;were&#160;observed. Dolutegravir&#160;has&#160;not&#160;been&#160;</p>
<p style="position:absolute;top:396px;left:85px;white-space:nowrap" class="ft242">studied&#160;in patients&#160;on&#160;dialysis,&#160;though differences&#160;in&#160;exposure&#160;are&#160;not&#160;expected.&#160;</p>
<p style="position:absolute;top:415px;left:85px;white-space:nowrap" class="ft242">&#160;</p>
<p style="position:absolute;top:434px;left:85px;white-space:nowrap" class="ft242">Studies with&#160;lamivudine show&#160;that&#160;plasma concentrations (AUC)&#160;are&#160;increased&#160;in&#160;patients&#160;with&#160;renal&#160;</p>
<p style="position:absolute;top:454px;left:85px;white-space:nowrap" class="ft242">dysfunction due&#160;to decreased clearance.&#160;&#160;</p>
<p style="position:absolute;top:474px;left:85px;white-space:nowrap" class="ft242">&#160;</p>
<p style="position:absolute;top:493px;left:85px;white-space:nowrap" class="ft242">Based on&#160;the&#160;lamivudine&#160;data,&#160;Dovato&#160;is not&#160;recommended&#160;for&#160;patients with&#160;creatinine&#160;clearance&#160;of&#160;</p>
<p style="position:absolute;top:513px;left:85px;white-space:nowrap" class="ft242">&lt;&#160;30&#160;mL/min.&#160;</p>
<p style="position:absolute;top:532px;left:85px;white-space:nowrap" class="ft242">&#160;</p>
<p style="position:absolute;top:552px;left:85px;white-space:nowrap" class="ft245"><i>Hepatic&#160;impairment&#160;</i></p>
<p style="position:absolute;top:571px;left:85px;white-space:nowrap" class="ft242">Pharmacokinetic data&#160;has been&#160;obtained&#160;for&#160;dolutegravir&#160;and&#160;lamivudine&#160;separately.&#160;<i>&#160;</i></p>
<p style="position:absolute;top:591px;left:85px;white-space:nowrap" class="ft242">&#160;</p>
<p style="position:absolute;top:610px;left:85px;white-space:nowrap" class="ft242">Dolutegravir&#160;is&#160;primarily&#160;metabolized&#160;and eliminated by the&#160;liver. A&#160;single&#160;dose&#160;of&#160;50&#160;mg&#160;of&#160;dolutegravir&#160;</p>
<p style="position:absolute;top:630px;left:85px;white-space:nowrap" class="ft242">was&#160;administered&#160;to&#160;8&#160;subjects&#160;with&#160;moderate&#160;hepatic&#160;impairment (Child-Pugh class&#160;B)&#160;and to 8&#160;matched&#160;</p>
<p style="position:absolute;top:649px;left:85px;white-space:nowrap" class="ft242">healthy&#160;adult&#160;controls. While&#160;the&#160;total&#160;dolutegravir&#160;concentration&#160;in&#160;plasma&#160;was&#160;similar, a&#160;1.5&#160;to&#160;2&#160;fold&#160;</p>
<p style="position:absolute;top:668px;left:85px;white-space:nowrap" class="ft242">increase&#160;in unbound exposure&#160;to dolutegravir&#160;was&#160;observed in&#160;subjects&#160;with&#160;moderate&#160;hepatic&#160;impairment&#160;</p>
<p style="position:absolute;top:688px;left:85px;white-space:nowrap" class="ft242">compared to&#160;healthy controls. No dosage&#160;adjustment&#160;is&#160;considered necessary for&#160;patients&#160;with&#160;mild to&#160;</p>
<p style="position:absolute;top:708px;left:85px;white-space:nowrap" class="ft242">moderate hepatic&#160;impairment.&#160;The&#160;effect&#160;of&#160;severe hepatic impairment&#160;on&#160;the pharmacokinetics&#160;of&#160;</p>
<p style="position:absolute;top:727px;left:85px;white-space:nowrap" class="ft242">dolutegravir&#160;has&#160;not&#160;been studied.&#160;</p>
<p style="position:absolute;top:747px;left:85px;white-space:nowrap" class="ft242">&#160;</p>
<p style="position:absolute;top:766px;left:85px;white-space:nowrap" class="ft242">Data&#160;obtained&#160;in&#160;patients&#160;with&#160;moderate&#160;to&#160;severe&#160;hepatic&#160;impairment show&#160;that lamivudine&#160;</p>
<p style="position:absolute;top:785px;left:85px;white-space:nowrap" class="ft242">pharmacokinetics&#160;are&#160;not&#160;significantly affected by hepatic&#160;dysfunction.&#160;</p>
<p style="position:absolute;top:805px;left:85px;white-space:nowrap" class="ft242">&#160;</p>
<p style="position:absolute;top:825px;left:85px;white-space:nowrap" class="ft245"><i>Polymorphisms&#160;in&#160;drug metabolising enzymes&#160;</i></p>
<p style="position:absolute;top:844px;left:85px;white-space:nowrap" class="ft242">There&#160;is&#160;no evidence&#160;that&#160;common polymorphisms&#160;in&#160;drug&#160;metabolising&#160;enzymes&#160;alter&#160;dolutegravir&#160;</p>
<p style="position:absolute;top:864px;left:85px;white-space:nowrap" class="ft242">pharmacokinetics&#160;to&#160;a clinically&#160;meaningful&#160;extent.&#160;In&#160;a&#160;meta-analysis using&#160;pharmacogenomics samples&#160;</p>
<p style="position:absolute;top:883px;left:85px;white-space:nowrap" class="ft242">collected&#160;in clinical&#160;studies&#160;in healthy subjects, subjects&#160;with UGT1A1 (n=7)&#160;genotypes&#160;conferring&#160;poor&#160;</p>
<p style="position:absolute;top:902px;left:85px;white-space:nowrap" class="ft242">dolutegravir&#160;metabolism&#160;had a&#160;32%&#160;lower&#160;clearance&#160;of&#160;dolutegravir&#160;and 46%&#160;higher&#160;AUC&#160;compared&#160;with&#160;</p>
<p style="position:absolute;top:922px;left:85px;white-space:nowrap" class="ft242">subjects&#160;with genotypes&#160;associated with&#160;normal&#160;metabolism&#160;via&#160;UGT1A1&#160;(n=41).&#160;</p>
<p style="position:absolute;top:942px;left:85px;white-space:nowrap" class="ft242">&#160;</p>
<p style="position:absolute;top:961px;left:85px;white-space:nowrap" class="ft245"><i>Gender&#160;</i></p>
<p style="position:absolute;top:981px;left:85px;white-space:nowrap" class="ft242">Population PK&#160;analyses&#160;using pooled pharmacokinetic&#160;data&#160;from&#160;clinical&#160;studies&#160;where dolutegravir&#160;or&#160;</p>
<p style="position:absolute;top:1000px;left:85px;white-space:nowrap" class="ft242">lamivudine&#160;was&#160;administered&#160;to adults&#160;in combination with&#160;other&#160;ARVs&#160;revealed no&#160;clinically relevant&#160;effect&#160;</p>
<p style="position:absolute;top:1020px;left:85px;white-space:nowrap" class="ft242">of&#160;gender&#160;on the&#160;exposure&#160;of&#160;dolutegravir&#160;or&#160;lamivudine. There&#160;is&#160;no evidence&#160;that&#160;a&#160;dose&#160;adjustment&#160;of&#160;</p>
<p style="position:absolute;top:1039px;left:85px;white-space:nowrap" class="ft242">dolutegravir&#160;or&#160;lamivudine&#160;would be&#160;required based&#160;on&#160;the&#160;effects of&#160;gender&#160;on&#160;PK&#160;parameters.&#160;</p>
<p style="position:absolute;top:1059px;left:85px;white-space:nowrap" class="ft242">&#160;</p>
<p style="position:absolute;top:1078px;left:85px;white-space:nowrap" class="ft245"><i>Race&#160;&#160;</i></p>
<p style="position:absolute;top:1098px;left:85px;white-space:nowrap" class="ft242">Population PK&#160;analyses&#160;using pooled pharmacokinetic&#160;data&#160;from&#160;clinical&#160;studies where&#160;dolutegravir&#160;was&#160;</p>
<p style="position:absolute;top:1117px;left:85px;white-space:nowrap" class="ft242">administered&#160;to adults&#160;in combination&#160;with other&#160;ARVs&#160;revealed&#160;no&#160;clinically&#160;relevant&#160;effect&#160;of&#160;race on&#160;the&#160;</p>
<p style="position:absolute;top:1137px;left:85px;white-space:nowrap" class="ft242">exposure&#160;of&#160;dolutegravir. The&#160;pharmacokinetics&#160;of&#160;dolutegravir&#160;following single&#160;dose&#160;oral&#160;administration to&#160;</p>
<p style="position:absolute;top:1156px;left:85px;white-space:nowrap" class="ft242">Japanese&#160;subjects appear&#160;similar&#160;to&#160;observed&#160;parameters in&#160;Western&#160;(US)&#160;subjects.&#160;There&#160;is&#160;no&#160;evidence&#160;that&#160;</p>
</div>
<!-- Page 25 -->
<a name="25"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page25-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1191px;left:436px;white-space:nowrap" class="ft250">25&#160;</p>
<p style="position:absolute;top:83px;left:85px;white-space:nowrap" class="ft252">a&#160;dose&#160;adjustment&#160;of&#160;dolutegravir&#160;or&#160;lamivudine&#160;would&#160;be&#160;required based on&#160;the&#160;effects&#160;of&#160;race&#160;on PK&#160;</p>
<p style="position:absolute;top:103px;left:85px;white-space:nowrap" class="ft252">parameters.&#160;&#160;</p>
<p style="position:absolute;top:122px;left:85px;white-space:nowrap" class="ft252">&#160;</p>
<p style="position:absolute;top:142px;left:85px;white-space:nowrap" class="ft255"><i>Co-infection&#160;with&#160;Hepatitis&#160;B&#160;or&#160;C&#160;&#160;</i></p>
<p style="position:absolute;top:162px;left:85px;white-space:nowrap" class="ft252">Population pharmacokinetic&#160;analysis&#160;indicated&#160;that&#160;hepatitis&#160;C&#160;virus&#160;co-infection had&#160;no&#160;clinically relevant&#160;</p>
<p style="position:absolute;top:181px;left:85px;white-space:nowrap" class="ft252">effect&#160;on the&#160;exposure&#160;to dolutegravir.&#160;There&#160;are&#160;limited pharmacokinetic&#160;data&#160;on&#160;subjects&#160;with hepatitis&#160;B&#160;</p>
<p style="position:absolute;top:200px;left:85px;white-space:nowrap" class="ft252">co-infection&#160;(see&#160;section 4.4).&#160;</p>
<p style="position:absolute;top:220px;left:85px;white-space:nowrap" class="ft252">&#160;</p>
<p style="position:absolute;top:239px;left:85px;white-space:nowrap" class="ft251"><b>5.3&#160;&#160;Preclinical&#160;safety&#160;data&#160;</b>&#160;</p>
<p style="position:absolute;top:259px;left:85px;white-space:nowrap" class="ft252">&#160;</p>
<p style="position:absolute;top:279px;left:85px;white-space:nowrap" class="ft252">There&#160;are&#160;no data&#160;available&#160;on the&#160;effects&#160;of&#160;the&#160;combination of&#160;dolutegravir&#160;and lamivudine&#160;in&#160;animals.&#160;</p>
<p style="position:absolute;top:298px;left:85px;white-space:nowrap" class="ft252">&#160;</p>
<p style="position:absolute;top:317px;left:85px;white-space:nowrap" class="ft252">Carcinogenesis and&#160;mutagenesis&#160;</p>
<p style="position:absolute;top:337px;left:85px;white-space:nowrap" class="ft252">&#160;</p>
<p style="position:absolute;top:356px;left:85px;white-space:nowrap" class="ft252">Dolutegravir&#160;was&#160;not&#160;mutagenic&#160;or&#160;clastogenic&#160;using&#160;<i>in&#160;vitro</i>&#160;tests&#160;in&#160;bacteria and&#160;cultured&#160;mammalian&#160;cells,&#160;</p>
<p style="position:absolute;top:376px;left:85px;white-space:nowrap" class="ft252">and an&#160;<i>in&#160;viv</i>o&#160;rodent&#160;micronucleus&#160;assay.&#160;Lamivudine&#160;was&#160;not&#160;mutagenic&#160;in&#160;bacterial tests,&#160;but consistent&#160;</p>
<p style="position:absolute;top:396px;left:85px;white-space:nowrap" class="ft252">with other&#160;nucleoside&#160;analogues,&#160;inhibits&#160;cellular&#160;DNA&#160;replication&#160;in&#160;<i>in&#160;vitro</i>&#160;mammalian&#160;tests such&#160;as&#160;the&#160;</p>
<p style="position:absolute;top:415px;left:85px;white-space:nowrap" class="ft252">mouse&#160;lymphoma&#160;assay.&#160;The&#160;results&#160;from&#160;two&#160;in&#160;vivo&#160;rat&#160;micronucleus&#160;tests&#160;with&#160;lamivudine&#160;were&#160;negative.&#160;</p>
<p style="position:absolute;top:434px;left:85px;white-space:nowrap" class="ft252">Lamivudine&#160;has&#160;not&#160;shown any&#160;genotoxic&#160;activity in the&#160;<i>in&#160;vivo</i>&#160;studies.&#160;&#160;</p>
<p style="position:absolute;top:454px;left:85px;white-space:nowrap" class="ft252">&#160;</p>
<p style="position:absolute;top:473px;left:85px;white-space:nowrap" class="ft252">The&#160;carcinogenic&#160;potential&#160;of&#160;a&#160;combination of&#160;dolutegravir&#160;and lamivudine&#160;has&#160;not&#160;been tested.&#160;Dolutegravir&#160;</p>
<p style="position:absolute;top:493px;left:85px;white-space:nowrap" class="ft252">was&#160;not&#160;carcinogenic&#160;in&#160;long term&#160;studies&#160;in&#160;the&#160;mouse&#160;and rat.&#160;In long-term&#160;oral&#160;carcinogenicity&#160;studies&#160;in&#160;</p>
<p style="position:absolute;top:513px;left:85px;white-space:nowrap" class="ft252">rats&#160;and&#160;mice,&#160;lamivudine&#160;did not&#160;show&#160;any carcinogenic&#160;potential.&#160;&#160;</p>
<p style="position:absolute;top:532px;left:85px;white-space:nowrap" class="ft252">&#160;</p>
<p style="position:absolute;top:551px;left:85px;white-space:nowrap" class="ft252">Reproductive&#160;toxicology studies&#160;</p>
<p style="position:absolute;top:571px;left:85px;white-space:nowrap" class="ft252">&#160;</p>
<p style="position:absolute;top:590px;left:85px;white-space:nowrap" class="ft252">In reproductive&#160;toxicity&#160;studies&#160;in animals,&#160;dolutegravir&#160;and&#160;lamivudine were shown&#160;to&#160;cross&#160;the&#160;placenta.&#160;</p>
<p style="position:absolute;top:610px;left:85px;white-space:nowrap" class="ft252">&#160;</p>
<p style="position:absolute;top:630px;left:85px;white-space:nowrap" class="ft252">Oral administration&#160;of&#160;dolutegravir&#160;to&#160;pregnant&#160;rats&#160;at&#160;doses&#160;up&#160;to&#160;1000&#160;mg/kg daily from&#160;days&#160;6 to 17 of&#160;</p>
<p style="position:absolute;top:649px;left:85px;white-space:nowrap" class="ft252">gestation&#160;did&#160;not elicit maternal&#160;toxicity,&#160;developmental&#160;toxicity&#160;or&#160;teratogenicity&#160;(37.2&#160;times the&#160;50&#160;mg&#160;</p>
<p style="position:absolute;top:668px;left:85px;white-space:nowrap" class="ft252">human&#160;clinical&#160;exposure,&#160;based&#160;on&#160;AUC&#160;following single&#160;dose&#160;in the&#160;fasted&#160;state).&#160;Oral&#160;administration&#160;of&#160;</p>
<p style="position:absolute;top:688px;left:85px;white-space:nowrap" class="ft252">dolutegravir&#160;to pregnant&#160;rabbits&#160;at&#160;doses&#160;up&#160;to 1000&#160;mg/kg daily from&#160;days&#160;6&#160;to 18 of&#160;gestation did not&#160;elicit&#160;</p>
<p style="position:absolute;top:707px;left:85px;white-space:nowrap" class="ft252">developmental toxicity&#160;or&#160;teratogenicity&#160;(0.55&#160;times the&#160;50&#160;mg&#160;human clinical&#160;exposure,&#160;based on AUC&#160;</p>
<p style="position:absolute;top:727px;left:85px;white-space:nowrap" class="ft252">following single&#160;dose&#160;in&#160;the&#160;fasted&#160;state). In rabbits,&#160;maternal&#160;toxicity&#160;(decreased food consumption, scant/no&#160;</p>
<p style="position:absolute;top:747px;left:85px;white-space:nowrap" class="ft252">faeces/urine,&#160;suppressed body weight&#160;gain)&#160;was&#160;observed at&#160;1000&#160;mg/kg (0.55&#160;times the 50&#160;mg human&#160;</p>
<p style="position:absolute;top:766px;left:85px;white-space:nowrap" class="ft252">clinical&#160;exposure,&#160;based&#160;on AUC&#160;following single&#160;dose&#160;in the&#160;fasted state).&#160;</p>
<p style="position:absolute;top:785px;left:85px;white-space:nowrap" class="ft252">&#160;</p>
<p style="position:absolute;top:805px;left:85px;white-space:nowrap" class="ft252">Lamivudine&#160;was&#160;not&#160;teratogenic&#160;in&#160;animal&#160;studies&#160;but&#160;there&#160;were&#160;indications&#160;of&#160;an&#160;increase&#160;in early&#160;</p>
<p style="position:absolute;top:824px;left:85px;white-space:nowrap" class="ft252">embryonic&#160;deaths&#160;in rabbits&#160;at&#160;relatively low&#160;systemic&#160;exposures,&#160;comparable&#160;to those&#160;achieved&#160;in humans. A&#160;</p>
<p style="position:absolute;top:844px;left:85px;white-space:nowrap" class="ft252">similar&#160;effect&#160;was not&#160;seen&#160;in&#160;rats even&#160;at&#160;very&#160;high&#160;systemic exposure.&#160;</p>
<p style="position:absolute;top:864px;left:85px;white-space:nowrap" class="ft252">&#160;</p>
<p style="position:absolute;top:883px;left:85px;white-space:nowrap" class="ft252">Fertility&#160;studies&#160;in&#160;rats have&#160;shown&#160;that&#160;dolutegravir&#160;or&#160;lamivudine have no&#160;effect&#160;on&#160;male or&#160;female fertility.&#160;</p>
<p style="position:absolute;top:902px;left:85px;white-space:nowrap" class="ft252">&#160;</p>
<p style="position:absolute;top:922px;left:85px;white-space:nowrap" class="ft252">Repeated&#160;dose toxicity&#160;</p>
<p style="position:absolute;top:941px;left:85px;white-space:nowrap" class="ft252">&#160;</p>
<p style="position:absolute;top:961px;left:85px;white-space:nowrap" class="ft252">The&#160;effect&#160;of&#160;prolonged daily&#160;treatment&#160;with&#160;high&#160;doses of&#160;dolutegravir&#160;has been&#160;evaluated&#160;in&#160;repeat&#160;oral&#160;</p>
<p style="position:absolute;top:981px;left:85px;white-space:nowrap" class="ft252">dose&#160;toxicity&#160;studies&#160;in rats&#160;(up&#160;to&#160;26&#160;weeks)&#160;and in monkeys&#160;(up to&#160;38&#160;weeks). The&#160;primary&#160;effect&#160;of&#160;</p>
<p style="position:absolute;top:1000px;left:85px;white-space:nowrap" class="ft252">dolutegravir&#160;was&#160;gastrointestinal&#160;intolerance&#160;or&#160;irritation in&#160;rats&#160;and monkeys&#160;at&#160;doses&#160;that&#160;produce&#160;systemic&#160;</p>
<p style="position:absolute;top:1019px;left:85px;white-space:nowrap" class="ft252">exposures&#160;approximately&#160;28.5&#160;and&#160;1.1&#160;times the&#160;50&#160;mg&#160;human clinical&#160;exposure&#160;following single&#160;dose&#160;in the&#160;</p>
<p style="position:absolute;top:1039px;left:85px;white-space:nowrap" class="ft252">fasted&#160;state&#160;based&#160;on&#160;AUC,&#160;respectively.&#160;Because gastrointestinal&#160;(GI)&#160;intolerance&#160;is considered&#160;to&#160;be due&#160;to&#160;</p>
<p style="position:absolute;top:1058px;left:85px;white-space:nowrap" class="ft252">local active&#160;substance&#160;administration,&#160;mg/kg or&#160;mg/m2&#160;metrics are appropriate&#160;determinates of&#160;safety&#160;cover&#160;</p>
<p style="position:absolute;top:1078px;left:85px;white-space:nowrap" class="ft252">for&#160;this&#160;toxicity. GI&#160;intolerance&#160;in monkeys&#160;occurred at&#160;30&#160;times&#160;the&#160;human mg/kg&#160;equivalent&#160;dose&#160;(based on&#160;</p>
<p style="position:absolute;top:1098px;left:85px;white-space:nowrap" class="ft252">50&#160;kg human), and&#160;11&#160;times&#160;the&#160;human&#160;mg/m2&#160;equivalent&#160;dose&#160;for&#160;a&#160;total&#160;daily clinical&#160;dose&#160;of&#160;50&#160;mg.&#160;</p>
<p style="position:absolute;top:1117px;left:85px;white-space:nowrap" class="ft252">&#160;</p>
<p style="position:absolute;top:1136px;left:85px;white-space:nowrap" class="ft251"><b>6.&#160;</b></p>
<p style="position:absolute;top:1136px;left:127px;white-space:nowrap" class="ft251"><b>PHARMACEUTICAL&#160;PARTICULARS&#160;</b></p>
<p style="position:absolute;top:1156px;left:85px;white-space:nowrap" class="ft252">&#160;</p>
</div>
<!-- Page 26 -->
<a name="26"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page26-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1191px;left:436px;white-space:nowrap" class="ft260">26&#160;</p>
<p style="position:absolute;top:83px;left:85px;white-space:nowrap" class="ft261"><b>6.1&#160;&#160;List&#160;of&#160;excipients&#160;</b>&#160;</p>
<p style="position:absolute;top:103px;left:85px;white-space:nowrap" class="ft265"><i>&#160;</i></p>
<p style="position:absolute;top:122px;left:85px;white-space:nowrap" class="ft262">Tablet&#160;core&#160;</p>
<p style="position:absolute;top:142px;left:85px;white-space:nowrap" class="ft262">&#160;</p>
<p style="position:absolute;top:162px;left:85px;white-space:nowrap" class="ft262">Microcrystalline&#160;cellulose&#160;&#160;</p>
<p style="position:absolute;top:181px;left:85px;white-space:nowrap" class="ft262">Sodium starch&#160;glycolate&#160;</p>
<p style="position:absolute;top:200px;left:85px;white-space:nowrap" class="ft262">Magnesium&#160;Stearate&#160;</p>
<p style="position:absolute;top:220px;left:85px;white-space:nowrap" class="ft262">Mannitol&#160;(E421)&#160;</p>
<p style="position:absolute;top:239px;left:85px;white-space:nowrap" class="ft262">Povidone&#160;(K29/32)&#160;</p>
<p style="position:absolute;top:259px;left:85px;white-space:nowrap" class="ft262">Sodium&#160;stearyl&#160;fumarate&#160;</p>
<p style="position:absolute;top:279px;left:85px;white-space:nowrap" class="ft262">&#160;</p>
<p style="position:absolute;top:298px;left:85px;white-space:nowrap" class="ft262">Tablet&#160;coating&#160;</p>
<p style="position:absolute;top:317px;left:85px;white-space:nowrap" class="ft262">&#160;</p>
<p style="position:absolute;top:337px;left:85px;white-space:nowrap" class="ft262">Hypromellose&#160;(E464)&#160;</p>
<p style="position:absolute;top:356px;left:85px;white-space:nowrap" class="ft262">Macrogol&#160;</p>
<p style="position:absolute;top:376px;left:85px;white-space:nowrap" class="ft262">Titanium&#160;dioxide&#160;(E171)&#160;</p>
<p style="position:absolute;top:396px;left:85px;white-space:nowrap" class="ft262">&#160;</p>
<p style="position:absolute;top:415px;left:85px;white-space:nowrap" class="ft261"><b>6.2&#160;&#160;Incompatibilities&#160;</b>&#160;</p>
<p style="position:absolute;top:434px;left:85px;white-space:nowrap" class="ft262">&#160;</p>
<p style="position:absolute;top:454px;left:85px;white-space:nowrap" class="ft262">Not&#160;applicable.&#160;</p>
<p style="position:absolute;top:473px;left:85px;white-space:nowrap" class="ft262">&#160;</p>
<p style="position:absolute;top:493px;left:85px;white-space:nowrap" class="ft261"><b>6.3&#160;&#160;Shelf&#160;life&#160;</b>&#160;</p>
<p style="position:absolute;top:513px;left:85px;white-space:nowrap" class="ft262">&#160;</p>
<p style="position:absolute;top:532px;left:85px;white-space:nowrap" class="ft262">3&#160;years.&#160;</p>
<p style="position:absolute;top:551px;left:85px;white-space:nowrap" class="ft262">&#160;</p>
<p style="position:absolute;top:571px;left:85px;white-space:nowrap" class="ft261"><b>6.4&#160;&#160;Special&#160;precautions for&#160;storage&#160;&#160;</b></p>
<p style="position:absolute;top:590px;left:85px;white-space:nowrap" class="ft262">&#160;</p>
<p style="position:absolute;top:610px;left:85px;white-space:nowrap" class="ft262">This&#160;medicinal&#160;product&#160;does&#160;not&#160;require&#160;any&#160;special&#160;storage&#160;conditions.&#160;</p>
<p style="position:absolute;top:630px;left:85px;white-space:nowrap" class="ft262">&#160;</p>
<p style="position:absolute;top:648px;left:85px;white-space:nowrap" class="ft261"><b>6.5&#160;&#160;Nature&#160;and&#160;contents&#160;of&#160;container&#160;&#160;</b></p>
<p style="position:absolute;top:668px;left:85px;white-space:nowrap" class="ft262">&#160;</p>
<p style="position:absolute;top:688px;left:85px;white-space:nowrap" class="ft262">Opaque, white&#160;HDPE&#160;(high&#160;density&#160;polyethylene)&#160;bottles&#160;closed with child&#160;resistant&#160;polypropylene&#160;closures,&#160;</p>
<p style="position:absolute;top:707px;left:85px;white-space:nowrap" class="ft262">with a&#160;polyethylene&#160;faced induction heat&#160;seal&#160;liner. Each pack consists&#160;of&#160;one&#160;bottle&#160;containing 30&#160;film-</p>
<p style="position:absolute;top:727px;left:85px;white-space:nowrap" class="ft262">coated&#160;tablets.&#160;</p>
<p style="position:absolute;top:746px;left:85px;white-space:nowrap" class="ft262">&#160;</p>
<p style="position:absolute;top:765px;left:85px;white-space:nowrap" class="ft262">Multipacks&#160;containing 90&#160;(3 packs&#160;of&#160;30)&#160;film-coated&#160;tablets.&#160;</p>
<p style="position:absolute;top:785px;left:85px;white-space:nowrap" class="ft262">&#160;</p>
<p style="position:absolute;top:804px;left:85px;white-space:nowrap" class="ft261"><b>6.6&#160;&#160;Special&#160;precautions for disposal&#160;</b>&#160;</p>
<p style="position:absolute;top:824px;left:85px;white-space:nowrap" class="ft262">&#160;</p>
<p style="position:absolute;top:844px;left:85px;white-space:nowrap" class="ft262">Any unused&#160;medicinal&#160;product&#160;or&#160;waste&#160;material&#160;should be&#160;disposed of&#160;in&#160;accordance&#160;with&#160;local&#160;</p>
<p style="position:absolute;top:863px;left:85px;white-space:nowrap" class="ft262">requirements.&#160;</p>
<p style="position:absolute;top:882px;left:85px;white-space:nowrap" class="ft262">&#160;</p>
<p style="position:absolute;top:902px;left:85px;white-space:nowrap" class="ft262">&#160;</p>
<p style="position:absolute;top:921px;left:85px;white-space:nowrap" class="ft261"><b>7.&#160;</b></p>
<p style="position:absolute;top:921px;left:127px;white-space:nowrap" class="ft261"><b>MARKETING&#160;AUTHORISATION HOLDER</b>&#160;</p>
<p style="position:absolute;top:941px;left:85px;white-space:nowrap" class="ft262">&#160;</p>
<p style="position:absolute;top:961px;left:85px;white-space:nowrap" class="ft262">ViiV&#160;Healthcare BV&#160;</p>
<p style="position:absolute;top:980px;left:85px;white-space:nowrap" class="ft262">Van Asch van Wijckstraat&#160;55H&#160;</p>
<p style="position:absolute;top:999px;left:85px;white-space:nowrap" class="ft262">3811 LP&#160;Amersfoort&#160;</p>
<p style="position:absolute;top:1019px;left:85px;white-space:nowrap" class="ft262">Netherlands&#160;</p>
<p style="position:absolute;top:1039px;left:85px;white-space:nowrap" class="ft262">&#160;</p>
<p style="position:absolute;top:1058px;left:85px;white-space:nowrap" class="ft262">&#160;</p>
<p style="position:absolute;top:1077px;left:85px;white-space:nowrap" class="ft261"><b>8.&#160;</b></p>
<p style="position:absolute;top:1077px;left:127px;white-space:nowrap" class="ft261"><b>MARKETING&#160;AUTHORISATION NUMBER(S)&#160;&#160;</b></p>
<p style="position:absolute;top:1097px;left:85px;white-space:nowrap" class="ft262">&#160;</p>
<p style="position:absolute;top:1117px;left:85px;white-space:nowrap" class="ft262">EU/1/19/1370/001&#160;</p>
<p style="position:absolute;top:1136px;left:85px;white-space:nowrap" class="ft262">EU/1/19/1370/002&#160;</p>
<p style="position:absolute;top:1156px;left:85px;white-space:nowrap" class="ft262">&#160;</p>
</div>
<!-- Page 27 -->
<a name="27"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft2727{font-size:14px;font-family:BOVTIM+Verdana;color:#000000;}
-->
</style>
<div id="page27-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1191px;left:436px;white-space:nowrap" class="ft270">27&#160;</p>
<p style="position:absolute;top:83px;left:85px;white-space:nowrap" class="ft272">&#160;</p>
<p style="position:absolute;top:103px;left:85px;white-space:nowrap" class="ft271"><b>9.&#160;</b></p>
<p style="position:absolute;top:103px;left:127px;white-space:nowrap" class="ft271"><b>DATE&#160;OF&#160;FIRST&#160;AUTHORISATION/RENEWAL&#160;OF&#160;THE&#160;AUTHORISATION</b>&#160;</p>
<p style="position:absolute;top:122px;left:85px;white-space:nowrap" class="ft272">&#160;</p>
<p style="position:absolute;top:142px;left:85px;white-space:nowrap" class="ft272">Date&#160;of&#160;first&#160;authorization:&#160;1st&#160;July&#160;2019&#160;</p>
<p style="position:absolute;top:162px;left:85px;white-space:nowrap" class="ft272">&#160;</p>
<p style="position:absolute;top:181px;left:85px;white-space:nowrap" class="ft272">&#160;</p>
<p style="position:absolute;top:200px;left:85px;white-space:nowrap" class="ft271"><b>10.&#160;&#160;DATE OF&#160;REVISION&#160;OF&#160;THE TEXT&#160;</b></p>
<p style="position:absolute;top:220px;left:85px;white-space:nowrap" class="ft272">&#160;</p>
<p style="position:absolute;top:239px;left:85px;white-space:nowrap" class="ft272">Detailed&#160;information on&#160;this&#160;medicinal&#160;product&#160;is available&#160;on&#160;the website of&#160;the European&#160;Medicines&#160;</p>
<p style="position:absolute;top:259px;left:85px;white-space:nowrap" class="ft272">Agenc<a href="http://www.ema.europa.eu/">y&#160;http://www.ema.europa.eu.</a>&#160;</p>
<p style="position:absolute;top:279px;left:85px;white-space:nowrap" class="ft2727">&#160;</p>
<p style="position:absolute;top:295px;left:85px;white-space:nowrap" class="ft272">&#160;</p>
<p style="position:absolute;top:312px;left:85px;white-space:nowrap" class="ft272">&#160;</p>
<p style="position:absolute;top:315px;left:301px;white-space:nowrap" class="ft2727">&#160;</p>
</div>
<!-- Page 28 -->
<a name="28"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page28-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1191px;left:436px;white-space:nowrap" class="ft280">28&#160;</p>
<p style="position:absolute;top:83px;left:95px;white-space:nowrap" class="ft282">&#160;</p>
<p style="position:absolute;top:103px;left:95px;white-space:nowrap" class="ft282">&#160;</p>
<p style="position:absolute;top:122px;left:95px;white-space:nowrap" class="ft282">&#160;</p>
<p style="position:absolute;top:142px;left:95px;white-space:nowrap" class="ft282">&#160;</p>
<p style="position:absolute;top:162px;left:95px;white-space:nowrap" class="ft282">&#160;</p>
<p style="position:absolute;top:181px;left:95px;white-space:nowrap" class="ft282">&#160;</p>
<p style="position:absolute;top:200px;left:95px;white-space:nowrap" class="ft282">&#160;</p>
<p style="position:absolute;top:220px;left:95px;white-space:nowrap" class="ft282">&#160;</p>
<p style="position:absolute;top:239px;left:95px;white-space:nowrap" class="ft282">&#160;</p>
<p style="position:absolute;top:259px;left:95px;white-space:nowrap" class="ft282">&#160;</p>
<p style="position:absolute;top:279px;left:95px;white-space:nowrap" class="ft282">&#160;</p>
<p style="position:absolute;top:298px;left:95px;white-space:nowrap" class="ft282">&#160;</p>
<p style="position:absolute;top:317px;left:95px;white-space:nowrap" class="ft282">&#160;</p>
<p style="position:absolute;top:337px;left:95px;white-space:nowrap" class="ft282">&#160;</p>
<p style="position:absolute;top:356px;left:95px;white-space:nowrap" class="ft282">&#160;</p>
<p style="position:absolute;top:376px;left:95px;white-space:nowrap" class="ft282">&#160;</p>
<p style="position:absolute;top:396px;left:95px;white-space:nowrap" class="ft282">&#160;</p>
<p style="position:absolute;top:415px;left:95px;white-space:nowrap" class="ft282">&#160;</p>
<p style="position:absolute;top:434px;left:95px;white-space:nowrap" class="ft282">&#160;</p>
<p style="position:absolute;top:454px;left:95px;white-space:nowrap" class="ft282">&#160;</p>
<p style="position:absolute;top:474px;left:95px;white-space:nowrap" class="ft282">&#160;</p>
<p style="position:absolute;top:493px;left:95px;white-space:nowrap" class="ft282">&#160;</p>
<p style="position:absolute;top:513px;left:95px;white-space:nowrap" class="ft282">&#160;</p>
<p style="position:absolute;top:553px;left:409px;white-space:nowrap" class="ft281"><b>ANNEX II&#160;</b></p>
<p style="position:absolute;top:589px;left:95px;white-space:nowrap" class="ft282">&#160;</p>
<p style="position:absolute;top:629px;left:169px;white-space:nowrap" class="ft281"><b>A.&#160;</b></p>
<p style="position:absolute;top:629px;left:223px;white-space:nowrap" class="ft281"><b>MANUFACTURERS&#160;RESPONSIBLE&#160;FOR BATCH&#160;RELEASE&#160;&#160;</b></p>
<p style="position:absolute;top:670px;left:169px;white-space:nowrap" class="ft281"><b>B.&#160;</b></p>
<p style="position:absolute;top:670px;left:223px;white-space:nowrap" class="ft281"><b>CONDITIONS&#160;OR&#160;RESTRICTIONS&#160;REGARDING&#160;SUPPLY AND USE&#160;</b></p>
<p style="position:absolute;top:706px;left:223px;white-space:nowrap" class="ft282">&#160;</p>
<p style="position:absolute;top:725px;left:169px;white-space:nowrap" class="ft281"><b>C.&#160;</b></p>
<p style="position:absolute;top:725px;left:223px;white-space:nowrap" class="ft281"><b>OTHER CONDITIONS&#160;AND REQUIREMENTS&#160;OF&#160;THE&#160;MARKETING&#160;</b></p>
<p style="position:absolute;top:745px;left:223px;white-space:nowrap" class="ft281"><b>AUTHORISATION&#160;</b></p>
<p style="position:absolute;top:765px;left:223px;white-space:nowrap" class="ft282">&#160;</p>
<p style="position:absolute;top:784px;left:169px;white-space:nowrap" class="ft281"><b>D.&#160;</b></p>
<p style="position:absolute;top:784px;left:223px;white-space:nowrap" class="ft281"><b>CONDITIONS&#160;OR RESTRICTIONS&#160;WITH&#160;REGARD TO&#160;THE&#160;SAFE&#160;AND&#160;</b></p>
<p style="position:absolute;top:803px;left:223px;white-space:nowrap" class="ft281"><b>EFFECTIVE&#160;USE&#160;OF&#160;THE&#160;MEDICINAL&#160;PRODUCT&#160;</b></p>
<p style="position:absolute;top:823px;left:94px;white-space:nowrap" class="ft282">&#160;</p>
<p style="position:absolute;top:863px;left:94px;white-space:nowrap" class="ft282">&#160;</p>
</div>
<!-- Page 29 -->
<a name="29"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft2928{font-size:18px;font-family:FLHGME+ArialMT;color:#000000;}
-->
</style>
<div id="page29-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1191px;left:436px;white-space:nowrap" class="ft290">29&#160;</p>
<p style="position:absolute;top:83px;left:95px;white-space:nowrap" class="ft291"><b>A.&#160;&#160;&#160;MANUFACTURER RESPONSIBLE&#160;FOR BATCH&#160;RELEASE&#160;</b></p>
<p style="position:absolute;top:119px;left:95px;white-space:nowrap" class="ft292">Name&#160;and&#160;address of&#160;the&#160;manufacturer(s)&#160;responsible&#160;for&#160;batch&#160;release&#160;&#160;</p>
<p style="position:absolute;top:139px;left:95px;white-space:nowrap" class="ft292">&#160;</p>
<p style="position:absolute;top:158px;left:95px;white-space:nowrap" class="ft292">GLAXO WELLCOME,&#160;S.A.&#160;</p>
<p style="position:absolute;top:178px;left:95px;white-space:nowrap" class="ft292">Avda.&#160;Extremadura, 3&#160;</p>
<p style="position:absolute;top:198px;left:95px;white-space:nowrap" class="ft292">09400 Aranda&#160;De&#160;Duero&#160;</p>
<p style="position:absolute;top:217px;left:95px;white-space:nowrap" class="ft292">Burgos&#160;</p>
<p style="position:absolute;top:236px;left:95px;white-space:nowrap" class="ft292">Spain&#160;</p>
<p style="position:absolute;top:277px;left:95px;white-space:nowrap" class="ft291"><b>B.&#160;&#160;CONDITIONS&#160;OR RESTRICTIONS&#160;REGARDING&#160;SUPPLY AND USE&#160;</b></p>
<p style="position:absolute;top:313px;left:95px;white-space:nowrap" class="ft292">Medicinal&#160;product&#160;subject&#160;to&#160;restricted&#160;medical&#160;prescription&#160;(see Annex&#160;I:&#160;Summary&#160;of&#160;Product&#160;</p>
<p style="position:absolute;top:333px;left:95px;white-space:nowrap" class="ft292">Characteristics,&#160;section&#160;4.2).&#160;</p>
<p style="position:absolute;top:373px;left:95px;white-space:nowrap" class="ft291"><b>C.&#160;&#160;OTHER CONDITIONS&#160;AND REQUIREMENTS&#160;OF&#160;THE&#160;MARKETING&#160;</b></p>
<p style="position:absolute;top:392px;left:149px;white-space:nowrap" class="ft291"><b>AUTHORISATION&#160;&#160;</b></p>
<p style="position:absolute;top:430px;left:93px;white-space:nowrap" class="ft2910">•</p>
<p style="position:absolute;top:429px;left:101px;white-space:nowrap" class="ft2928">&#160;&#160;<b>Periodic safety&#160;update reports&#160;(PSURs)</b>&#160;</p>
<p style="position:absolute;top:450px;left:94px;white-space:nowrap" class="ft292">&#160;</p>
<p style="position:absolute;top:470px;left:94px;white-space:nowrap" class="ft292">The&#160;requirements&#160;for&#160;submission&#160;of&#160;PSURs&#160;for&#160;this&#160;medicinal product are&#160;set out&#160;in&#160;the&#160;list of&#160;Union&#160;</p>
<p style="position:absolute;top:489px;left:94px;white-space:nowrap" class="ft292">reference&#160;dates&#160;(EURD&#160;list)&#160;provided&#160;for&#160;under&#160;Article&#160;107c(7)&#160;of&#160;Directive&#160;2001/83/EC&#160;and&#160;any&#160;</p>
<p style="position:absolute;top:509px;left:94px;white-space:nowrap" class="ft292">subsequent&#160;updates&#160;published on the&#160;European&#160;medicines&#160;web-portal.&#160;</p>
<p style="position:absolute;top:549px;left:94px;white-space:nowrap" class="ft291"><b>D.&#160;&#160;CONDITIONS&#160;OR RESTRICTIONS&#160;WITH&#160;REGARD TO&#160;THE&#160;SAFE&#160;AND EFFECTIVE&#160;</b></p>
<p style="position:absolute;top:569px;left:148px;white-space:nowrap" class="ft291"><b>USE&#160;OF&#160;THE&#160;MEDICINAL&#160;PRODUCT&#160;</b></p>
<p style="position:absolute;top:606px;left:93px;white-space:nowrap" class="ft2910">•</p>
<p style="position:absolute;top:606px;left:101px;white-space:nowrap" class="ft2928">&#160;&#160;<b>Risk&#160;management&#160;plan&#160;(RMP)</b>&#160;</p>
<p style="position:absolute;top:626px;left:95px;white-space:nowrap" class="ft292">&#160;</p>
<p style="position:absolute;top:646px;left:95px;white-space:nowrap" class="ft292">The&#160;marketing authorisation holder&#160;(MAH)&#160;shall&#160;perform&#160;the required&#160;pharmacovigilance activities&#160;and&#160;</p>
<p style="position:absolute;top:665px;left:95px;white-space:nowrap" class="ft292">interventions&#160;detailed&#160;in the&#160;agreed&#160;RMP&#160;presented in Module&#160;1.8.2&#160;of&#160;the&#160;marketing&#160;authorisation and&#160;</p>
<p style="position:absolute;top:685px;left:95px;white-space:nowrap" class="ft292">any&#160;agreed&#160;subsequent&#160;updates&#160;of&#160;the&#160;RMP.&#160;</p>
<p style="position:absolute;top:704px;left:95px;white-space:nowrap" class="ft292">&#160;</p>
<p style="position:absolute;top:724px;left:95px;white-space:nowrap" class="ft292">An updated RMP&#160;should be&#160;submitted:&#160;</p>
<p style="position:absolute;top:743px;left:95px;white-space:nowrap" class="ft292">&#160;</p>
<p style="position:absolute;top:765px;left:120px;white-space:nowrap" class="ft2910">•</p>
<p style="position:absolute;top:764px;left:128px;white-space:nowrap" class="ft2928">&#160;&#160;At&#160;the&#160;request&#160;of&#160;the European&#160;Medicines Agency;&#160;</p>
<p style="position:absolute;top:796px;left:120px;white-space:nowrap" class="ft2910">•</p>
<p style="position:absolute;top:796px;left:128px;white-space:nowrap" class="ft2928">&#160;&#160;Whenever&#160;the&#160;risk&#160;management&#160;system&#160;is modified,&#160;especially&#160;as the result&#160;of&#160;new&#160;information&#160;</p>
<p style="position:absolute;top:818px;left:147px;white-space:nowrap" class="ft292">being&#160;received&#160;that&#160;may lead to a&#160;significant&#160;change&#160;to&#160;the&#160;benefit/risk profile&#160;or&#160;as&#160;the&#160;result&#160;of&#160;an&#160;</p>
<p style="position:absolute;top:839px;left:147px;white-space:nowrap" class="ft292">important&#160;(pharmacovigilance&#160;or&#160;risk&#160;minimisation)&#160;milestone&#160;being&#160;reached.&#160;&#160;</p>
<p style="position:absolute;top:869px;left:85px;white-space:nowrap" class="ft292">&#160;</p>
<p style="position:absolute;top:869px;left:301px;white-space:nowrap" class="ft292">&#160;</p>
</div>
<!-- Page 30 -->
<a name="30"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page30-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1191px;left:436px;white-space:nowrap" class="ft300">30&#160;</p>
<p style="position:absolute;top:83px;left:85px;white-space:nowrap" class="ft302">&#160;</p>
<p style="position:absolute;top:102px;left:85px;white-space:nowrap" class="ft302">&#160;</p>
<p style="position:absolute;top:121px;left:85px;white-space:nowrap" class="ft302">&#160;</p>
<p style="position:absolute;top:140px;left:85px;white-space:nowrap" class="ft302">&#160;</p>
<p style="position:absolute;top:159px;left:85px;white-space:nowrap" class="ft302">&#160;</p>
<p style="position:absolute;top:178px;left:85px;white-space:nowrap" class="ft302">&#160;</p>
<p style="position:absolute;top:197px;left:85px;white-space:nowrap" class="ft302">&#160;</p>
<p style="position:absolute;top:216px;left:85px;white-space:nowrap" class="ft302">&#160;</p>
<p style="position:absolute;top:235px;left:85px;white-space:nowrap" class="ft302">&#160;</p>
<p style="position:absolute;top:254px;left:85px;white-space:nowrap" class="ft302">&#160;</p>
<p style="position:absolute;top:273px;left:85px;white-space:nowrap" class="ft302">&#160;</p>
<p style="position:absolute;top:292px;left:85px;white-space:nowrap" class="ft302">&#160;</p>
<p style="position:absolute;top:311px;left:85px;white-space:nowrap" class="ft302">&#160;</p>
<p style="position:absolute;top:330px;left:85px;white-space:nowrap" class="ft302">&#160;</p>
<p style="position:absolute;top:349px;left:85px;white-space:nowrap" class="ft302">&#160;</p>
<p style="position:absolute;top:368px;left:85px;white-space:nowrap" class="ft302">&#160;</p>
<p style="position:absolute;top:387px;left:85px;white-space:nowrap" class="ft302">&#160;</p>
<p style="position:absolute;top:405px;left:85px;white-space:nowrap" class="ft301"><b>&#160;</b></p>
<p style="position:absolute;top:424px;left:85px;white-space:nowrap" class="ft301"><b>&#160;</b></p>
<p style="position:absolute;top:443px;left:85px;white-space:nowrap" class="ft301"><b>&#160;</b></p>
<p style="position:absolute;top:462px;left:85px;white-space:nowrap" class="ft301"><b>&#160;</b></p>
<p style="position:absolute;top:481px;left:85px;white-space:nowrap" class="ft301"><b>&#160;</b></p>
<p style="position:absolute;top:500px;left:85px;white-space:nowrap" class="ft301"><b>&#160;</b></p>
<p style="position:absolute;top:519px;left:405px;white-space:nowrap" class="ft301"><b>ANNEX III&#160;&#160;</b></p>
<p style="position:absolute;top:538px;left:446px;white-space:nowrap" class="ft301"><b>&#160;</b></p>
<p style="position:absolute;top:557px;left:293px;white-space:nowrap" class="ft301"><b>LABELLING&#160;AND&#160;PACKAGE LEAFLET&#160;&#160;</b></p>
<p style="position:absolute;top:576px;left:85px;white-space:nowrap" class="ft301"><b>&#160;</b></p>
<p style="position:absolute;top:576px;left:301px;white-space:nowrap" class="ft301"><b>&#160;</b></p>
</div>
<!-- Page 31 -->
<a name="31"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page31-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1191px;left:436px;white-space:nowrap" class="ft310">31&#160;</p>
<p style="position:absolute;top:83px;left:85px;white-space:nowrap" class="ft311"><b>&#160;</b></p>
<p style="position:absolute;top:102px;left:85px;white-space:nowrap" class="ft311"><b>&#160;</b></p>
<p style="position:absolute;top:121px;left:85px;white-space:nowrap" class="ft311"><b>&#160;</b></p>
<p style="position:absolute;top:140px;left:85px;white-space:nowrap" class="ft311"><b>&#160;</b></p>
<p style="position:absolute;top:159px;left:85px;white-space:nowrap" class="ft311"><b>&#160;</b></p>
<p style="position:absolute;top:178px;left:85px;white-space:nowrap" class="ft311"><b>&#160;</b></p>
<p style="position:absolute;top:197px;left:85px;white-space:nowrap" class="ft311"><b>&#160;</b></p>
<p style="position:absolute;top:216px;left:85px;white-space:nowrap" class="ft311"><b>&#160;</b></p>
<p style="position:absolute;top:235px;left:85px;white-space:nowrap" class="ft311"><b>&#160;</b></p>
<p style="position:absolute;top:254px;left:85px;white-space:nowrap" class="ft311"><b>&#160;</b></p>
<p style="position:absolute;top:273px;left:85px;white-space:nowrap" class="ft311"><b>&#160;</b></p>
<p style="position:absolute;top:292px;left:85px;white-space:nowrap" class="ft311"><b>&#160;</b></p>
<p style="position:absolute;top:311px;left:85px;white-space:nowrap" class="ft311"><b>&#160;</b></p>
<p style="position:absolute;top:330px;left:85px;white-space:nowrap" class="ft311"><b>&#160;</b></p>
<p style="position:absolute;top:348px;left:85px;white-space:nowrap" class="ft311"><b>&#160;</b></p>
<p style="position:absolute;top:368px;left:85px;white-space:nowrap" class="ft311"><b>&#160;</b></p>
<p style="position:absolute;top:386px;left:85px;white-space:nowrap" class="ft311"><b>&#160;</b></p>
<p style="position:absolute;top:405px;left:85px;white-space:nowrap" class="ft311"><b>&#160;</b></p>
<p style="position:absolute;top:424px;left:85px;white-space:nowrap" class="ft311"><b>&#160;</b></p>
<p style="position:absolute;top:443px;left:85px;white-space:nowrap" class="ft311"><b>&#160;</b></p>
<p style="position:absolute;top:462px;left:85px;white-space:nowrap" class="ft311"><b>&#160;</b></p>
<p style="position:absolute;top:481px;left:85px;white-space:nowrap" class="ft311"><b>&#160;</b></p>
<p style="position:absolute;top:500px;left:85px;white-space:nowrap" class="ft311"><b>&#160;</b></p>
<p style="position:absolute;top:519px;left:387px;white-space:nowrap" class="ft311"><b>A.&#160;LABELLING&#160;</b>&#160;</p>
<p style="position:absolute;top:538px;left:85px;white-space:nowrap" class="ft312">&#160;</p>
<p style="position:absolute;top:538px;left:301px;white-space:nowrap" class="ft312">&#160;</p>
</div>
<!-- Page 32 -->
<a name="32"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page32-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1191px;left:436px;white-space:nowrap" class="ft320">32&#160;</p>
<p style="position:absolute;top:85px;left:85px;white-space:nowrap" class="ft321"><b>PARTICULARS&#160;TO&#160;APPEAR ON THE&#160;OUTER PACKAGING&#160;</b></p>
<p style="position:absolute;top:104px;left:85px;white-space:nowrap" class="ft322">&#160;</p>
<p style="position:absolute;top:123px;left:85px;white-space:nowrap" class="ft321"><b>OUTER CARTON (INDIVIDUAL&#160;PACKS&#160;ONLY)</b>&#160;</p>
<p style="position:absolute;top:145px;left:85px;white-space:nowrap" class="ft322">&#160;</p>
<p style="position:absolute;top:163px;left:85px;white-space:nowrap" class="ft322">&#160;</p>
<p style="position:absolute;top:185px;left:85px;white-space:nowrap" class="ft321"><b>1.&#160;</b></p>
<p style="position:absolute;top:185px;left:127px;white-space:nowrap" class="ft321"><b>NAME&#160;OF&#160;THE&#160;MEDICINAL&#160;PRODUCT&#160;</b>&#160;</p>
<p style="position:absolute;top:206px;left:85px;white-space:nowrap" class="ft322">&#160;</p>
<p style="position:absolute;top:225px;left:85px;white-space:nowrap" class="ft322">Dovato&#160;50&#160;mg/300&#160;mg&#160;film-coated&#160;tablets&#160;</p>
<p style="position:absolute;top:244px;left:85px;white-space:nowrap" class="ft322">dolutegravir/lamivudine</p>
<p style="position:absolute;top:244px;left:245px;white-space:nowrap" class="ft321"><b>&#160;</b>&#160;</p>
<p style="position:absolute;top:263px;left:85px;white-space:nowrap" class="ft322">&#160;</p>
<p style="position:absolute;top:282px;left:85px;white-space:nowrap" class="ft322">&#160;</p>
<p style="position:absolute;top:304px;left:85px;white-space:nowrap" class="ft321"><b>2.&#160;</b></p>
<p style="position:absolute;top:304px;left:127px;white-space:nowrap" class="ft321"><b>STATEMENT OF&#160;ACTIVE SUBSTANCE(S)&#160;&#160;</b></p>
<p style="position:absolute;top:325px;left:85px;white-space:nowrap" class="ft322">&#160;</p>
<p style="position:absolute;top:344px;left:85px;white-space:nowrap" class="ft322">Each&#160;film-coated&#160;tablet&#160;contains&#160;dolutegravir&#160;sodium&#160;equivalent&#160;to 50&#160;mg dolutegravir&#160;and&#160;300&#160;mg&#160;</p>
<p style="position:absolute;top:364px;left:85px;white-space:nowrap" class="ft322">lamivudine.&#160;</p>
<p style="position:absolute;top:383px;left:85px;white-space:nowrap" class="ft322">&#160;</p>
<p style="position:absolute;top:402px;left:85px;white-space:nowrap" class="ft322">&#160;</p>
<p style="position:absolute;top:423px;left:85px;white-space:nowrap" class="ft321"><b>3.&#160;</b></p>
<p style="position:absolute;top:423px;left:127px;white-space:nowrap" class="ft321"><b>LIST OF&#160;EXCIPIENTS&#160;</b>&#160;</p>
<p style="position:absolute;top:444px;left:85px;white-space:nowrap" class="ft322">&#160;</p>
<p style="position:absolute;top:463px;left:85px;white-space:nowrap" class="ft322">&#160;</p>
<p style="position:absolute;top:484px;left:85px;white-space:nowrap" class="ft321"><b>4.&#160;</b></p>
<p style="position:absolute;top:484px;left:127px;white-space:nowrap" class="ft321"><b>PHARMACEUTICAL&#160;FORM&#160;AND CONTENTS&#160;</b>&#160;</p>
<p style="position:absolute;top:506px;left:85px;white-space:nowrap" class="ft322">&#160;</p>
<p style="position:absolute;top:525px;left:85px;white-space:nowrap" class="ft322">30&#160;tablets&#160;</p>
<p style="position:absolute;top:544px;left:85px;white-space:nowrap" class="ft322">&#160;</p>
<p style="position:absolute;top:565px;left:85px;white-space:nowrap" class="ft321"><b>5.&#160;</b></p>
<p style="position:absolute;top:565px;left:127px;white-space:nowrap" class="ft321"><b>METHOD AND ROUTE(S)&#160;OF&#160;ADMINISTRATION&#160;</b>&#160;</p>
<p style="position:absolute;top:586px;left:85px;white-space:nowrap" class="ft322">&#160;</p>
<p style="position:absolute;top:605px;left:85px;white-space:nowrap" class="ft322">Read&#160;the package leaflet&#160;before&#160;use.&#160;</p>
<p style="position:absolute;top:624px;left:85px;white-space:nowrap" class="ft322">Oral&#160;use&#160;</p>
<p style="position:absolute;top:643px;left:85px;white-space:nowrap" class="ft322">&#160;</p>
<p style="position:absolute;top:662px;left:85px;white-space:nowrap" class="ft322">&#160;</p>
<p style="position:absolute;top:683px;left:85px;white-space:nowrap" class="ft321"><b>6.&#160;</b></p>
<p style="position:absolute;top:683px;left:127px;white-space:nowrap" class="ft321"><b>SPECIAL&#160;WARNING&#160;THAT&#160;THE&#160;MEDICINAL&#160;PRODUCT&#160;MUST&#160;BE&#160;STORED OUT&#160;OF&#160;</b></p>
<p style="position:absolute;top:702px;left:127px;white-space:nowrap" class="ft321"><b>THE&#160;SIGHT&#160;AND REACH&#160;OF&#160;CHILDREN&#160;</b>&#160;</p>
<p style="position:absolute;top:723px;left:85px;white-space:nowrap" class="ft322">&#160;</p>
<p style="position:absolute;top:742px;left:85px;white-space:nowrap" class="ft322">Keep out&#160;of&#160;the&#160;sight&#160;and reach of&#160;children.&#160;&#160;</p>
<p style="position:absolute;top:761px;left:85px;white-space:nowrap" class="ft322">&#160;</p>
<p style="position:absolute;top:780px;left:85px;white-space:nowrap" class="ft322">&#160;</p>
<p style="position:absolute;top:801px;left:85px;white-space:nowrap" class="ft321"><b>7.&#160;</b></p>
<p style="position:absolute;top:801px;left:127px;white-space:nowrap" class="ft321"><b>OTHER SPECIAL&#160;WARNING(S),&#160;IF&#160;NECESSARY&#160;</b>&#160;</p>
<p style="position:absolute;top:823px;left:85px;white-space:nowrap" class="ft322">&#160;</p>
<p style="position:absolute;top:842px;left:85px;white-space:nowrap" class="ft322">&#160;</p>
<p style="position:absolute;top:863px;left:85px;white-space:nowrap" class="ft321"><b>8.&#160;</b></p>
<p style="position:absolute;top:863px;left:127px;white-space:nowrap" class="ft321"><b>EXPIRY DATE&#160;</b>&#160;</p>
<p style="position:absolute;top:884px;left:85px;white-space:nowrap" class="ft322">&#160;</p>
<p style="position:absolute;top:903px;left:85px;white-space:nowrap" class="ft322">EXP&#160;&#160;</p>
<p style="position:absolute;top:922px;left:85px;white-space:nowrap" class="ft322">&#160;</p>
<p style="position:absolute;top:941px;left:85px;white-space:nowrap" class="ft322">&#160;</p>
<p style="position:absolute;top:962px;left:85px;white-space:nowrap" class="ft321"><b>9.&#160;</b></p>
<p style="position:absolute;top:962px;left:127px;white-space:nowrap" class="ft321"><b>SPECIAL&#160;STORAGE&#160;CONDITIONS&#160;</b>&#160;</p>
<p style="position:absolute;top:984px;left:85px;white-space:nowrap" class="ft322">&#160;</p>
<p style="position:absolute;top:1002px;left:85px;white-space:nowrap" class="ft322">&#160;</p>
<p style="position:absolute;top:1024px;left:85px;white-space:nowrap" class="ft321"><b>10.&#160;&#160;SPECIAL&#160;PRECAUTIONS&#160;FOR DISPOSAL&#160;OF&#160;UNUSED MEDICINAL&#160;PRODUCTS&#160;OR&#160;</b></p>
<p style="position:absolute;top:1042px;left:127px;white-space:nowrap" class="ft321"><b>WASTE&#160;MATERIALS&#160;DERIVED FROM&#160;SUCH&#160;MEDICINAL&#160;PRODUCTS,&#160;IF&#160;</b></p>
<p style="position:absolute;top:1062px;left:127px;white-space:nowrap" class="ft321"><b>APPROPRIATE&#160;&#160;</b></p>
<p style="position:absolute;top:1083px;left:85px;white-space:nowrap" class="ft322">&#160;</p>
<p style="position:absolute;top:1102px;left:85px;white-space:nowrap" class="ft322">&#160;</p>
<p style="position:absolute;top:1123px;left:85px;white-space:nowrap" class="ft321"><b>11.&#160;&#160;NAME&#160;AND ADDRESS&#160;OF&#160;THE&#160;MARKETING&#160;AUTHORISATION HOLDER&#160;&#160;</b></p>
<p style="position:absolute;top:1144px;left:85px;white-space:nowrap" class="ft322">&#160;</p>
</div>
<!-- Page 33 -->
<a name="33"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft3329{font-size:17px;line-height:22px;font-family:DTAKKI+TimesNewRomanPSMT;color:#000000;}
-->
</style>
<div id="page33-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1191px;left:436px;white-space:nowrap" class="ft330">33&#160;</p>
<p style="position:absolute;top:83px;left:85px;white-space:nowrap" class="ft332">ViiV&#160;Healthcare BV&#160;</p>
<p style="position:absolute;top:103px;left:85px;white-space:nowrap" class="ft332">Van&#160;Asch&#160;van&#160;Wijckstraat&#160;55H&#160;</p>
<p style="position:absolute;top:122px;left:85px;white-space:nowrap" class="ft332">3811 LP&#160;Amersfoort&#160;</p>
<p style="position:absolute;top:142px;left:85px;white-space:nowrap" class="ft332">Netherlands&#160;</p>
<p style="position:absolute;top:161px;left:85px;white-space:nowrap" class="ft332">&#160;</p>
<p style="position:absolute;top:180px;left:85px;white-space:nowrap" class="ft332">&#160;</p>
<p style="position:absolute;top:201px;left:85px;white-space:nowrap" class="ft331"><b>12.&#160;&#160;MARKETING&#160;AUTHORISATION NUMBER(S)&#160;</b>&#160;</p>
<p style="position:absolute;top:222px;left:85px;white-space:nowrap" class="ft332">&#160;</p>
<p style="position:absolute;top:241px;left:85px;white-space:nowrap" class="ft332">EU/1/19/1370/001&#160;&#160;</p>
<p style="position:absolute;top:260px;left:85px;white-space:nowrap" class="ft332">&#160;</p>
<p style="position:absolute;top:279px;left:85px;white-space:nowrap" class="ft332">&#160;</p>
<p style="position:absolute;top:300px;left:85px;white-space:nowrap" class="ft331"><b>13.&#160;&#160;BATCH&#160;NUMBER&#160;</b>&#160;</p>
<p style="position:absolute;top:322px;left:85px;white-space:nowrap" class="ft335"><i>&#160;</i></p>
<p style="position:absolute;top:340px;left:85px;white-space:nowrap" class="ft332">Lot&#160;</p>
<p style="position:absolute;top:360px;left:85px;white-space:nowrap" class="ft335"><i>&#160;</i></p>
<p style="position:absolute;top:378px;left:85px;white-space:nowrap" class="ft332">&#160;</p>
<p style="position:absolute;top:399px;left:85px;white-space:nowrap" class="ft331"><b>14.&#160;&#160;GENERAL&#160;CLASSIFICATION FOR SUPPLY&#160;</b>&#160;</p>
<p style="position:absolute;top:421px;left:85px;white-space:nowrap" class="ft335"><i>&#160;</i></p>
<p style="position:absolute;top:440px;left:85px;white-space:nowrap" class="ft3329">&#160;<br/><b>15.&#160;&#160;INSTRUCTIONS&#160;ON USE&#160;</b>&#160;</p>
<p style="position:absolute;top:484px;left:85px;white-space:nowrap" class="ft332">&#160;</p>
<p style="position:absolute;top:503px;left:85px;white-space:nowrap" class="ft332">&#160;</p>
<p style="position:absolute;top:524px;left:85px;white-space:nowrap" class="ft331"><b>16.&#160;&#160;INFORMATION IN BRAILLE</b>&#160;</p>
<p style="position:absolute;top:544px;left:85px;white-space:nowrap" class="ft332">&#160;</p>
<p style="position:absolute;top:563px;left:85px;white-space:nowrap" class="ft332">dovato&#160;&#160;</p>
<p style="position:absolute;top:581px;left:85px;white-space:nowrap" class="ft332">&#160;</p>
<p style="position:absolute;top:601px;left:85px;white-space:nowrap" class="ft332">&#160;</p>
<p style="position:absolute;top:622px;left:85px;white-space:nowrap" class="ft331"><b>17.&#160;</b></p>
<p style="position:absolute;top:622px;left:139px;white-space:nowrap" class="ft331"><b>UNIQUE&#160;IDENTIFIER&#160;–&#160;2D&#160;BARCODE</b><i>&#160;</i></p>
<p style="position:absolute;top:641px;left:85px;white-space:nowrap" class="ft332">&#160;</p>
<p style="position:absolute;top:660px;left:85px;white-space:nowrap" class="ft332">2D&#160;barcode&#160;carrying the&#160;unique&#160;identifier&#160;included.&#160;</p>
<p style="position:absolute;top:679px;left:85px;white-space:nowrap" class="ft332">&#160;</p>
<p style="position:absolute;top:701px;left:85px;white-space:nowrap" class="ft331"><b>18.&#160;</b></p>
<p style="position:absolute;top:701px;left:139px;white-space:nowrap" class="ft331"><b>UNIQUE&#160;IDENTIFIER&#160;-&#160;HUMAN READABLE&#160;DATA</b><i>&#160;</i></p>
<p style="position:absolute;top:720px;left:85px;white-space:nowrap" class="ft332">&#160;</p>
<p style="position:absolute;top:740px;left:85px;white-space:nowrap" class="ft332">PC:&#160;</p>
<p style="position:absolute;top:759px;left:85px;white-space:nowrap" class="ft332">SN:&#160;</p>
<p style="position:absolute;top:779px;left:85px;white-space:nowrap" class="ft332">NN:&#160;&#160;</p>
<p style="position:absolute;top:798px;left:85px;white-space:nowrap" class="ft332">&#160;</p>
<p style="position:absolute;top:817px;left:85px;white-space:nowrap" class="ft332">&#160;</p>
</div>
<!-- Page 34 -->
<a name="34"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page34-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1191px;left:436px;white-space:nowrap" class="ft340">34&#160;</p>
<p style="position:absolute;top:85px;left:85px;white-space:nowrap" class="ft341"><b>PARTICULARS&#160;TO&#160;APPEAR ON THE&#160;OUTER PACKAGING&#160;</b></p>
<p style="position:absolute;top:104px;left:85px;white-space:nowrap" class="ft342">&#160;</p>
<p style="position:absolute;top:123px;left:85px;white-space:nowrap" class="ft341"><b>OUTER CARTON (MULTIPACKS&#160;ONLY&#160;–&#160;WITH&#160;BLUE BOX)</b>&#160;</p>
<p style="position:absolute;top:145px;left:85px;white-space:nowrap" class="ft342">&#160;</p>
<p style="position:absolute;top:163px;left:85px;white-space:nowrap" class="ft342">&#160;</p>
<p style="position:absolute;top:185px;left:85px;white-space:nowrap" class="ft341"><b>1.&#160;</b></p>
<p style="position:absolute;top:185px;left:127px;white-space:nowrap" class="ft341"><b>NAME&#160;OF&#160;THE&#160;MEDICINAL&#160;PRODUCT&#160;</b>&#160;</p>
<p style="position:absolute;top:206px;left:85px;white-space:nowrap" class="ft342">&#160;</p>
<p style="position:absolute;top:225px;left:85px;white-space:nowrap" class="ft342">Dovato&#160;50&#160;mg/300&#160;mg&#160;film-coated&#160;tablets&#160;</p>
<p style="position:absolute;top:244px;left:85px;white-space:nowrap" class="ft342">dolutegravir/lamivudine</p>
<p style="position:absolute;top:244px;left:245px;white-space:nowrap" class="ft341"><b>&#160;</b>&#160;</p>
<p style="position:absolute;top:263px;left:85px;white-space:nowrap" class="ft342">&#160;</p>
<p style="position:absolute;top:282px;left:85px;white-space:nowrap" class="ft342">&#160;</p>
<p style="position:absolute;top:304px;left:85px;white-space:nowrap" class="ft341"><b>2.&#160;</b></p>
<p style="position:absolute;top:304px;left:127px;white-space:nowrap" class="ft341"><b>STATEMENT OF&#160;ACTIVE SUBSTANCE(S)&#160;&#160;</b></p>
<p style="position:absolute;top:325px;left:85px;white-space:nowrap" class="ft342">&#160;</p>
<p style="position:absolute;top:344px;left:85px;white-space:nowrap" class="ft342">Each&#160;film-coated&#160;tablet&#160;contains&#160;dolutegravir&#160;sodium&#160;equivalent&#160;to 50&#160;mg dolutegravir&#160;and&#160;300&#160;mg&#160;</p>
<p style="position:absolute;top:364px;left:85px;white-space:nowrap" class="ft342">lamivudine.&#160;</p>
<p style="position:absolute;top:383px;left:85px;white-space:nowrap" class="ft342">&#160;</p>
<p style="position:absolute;top:402px;left:85px;white-space:nowrap" class="ft342">&#160;</p>
<p style="position:absolute;top:423px;left:85px;white-space:nowrap" class="ft341"><b>3.&#160;</b></p>
<p style="position:absolute;top:423px;left:127px;white-space:nowrap" class="ft341"><b>LIST OF&#160;EXCIPIENTS&#160;</b>&#160;</p>
<p style="position:absolute;top:444px;left:85px;white-space:nowrap" class="ft342">&#160;</p>
<p style="position:absolute;top:463px;left:85px;white-space:nowrap" class="ft342">&#160;</p>
<p style="position:absolute;top:484px;left:85px;white-space:nowrap" class="ft341"><b>4.&#160;</b></p>
<p style="position:absolute;top:484px;left:127px;white-space:nowrap" class="ft341"><b>PHARMACEUTICAL&#160;FORM&#160;AND CONTENTS&#160;</b>&#160;</p>
<p style="position:absolute;top:506px;left:85px;white-space:nowrap" class="ft342">&#160;</p>
<p style="position:absolute;top:525px;left:85px;white-space:nowrap" class="ft342">Multipack:&#160;90&#160;(3 packs&#160;of&#160;30)&#160;tablets&#160;</p>
<p style="position:absolute;top:544px;left:85px;white-space:nowrap" class="ft342">&#160;</p>
<p style="position:absolute;top:565px;left:85px;white-space:nowrap" class="ft341"><b>5.&#160;</b></p>
<p style="position:absolute;top:565px;left:127px;white-space:nowrap" class="ft341"><b>METHOD AND ROUTE(S)&#160;OF&#160;ADMINISTRATION&#160;</b>&#160;</p>
<p style="position:absolute;top:586px;left:85px;white-space:nowrap" class="ft342">&#160;</p>
<p style="position:absolute;top:605px;left:85px;white-space:nowrap" class="ft342">Read&#160;the package leaflet&#160;before&#160;use.&#160;</p>
<p style="position:absolute;top:624px;left:85px;white-space:nowrap" class="ft342">Oral&#160;use&#160;</p>
<p style="position:absolute;top:643px;left:85px;white-space:nowrap" class="ft342">&#160;</p>
<p style="position:absolute;top:662px;left:85px;white-space:nowrap" class="ft342">&#160;</p>
<p style="position:absolute;top:683px;left:85px;white-space:nowrap" class="ft341"><b>6.&#160;</b></p>
<p style="position:absolute;top:683px;left:127px;white-space:nowrap" class="ft341"><b>SPECIAL&#160;WARNING&#160;THAT&#160;THE&#160;MEDICINAL&#160;PRODUCT&#160;MUST&#160;BE&#160;STORED OUT&#160;OF&#160;</b></p>
<p style="position:absolute;top:702px;left:127px;white-space:nowrap" class="ft341"><b>THE&#160;SIGHT&#160;AND REACH&#160;OF&#160;CHILDREN&#160;</b>&#160;</p>
<p style="position:absolute;top:723px;left:85px;white-space:nowrap" class="ft342">&#160;</p>
<p style="position:absolute;top:742px;left:85px;white-space:nowrap" class="ft342">Keep out&#160;of&#160;the&#160;sight&#160;and reach of&#160;children.&#160;&#160;</p>
<p style="position:absolute;top:761px;left:85px;white-space:nowrap" class="ft342">&#160;</p>
<p style="position:absolute;top:780px;left:85px;white-space:nowrap" class="ft342">&#160;</p>
<p style="position:absolute;top:801px;left:85px;white-space:nowrap" class="ft341"><b>7.&#160;</b></p>
<p style="position:absolute;top:801px;left:127px;white-space:nowrap" class="ft341"><b>OTHER SPECIAL&#160;WARNING(S),&#160;IF&#160;NECESSARY&#160;</b>&#160;</p>
<p style="position:absolute;top:823px;left:85px;white-space:nowrap" class="ft342">&#160;</p>
<p style="position:absolute;top:842px;left:85px;white-space:nowrap" class="ft342">&#160;</p>
<p style="position:absolute;top:863px;left:85px;white-space:nowrap" class="ft341"><b>8.&#160;</b></p>
<p style="position:absolute;top:863px;left:127px;white-space:nowrap" class="ft341"><b>EXPIRY DATE&#160;</b>&#160;</p>
<p style="position:absolute;top:884px;left:85px;white-space:nowrap" class="ft342">&#160;</p>
<p style="position:absolute;top:903px;left:85px;white-space:nowrap" class="ft342">EXP&#160;&#160;</p>
<p style="position:absolute;top:922px;left:85px;white-space:nowrap" class="ft342">&#160;</p>
<p style="position:absolute;top:941px;left:85px;white-space:nowrap" class="ft342">&#160;</p>
<p style="position:absolute;top:962px;left:85px;white-space:nowrap" class="ft341"><b>9.&#160;</b></p>
<p style="position:absolute;top:962px;left:127px;white-space:nowrap" class="ft341"><b>SPECIAL&#160;STORAGE&#160;CONDITIONS&#160;</b>&#160;</p>
<p style="position:absolute;top:984px;left:85px;white-space:nowrap" class="ft342">&#160;</p>
<p style="position:absolute;top:1002px;left:85px;white-space:nowrap" class="ft342">&#160;</p>
<p style="position:absolute;top:1024px;left:85px;white-space:nowrap" class="ft341"><b>10.&#160;&#160;SPECIAL&#160;PRECAUTIONS&#160;FOR DISPOSAL&#160;OF&#160;UNUSED MEDICINAL&#160;PRODUCTS&#160;OR&#160;</b></p>
<p style="position:absolute;top:1042px;left:127px;white-space:nowrap" class="ft341"><b>WASTE MATERIALS&#160;DERIVED FROM&#160;SUCH&#160;MEDICINAL&#160;PRODUCTS,&#160;IF&#160;</b></p>
<p style="position:absolute;top:1062px;left:127px;white-space:nowrap" class="ft341"><b>APPROPRIATE&#160;&#160;</b></p>
<p style="position:absolute;top:1083px;left:85px;white-space:nowrap" class="ft342">&#160;</p>
<p style="position:absolute;top:1102px;left:85px;white-space:nowrap" class="ft342">&#160;</p>
<p style="position:absolute;top:1123px;left:85px;white-space:nowrap" class="ft341"><b>11.&#160;&#160;NAME&#160;AND ADDRESS&#160;OF&#160;THE&#160;MARKETING&#160;AUTHORISATION HOLDER&#160;&#160;</b></p>
<p style="position:absolute;top:1144px;left:85px;white-space:nowrap" class="ft342">&#160;</p>
</div>
<!-- Page 35 -->
<a name="35"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page35-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1191px;left:436px;white-space:nowrap" class="ft350">35&#160;</p>
<p style="position:absolute;top:83px;left:85px;white-space:nowrap" class="ft352">ViiV&#160;Healthcare BV&#160;</p>
<p style="position:absolute;top:103px;left:85px;white-space:nowrap" class="ft352">Van Asch van Wijckstraat&#160;55H&#160;</p>
<p style="position:absolute;top:122px;left:85px;white-space:nowrap" class="ft352">3811 LP&#160;Amersfoort&#160;</p>
<p style="position:absolute;top:142px;left:85px;white-space:nowrap" class="ft352">Netherlands&#160;</p>
<p style="position:absolute;top:161px;left:85px;white-space:nowrap" class="ft352">&#160;</p>
<p style="position:absolute;top:180px;left:85px;white-space:nowrap" class="ft352">&#160;</p>
<p style="position:absolute;top:201px;left:85px;white-space:nowrap" class="ft351"><b>12.&#160;&#160;MARKETING&#160;AUTHORISATION NUMBER(S)&#160;</b>&#160;</p>
<p style="position:absolute;top:222px;left:85px;white-space:nowrap" class="ft352">&#160;</p>
<p style="position:absolute;top:241px;left:85px;white-space:nowrap" class="ft352">EU/1/19/1370/002&#160;&#160;</p>
<p style="position:absolute;top:260px;left:85px;white-space:nowrap" class="ft352">&#160;</p>
<p style="position:absolute;top:279px;left:85px;white-space:nowrap" class="ft352">&#160;</p>
<p style="position:absolute;top:300px;left:85px;white-space:nowrap" class="ft351"><b>13.&#160;&#160;BATCH&#160;NUMBER&#160;</b>&#160;</p>
<p style="position:absolute;top:322px;left:85px;white-space:nowrap" class="ft355"><i>&#160;</i></p>
<p style="position:absolute;top:340px;left:85px;white-space:nowrap" class="ft352">Lot&#160;</p>
<p style="position:absolute;top:360px;left:85px;white-space:nowrap" class="ft355"><i>&#160;</i></p>
<p style="position:absolute;top:378px;left:85px;white-space:nowrap" class="ft352">&#160;</p>
<p style="position:absolute;top:399px;left:85px;white-space:nowrap" class="ft351"><b>14.&#160;&#160;GENERAL&#160;CLASSIFICATION FOR SUPPLY&#160;</b>&#160;</p>
<p style="position:absolute;top:421px;left:85px;white-space:nowrap" class="ft355"><i>&#160;</i></p>
<p style="position:absolute;top:440px;left:85px;white-space:nowrap" class="ft3529">&#160;<br/><b>15.&#160;&#160;INSTRUCTIONS&#160;ON USE&#160;</b>&#160;</p>
<p style="position:absolute;top:484px;left:85px;white-space:nowrap" class="ft352">&#160;</p>
<p style="position:absolute;top:503px;left:85px;white-space:nowrap" class="ft352">&#160;</p>
<p style="position:absolute;top:524px;left:85px;white-space:nowrap" class="ft351"><b>16.&#160;&#160;INFORMATION IN BRAILLE</b>&#160;</p>
<p style="position:absolute;top:544px;left:85px;white-space:nowrap" class="ft352">&#160;</p>
<p style="position:absolute;top:563px;left:85px;white-space:nowrap" class="ft352">dovato&#160;</p>
<p style="position:absolute;top:581px;left:85px;white-space:nowrap" class="ft352">&#160;</p>
<p style="position:absolute;top:601px;left:85px;white-space:nowrap" class="ft352">&#160;</p>
<p style="position:absolute;top:622px;left:85px;white-space:nowrap" class="ft351"><b>17.&#160;</b></p>
<p style="position:absolute;top:622px;left:139px;white-space:nowrap" class="ft351"><b>UNIQUE&#160;IDENTIFIER&#160;–&#160;2D BARCODE</b><i>&#160;</i></p>
<p style="position:absolute;top:641px;left:85px;white-space:nowrap" class="ft352">&#160;</p>
<p style="position:absolute;top:660px;left:85px;white-space:nowrap" class="ft352">2D&#160;barcode&#160;carrying the&#160;unique&#160;identifier&#160;included.&#160;</p>
<p style="position:absolute;top:679px;left:85px;white-space:nowrap" class="ft352">&#160;</p>
<p style="position:absolute;top:701px;left:85px;white-space:nowrap" class="ft351"><b>18.&#160;</b></p>
<p style="position:absolute;top:701px;left:139px;white-space:nowrap" class="ft351"><b>UNIQUE&#160;IDENTIFIER&#160;-&#160;HUMAN READABLE&#160;DATA</b><i>&#160;</i></p>
<p style="position:absolute;top:720px;left:85px;white-space:nowrap" class="ft352">&#160;</p>
<p style="position:absolute;top:740px;left:85px;white-space:nowrap" class="ft352">PC:&#160;</p>
<p style="position:absolute;top:759px;left:85px;white-space:nowrap" class="ft352">SN:&#160;</p>
<p style="position:absolute;top:779px;left:85px;white-space:nowrap" class="ft352">NN:&#160;&#160;</p>
<p style="position:absolute;top:798px;left:85px;white-space:nowrap" class="ft352">&#160;</p>
<p style="position:absolute;top:817px;left:85px;white-space:nowrap" class="ft352">&#160;</p>
<p style="position:absolute;top:836px;left:85px;white-space:nowrap" class="ft352">&#160;</p>
<p style="position:absolute;top:836px;left:301px;white-space:nowrap" class="ft352">&#160;</p>
</div>
<!-- Page 36 -->
<a name="36"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page36-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1191px;left:436px;white-space:nowrap" class="ft360">36&#160;</p>
<p style="position:absolute;top:85px;left:85px;white-space:nowrap" class="ft361"><b>PARTICULARS&#160;TO&#160;APPEAR ON THE&#160;OUTER PACKAGING&#160;</b></p>
<p style="position:absolute;top:104px;left:85px;white-space:nowrap" class="ft362">&#160;</p>
<p style="position:absolute;top:123px;left:85px;white-space:nowrap" class="ft361"><b>INTERMEDIATE&#160;CARTON (WITHOUT&#160;BLUE&#160;BOX&#160;–&#160;COMPONENT&#160;OF&#160;MULTIPACK)&#160;</b></p>
<p style="position:absolute;top:145px;left:85px;white-space:nowrap" class="ft362">&#160;</p>
<p style="position:absolute;top:163px;left:85px;white-space:nowrap" class="ft362">&#160;</p>
<p style="position:absolute;top:185px;left:85px;white-space:nowrap" class="ft361"><b>1.&#160;</b></p>
<p style="position:absolute;top:185px;left:127px;white-space:nowrap" class="ft361"><b>NAME&#160;OF&#160;THE&#160;MEDICINAL&#160;PRODUCT&#160;</b>&#160;</p>
<p style="position:absolute;top:206px;left:85px;white-space:nowrap" class="ft362">&#160;</p>
<p style="position:absolute;top:225px;left:85px;white-space:nowrap" class="ft362">Dovato&#160;50&#160;mg/300&#160;mg&#160;film-coated&#160;tablets&#160;</p>
<p style="position:absolute;top:244px;left:85px;white-space:nowrap" class="ft362">dolutegravir/lamivudine</p>
<p style="position:absolute;top:244px;left:245px;white-space:nowrap" class="ft361"><b>&#160;</b>&#160;</p>
<p style="position:absolute;top:263px;left:85px;white-space:nowrap" class="ft362">&#160;</p>
<p style="position:absolute;top:282px;left:85px;white-space:nowrap" class="ft362">&#160;</p>
<p style="position:absolute;top:304px;left:85px;white-space:nowrap" class="ft361"><b>2.&#160;</b></p>
<p style="position:absolute;top:304px;left:127px;white-space:nowrap" class="ft361"><b>STATEMENT OF&#160;ACTIVE SUBSTANCE(S)&#160;&#160;</b></p>
<p style="position:absolute;top:325px;left:85px;white-space:nowrap" class="ft362">&#160;</p>
<p style="position:absolute;top:344px;left:85px;white-space:nowrap" class="ft362">Each&#160;film-coated&#160;tablet&#160;contains&#160;dolutegravir&#160;sodium&#160;equivalent&#160;to 50&#160;mg dolutegravir&#160;and&#160;300&#160;mg&#160;</p>
<p style="position:absolute;top:364px;left:85px;white-space:nowrap" class="ft362">lamivudine.&#160;</p>
<p style="position:absolute;top:383px;left:85px;white-space:nowrap" class="ft362">&#160;</p>
<p style="position:absolute;top:402px;left:85px;white-space:nowrap" class="ft362">&#160;</p>
<p style="position:absolute;top:423px;left:85px;white-space:nowrap" class="ft361"><b>3.&#160;</b></p>
<p style="position:absolute;top:423px;left:127px;white-space:nowrap" class="ft361"><b>LIST OF&#160;EXCIPIENTS&#160;</b>&#160;</p>
<p style="position:absolute;top:444px;left:85px;white-space:nowrap" class="ft362">&#160;</p>
<p style="position:absolute;top:463px;left:85px;white-space:nowrap" class="ft362">&#160;</p>
<p style="position:absolute;top:484px;left:85px;white-space:nowrap" class="ft361"><b>4.&#160;</b></p>
<p style="position:absolute;top:484px;left:127px;white-space:nowrap" class="ft361"><b>PHARMACEUTICAL&#160;FORM&#160;AND CONTENTS&#160;</b>&#160;</p>
<p style="position:absolute;top:506px;left:85px;white-space:nowrap" class="ft362">&#160;</p>
<p style="position:absolute;top:525px;left:85px;white-space:nowrap" class="ft362">30 tablets. Component&#160;of&#160;a&#160;multipack,&#160;can’t&#160;be&#160;sold&#160;separately.&#160;</p>
<p style="position:absolute;top:544px;left:85px;white-space:nowrap" class="ft362">&#160;</p>
<p style="position:absolute;top:565px;left:85px;white-space:nowrap" class="ft361"><b>5.&#160;</b></p>
<p style="position:absolute;top:565px;left:127px;white-space:nowrap" class="ft361"><b>METHOD AND ROUTE(S)&#160;OF&#160;ADMINISTRATION&#160;</b>&#160;</p>
<p style="position:absolute;top:586px;left:85px;white-space:nowrap" class="ft362">&#160;</p>
<p style="position:absolute;top:605px;left:85px;white-space:nowrap" class="ft362">Read&#160;the package leaflet&#160;before&#160;use.&#160;</p>
<p style="position:absolute;top:624px;left:85px;white-space:nowrap" class="ft362">Oral&#160;use&#160;</p>
<p style="position:absolute;top:643px;left:85px;white-space:nowrap" class="ft362">&#160;</p>
<p style="position:absolute;top:662px;left:85px;white-space:nowrap" class="ft362">&#160;</p>
<p style="position:absolute;top:683px;left:85px;white-space:nowrap" class="ft361"><b>6.&#160;</b></p>
<p style="position:absolute;top:683px;left:127px;white-space:nowrap" class="ft361"><b>SPECIAL&#160;WARNING&#160;THAT&#160;THE&#160;MEDICINAL&#160;PRODUCT&#160;MUST&#160;BE&#160;STORED OUT&#160;OF&#160;</b></p>
<p style="position:absolute;top:702px;left:127px;white-space:nowrap" class="ft361"><b>THE SIGHT&#160;AND REACH&#160;OF&#160;CHILDREN&#160;</b>&#160;</p>
<p style="position:absolute;top:723px;left:85px;white-space:nowrap" class="ft362">&#160;</p>
<p style="position:absolute;top:742px;left:85px;white-space:nowrap" class="ft362">Keep out&#160;of&#160;the&#160;sight&#160;and reach of&#160;children.&#160;&#160;</p>
<p style="position:absolute;top:761px;left:85px;white-space:nowrap" class="ft362">&#160;</p>
<p style="position:absolute;top:780px;left:85px;white-space:nowrap" class="ft362">&#160;</p>
<p style="position:absolute;top:801px;left:85px;white-space:nowrap" class="ft361"><b>7.&#160;</b></p>
<p style="position:absolute;top:801px;left:127px;white-space:nowrap" class="ft361"><b>OTHER&#160;SPECIAL&#160;WARNING(S),&#160;IF&#160;NECESSARY&#160;</b>&#160;</p>
<p style="position:absolute;top:823px;left:85px;white-space:nowrap" class="ft362">&#160;</p>
<p style="position:absolute;top:842px;left:85px;white-space:nowrap" class="ft362">&#160;</p>
<p style="position:absolute;top:863px;left:85px;white-space:nowrap" class="ft361"><b>8.&#160;</b></p>
<p style="position:absolute;top:863px;left:127px;white-space:nowrap" class="ft361"><b>EXPIRY DATE&#160;</b>&#160;</p>
<p style="position:absolute;top:884px;left:85px;white-space:nowrap" class="ft362">&#160;</p>
<p style="position:absolute;top:903px;left:85px;white-space:nowrap" class="ft362">EXP&#160;&#160;</p>
<p style="position:absolute;top:922px;left:85px;white-space:nowrap" class="ft362">&#160;</p>
<p style="position:absolute;top:941px;left:85px;white-space:nowrap" class="ft362">&#160;</p>
<p style="position:absolute;top:962px;left:85px;white-space:nowrap" class="ft361"><b>9.&#160;</b></p>
<p style="position:absolute;top:962px;left:127px;white-space:nowrap" class="ft361"><b>SPECIAL&#160;STORAGE&#160;CONDITIONS&#160;</b>&#160;</p>
<p style="position:absolute;top:984px;left:85px;white-space:nowrap" class="ft362">&#160;</p>
<p style="position:absolute;top:1002px;left:85px;white-space:nowrap" class="ft362">&#160;</p>
<p style="position:absolute;top:1024px;left:85px;white-space:nowrap" class="ft361"><b>10.&#160;&#160;SPECIAL&#160;PRECAUTIONS&#160;FOR DISPOSAL&#160;OF&#160;UNUSED MEDICINAL&#160;PRODUCTS&#160;OR&#160;</b></p>
<p style="position:absolute;top:1042px;left:127px;white-space:nowrap" class="ft361"><b>WASTE&#160;MATERIALS&#160;DERIVED FROM&#160;SUCH&#160;MEDICINAL&#160;PRODUCTS,&#160;IF&#160;</b></p>
<p style="position:absolute;top:1062px;left:127px;white-space:nowrap" class="ft361"><b>APPROPRIATE&#160;&#160;</b></p>
<p style="position:absolute;top:1083px;left:85px;white-space:nowrap" class="ft362">&#160;</p>
<p style="position:absolute;top:1102px;left:85px;white-space:nowrap" class="ft362">&#160;</p>
<p style="position:absolute;top:1123px;left:85px;white-space:nowrap" class="ft361"><b>11.&#160;&#160;NAME&#160;AND ADDRESS&#160;OF&#160;THE&#160;MARKETING&#160;AUTHORISATION HOLDER&#160;&#160;</b></p>
<p style="position:absolute;top:1144px;left:85px;white-space:nowrap" class="ft362">&#160;</p>
</div>
<!-- Page 37 -->
<a name="37"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page37-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1191px;left:436px;white-space:nowrap" class="ft370">37&#160;</p>
<p style="position:absolute;top:83px;left:85px;white-space:nowrap" class="ft372">ViiV&#160;Healthcare BV&#160;</p>
<p style="position:absolute;top:103px;left:85px;white-space:nowrap" class="ft372">Van&#160;Asch&#160;van&#160;Wijckstraat&#160;55H&#160;</p>
<p style="position:absolute;top:122px;left:85px;white-space:nowrap" class="ft372">3811 LP&#160;Amersfoort&#160;</p>
<p style="position:absolute;top:142px;left:85px;white-space:nowrap" class="ft372">Netherlands&#160;</p>
<p style="position:absolute;top:161px;left:85px;white-space:nowrap" class="ft372">&#160;</p>
<p style="position:absolute;top:180px;left:85px;white-space:nowrap" class="ft372">&#160;</p>
<p style="position:absolute;top:201px;left:85px;white-space:nowrap" class="ft371"><b>12.&#160;&#160;MARKETING&#160;AUTHORISATION NUMBER(S)&#160;</b>&#160;</p>
<p style="position:absolute;top:223px;left:85px;white-space:nowrap" class="ft372">&#160;</p>
<p style="position:absolute;top:241px;left:85px;white-space:nowrap" class="ft372">EU/1/19/1370/002&#160;&#160;</p>
<p style="position:absolute;top:261px;left:85px;white-space:nowrap" class="ft372">&#160;</p>
<p style="position:absolute;top:279px;left:85px;white-space:nowrap" class="ft372">&#160;</p>
<p style="position:absolute;top:301px;left:85px;white-space:nowrap" class="ft371"><b>13.&#160;&#160;BATCH&#160;NUMBER&#160;</b>&#160;</p>
<p style="position:absolute;top:322px;left:85px;white-space:nowrap" class="ft375"><i>&#160;</i></p>
<p style="position:absolute;top:341px;left:85px;white-space:nowrap" class="ft372">Lot&#160;</p>
<p style="position:absolute;top:360px;left:85px;white-space:nowrap" class="ft375"><i>&#160;</i></p>
<p style="position:absolute;top:379px;left:85px;white-space:nowrap" class="ft372">&#160;</p>
<p style="position:absolute;top:400px;left:85px;white-space:nowrap" class="ft371"><b>14.&#160;&#160;GENERAL&#160;CLASSIFICATION FOR SUPPLY&#160;</b>&#160;</p>
<p style="position:absolute;top:422px;left:85px;white-space:nowrap" class="ft375"><i>&#160;</i></p>
<p style="position:absolute;top:440px;left:85px;white-space:nowrap" class="ft3729">&#160;<br/><b>15.&#160;&#160;INSTRUCTIONS&#160;ON USE&#160;</b>&#160;</p>
<p style="position:absolute;top:484px;left:85px;white-space:nowrap" class="ft372">&#160;</p>
<p style="position:absolute;top:503px;left:85px;white-space:nowrap" class="ft372">&#160;</p>
<p style="position:absolute;top:525px;left:85px;white-space:nowrap" class="ft371"><b>16.&#160;&#160;INFORMATION IN BRAILLE</b>&#160;</p>
<p style="position:absolute;top:544px;left:85px;white-space:nowrap" class="ft372">&#160;</p>
<p style="position:absolute;top:563px;left:85px;white-space:nowrap" class="ft372">dovato&#160;</p>
<p style="position:absolute;top:582px;left:85px;white-space:nowrap" class="ft372">&#160;</p>
<p style="position:absolute;top:601px;left:85px;white-space:nowrap" class="ft372">&#160;</p>
<p style="position:absolute;top:622px;left:85px;white-space:nowrap" class="ft371"><b>17.&#160;</b></p>
<p style="position:absolute;top:622px;left:139px;white-space:nowrap" class="ft371"><b>UNIQUE&#160;IDENTIFIER&#160;–&#160;2D BARCODE</b><i>&#160;</i></p>
<p style="position:absolute;top:642px;left:85px;white-space:nowrap" class="ft372">&#160;</p>
<p style="position:absolute;top:663px;left:85px;white-space:nowrap" class="ft371"><b>18.&#160;</b></p>
<p style="position:absolute;top:663px;left:139px;white-space:nowrap" class="ft371"><b>UNIQUE&#160;IDENTIFIER&#160;-&#160;HUMAN READABLE&#160;DATA</b><i>&#160;</i></p>
<p style="position:absolute;top:683px;left:85px;white-space:nowrap" class="ft372">&#160;</p>
<p style="position:absolute;top:702px;left:85px;white-space:nowrap" class="ft372">&#160;</p>
<p style="position:absolute;top:721px;left:85px;white-space:nowrap" class="ft372">&#160;</p>
<p style="position:absolute;top:721px;left:301px;white-space:nowrap" class="ft371"><b>&#160;</b></p>
</div>
<!-- Page 38 -->
<a name="38"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page38-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1191px;left:436px;white-space:nowrap" class="ft380">38&#160;</p>
<p style="position:absolute;top:83px;left:85px;white-space:nowrap" class="ft381"><b>&#160;</b></p>
<p style="position:absolute;top:102px;left:85px;white-space:nowrap" class="ft381"><b>&#160;</b></p>
<p style="position:absolute;top:123px;left:85px;white-space:nowrap" class="ft381"><b>PARTICULARS&#160;TO&#160;APPEAR ON THE&#160;IMMEDIATE&#160;PACKAGING&#160;</b></p>
<p style="position:absolute;top:142px;left:85px;white-space:nowrap" class="ft382">&#160;</p>
<p style="position:absolute;top:161px;left:85px;white-space:nowrap" class="ft381"><b>BOTTLE LABEL</b>&#160;</p>
<p style="position:absolute;top:183px;left:85px;white-space:nowrap" class="ft382">&#160;</p>
<p style="position:absolute;top:201px;left:85px;white-space:nowrap" class="ft382">&#160;</p>
<p style="position:absolute;top:223px;left:85px;white-space:nowrap" class="ft381"><b>1.&#160;</b></p>
<p style="position:absolute;top:223px;left:127px;white-space:nowrap" class="ft381"><b>NAME&#160;OF&#160;THE&#160;MEDICINAL&#160;PRODUCT&#160;</b>&#160;</p>
<p style="position:absolute;top:244px;left:85px;white-space:nowrap" class="ft382">&#160;</p>
<p style="position:absolute;top:263px;left:85px;white-space:nowrap" class="ft382">Dovato&#160;50&#160;mg/300&#160;mg&#160;tablets&#160;</p>
<p style="position:absolute;top:282px;left:85px;white-space:nowrap" class="ft382">dolutegravir/lamivudine</p>
<p style="position:absolute;top:282px;left:245px;white-space:nowrap" class="ft381"><b>&#160;</b>&#160;</p>
<p style="position:absolute;top:301px;left:85px;white-space:nowrap" class="ft382">&#160;</p>
<p style="position:absolute;top:320px;left:85px;white-space:nowrap" class="ft382">&#160;</p>
<p style="position:absolute;top:342px;left:85px;white-space:nowrap" class="ft381"><b>2.&#160;</b></p>
<p style="position:absolute;top:342px;left:127px;white-space:nowrap" class="ft381"><b>STATEMENT OF&#160;ACTIVE SUBSTANCE(S)&#160;&#160;</b></p>
<p style="position:absolute;top:363px;left:85px;white-space:nowrap" class="ft382">&#160;</p>
<p style="position:absolute;top:382px;left:85px;white-space:nowrap" class="ft382">Each&#160;film-coated&#160;tablet&#160;contains&#160;dolutegravir&#160;sodium&#160;equivalent&#160;to 50&#160;mg dolutegravir&#160;and&#160;300&#160;mg&#160;</p>
<p style="position:absolute;top:402px;left:85px;white-space:nowrap" class="ft382">lamivudine.&#160;</p>
<p style="position:absolute;top:421px;left:85px;white-space:nowrap" class="ft382">&#160;</p>
<p style="position:absolute;top:440px;left:85px;white-space:nowrap" class="ft382">&#160;</p>
<p style="position:absolute;top:461px;left:85px;white-space:nowrap" class="ft381"><b>3.&#160;</b></p>
<p style="position:absolute;top:461px;left:127px;white-space:nowrap" class="ft381"><b>LIST OF&#160;EXCIPIENTS&#160;</b>&#160;</p>
<p style="position:absolute;top:482px;left:85px;white-space:nowrap" class="ft382">&#160;</p>
<p style="position:absolute;top:501px;left:85px;white-space:nowrap" class="ft382">&#160;</p>
<p style="position:absolute;top:522px;left:85px;white-space:nowrap" class="ft381"><b>4.&#160;</b></p>
<p style="position:absolute;top:522px;left:127px;white-space:nowrap" class="ft381"><b>PHARMACEUTICAL&#160;FORM&#160;AND CONTENTS&#160;</b>&#160;</p>
<p style="position:absolute;top:544px;left:85px;white-space:nowrap" class="ft382">&#160;</p>
<p style="position:absolute;top:563px;left:85px;white-space:nowrap" class="ft382">30&#160;tablets&#160;</p>
<p style="position:absolute;top:581px;left:85px;white-space:nowrap" class="ft382">&#160;</p>
<p style="position:absolute;top:603px;left:85px;white-space:nowrap" class="ft381"><b>5.&#160;</b></p>
<p style="position:absolute;top:603px;left:127px;white-space:nowrap" class="ft381"><b>METHOD AND ROUTE(S)&#160;OF&#160;ADMINISTRATION&#160;</b>&#160;</p>
<p style="position:absolute;top:624px;left:85px;white-space:nowrap" class="ft382">&#160;</p>
<p style="position:absolute;top:643px;left:85px;white-space:nowrap" class="ft382">Read&#160;the package leaflet&#160;before&#160;use.&#160;</p>
<p style="position:absolute;top:662px;left:85px;white-space:nowrap" class="ft382">Oral&#160;use&#160;</p>
<p style="position:absolute;top:681px;left:85px;white-space:nowrap" class="ft382">&#160;</p>
<p style="position:absolute;top:700px;left:85px;white-space:nowrap" class="ft382">&#160;</p>
<p style="position:absolute;top:721px;left:85px;white-space:nowrap" class="ft381"><b>6.&#160;</b></p>
<p style="position:absolute;top:721px;left:127px;white-space:nowrap" class="ft381"><b>SPECIAL&#160;WARNING&#160;THAT&#160;THE&#160;MEDICINAL&#160;PRODUCT&#160;MUST&#160;BE&#160;STORED OUT&#160;OF&#160;</b></p>
<p style="position:absolute;top:740px;left:127px;white-space:nowrap" class="ft381"><b>THE&#160;SIGHT&#160;AND REACH&#160;OF&#160;CHILDREN&#160;</b>&#160;</p>
<p style="position:absolute;top:761px;left:85px;white-space:nowrap" class="ft382">&#160;</p>
<p style="position:absolute;top:780px;left:85px;white-space:nowrap" class="ft382">Keep out&#160;of&#160;the&#160;sight&#160;and reach of&#160;children.&#160;&#160;</p>
<p style="position:absolute;top:799px;left:85px;white-space:nowrap" class="ft382">&#160;</p>
<p style="position:absolute;top:818px;left:85px;white-space:nowrap" class="ft382">&#160;</p>
<p style="position:absolute;top:839px;left:85px;white-space:nowrap" class="ft381"><b>7.&#160;</b></p>
<p style="position:absolute;top:839px;left:127px;white-space:nowrap" class="ft381"><b>OTHER SPECIAL&#160;WARNING(S),&#160;IF&#160;NECESSARY&#160;</b>&#160;</p>
<p style="position:absolute;top:861px;left:85px;white-space:nowrap" class="ft382">&#160;</p>
<p style="position:absolute;top:880px;left:85px;white-space:nowrap" class="ft382">&#160;</p>
<p style="position:absolute;top:901px;left:85px;white-space:nowrap" class="ft381"><b>8.&#160;</b></p>
<p style="position:absolute;top:901px;left:127px;white-space:nowrap" class="ft381"><b>EXPIRY DATE&#160;</b>&#160;</p>
<p style="position:absolute;top:922px;left:85px;white-space:nowrap" class="ft382">&#160;</p>
<p style="position:absolute;top:941px;left:85px;white-space:nowrap" class="ft382">EXP&#160;&#160;</p>
<p style="position:absolute;top:960px;left:85px;white-space:nowrap" class="ft382">&#160;</p>
<p style="position:absolute;top:979px;left:85px;white-space:nowrap" class="ft382">&#160;</p>
<p style="position:absolute;top:1000px;left:85px;white-space:nowrap" class="ft381"><b>9.&#160;</b></p>
<p style="position:absolute;top:1000px;left:127px;white-space:nowrap" class="ft381"><b>SPECIAL&#160;STORAGE&#160;CONDITIONS&#160;</b>&#160;</p>
<p style="position:absolute;top:1021px;left:85px;white-space:nowrap" class="ft382">&#160;</p>
<p style="position:absolute;top:1040px;left:85px;white-space:nowrap" class="ft382">&#160;</p>
<p style="position:absolute;top:1062px;left:85px;white-space:nowrap" class="ft381"><b>10.&#160;&#160;SPECIAL&#160;PRECAUTIONS&#160;FOR DISPOSAL&#160;OF&#160;UNUSED MEDICINAL&#160;PRODUCTS&#160;OR&#160;</b></p>
<p style="position:absolute;top:1080px;left:127px;white-space:nowrap" class="ft381"><b>WASTE MATERIALS&#160;DERIVED FROM&#160;SUCH&#160;MEDICINAL&#160;PRODUCTS,&#160;IF&#160;</b></p>
<p style="position:absolute;top:1100px;left:127px;white-space:nowrap" class="ft381"><b>APPROPRIATE&#160;&#160;</b></p>
<p style="position:absolute;top:1121px;left:85px;white-space:nowrap" class="ft382">&#160;</p>
<p style="position:absolute;top:1140px;left:85px;white-space:nowrap" class="ft382">&#160;</p>
</div>
<!-- Page 39 -->
<a name="39"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page39-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1191px;left:436px;white-space:nowrap" class="ft390">39&#160;</p>
<p style="position:absolute;top:85px;left:85px;white-space:nowrap" class="ft391"><b>11.&#160;&#160;NAME&#160;AND ADDRESS&#160;OF&#160;THE&#160;MARKETING&#160;AUTHORISATION HOLDER&#160;&#160;</b></p>
<p style="position:absolute;top:107px;left:85px;white-space:nowrap" class="ft392">&#160;</p>
<p style="position:absolute;top:126px;left:85px;white-space:nowrap" class="ft392">ViiV&#160;Healthcare BV&#160;</p>
<p style="position:absolute;top:145px;left:85px;white-space:nowrap" class="ft392">&#160;</p>
<p style="position:absolute;top:164px;left:85px;white-space:nowrap" class="ft392">&#160;</p>
<p style="position:absolute;top:185px;left:85px;white-space:nowrap" class="ft391"><b>12.&#160;&#160;MARKETING&#160;AUTHORISATION NUMBER(S)&#160;</b>&#160;</p>
<p style="position:absolute;top:207px;left:85px;white-space:nowrap" class="ft392">&#160;</p>
<p style="position:absolute;top:225px;left:85px;white-space:nowrap" class="ft392">EU/1/19/1370/001&#160;&#160;</p>
<p style="position:absolute;top:244px;left:85px;white-space:nowrap" class="ft392">EU/1/19/1370/002&#160;</p>
<p style="position:absolute;top:263px;left:85px;white-space:nowrap" class="ft392">&#160;</p>
<p style="position:absolute;top:282px;left:85px;white-space:nowrap" class="ft392">&#160;</p>
<p style="position:absolute;top:304px;left:85px;white-space:nowrap" class="ft391"><b>13.&#160;&#160;BATCH&#160;NUMBER&#160;</b>&#160;</p>
<p style="position:absolute;top:325px;left:85px;white-space:nowrap" class="ft395"><i>&#160;</i></p>
<p style="position:absolute;top:344px;left:85px;white-space:nowrap" class="ft392">Lot&#160;</p>
<p style="position:absolute;top:363px;left:85px;white-space:nowrap" class="ft395"><i>&#160;</i></p>
<p style="position:absolute;top:382px;left:85px;white-space:nowrap" class="ft392">&#160;</p>
<p style="position:absolute;top:403px;left:85px;white-space:nowrap" class="ft391"><b>14.&#160;&#160;GENERAL&#160;CLASSIFICATION FOR SUPPLY&#160;</b>&#160;</p>
<p style="position:absolute;top:424px;left:85px;white-space:nowrap" class="ft395"><i>&#160;</i></p>
<p style="position:absolute;top:443px;left:85px;white-space:nowrap" class="ft3929">&#160;<br/><b>15.&#160;&#160;INSTRUCTIONS&#160;ON USE&#160;</b>&#160;</p>
<p style="position:absolute;top:487px;left:85px;white-space:nowrap" class="ft392">&#160;</p>
<p style="position:absolute;top:506px;left:85px;white-space:nowrap" class="ft392">&#160;</p>
<p style="position:absolute;top:527px;left:85px;white-space:nowrap" class="ft391"><b>16.&#160;&#160;INFORMATION IN BRAILLE</b>&#160;</p>
<p style="position:absolute;top:547px;left:85px;white-space:nowrap" class="ft392">&#160;</p>
<p style="position:absolute;top:566px;left:85px;white-space:nowrap" class="ft392">&#160;</p>
<p style="position:absolute;top:587px;left:85px;white-space:nowrap" class="ft391"><b>17.&#160;</b></p>
<p style="position:absolute;top:587px;left:139px;white-space:nowrap" class="ft391"><b>UNIQUE&#160;IDENTIFIER&#160;–&#160;2D BARCODE</b><i>&#160;</i></p>
<p style="position:absolute;top:607px;left:85px;white-space:nowrap" class="ft392">&#160;</p>
<p style="position:absolute;top:628px;left:85px;white-space:nowrap" class="ft391"><b>18.&#160;</b></p>
<p style="position:absolute;top:628px;left:139px;white-space:nowrap" class="ft391"><b>UNIQUE&#160;IDENTIFIER&#160;-&#160;HUMAN READABLE&#160;DATA</b><i>&#160;</i></p>
<p style="position:absolute;top:648px;left:85px;white-space:nowrap" class="ft392">&#160;</p>
<p style="position:absolute;top:667px;left:85px;white-space:nowrap" class="ft392">&#160;</p>
<p style="position:absolute;top:686px;left:85px;white-space:nowrap" class="ft391"><b>&#160;</b></p>
<p style="position:absolute;top:686px;left:301px;white-space:nowrap" class="ft391"><b>&#160;</b></p>
</div>
<!-- Page 40 -->
<a name="40"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page40-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1191px;left:436px;white-space:nowrap" class="ft400">40&#160;</p>
<p style="position:absolute;top:83px;left:85px;white-space:nowrap" class="ft401"><b>&#160;</b></p>
<p style="position:absolute;top:102px;left:85px;white-space:nowrap" class="ft401"><b>&#160;</b></p>
<p style="position:absolute;top:121px;left:85px;white-space:nowrap" class="ft401"><b>&#160;</b></p>
<p style="position:absolute;top:140px;left:85px;white-space:nowrap" class="ft401"><b>&#160;</b></p>
<p style="position:absolute;top:159px;left:85px;white-space:nowrap" class="ft401"><b>&#160;</b></p>
<p style="position:absolute;top:178px;left:85px;white-space:nowrap" class="ft401"><b>&#160;</b></p>
<p style="position:absolute;top:197px;left:85px;white-space:nowrap" class="ft401"><b>&#160;</b></p>
<p style="position:absolute;top:216px;left:85px;white-space:nowrap" class="ft401"><b>&#160;</b></p>
<p style="position:absolute;top:235px;left:85px;white-space:nowrap" class="ft401"><b>&#160;</b></p>
<p style="position:absolute;top:254px;left:85px;white-space:nowrap" class="ft401"><b>&#160;</b></p>
<p style="position:absolute;top:273px;left:85px;white-space:nowrap" class="ft401"><b>&#160;</b></p>
<p style="position:absolute;top:292px;left:85px;white-space:nowrap" class="ft401"><b>&#160;</b></p>
<p style="position:absolute;top:311px;left:85px;white-space:nowrap" class="ft401"><b>&#160;</b></p>
<p style="position:absolute;top:330px;left:85px;white-space:nowrap" class="ft401"><b>&#160;</b></p>
<p style="position:absolute;top:348px;left:85px;white-space:nowrap" class="ft401"><b>&#160;</b></p>
<p style="position:absolute;top:368px;left:85px;white-space:nowrap" class="ft401"><b>&#160;</b></p>
<p style="position:absolute;top:386px;left:85px;white-space:nowrap" class="ft401"><b>&#160;</b></p>
<p style="position:absolute;top:405px;left:85px;white-space:nowrap" class="ft401"><b>&#160;</b></p>
<p style="position:absolute;top:424px;left:85px;white-space:nowrap" class="ft401"><b>&#160;</b></p>
<p style="position:absolute;top:443px;left:85px;white-space:nowrap" class="ft401"><b>&#160;</b></p>
<p style="position:absolute;top:462px;left:85px;white-space:nowrap" class="ft401"><b>&#160;</b></p>
<p style="position:absolute;top:481px;left:85px;white-space:nowrap" class="ft401"><b>&#160;</b></p>
<p style="position:absolute;top:500px;left:85px;white-space:nowrap" class="ft401"><b>&#160;</b></p>
<p style="position:absolute;top:519px;left:355px;white-space:nowrap" class="ft401"><b>B.&#160;PACKAGE LEAFLET&#160;&#160;</b></p>
</div>
<!-- Page 41 -->
<a name="41"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page41-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1191px;left:436px;white-space:nowrap" class="ft410">41&#160;</p>
<p style="position:absolute;top:83px;left:293px;white-space:nowrap" class="ft411"><b>Package&#160;leaflet:&#160;Information&#160;for&#160;the&#160;patient&#160;</b>&#160;</p>
<p style="position:absolute;top:102px;left:446px;white-space:nowrap" class="ft412">&#160;</p>
<p style="position:absolute;top:121px;left:303px;white-space:nowrap" class="ft411"><b>Dovato&#160;50&#160;mg/300&#160;mg&#160;film-coated&#160;tablets&#160;&#160;</b></p>
<p style="position:absolute;top:140px;left:367px;white-space:nowrap" class="ft412">dolutegravir/lamivudine&#160;</p>
<p style="position:absolute;top:159px;left:85px;white-space:nowrap" class="ft412">&#160;</p>
<p style="position:absolute;top:178px;left:85px;white-space:nowrap" class="ft411"><b>Read&#160;all&#160;of&#160;this&#160;leaflet&#160;carefully before&#160;you&#160;start&#160;taking&#160;this medicine&#160;because it&#160;contains important&#160;</b></p>
<p style="position:absolute;top:197px;left:96px;white-space:nowrap" class="ft411"><b>information&#160;for&#160;you.</b>&#160;</p>
<p style="position:absolute;top:216px;left:85px;white-space:nowrap" class="ft412">-&#160;</p>
<p style="position:absolute;top:216px;left:127px;white-space:nowrap" class="ft412">Keep&#160;this&#160;leaflet.&#160;You&#160;may need to&#160;read it&#160;again.&#160;&#160;</p>
<p style="position:absolute;top:235px;left:85px;white-space:nowrap" class="ft412">-&#160;</p>
<p style="position:absolute;top:235px;left:127px;white-space:nowrap" class="ft412">If&#160;you have&#160;any&#160;further&#160;questions,&#160;ask your&#160;doctor,&#160;or&#160;pharmacist.&#160;</p>
<p style="position:absolute;top:254px;left:85px;white-space:nowrap" class="ft412">-&#160;</p>
<p style="position:absolute;top:254px;left:127px;white-space:nowrap" class="ft412">This&#160;medicine&#160;has&#160;been prescribed&#160;for&#160;you only. Do&#160;not&#160;pass&#160;it&#160;on&#160;to others. It&#160;may&#160;harm&#160;them, even if&#160;</p>
<p style="position:absolute;top:273px;left:127px;white-space:nowrap" class="ft412">their&#160;signs&#160;of&#160;illness are&#160;the&#160;same&#160;as&#160;yours.&#160;&#160;</p>
<p style="position:absolute;top:292px;left:85px;white-space:nowrap" class="ft412">-&#160;</p>
<p style="position:absolute;top:292px;left:127px;white-space:nowrap" class="ft412">If&#160;you get&#160;any&#160;side&#160;effects, talk&#160;to your&#160;doctor,&#160;or&#160;pharmacist.&#160;This includes&#160;any&#160;possible&#160;side effects&#160;</p>
<p style="position:absolute;top:311px;left:127px;white-space:nowrap" class="ft412">not&#160;listed&#160;in&#160;this&#160;leaflet. See&#160;section&#160;4.&#160;</p>
<p style="position:absolute;top:330px;left:85px;white-space:nowrap" class="ft412">&#160;</p>
<p style="position:absolute;top:349px;left:85px;white-space:nowrap" class="ft412">&#160;</p>
<p style="position:absolute;top:368px;left:85px;white-space:nowrap" class="ft411"><b>What&#160;is&#160;in&#160;this&#160;leaflet&#160;</b></p>
<p style="position:absolute;top:387px;left:85px;white-space:nowrap" class="ft412">&#160;</p>
<p style="position:absolute;top:406px;left:85px;white-space:nowrap" class="ft412">1.&#160;&#160;What&#160;Dovato&#160;is and&#160;what&#160;it&#160;is used&#160;for&#160;&#160;</p>
<p style="position:absolute;top:425px;left:85px;white-space:nowrap" class="ft412">2.&#160;&#160;What&#160;you need&#160;to know&#160;before&#160;you&#160;take&#160;Dovato&#160;&#160;</p>
<p style="position:absolute;top:444px;left:85px;white-space:nowrap" class="ft412">3.&#160;&#160;How&#160;to take&#160;Dovato&#160;</p>
<p style="position:absolute;top:463px;left:85px;white-space:nowrap" class="ft412">4.&#160;&#160;Possible side&#160;effects&#160;&#160;</p>
<p style="position:absolute;top:481px;left:85px;white-space:nowrap" class="ft412">5.&#160;&#160;How&#160;to store&#160;Dovato&#160;&#160;</p>
<p style="position:absolute;top:500px;left:85px;white-space:nowrap" class="ft412">6.&#160;&#160;Contents&#160;of&#160;the&#160;pack and other&#160;information&#160;</p>
<p style="position:absolute;top:519px;left:85px;white-space:nowrap" class="ft412">&#160;</p>
<p style="position:absolute;top:538px;left:85px;white-space:nowrap" class="ft412">&#160;</p>
<p style="position:absolute;top:557px;left:85px;white-space:nowrap" class="ft411"><b>1.&#160;</b></p>
<p style="position:absolute;top:557px;left:127px;white-space:nowrap" class="ft411"><b>What&#160;Dovato&#160;is&#160;and what&#160;it&#160;is&#160;used&#160;for&#160;</b></p>
<p style="position:absolute;top:576px;left:85px;white-space:nowrap" class="ft412">&#160;</p>
<p style="position:absolute;top:596px;left:85px;white-space:nowrap" class="ft412">Dovato&#160;is a&#160;medicine that&#160;contains&#160;two&#160;active&#160;ingredients&#160;used&#160;to treat&#160;human immunodeficiency&#160;virus&#160;(HIV)&#160;</p>
<p style="position:absolute;top:615px;left:85px;white-space:nowrap" class="ft412">infection:&#160;dolutegravir&#160;and&#160;lamivudine.&#160;Dolutegravir&#160;belongs&#160;to a&#160;group&#160;of&#160;anti-retroviral&#160;medicines called&#160;</p>
<p style="position:absolute;top:635px;left:85px;white-space:nowrap" class="ft415"><i>integrase inhibitors&#160;</i>(INIs), and&#160;lamivudine&#160;belongs&#160;to a&#160;group&#160;of&#160;anti-retroviral medicines&#160;called&#160;<i>nucleoside&#160;</i></p>
<p style="position:absolute;top:655px;left:85px;white-space:nowrap" class="ft415"><i>analogue&#160;reverse transcriptase&#160;inhibitors&#160;</i>(NRTIs).&#160;</p>
<p style="position:absolute;top:674px;left:85px;white-space:nowrap" class="ft412">&#160;</p>
<p style="position:absolute;top:693px;left:85px;white-space:nowrap" class="ft412">Dovato&#160;is used&#160;to&#160;treat&#160;HIV&#160;in adults&#160;and&#160;adolescents&#160;over&#160;12&#160;years&#160;old who weigh&#160;at&#160;least&#160;40&#160;kg.&#160;</p>
<p style="position:absolute;top:712px;left:85px;white-space:nowrap" class="ft412">&#160;</p>
<p style="position:absolute;top:731px;left:85px;white-space:nowrap" class="ft412">Dovato&#160;does&#160;not cure&#160;HIV&#160;infection;&#160;it&#160;keeps&#160;the&#160;amount&#160;of&#160;virus&#160;in your&#160;body at&#160;a&#160;low&#160;level.&#160;This&#160;helps&#160;</p>
<p style="position:absolute;top:750px;left:85px;white-space:nowrap" class="ft412">maintain&#160;the&#160;number&#160;of&#160;CD4 cells&#160;in your&#160;blood. CD4&#160;cells&#160;are&#160;a&#160;type&#160;of&#160;white&#160;blood cells&#160;that&#160;are&#160;important&#160;</p>
<p style="position:absolute;top:769px;left:85px;white-space:nowrap" class="ft412">in helping your&#160;body to&#160;fight&#160;infection.&#160;</p>
<p style="position:absolute;top:788px;left:85px;white-space:nowrap" class="ft412">&#160;</p>
<p style="position:absolute;top:807px;left:85px;white-space:nowrap" class="ft412">Not&#160;everyone&#160;responds&#160;to treatment&#160;with&#160;Dovato&#160;in&#160;the&#160;same&#160;way. Your&#160;doctor&#160;will&#160;monitor&#160;the&#160;effectiveness&#160;</p>
<p style="position:absolute;top:826px;left:85px;white-space:nowrap" class="ft412">of&#160;your&#160;treatment.&#160;</p>
<p style="position:absolute;top:844px;left:85px;white-space:nowrap" class="ft412">&#160;</p>
<p style="position:absolute;top:864px;left:85px;white-space:nowrap" class="ft412">&#160;</p>
<p style="position:absolute;top:882px;left:85px;white-space:nowrap" class="ft411"><b>2.&#160;</b></p>
<p style="position:absolute;top:882px;left:127px;white-space:nowrap" class="ft411"><b>What&#160;you need&#160;to&#160;know&#160;before&#160;you&#160;take&#160;Dovato&#160;</b></p>
<p style="position:absolute;top:902px;left:85px;white-space:nowrap" class="ft415"><i>&#160;</i></p>
<p style="position:absolute;top:920px;left:85px;white-space:nowrap" class="ft411"><b>Do not&#160;take&#160;Dovato&#160;</b>&#160;</p>
<p style="position:absolute;top:941px;left:112px;white-space:nowrap" class="ft419">•</p>
<p style="position:absolute;top:941px;left:119px;white-space:nowrap" class="ft4124">&#160;&#160;if&#160;you are&#160;</p>
<p style="position:absolute;top:940px;left:206px;white-space:nowrap" class="ft411"><b>allergic</b>&#160;(<i>hypersensitive</i>)&#160;to&#160;dolutegravir&#160;or&#160;lamivudine&#160;or&#160;any&#160;of&#160;the&#160;other&#160;ingredients&#160;of&#160;</p>
<p style="position:absolute;top:959px;left:139px;white-space:nowrap" class="ft412">this medicine (listed&#160;in&#160;section&#160;6).&#160;</p>
<p style="position:absolute;top:980px;left:112px;white-space:nowrap" class="ft419">•</p>
<p style="position:absolute;top:980px;left:120px;white-space:nowrap" class="ft4124">&#160;&#160;If&#160;you&#160;are taking&#160;a&#160;medicine called&#160;</p>
<p style="position:absolute;top:980px;left:372px;white-space:nowrap" class="ft411"><b>fampridine</b>&#160;(also known as&#160;dalfampridine;&#160;used&#160;in multiple&#160;</p>
<p style="position:absolute;top:999px;left:139px;white-space:nowrap" class="ft412">sclerosis).&#160;</p>
<p style="position:absolute;top:1018px;left:85px;white-space:nowrap" class="ft412">&#160;</p>
<p style="position:absolute;top:1039px;left:85px;white-space:nowrap" class="ft419">→</p>
<p style="position:absolute;top:1038px;left:101px;white-space:nowrap" class="ft412">&#160;If&#160;you&#160;think any&#160;of&#160;these&#160;apply&#160;to you,&#160;</p>
<p style="position:absolute;top:1038px;left:362px;white-space:nowrap" class="ft411"><b>tell&#160;your&#160;doctor</b>.&#160;</p>
<p style="position:absolute;top:1057px;left:85px;white-space:nowrap" class="ft412">&#160;</p>
<p style="position:absolute;top:1076px;left:85px;white-space:nowrap" class="ft411"><b>Warnings&#160;and&#160;precautions&#160;&#160;</b></p>
<p style="position:absolute;top:1095px;left:85px;white-space:nowrap" class="ft412">Some&#160;people&#160;taking&#160;Dovato&#160;or&#160;other&#160;combination&#160;treatments&#160;for&#160;HIV&#160;are more&#160;at&#160;risk&#160;of&#160;serious&#160;side&#160;effects&#160;</p>
<p style="position:absolute;top:1114px;left:85px;white-space:nowrap" class="ft412">than others. You&#160;need to&#160;be&#160;aware&#160;of&#160;the&#160;extra&#160;risks:&#160;</p>
<p style="position:absolute;top:1135px;left:112px;white-space:nowrap" class="ft419">•</p>
<p style="position:absolute;top:1134px;left:120px;white-space:nowrap" class="ft4124">&#160;&#160;if&#160;you have&#160;moderate&#160;or&#160;severe liver&#160;disease&#160;</p>
</div>
<!-- Page 42 -->
<a name="42"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft4230{font-size:17px;font-family:UGJYOA+Calibri;color:#000000;}
	.ft4231{font-size:17px;font-family:LQTWSS+Wingdings;color:#000000;}
-->
</style>
<div id="page42-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1191px;left:436px;white-space:nowrap" class="ft420">42&#160;</p>
<p style="position:absolute;top:85px;left:112px;white-space:nowrap" class="ft429">•</p>
<p style="position:absolute;top:84px;left:120px;white-space:nowrap" class="ft4224">&#160;&#160;if&#160;you have&#160;ever&#160;had liver&#160;disease,&#160;including hepatitis&#160;B&#160;or&#160;C&#160;(if&#160;you have&#160;hepatitis&#160;B&#160;infection, don’t&#160;</p>
<p style="position:absolute;top:103px;left:139px;white-space:nowrap" class="ft422">stop&#160;Dovato&#160;without&#160;your&#160;doctor’s&#160;advice,&#160;as&#160;your&#160;hepatitis&#160;may come&#160;back)&#160;</p>
<p style="position:absolute;top:124px;left:112px;white-space:nowrap" class="ft429">•</p>
<p style="position:absolute;top:124px;left:120px;white-space:nowrap" class="ft4224">&#160;&#160;if&#160;you have&#160;a&#160;kidney problem.&#160;</p>
<p style="position:absolute;top:144px;left:112px;white-space:nowrap" class="ft429">→</p>
<p style="position:absolute;top:144px;left:128px;white-space:nowrap" class="ft4230"><b>&#160;Talk&#160;to your&#160;doctor&#160;before&#160;using Dovato&#160;</b>if&#160;any of&#160;these&#160;apply&#160;to you.&#160;You may need&#160;extra&#160;check-</p>
<p style="position:absolute;top:163px;left:112px;white-space:nowrap" class="ft422">ups, including blood tests,&#160;while&#160;you’re&#160;taking your&#160;medicine. See&#160;section&#160;4&#160;for&#160;more&#160;information.&#160;</p>
<p style="position:absolute;top:182px;left:85px;white-space:nowrap" class="ft422">&#160;</p>
<p style="position:absolute;top:201px;left:85px;white-space:nowrap" class="ft422">Allergic&#160;reactions&#160;</p>
<p style="position:absolute;top:219px;left:85px;white-space:nowrap" class="ft422">Dovato&#160;contains dolutegravir.&#160;Dolutegravir&#160;can&#160;cause&#160;a&#160;serious&#160;allergic reaction&#160;known&#160;as a&#160;<i>hypersensitivity&#160;</i></p>
<p style="position:absolute;top:239px;left:85px;white-space:nowrap" class="ft425"><i>reaction</i>. You need to know&#160;about&#160;important&#160;signs&#160;and symptoms&#160;to&#160;look out&#160;for&#160;while&#160;you’re&#160;taking&#160;Dovato.&#160;</p>
<p style="position:absolute;top:259px;left:139px;white-space:nowrap" class="ft429">→</p>
<p style="position:absolute;top:259px;left:155px;white-space:nowrap" class="ft422">&#160;</p>
<p style="position:absolute;top:259px;left:159px;white-space:nowrap" class="ft421"><b>Read&#160;the&#160;information</b>&#160;‘Allergic&#160;reactions’&#160;in&#160;section&#160;4&#160;of&#160;this&#160;leaflet.&#160;</p>
<p style="position:absolute;top:278px;left:85px;white-space:nowrap" class="ft422">&#160;</p>
<p style="position:absolute;top:297px;left:85px;white-space:nowrap" class="ft422">Look out&#160;for&#160;important&#160;symptoms&#160;</p>
<p style="position:absolute;top:316px;left:85px;white-space:nowrap" class="ft422">Some&#160;people&#160;taking&#160;medicines&#160;for&#160;HIV&#160;infection&#160;develop other&#160;conditions, which&#160;can be&#160;serious.&#160;These&#160;</p>
<p style="position:absolute;top:336px;left:85px;white-space:nowrap" class="ft422">include:&#160;&#160;</p>
<p style="position:absolute;top:356px;left:112px;white-space:nowrap" class="ft429">•</p>
<p style="position:absolute;top:356px;left:120px;white-space:nowrap" class="ft4224">&#160;&#160;symptoms&#160;of&#160;infections&#160;and&#160;inflammation&#160;</p>
<p style="position:absolute;top:377px;left:112px;white-space:nowrap" class="ft429">•</p>
<p style="position:absolute;top:376px;left:120px;white-space:nowrap" class="ft4224">&#160;&#160;joint&#160;pain,&#160;stiffness&#160;and&#160;bone&#160;problems.&#160;</p>
<p style="position:absolute;top:395px;left:85px;white-space:nowrap" class="ft422">You need&#160;to know&#160;about&#160;important&#160;signs&#160;and symptoms&#160;to&#160;look out&#160;for&#160;while&#160;you’re&#160;taking&#160;Dovato.&#160;&#160;</p>
<p style="position:absolute;top:415px;left:127px;white-space:nowrap" class="ft429">→</p>
<p style="position:absolute;top:415px;left:144px;white-space:nowrap" class="ft422">&#160;</p>
<p style="position:absolute;top:415px;left:148px;white-space:nowrap" class="ft421"><b>Read&#160;the&#160;information&#160;‘Other&#160;possible side effects’&#160;in&#160;section&#160;4&#160;</b>of&#160;this&#160;leaflet.&#160;<b>&#160;</b></p>
<p style="position:absolute;top:434px;left:127px;white-space:nowrap" class="ft421"><b>&#160;</b></p>
<p style="position:absolute;top:453px;left:85px;white-space:nowrap" class="ft422">&#160;</p>
<p style="position:absolute;top:472px;left:85px;white-space:nowrap" class="ft421"><b>Children&#160;</b></p>
<p style="position:absolute;top:491px;left:85px;white-space:nowrap" class="ft422">This&#160;medicine&#160;is&#160;not&#160;for&#160;use&#160;in&#160;children&#160;under&#160;12&#160;years of&#160;age, because&#160;it&#160;has&#160;not&#160;been&#160;studied in&#160;these&#160;</p>
<p style="position:absolute;top:510px;left:85px;white-space:nowrap" class="ft422">patients.&#160;</p>
<p style="position:absolute;top:529px;left:85px;white-space:nowrap" class="ft421"><b>&#160;</b></p>
<p style="position:absolute;top:548px;left:85px;white-space:nowrap" class="ft421"><b>Other medicines&#160;and&#160;Dovato&#160;</b></p>
<p style="position:absolute;top:567px;left:85px;white-space:nowrap" class="ft422">Tell&#160;your&#160;doctor&#160;if&#160;you&#160;are&#160;taking, have&#160;recently taken&#160;or&#160;might&#160;take&#160;any other&#160;medicines.&#160;</p>
<p style="position:absolute;top:586px;left:85px;white-space:nowrap" class="ft422">&#160;</p>
<p style="position:absolute;top:605px;left:85px;white-space:nowrap" class="ft422">Don't&#160;take&#160;Dovato&#160;with the&#160;following medicine:&#160;</p>
<p style="position:absolute;top:626px;left:112px;white-space:nowrap" class="ft429">•</p>
<p style="position:absolute;top:626px;left:120px;white-space:nowrap" class="ft4224">&#160;&#160;fampridine&#160;(also&#160;known as&#160;dalfampridine),&#160;used&#160;in&#160;</p>
<p style="position:absolute;top:625px;left:476px;white-space:nowrap" class="ft421"><b>multiple sclerosis.</b>&#160;</p>
<p style="position:absolute;top:644px;left:85px;white-space:nowrap" class="ft422">&#160;</p>
<p style="position:absolute;top:663px;left:85px;white-space:nowrap" class="ft422">Some medicines&#160;can&#160;affect&#160;how&#160;Dovato&#160;works&#160;or&#160;make&#160;it more&#160;likely&#160;that&#160;you will&#160;have&#160;side&#160;effects.&#160;Dovato&#160;</p>
<p style="position:absolute;top:682px;left:85px;white-space:nowrap" class="ft422">can&#160;also&#160;affect&#160;how&#160;some&#160;other&#160;medicines work.&#160;</p>
<p style="position:absolute;top:701px;left:85px;white-space:nowrap" class="ft421"><b>Tell&#160;your doctor&#160;</b>if&#160;you&#160;are&#160;taking any of&#160;the&#160;medicines&#160;in the&#160;following&#160;list:&#160;</p>
<p style="position:absolute;top:722px;left:112px;white-space:nowrap" class="ft429">•</p>
<p style="position:absolute;top:721px;left:119px;white-space:nowrap" class="ft4224">&#160;&#160;metformin,&#160;to&#160;treat&#160;</p>
<p style="position:absolute;top:721px;left:267px;white-space:nowrap" class="ft421"><b>diabetes</b>&#160;</p>
<p style="position:absolute;top:742px;left:112px;white-space:nowrap" class="ft429">•</p>
<p style="position:absolute;top:742px;left:120px;white-space:nowrap" class="ft4224">&#160;&#160;medicines&#160;called&#160;</p>
<p style="position:absolute;top:741px;left:254px;white-space:nowrap" class="ft421"><b>antacids</b>, to&#160;treat&#160;<b>indigestion</b>&#160;and&#160;<b>heartburn.&#160;Do&#160;not&#160;take&#160;an&#160;antacid&#160;</b>during the&#160;</p>
<p style="position:absolute;top:760px;left:139px;white-space:nowrap" class="ft422">6&#160;hours&#160;before&#160;you&#160;take&#160;Dovato,&#160;or&#160;for&#160;at&#160;least&#160;2&#160;hours&#160;after&#160;you&#160;take&#160;it&#160;(see&#160;also&#160;section&#160;3, ‘How&#160;to&#160;</p>
<p style="position:absolute;top:780px;left:139px;white-space:nowrap" class="ft422">take&#160;Dovato’)&#160;</p>
<p style="position:absolute;top:800px;left:112px;white-space:nowrap" class="ft429">•</p>
<p style="position:absolute;top:800px;left:120px;white-space:nowrap" class="ft4224">&#160;&#160;supplements&#160;or&#160;multivitamins&#160;containing&#160;calcium,&#160;iron or&#160;magnesium.</p>
<p style="position:absolute;top:800px;left:602px;white-space:nowrap" class="ft421"><b>&#160;If&#160;you&#160;take&#160;Dovato with&#160;</b></p>
<p style="position:absolute;top:818px;left:139px;white-space:nowrap" class="ft421"><b>food,&#160;</b>you&#160;can&#160;take&#160;supplements&#160;or&#160;multivitamins&#160;containing&#160;calcium,&#160;iron&#160;or&#160;magnesium at&#160;the&#160;same&#160;</p>
<p style="position:absolute;top:837px;left:139px;white-space:nowrap" class="ft422">time&#160;as&#160;Dovato.&#160;</p>
<p style="position:absolute;top:837px;left:247px;white-space:nowrap" class="ft421"><b>If&#160;you&#160;do&#160;not&#160;take&#160;Dovato&#160;with&#160;food,&#160;do not&#160;take&#160;a&#160;supplement&#160;or&#160;multivitamin&#160;</b></p>
<p style="position:absolute;top:856px;left:139px;white-space:nowrap" class="ft421"><b>containing calcium, iron&#160;or&#160;magnesium&#160;</b>during the&#160;6&#160;hours&#160;before&#160;you&#160;take&#160;Dovato,&#160;or&#160;for&#160;at&#160;least&#160;</p>
<p style="position:absolute;top:875px;left:139px;white-space:nowrap" class="ft422">2&#160;hours&#160;after&#160;you&#160;take&#160;it&#160;(see also&#160;section 3,<i>&#160;</i>‘How&#160;to take&#160;Dovato’)&#160;</p>
<p style="position:absolute;top:896px;left:112px;white-space:nowrap" class="ft429">•</p>
<p style="position:absolute;top:896px;left:119px;white-space:nowrap" class="ft4224">&#160;&#160;emtricitabine,&#160;etravirine,&#160;efavirenz,&#160;nevirapine&#160;or&#160;tipranavir/ritonavir, to&#160;treat&#160;</p>
<p style="position:absolute;top:896px;left:651px;white-space:nowrap" class="ft421"><b>HIV&#160;infection</b>&#160;</p>
<p style="position:absolute;top:917px;left:112px;white-space:nowrap" class="ft429">•</p>
<p style="position:absolute;top:916px;left:120px;white-space:nowrap" class="ft4224">&#160;&#160;medicines&#160;(usually&#160;liquids)&#160;containing sorbitol&#160;and other&#160;sugar&#160;alcohols&#160;(such&#160;as&#160;xylitol, mannitol,&#160;</p>
<p style="position:absolute;top:935px;left:139px;white-space:nowrap" class="ft422">lactitol&#160;or&#160;maltitol),&#160;if&#160;taken&#160;regularly&#160;</p>
<p style="position:absolute;top:956px;left:112px;white-space:nowrap" class="ft429">•</p>
<p style="position:absolute;top:955px;left:120px;white-space:nowrap" class="ft4224">&#160;&#160;cladribine,&#160;to&#160;treat&#160;</p>
<p style="position:absolute;top:955px;left:264px;white-space:nowrap" class="ft421"><b>leukaemia</b>&#160;or&#160;<b>multiple sclerosis</b>&#160;&#160;</p>
<p style="position:absolute;top:976px;left:112px;white-space:nowrap" class="ft429">•</p>
<p style="position:absolute;top:975px;left:120px;white-space:nowrap" class="ft4224">&#160;&#160;rifampicin, to treat&#160;tuberculosis&#160;(TB)&#160;and&#160;other&#160;</p>
<p style="position:absolute;top:975px;left:453px;white-space:nowrap" class="ft421"><b>bacterial&#160;infections&#160;</b></p>
<p style="position:absolute;top:996px;left:112px;white-space:nowrap" class="ft429">•</p>
<p style="position:absolute;top:995px;left:120px;white-space:nowrap" class="ft4224">&#160;&#160;phenytoin and&#160;phenobarbital,&#160;to treat&#160;</p>
<p style="position:absolute;top:995px;left:387px;white-space:nowrap" class="ft421"><b>epilepsy&#160;</b></p>
<p style="position:absolute;top:1016px;left:112px;white-space:nowrap" class="ft429">•</p>
<p style="position:absolute;top:1015px;left:120px;white-space:nowrap" class="ft4224">&#160;&#160;oxcarbazepine and&#160;carbamazepine,&#160;to&#160;treat&#160;</p>
<p style="position:absolute;top:1015px;left:424px;white-space:nowrap" class="ft421"><b>epilepsy&#160;</b>or&#160;<b>bipolar&#160;disorder&#160;</b></p>
<p style="position:absolute;top:1036px;left:112px;white-space:nowrap" class="ft429">•</p>
<p style="position:absolute;top:1036px;left:119px;white-space:nowrap" class="ft4224">&#160;</p>
<p style="position:absolute;top:1035px;left:139px;white-space:nowrap" class="ft421"><b>St.&#160;John’s&#160;wort&#160;</b>(<i>Hypericum&#160;perforatum</i>),&#160;a&#160;herbal&#160;remedy to treat&#160;<b>depression.</b>&#160;</p>
<p style="position:absolute;top:1064px;left:85px;white-space:nowrap" class="ft422">&#160;</p>
<p style="position:absolute;top:1064px;left:112px;white-space:nowrap" class="ft429">→</p>
<p style="position:absolute;top:1064px;left:128px;white-space:nowrap" class="ft422">&#160;</p>
<p style="position:absolute;top:1064px;left:132px;white-space:nowrap" class="ft421"><b>Tell&#160;your doctor or pharmacist</b>&#160;if&#160;you are&#160;taking&#160;any of&#160;these. Your&#160;doctor&#160;may&#160;decide&#160;to&#160;adjust&#160;</p>
<p style="position:absolute;top:1083px;left:112px;white-space:nowrap" class="ft422">your&#160;dose&#160;or&#160;that&#160;you need&#160;extra&#160;check ups.&#160;</p>
<p style="position:absolute;top:1103px;left:85px;white-space:nowrap" class="ft422">&#160;</p>
<p style="position:absolute;top:1121px;left:85px;white-space:nowrap" class="ft421"><b>Pregnancy&#160;&#160;</b></p>
<p style="position:absolute;top:1141px;left:85px;white-space:nowrap" class="ft422">If&#160;you are&#160;pregnant,&#160;think you may be&#160;pregnant, or&#160;if&#160;you are&#160;planning to have&#160;a&#160;baby:&#160;&#160;</p>
</div>
<!-- Page 43 -->
<a name="43"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page43-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1191px;left:436px;white-space:nowrap" class="ft430">43&#160;</p>
<p style="position:absolute;top:83px;left:85px;white-space:nowrap" class="ft431"><b>&#160;</b></p>
<p style="position:absolute;top:84px;left:127px;white-space:nowrap" class="ft439">→</p>
<p style="position:absolute;top:83px;left:144px;white-space:nowrap" class="ft431"><b>&#160;Talk&#160;to your&#160;doctor&#160;</b>about&#160;the&#160;risks&#160;and benefits&#160;of&#160;taking Dovato<b>.&#160;</b>&#160;</p>
<p style="position:absolute;top:103px;left:85px;white-space:nowrap" class="ft432">&#160;</p>
<p style="position:absolute;top:122px;left:85px;white-space:nowrap" class="ft432">Taking&#160;Dovato&#160;at&#160;the&#160;time&#160;of&#160;becoming pregnant&#160;or&#160;during&#160;the&#160;first&#160;six&#160;weeks&#160;of&#160;pregnancy, may increase&#160;the&#160;</p>
<p style="position:absolute;top:141px;left:85px;white-space:nowrap" class="ft432">risk&#160;of&#160;a&#160;birth defect, called&#160;neural&#160;tube&#160;defect, such as&#160;spina&#160;bifida&#160;(malformed&#160;spinal&#160;cord).&#160;</p>
<p style="position:absolute;top:160px;left:85px;white-space:nowrap" class="ft432">&#160;</p>
<p style="position:absolute;top:179px;left:85px;white-space:nowrap" class="ft432">If&#160;you could get&#160;pregnant&#160;while&#160;taking&#160;Dovato:&#160;</p>
<p style="position:absolute;top:199px;left:85px;white-space:nowrap" class="ft432">&#160;</p>
<p style="position:absolute;top:200px;left:139px;white-space:nowrap" class="ft439">→</p>
<p style="position:absolute;top:199px;left:155px;white-space:nowrap" class="ft431"><b>&#160;Talk&#160;to your&#160;doctor</b>&#160;and discuss&#160;whether&#160;there&#160;is&#160;a&#160;need&#160;for&#160;contraception, such as&#160;condom&#160;or&#160;</p>
<p style="position:absolute;top:218px;left:85px;white-space:nowrap" class="ft432">pills.&#160;</p>
<p style="position:absolute;top:237px;left:85px;white-space:nowrap" class="ft432">&#160;</p>
<p style="position:absolute;top:256px;left:85px;white-space:nowrap" class="ft432">Tell&#160;your&#160;doctor&#160;immediately&#160;if&#160;you become&#160;pregnant&#160;or&#160;are&#160;planning to&#160;become&#160;pregnant.&#160;Your&#160;doctor&#160;will&#160;</p>
<p style="position:absolute;top:275px;left:85px;white-space:nowrap" class="ft432">review&#160;your&#160;treatment. Do&#160;not&#160;stop taking&#160;Dovato&#160;without&#160;consulting your&#160;doctor, as&#160;this&#160;may harm&#160;you and&#160;</p>
<p style="position:absolute;top:294px;left:85px;white-space:nowrap" class="ft432">your&#160;unborn child.&#160;&#160;</p>
<p style="position:absolute;top:313px;left:85px;white-space:nowrap" class="ft431"><b>&#160;</b></p>
<p style="position:absolute;top:333px;left:85px;white-space:nowrap" class="ft431"><b>Breast-feeding&#160;&#160;</b></p>
<p style="position:absolute;top:352px;left:85px;white-space:nowrap" class="ft432">Breast-feeding is&#160;</p>
<p style="position:absolute;top:352px;left:202px;white-space:nowrap" class="ft431"><b>not&#160;recommended</b>&#160;in women&#160;living&#160;with&#160;HIV&#160;because&#160;HIV&#160;infection can be&#160;passed on to&#160;</p>
<p style="position:absolute;top:372px;left:85px;white-space:nowrap" class="ft432">the&#160;baby in breast&#160;milk.&#160;&#160;</p>
<p style="position:absolute;top:391px;left:85px;white-space:nowrap" class="ft432">&#160;</p>
<p style="position:absolute;top:411px;left:85px;white-space:nowrap" class="ft432">A&#160;small amount of&#160;the&#160;ingredients&#160;in&#160;Dovato&#160;can also pass&#160;into&#160;your&#160;breast&#160;milk.&#160;&#160;</p>
<p style="position:absolute;top:430px;left:85px;white-space:nowrap" class="ft432">&#160;</p>
<p style="position:absolute;top:450px;left:85px;white-space:nowrap" class="ft432">If&#160;you are&#160;breast-feeding, or&#160;thinking about&#160;breast-feeding, you should&#160;</p>
<p style="position:absolute;top:450px;left:554px;white-space:nowrap" class="ft431"><b>discuss it&#160;with&#160;your&#160;doctor&#160;as&#160;soon&#160;</b></p>
<p style="position:absolute;top:469px;left:85px;white-space:nowrap" class="ft431"><b>as&#160;possible.&#160;</b>&#160;</p>
<p style="position:absolute;top:489px;left:85px;white-space:nowrap" class="ft431"><b>&#160;</b></p>
<p style="position:absolute;top:489px;left:127px;white-space:nowrap" class="ft431"><b>&#160;&#160;</b></p>
<p style="position:absolute;top:508px;left:85px;white-space:nowrap" class="ft432">&#160;</p>
<p style="position:absolute;top:527px;left:85px;white-space:nowrap" class="ft431"><b>Driving and&#160;using&#160;machines&#160;</b>&#160;</p>
<p style="position:absolute;top:547px;left:85px;white-space:nowrap" class="ft432">Dovato&#160;can&#160;make you&#160;dizzy,&#160;and&#160;have other&#160;side effects&#160;that&#160;make you&#160;less&#160;alert.&#160;</p>
<p style="position:absolute;top:567px;left:85px;white-space:nowrap" class="ft432">&#160;</p>
<p style="position:absolute;top:567px;left:127px;white-space:nowrap" class="ft439">→</p>
<p style="position:absolute;top:567px;left:144px;white-space:nowrap" class="ft432">&#160;Don’t&#160;drive&#160;or&#160;operate&#160;machinery unless&#160;you are&#160;sure&#160;you’re&#160;not&#160;affected.&#160;&#160;</p>
<p style="position:absolute;top:586px;left:85px;white-space:nowrap" class="ft432">&#160;</p>
<p style="position:absolute;top:604px;left:85px;white-space:nowrap" class="ft432">&#160;</p>
<p style="position:absolute;top:623px;left:85px;white-space:nowrap" class="ft431"><b>3.&#160;</b></p>
<p style="position:absolute;top:623px;left:127px;white-space:nowrap" class="ft431"><b>How&#160;to take&#160;Dovato&#160;</b></p>
<p style="position:absolute;top:642px;left:85px;white-space:nowrap" class="ft432">&#160;</p>
<p style="position:absolute;top:662px;left:85px;white-space:nowrap" class="ft432">Always take&#160;this&#160;medicine&#160;exactly&#160;as&#160;your&#160;doctor&#160;has&#160;told you. Check with&#160;your&#160;doctor&#160;or&#160;pharmacist&#160;if&#160;you&#160;</p>
<p style="position:absolute;top:680px;left:85px;white-space:nowrap" class="ft432">are not&#160;sure.&#160;</p>
<p style="position:absolute;top:699px;left:85px;white-space:nowrap" class="ft432">&#160;</p>
<p style="position:absolute;top:720px;left:112px;white-space:nowrap" class="ft439">•</p>
<p style="position:absolute;top:720px;left:120px;white-space:nowrap" class="ft4324">&#160;&#160;The&#160;recommended&#160;dose&#160;of&#160;Dovato&#160;is</p>
<p style="position:absolute;top:720px;left:383px;white-space:nowrap" class="ft431"><b>&#160;one&#160;tablet&#160;once&#160;a day.</b>&#160;</p>
<p style="position:absolute;top:739px;left:85px;white-space:nowrap" class="ft432">&#160;</p>
<p style="position:absolute;top:758px;left:85px;white-space:nowrap" class="ft432">Swallow&#160;the&#160;tablet&#160;with&#160;some&#160;liquid.&#160;Dovato&#160;can be&#160;taken&#160;with or&#160;without&#160;food.&#160;</p>
<p style="position:absolute;top:778px;left:85px;white-space:nowrap" class="ft432">&#160;</p>
<p style="position:absolute;top:797px;left:85px;white-space:nowrap" class="ft431"><b>Use in&#160;adolescents&#160;</b></p>
<p style="position:absolute;top:816px;left:85px;white-space:nowrap" class="ft432">Adolescents&#160;aged between&#160;12 and 17&#160;years&#160;and&#160;weighing&#160;at&#160;least&#160;40&#160;kg&#160;can&#160;take the&#160;adult&#160;dose&#160;of&#160;one&#160;tablet&#160;</p>
<p style="position:absolute;top:835px;left:85px;white-space:nowrap" class="ft432">once&#160;a&#160;day.&#160;</p>
<p style="position:absolute;top:854px;left:85px;white-space:nowrap" class="ft432">&#160;</p>
<p style="position:absolute;top:873px;left:85px;white-space:nowrap" class="ft431"><b>Antacid medicines&#160;</b></p>
<p style="position:absolute;top:892px;left:85px;white-space:nowrap" class="ft432">Antacids,&#160;to&#160;treat&#160;indigestion and heartburn, can stop&#160;Dovato&#160;being&#160;absorbed into your&#160;body&#160;and make&#160;it&#160;less&#160;</p>
<p style="position:absolute;top:911px;left:85px;white-space:nowrap" class="ft432">effective.&#160;</p>
<p style="position:absolute;top:930px;left:85px;white-space:nowrap" class="ft432">Do not&#160;take&#160;an antacid during the&#160;6&#160;hours&#160;before&#160;you take&#160;Dovato,&#160;or&#160;for&#160;at&#160;least&#160;2&#160;hours&#160;after&#160;you take&#160;it.&#160;</p>
<p style="position:absolute;top:949px;left:85px;white-space:nowrap" class="ft432">You&#160;can take&#160;other&#160;acid-lowering&#160;medicines like&#160;ranitidine and&#160;omeprazole at&#160;the&#160;same time as&#160;Dovato.&#160;</p>
<p style="position:absolute;top:969px;left:85px;white-space:nowrap" class="ft432">&#160;</p>
<p style="position:absolute;top:970px;left:127px;white-space:nowrap" class="ft439">→</p>
<p style="position:absolute;top:969px;left:144px;white-space:nowrap" class="ft432">&#160;Talk&#160;to your&#160;doctor&#160;for&#160;further&#160;advice&#160;on taking acid-lowering&#160;medicines with&#160;Dovato.&#160;</p>
<p style="position:absolute;top:989px;left:85px;white-space:nowrap" class="ft432">&#160;</p>
<p style="position:absolute;top:1007px;left:85px;white-space:nowrap" class="ft431"><b>Supplements&#160;or&#160;multivitamins&#160;containing calcium,&#160;iron&#160;or&#160;magnesium&#160;</b></p>
<p style="position:absolute;top:1026px;left:85px;white-space:nowrap" class="ft432">Supplements&#160;or&#160;multivitamins&#160;containing calcium, iron&#160;or&#160;magnesium&#160;can stop&#160;Dovato&#160;being absorbed into&#160;</p>
<p style="position:absolute;top:1045px;left:85px;white-space:nowrap" class="ft432">your&#160;body&#160;and make&#160;it&#160;less&#160;effective.&#160;</p>
<p style="position:absolute;top:1064px;left:85px;white-space:nowrap" class="ft432">If&#160;you take&#160;Dovato with&#160;food, you can take&#160;supplements&#160;or&#160;multivitamins&#160;containing calcium,&#160;iron or&#160;</p>
<p style="position:absolute;top:1083px;left:85px;white-space:nowrap" class="ft432">magnesium&#160;at&#160;the&#160;same&#160;time&#160;as&#160;Dovato.&#160;If&#160;you&#160;do not&#160;take&#160;Dovato&#160;with food,&#160;do&#160;not&#160;take a&#160;supplement&#160;or&#160;</p>
<p style="position:absolute;top:1102px;left:85px;white-space:nowrap" class="ft432">multivitamin&#160;containing&#160;calcium, iron or&#160;magnesium&#160;during the&#160;6&#160;hours&#160;before&#160;you&#160;take&#160;Dovato,&#160;or for at&#160;</p>
<p style="position:absolute;top:1121px;left:85px;white-space:nowrap" class="ft432">least&#160;2&#160;hours&#160;after&#160;you take&#160;it.&#160;</p>
</div>
<!-- Page 44 -->
<a name="44"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page44-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1191px;left:436px;white-space:nowrap" class="ft440">44&#160;</p>
<p style="position:absolute;top:84px;left:85px;white-space:nowrap" class="ft442">&#160;</p>
<p style="position:absolute;top:85px;left:139px;white-space:nowrap" class="ft449">→</p>
<p style="position:absolute;top:84px;left:155px;white-space:nowrap" class="ft442">&#160;Talk&#160;to your&#160;doctor&#160;for&#160;further&#160;advice&#160;on taking&#160;supplements&#160;or&#160;multivitamins&#160;containing calcium,&#160;</p>
<p style="position:absolute;top:103px;left:85px;white-space:nowrap" class="ft442">iron or&#160;magnesium&#160;with&#160;Dovato.&#160;</p>
<p style="position:absolute;top:122px;left:85px;white-space:nowrap" class="ft442">&#160;</p>
<p style="position:absolute;top:141px;left:85px;white-space:nowrap" class="ft441"><b>If&#160;you&#160;take&#160;more&#160;Dovato&#160;than you should&#160;</b>&#160;</p>
<p style="position:absolute;top:160px;left:85px;white-space:nowrap" class="ft442">If&#160;you&#160;take&#160;too many tablets&#160;of&#160;Dovato&#160;</p>
<p style="position:absolute;top:160px;left:344px;white-space:nowrap" class="ft441"><b>contact&#160;your doctor&#160;or pharmacist&#160;for&#160;advice.</b>&#160;If&#160;possible, show&#160;</p>
<p style="position:absolute;top:179px;left:85px;white-space:nowrap" class="ft442">them the&#160;Dovato&#160;pack.&#160;&#160;</p>
<p style="position:absolute;top:198px;left:85px;white-space:nowrap" class="ft442">&#160;</p>
<p style="position:absolute;top:217px;left:85px;white-space:nowrap" class="ft441"><b>If&#160;you&#160;forget&#160;to&#160;take&#160;Dovato&#160;</b>&#160;</p>
<p style="position:absolute;top:236px;left:85px;white-space:nowrap" class="ft442">If&#160;you miss&#160;a&#160;dose,&#160;take&#160;it&#160;as&#160;soon&#160;as&#160;you remember. But&#160;if&#160;your&#160;next&#160;dose&#160;is&#160;due&#160;within 4 hours,&#160;skip&#160;the&#160;</p>
<p style="position:absolute;top:255px;left:85px;white-space:nowrap" class="ft442">dose&#160;you missed and take&#160;the&#160;next&#160;one&#160;at&#160;the&#160;usual&#160;time. Then&#160;continue&#160;your&#160;treatment&#160;as&#160;before.&#160;</p>
<p style="position:absolute;top:275px;left:85px;white-space:nowrap" class="ft442">&#160;</p>
<p style="position:absolute;top:276px;left:139px;white-space:nowrap" class="ft449">→</p>
<p style="position:absolute;top:275px;left:155px;white-space:nowrap" class="ft441"><b>Do&#160;not&#160;take&#160;a&#160;double&#160;dose</b>&#160;to make&#160;up for&#160;a&#160;forgotten&#160;dose.&#160;</p>
<p style="position:absolute;top:294px;left:85px;white-space:nowrap" class="ft442">&#160;</p>
<p style="position:absolute;top:313px;left:85px;white-space:nowrap" class="ft441"><b>Don’t&#160;stop taking&#160;Dovato&#160;without&#160;advice&#160;from&#160;your&#160;doctor&#160;&#160;</b></p>
<p style="position:absolute;top:333px;left:85px;white-space:nowrap" class="ft442">Take&#160;Dovato&#160;for&#160;as long as&#160;your&#160;doctor&#160;recommends.&#160;Don’t&#160;stop unless&#160;your&#160;doctor&#160;tells&#160;you to.&#160;Stopping&#160;</p>
<p style="position:absolute;top:352px;left:85px;white-space:nowrap" class="ft442">Dovato&#160;can affect&#160;your&#160;health and&#160;how&#160;future&#160;treatment&#160;works.&#160;</p>
<p style="position:absolute;top:371px;left:85px;white-space:nowrap" class="ft442">&#160;</p>
<p style="position:absolute;top:390px;left:85px;white-space:nowrap" class="ft442">If&#160;you have&#160;any&#160;further&#160;questions&#160;on&#160;the&#160;use&#160;of&#160;this&#160;medicine, ask your&#160;doctor&#160;or&#160;pharmacist.&#160;</p>
<p style="position:absolute;top:409px;left:85px;white-space:nowrap" class="ft442">&#160;</p>
<p style="position:absolute;top:428px;left:85px;white-space:nowrap" class="ft442">&#160;</p>
<p style="position:absolute;top:447px;left:85px;white-space:nowrap" class="ft441"><b>4.&#160;</b></p>
<p style="position:absolute;top:447px;left:128px;white-space:nowrap" class="ft441"><b>Possible side&#160;effects&#160;&#160;</b>&#160;</p>
<p style="position:absolute;top:466px;left:85px;white-space:nowrap" class="ft442">&#160;</p>
<p style="position:absolute;top:485px;left:85px;white-space:nowrap" class="ft442">Like all&#160;medicines,&#160;this&#160;medicine&#160;can cause&#160;side&#160;effects, although not&#160;everybody gets&#160;them,&#160;</p>
<p style="position:absolute;top:485px;left:691px;white-space:nowrap" class="ft441"><b>so&#160;it&#160;is&#160;very&#160;</b></p>
<p style="position:absolute;top:504px;left:85px;white-space:nowrap" class="ft441"><b>important to&#160;talk&#160;to&#160;your&#160;doctor&#160;about&#160;any changes&#160;in&#160;your&#160;health</b>.&#160;</p>
<p style="position:absolute;top:523px;left:85px;white-space:nowrap" class="ft442">&#160;</p>
<p style="position:absolute;top:542px;left:85px;white-space:nowrap" class="ft441"><b>Allergic&#160;reactions&#160;</b></p>
<p style="position:absolute;top:562px;left:85px;white-space:nowrap" class="ft442">Dovato&#160;contains&#160;dolutegravir.&#160;Dolutegravir&#160;can&#160;cause&#160;a&#160;serious&#160;allergic reaction&#160;known&#160;as a&#160;<i>hypersensitivity&#160;</i></p>
<p style="position:absolute;top:582px;left:85px;white-space:nowrap" class="ft445"><i>reaction</i>.&#160;This&#160;is&#160;an uncommon&#160;reaction&#160;(may affect&#160;up to 1&#160;in 100 people)&#160;in&#160;people&#160;taking&#160;dolutegravir.&#160;If&#160;</p>
<p style="position:absolute;top:601px;left:85px;white-space:nowrap" class="ft442">you&#160;get&#160;any of&#160;the&#160;following&#160;symptoms:&#160;</p>
<p style="position:absolute;top:621px;left:112px;white-space:nowrap" class="ft449">•</p>
<p style="position:absolute;top:620px;left:120px;white-space:nowrap" class="ft4424">&#160;&#160;skin rash&#160;</p>
<p style="position:absolute;top:640px;left:112px;white-space:nowrap" class="ft449">•</p>
<p style="position:absolute;top:640px;left:120px;white-space:nowrap" class="ft4424">&#160;&#160;a&#160;high&#160;temperature&#160;(<i>fever</i>)&#160;</p>
<p style="position:absolute;top:660px;left:112px;white-space:nowrap" class="ft449">•</p>
<p style="position:absolute;top:659px;left:120px;white-space:nowrap" class="ft4424">&#160;&#160;lack&#160;of&#160;energy (<i>fatigue</i>)&#160;</p>
<p style="position:absolute;top:679px;left:112px;white-space:nowrap" class="ft449">•</p>
<p style="position:absolute;top:679px;left:120px;white-space:nowrap" class="ft4424">&#160;&#160;swelling,&#160;sometimes of&#160;the face or&#160;mouth&#160;(<i>angioedema</i>), causing difficulty in&#160;breathing&#160;</p>
<p style="position:absolute;top:699px;left:112px;white-space:nowrap" class="ft449">•</p>
<p style="position:absolute;top:698px;left:120px;white-space:nowrap" class="ft4424">&#160;&#160;muscle&#160;or&#160;joint&#160;aches.&#160;</p>
<p style="position:absolute;top:718px;left:112px;white-space:nowrap" class="ft449">→</p>
<p style="position:absolute;top:718px;left:128px;white-space:nowrap" class="ft441"><b>&#160;See&#160;a&#160;doctor&#160;straight&#160;away.&#160;</b>Your&#160;doctor&#160;may decide&#160;to&#160;carry out&#160;tests&#160;to check your&#160;liver,&#160;kidneys&#160;or&#160;</p>
<p style="position:absolute;top:737px;left:112px;white-space:nowrap" class="ft442">blood,&#160;and&#160;may&#160;tell&#160;you to stop taking&#160;Dovato.</p>
<p style="position:absolute;top:737px;left:419px;white-space:nowrap" class="ft441"><b>&#160;</b></p>
<p style="position:absolute;top:757px;left:85px;white-space:nowrap" class="ft442">&#160;</p>
<p style="position:absolute;top:776px;left:85px;white-space:nowrap" class="ft441"><b>Very&#160;common&#160;side&#160;effects</b>&#160;&#160;</p>
<p style="position:absolute;top:795px;left:85px;white-space:nowrap" class="ft442">These may&#160;affect&#160;</p>
<p style="position:absolute;top:795px;left:203px;white-space:nowrap" class="ft441"><b>more&#160;than&#160;1 in&#160;10&#160;</b>people:&#160;</p>
<p style="position:absolute;top:816px;left:112px;white-space:nowrap" class="ft449">•</p>
<p style="position:absolute;top:815px;left:120px;white-space:nowrap" class="ft4424">&#160;&#160;headache&#160;</p>
<p style="position:absolute;top:836px;left:112px;white-space:nowrap" class="ft449">•</p>
<p style="position:absolute;top:835px;left:120px;white-space:nowrap" class="ft4424">&#160;&#160;diarrhoea&#160;</p>
<p style="position:absolute;top:856px;left:112px;white-space:nowrap" class="ft449">•</p>
<p style="position:absolute;top:855px;left:120px;white-space:nowrap" class="ft4424">&#160;&#160;feeling&#160;sick&#160;(<i>nausea</i>).&#160;&#160;</p>
<p style="position:absolute;top:874px;left:85px;white-space:nowrap" class="ft442">&#160;</p>
<p style="position:absolute;top:893px;left:85px;white-space:nowrap" class="ft441"><b>Common&#160;side&#160;effects</b>&#160;&#160;</p>
<p style="position:absolute;top:913px;left:85px;white-space:nowrap" class="ft442">These may&#160;affect&#160;</p>
<p style="position:absolute;top:913px;left:203px;white-space:nowrap" class="ft441"><b>up&#160;to&#160;1 in&#160;10</b>&#160;people:&#160;</p>
<p style="position:absolute;top:934px;left:112px;white-space:nowrap" class="ft449">•</p>
<p style="position:absolute;top:934px;left:120px;white-space:nowrap" class="ft4424">&#160;&#160;depression&#160;(feelings&#160;of&#160;deep sadness&#160;and unworthiness)&#160;</p>
<p style="position:absolute;top:953px;left:112px;white-space:nowrap" class="ft449">•</p>
<p style="position:absolute;top:953px;left:120px;white-space:nowrap" class="ft4424">&#160;&#160;rash&#160;</p>
<p style="position:absolute;top:974px;left:112px;white-space:nowrap" class="ft449">•</p>
<p style="position:absolute;top:973px;left:120px;white-space:nowrap" class="ft4424">&#160;&#160;itching (<i>pruritus</i>)&#160;</p>
<p style="position:absolute;top:994px;left:112px;white-space:nowrap" class="ft449">•</p>
<p style="position:absolute;top:993px;left:120px;white-space:nowrap" class="ft4424">&#160;&#160;being sick&#160;(<i>vomiting</i>)&#160;</p>
<p style="position:absolute;top:1014px;left:112px;white-space:nowrap" class="ft449">•</p>
<p style="position:absolute;top:1013px;left:120px;white-space:nowrap" class="ft4424">&#160;&#160;stomach&#160;(<i>abdominal</i>)&#160;pain or&#160;discomfort&#160;</p>
<p style="position:absolute;top:1034px;left:112px;white-space:nowrap" class="ft449">•</p>
<p style="position:absolute;top:1034px;left:120px;white-space:nowrap" class="ft4424">&#160;&#160;weight&#160;gain&#160;</p>
<p style="position:absolute;top:1054px;left:112px;white-space:nowrap" class="ft449">•</p>
<p style="position:absolute;top:1054px;left:120px;white-space:nowrap" class="ft4424">&#160;&#160;wind (<i>flatulence</i>)&#160;</p>
<p style="position:absolute;top:1074px;left:112px;white-space:nowrap" class="ft449">•</p>
<p style="position:absolute;top:1074px;left:120px;white-space:nowrap" class="ft4424">&#160;&#160;dizziness&#160;</p>
<p style="position:absolute;top:1095px;left:112px;white-space:nowrap" class="ft449">•</p>
<p style="position:absolute;top:1094px;left:120px;white-space:nowrap" class="ft4424">&#160;&#160;feeling&#160;drowsy&#160;</p>
<p style="position:absolute;top:1115px;left:112px;white-space:nowrap" class="ft449">•</p>
<p style="position:absolute;top:1114px;left:120px;white-space:nowrap" class="ft4424">&#160;&#160;difficulty sleeping&#160;(<i>insomnia</i>)&#160;</p>
<p style="position:absolute;top:1135px;left:112px;white-space:nowrap" class="ft449">•</p>
<p style="position:absolute;top:1134px;left:120px;white-space:nowrap" class="ft4424">&#160;&#160;abnormal&#160;dreams&#160;</p>
<p style="position:absolute;top:1155px;left:112px;white-space:nowrap" class="ft449">•</p>
<p style="position:absolute;top:1155px;left:120px;white-space:nowrap" class="ft4424">&#160;&#160;lack&#160;of&#160;energy (<i>fatigue</i>)&#160;</p>
</div>
<!-- Page 45 -->
<a name="45"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft4532{font-size:17px;font-family:IJFECY+MS-Gothic;color:#000000;}
	.ft4533{font-size:17px;line-height:16px;font-family:IJFECY+MS-Gothic;color:#000000;}
	.ft4534{font-size:17px;line-height:17px;font-family:IJFECY+MS-Gothic;color:#000000;}
	.ft4535{font-size:17px;line-height:28px;font-family:PVDJWK+TimesNewRomanPS;color:#000000;}
-->
</style>
<div id="page45-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1191px;left:436px;white-space:nowrap" class="ft450">45&#160;</p>
<p style="position:absolute;top:85px;left:112px;white-space:nowrap" class="ft459">•</p>
<p style="position:absolute;top:84px;left:120px;white-space:nowrap" class="ft4524">&#160;&#160;hair&#160;loss&#160;</p>
<p style="position:absolute;top:105px;left:112px;white-space:nowrap" class="ft459">•</p>
<p style="position:absolute;top:104px;left:120px;white-space:nowrap" class="ft4524">&#160;&#160;anxiety&#160;</p>
<p style="position:absolute;top:125px;left:112px;white-space:nowrap" class="ft459">•</p>
<p style="position:absolute;top:125px;left:120px;white-space:nowrap" class="ft4524">&#160;&#160;joint pain&#160;</p>
<p style="position:absolute;top:145px;left:112px;white-space:nowrap" class="ft459">•</p>
<p style="position:absolute;top:145px;left:120px;white-space:nowrap" class="ft4524">&#160;&#160;muscle pain.&#160;</p>
<p style="position:absolute;top:164px;left:85px;white-space:nowrap" class="ft452">&#160;</p>
<p style="position:absolute;top:183px;left:85px;white-space:nowrap" class="ft452">Common&#160;side&#160;effects&#160;that&#160;may show&#160;up in&#160;blood tests&#160;are:&#160;</p>
<p style="position:absolute;top:203px;left:112px;white-space:nowrap" class="ft459">•</p>
<p style="position:absolute;top:203px;left:120px;white-space:nowrap" class="ft4524">&#160;&#160;increase in&#160;the level&#160;of&#160;liver&#160;enzymes&#160;(<i>aminotransferases</i>)&#160;</p>
<p style="position:absolute;top:224px;left:112px;white-space:nowrap" class="ft459">•</p>
<p style="position:absolute;top:223px;left:120px;white-space:nowrap" class="ft4524">&#160;&#160;increase in&#160;the level&#160;of&#160;enzymes&#160;produced&#160;in&#160;the&#160;muscles&#160;(<i>creatine&#160;phosphokinase</i>).&#160;</p>
<p style="position:absolute;top:242px;left:139px;white-space:nowrap" class="ft452">&#160;</p>
<p style="position:absolute;top:261px;left:85px;white-space:nowrap" class="ft451"><b>Uncommon&#160;side effects</b>&#160;&#160;</p>
<p style="position:absolute;top:281px;left:85px;white-space:nowrap" class="ft452">These may&#160;affect&#160;</p>
<p style="position:absolute;top:281px;left:203px;white-space:nowrap" class="ft451"><b>up&#160;to&#160;1 in&#160;100&#160;</b>people:&#160;</p>
<p style="position:absolute;top:302px;left:112px;white-space:nowrap" class="ft459">•</p>
<p style="position:absolute;top:301px;left:120px;white-space:nowrap" class="ft4524">&#160;&#160;inflammation&#160;of&#160;the&#160;liver&#160;(<i>hepatitis</i>)&#160;</p>
<p style="position:absolute;top:322px;left:112px;white-space:nowrap" class="ft459">•</p>
<p style="position:absolute;top:321px;left:120px;white-space:nowrap" class="ft4524">&#160;&#160;suicidal attempt&#160;(particularly&#160;in&#160;patients&#160;who&#160;have&#160;had&#160;depression or&#160;mental&#160;health&#160;problems&#160;before)&#160;</p>
<p style="position:absolute;top:342px;left:112px;white-space:nowrap" class="ft459">•</p>
<p style="position:absolute;top:341px;left:120px;white-space:nowrap" class="ft4524">&#160;&#160;suicidal&#160;thoughts&#160;(particularly&#160;in patients&#160;who have&#160;had depression or&#160;mental&#160;health problems&#160;before).&#160;</p>
<p style="position:absolute;top:362px;left:112px;white-space:nowrap" class="ft459">•</p>
<p style="position:absolute;top:362px;left:120px;white-space:nowrap" class="ft4524">&#160;&#160;panic&#160;attack&#160;</p>
<p style="position:absolute;top:385px;left:85px;white-space:nowrap" class="ft4533">&#160;<br/>Uncommon&#160;side&#160;effects&#160;that&#160;may show&#160;up in&#160;blood tests&#160;are:&#160;</p>
<p style="position:absolute;top:423px;left:112px;white-space:nowrap" class="ft459">•</p>
<p style="position:absolute;top:422px;left:120px;white-space:nowrap" class="ft4524">&#160;&#160;a decreased&#160;number&#160;of&#160;cells&#160;involved&#160;in blood clotting (<i>thrombocytopenia</i>)&#160;</p>
<p style="position:absolute;top:443px;left:112px;white-space:nowrap" class="ft459">•</p>
<p style="position:absolute;top:442px;left:120px;white-space:nowrap" class="ft4524">&#160;&#160;a&#160;low&#160;red blood&#160;cell&#160;count&#160;(<i>anaemia</i>)&#160;or&#160;low&#160;white&#160;blood cell&#160;count&#160;(<i>neutropenia</i>).&#160;</p>
<p style="position:absolute;top:466px;left:85px;white-space:nowrap" class="ft4534">&#160;<br/><b>Rare side effects</b>&#160;&#160;</p>
<p style="position:absolute;top:503px;left:85px;white-space:nowrap" class="ft452">These may&#160;affect&#160;</p>
<p style="position:absolute;top:502px;left:203px;white-space:nowrap" class="ft451"><b>up&#160;to&#160;1 in&#160;1000&#160;</b>people:&#160;</p>
<p style="position:absolute;top:524px;left:112px;white-space:nowrap" class="ft459">•</p>
<p style="position:absolute;top:523px;left:120px;white-space:nowrap" class="ft4524">&#160;&#160;liver&#160;failure&#160;(signs&#160;may&#160;include&#160;yellowing of&#160;the&#160;skin&#160;and&#160;the&#160;whites&#160;of&#160;the&#160;eyes&#160;or&#160;unusually dark&#160;</p>
<p style="position:absolute;top:542px;left:139px;white-space:nowrap" class="ft452">urine)&#160;</p>
<p style="position:absolute;top:563px;left:112px;white-space:nowrap" class="ft459">•</p>
<p style="position:absolute;top:562px;left:120px;white-space:nowrap" class="ft4524">&#160;&#160;swelling,&#160;sometimes of&#160;the face or&#160;mouth&#160;(<i>angioedema</i>), causing difficulty in&#160;breathing&#160;</p>
<p style="position:absolute;top:583px;left:112px;white-space:nowrap" class="ft459">•</p>
<p style="position:absolute;top:582px;left:120px;white-space:nowrap" class="ft4524">&#160;&#160;inflammation of&#160;the&#160;pancreas&#160;(<i>pancreatitis</i>)&#160;</p>
<p style="position:absolute;top:603px;left:112px;white-space:nowrap" class="ft459">•</p>
<p style="position:absolute;top:602px;left:120px;white-space:nowrap" class="ft4524">&#160;&#160;breakdown of&#160;muscle&#160;tissue.&#160;</p>
<p style="position:absolute;top:623px;left:112px;white-space:nowrap" class="ft459">•</p>
<p style="position:absolute;top:622px;left:120px;white-space:nowrap" class="ft4524">&#160;&#160;suicide&#160;(particularly&#160;in patients&#160;who have&#160;had&#160;depression or&#160;mental&#160;health problems&#160;before)&#160;</p>
<p style="position:absolute;top:641px;left:85px;white-space:nowrap" class="ft452">&#160;</p>
<p style="position:absolute;top:662px;left:117px;white-space:nowrap" class="ft459">→</p>
<p style="position:absolute;top:662px;left:133px;white-space:nowrap" class="ft451"><b>&#160;&#160;Tell&#160;your&#160;doctor&#160;immediately</b>&#160;if&#160;you&#160;experience any&#160;mental&#160;health&#160;problems&#160;(see&#160;also&#160;other&#160;mental&#160;</p>
<p style="position:absolute;top:681px;left:117px;white-space:nowrap" class="ft452">health problems&#160;above).&#160;</p>
<p style="position:absolute;top:704px;left:85px;white-space:nowrap" class="ft4533">&#160;<br/>Rare&#160;side&#160;effects&#160;that&#160;may show&#160;up in&#160;blood tests&#160;are:&#160;</p>
<p style="position:absolute;top:742px;left:112px;white-space:nowrap" class="ft459">•</p>
<p style="position:absolute;top:741px;left:120px;white-space:nowrap" class="ft4524">&#160;&#160;increase&#160;in bilirubin (a&#160;test&#160;of&#160;liver&#160;function)&#160;</p>
<p style="position:absolute;top:762px;left:112px;white-space:nowrap" class="ft459">•</p>
<p style="position:absolute;top:761px;left:120px;white-space:nowrap" class="ft4524">&#160;&#160;increase in&#160;an&#160;enzyme called&#160;<i>amylase</i>.&#160;</p>
<p style="position:absolute;top:785px;left:85px;white-space:nowrap" class="ft4534">&#160;<br/><b>Very&#160;rare side effects&#160;</b></p>
<p style="position:absolute;top:822px;left:85px;white-space:nowrap" class="ft452">These may&#160;affect&#160;</p>
<p style="position:absolute;top:821px;left:203px;white-space:nowrap" class="ft451"><b>up&#160;to&#160;1 in&#160;10,000&#160;</b>people:&#160;</p>
<p style="position:absolute;top:842px;left:112px;white-space:nowrap" class="ft459">•</p>
<p style="position:absolute;top:842px;left:120px;white-space:nowrap" class="ft4524">&#160;&#160;lactic acidosis&#160;(excess lactic acid&#160;in&#160;the blood)&#160;</p>
<p style="position:absolute;top:863px;left:112px;white-space:nowrap" class="ft459">•</p>
<p style="position:absolute;top:862px;left:120px;white-space:nowrap" class="ft4524">&#160;&#160;numbness,&#160;tingly feelings&#160;in the&#160;skin (pins&#160;and needles)&#160;</p>
<p style="position:absolute;top:883px;left:112px;white-space:nowrap" class="ft459">•</p>
<p style="position:absolute;top:882px;left:120px;white-space:nowrap" class="ft4524">&#160;&#160;sensation&#160;of&#160;weakness&#160;in&#160;the limbs.&#160;</p>
<p style="position:absolute;top:906px;left:85px;white-space:nowrap" class="ft4533">&#160;<br/>Very&#160;rare&#160;side&#160;effects&#160;that&#160;may&#160;show&#160;up&#160;in blood&#160;tests&#160;are:&#160;</p>
<p style="position:absolute;top:943px;left:112px;white-space:nowrap" class="ft459">•</p>
<p style="position:absolute;top:943px;left:120px;white-space:nowrap" class="ft4524">&#160;&#160;a failure of&#160;the bone&#160;marrow&#160;to&#160;produce&#160;new&#160;red&#160;blood&#160;cells&#160;(<i>pure&#160;red cell&#160;aplasia</i>).&#160;</p>
<p style="position:absolute;top:966px;left:85px;white-space:nowrap" class="ft4535">&#160;<br/><b>Other&#160;possible side effects&#160;<br/></b>People&#160;taking&#160;combination&#160;therapy&#160;for&#160;HIV&#160;may get&#160;other&#160;side&#160;effects.&#160;</p>
<p style="position:absolute;top:1031px;left:85px;white-space:nowrap" class="ft452">&#160;</p>
<p style="position:absolute;top:1051px;left:85px;white-space:nowrap" class="ft4535"><b>Symptoms&#160;of&#160;infection and inflammation&#160;&#160;<br/></b>People&#160;with advanced HIV&#160;infection or&#160;AIDS&#160;have&#160;weak immune&#160;systems, and are&#160;more&#160;likely&#160;to&#160;develop&#160;</p>
<p style="position:absolute;top:1099px;left:85px;white-space:nowrap" class="ft452">serious infections&#160;(opportunistic&#160;infections).&#160;Such infections&#160;may have&#160;been “silent”&#160;and&#160;not&#160;detected by&#160;the&#160;</p>
<p style="position:absolute;top:1118px;left:85px;white-space:nowrap" class="ft452">weak&#160;immune&#160;system&#160;before treatment&#160;was started.&#160;After&#160;starting&#160;treatment,&#160;the&#160;immune&#160;system&#160;becomes&#160;</p>
</div>
<!-- Page 46 -->
<a name="46"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page46-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1191px;left:436px;white-space:nowrap" class="ft460">46&#160;</p>
<p style="position:absolute;top:83px;left:85px;white-space:nowrap" class="ft462">stronger, and&#160;may attack the&#160;infections, which can cause&#160;symptoms&#160;of&#160;infection&#160;or&#160;inflammation.&#160;Symptoms&#160;</p>
<p style="position:absolute;top:103px;left:85px;white-space:nowrap" class="ft462">usually include&#160;fever, plus&#160;some&#160;of&#160;the&#160;following:&#160;</p>
<p style="position:absolute;top:123px;left:112px;white-space:nowrap" class="ft469">•</p>
<p style="position:absolute;top:122px;left:120px;white-space:nowrap" class="ft4624">&#160;&#160;headache&#160;</p>
<p style="position:absolute;top:142px;left:112px;white-space:nowrap" class="ft469">•</p>
<p style="position:absolute;top:142px;left:120px;white-space:nowrap" class="ft4624">&#160;&#160;stomach&#160;ache&#160;</p>
<p style="position:absolute;top:162px;left:112px;white-space:nowrap" class="ft469">•</p>
<p style="position:absolute;top:162px;left:120px;white-space:nowrap" class="ft4624">&#160;&#160;difficulty breathing.&#160;</p>
<p style="position:absolute;top:181px;left:85px;white-space:nowrap" class="ft462">In&#160;rare&#160;cases,&#160;as the immune system&#160;becomes&#160;stronger,&#160;it&#160;can&#160;also&#160;attack&#160;healthy&#160;body&#160;tissue (<i>autoimmune&#160;</i></p>
<p style="position:absolute;top:201px;left:85px;white-space:nowrap" class="ft465"><i>disorders</i>).&#160;The&#160;symptoms&#160;of&#160;autoimmune&#160;disorders&#160;may develop&#160;many&#160;months&#160;after&#160;you start&#160;taking&#160;</p>
<p style="position:absolute;top:220px;left:85px;white-space:nowrap" class="ft462">medicine&#160;to treat&#160;your&#160;HIV&#160;infection. Symptoms&#160;may&#160;include:&#160;</p>
<p style="position:absolute;top:240px;left:112px;white-space:nowrap" class="ft469">•</p>
<p style="position:absolute;top:239px;left:120px;white-space:nowrap" class="ft4624">&#160;&#160;palpitations (rapid&#160;or&#160;irregular&#160;heartbeat)&#160;or&#160;tremor&#160;</p>
<p style="position:absolute;top:259px;left:112px;white-space:nowrap" class="ft469">•</p>
<p style="position:absolute;top:259px;left:120px;white-space:nowrap" class="ft4624">&#160;&#160;hyperactivity&#160;(excessive&#160;restlessness and&#160;movement)&#160;</p>
<p style="position:absolute;top:279px;left:112px;white-space:nowrap" class="ft469">•</p>
<p style="position:absolute;top:279px;left:120px;white-space:nowrap" class="ft4624">&#160;&#160;weakness&#160;beginning in the&#160;hands&#160;and&#160;feet&#160;and moving up&#160;towards&#160;the&#160;trunk&#160;of&#160;the&#160;body.&#160;</p>
<p style="position:absolute;top:298px;left:85px;white-space:nowrap" class="ft461"><b>&#160;</b></p>
<p style="position:absolute;top:317px;left:85px;white-space:nowrap" class="ft461"><b>If you&#160;get any&#160;symptoms&#160;of infection</b>&#160;or&#160;if&#160;you notice&#160;any of&#160;the&#160;symptoms&#160;above:&#160;</p>
<p style="position:absolute;top:337px;left:85px;white-space:nowrap" class="ft461"><b>&#160;&#160;</b>→<b>&#160;Tell&#160;your&#160;doctor&#160;immediately</b>. Don’t&#160;take&#160;other&#160;medicines&#160;for&#160;the&#160;infection without&#160;your&#160;doctor’s&#160;</p>
<p style="position:absolute;top:356px;left:85px;white-space:nowrap" class="ft462">advice.&#160;</p>
<p style="position:absolute;top:376px;left:85px;white-space:nowrap" class="ft462">&#160;</p>
<p style="position:absolute;top:395px;left:85px;white-space:nowrap" class="ft4635"><b>Joint&#160;pain,&#160;stiffness&#160;and bone&#160;problems&#160;<br/></b>Some&#160;people&#160;taking combination therapy&#160;for&#160;HIV&#160;develop&#160;a&#160;condition&#160;called&#160;<i>osteonecrosis</i>.&#160;With&#160;this&#160;</p>
<p style="position:absolute;top:443px;left:85px;white-space:nowrap" class="ft462">condition, parts&#160;of&#160;the&#160;bone&#160;tissue&#160;are&#160;permanently damaged&#160;because&#160;of&#160;reduced&#160;blood&#160;supply to the&#160;bone.&#160;</p>
<p style="position:absolute;top:462px;left:85px;white-space:nowrap" class="ft462">People&#160;may be&#160;more&#160;likely&#160;to&#160;get&#160;this&#160;condition:&#160;</p>
<p style="position:absolute;top:481px;left:112px;white-space:nowrap" class="ft469">•</p>
<p style="position:absolute;top:481px;left:120px;white-space:nowrap" class="ft4624">&#160;&#160;if&#160;they&#160;have&#160;been taking combination therapy&#160;for&#160;a&#160;long&#160;time&#160;</p>
<p style="position:absolute;top:501px;left:112px;white-space:nowrap" class="ft469">•</p>
<p style="position:absolute;top:500px;left:120px;white-space:nowrap" class="ft4624">&#160;&#160;if&#160;they&#160;are&#160;also taking anti-inflammatory&#160;medicines&#160;called&#160;corticosteroids&#160;</p>
<p style="position:absolute;top:520px;left:112px;white-space:nowrap" class="ft469">•</p>
<p style="position:absolute;top:520px;left:120px;white-space:nowrap" class="ft4624">&#160;&#160;if&#160;they drink alcohol&#160;</p>
<p style="position:absolute;top:540px;left:112px;white-space:nowrap" class="ft469">•</p>
<p style="position:absolute;top:539px;left:120px;white-space:nowrap" class="ft4624">&#160;&#160;if&#160;their&#160;immune systems&#160;are&#160;very&#160;weak&#160;</p>
<p style="position:absolute;top:560px;left:112px;white-space:nowrap" class="ft469">•</p>
<p style="position:absolute;top:559px;left:120px;white-space:nowrap" class="ft4624">&#160;&#160;if&#160;they are&#160;overweight.&#160;</p>
<p style="position:absolute;top:582px;left:85px;white-space:nowrap" class="ft4633">&#160;<br/><b>Signs of&#160;osteonecrosis include:</b>&#160;</p>
<p style="position:absolute;top:619px;left:112px;white-space:nowrap" class="ft469">•</p>
<p style="position:absolute;top:619px;left:120px;white-space:nowrap" class="ft4624">&#160;&#160;stiffness&#160;in&#160;the&#160;joints&#160;</p>
<p style="position:absolute;top:639px;left:112px;white-space:nowrap" class="ft469">•</p>
<p style="position:absolute;top:638px;left:120px;white-space:nowrap" class="ft4624">&#160;&#160;aches&#160;and pains&#160;in&#160;the&#160;joints&#160;(especially&#160;in&#160;the&#160;hip, knee&#160;or&#160;shoulder)&#160;</p>
<p style="position:absolute;top:658px;left:112px;white-space:nowrap" class="ft469">•</p>
<p style="position:absolute;top:658px;left:120px;white-space:nowrap" class="ft4624">&#160;&#160;difficulty moving.&#160;</p>
<p style="position:absolute;top:677px;left:85px;white-space:nowrap" class="ft462">If&#160;you notice&#160;any&#160;of&#160;these&#160;symptoms:&#160;</p>
<p style="position:absolute;top:697px;left:85px;white-space:nowrap" class="ft461"><b>&#160;</b></p>
<p style="position:absolute;top:698px;left:139px;white-space:nowrap" class="ft469">→</p>
<p style="position:absolute;top:697px;left:155px;white-space:nowrap" class="ft461"><b>&#160;Tell&#160;your&#160;doctor.&#160;</b></p>
<p style="position:absolute;top:716px;left:85px;white-space:nowrap" class="ft461"><b>&#160;</b></p>
<p style="position:absolute;top:735px;left:85px;white-space:nowrap" class="ft4635"><b>Weight, blood&#160;lipid&#160;and&#160;blood&#160;glucose&#160;effects:&#160;&#160;<br/></b>During HIV&#160;therapy there&#160;may be&#160;an&#160;increase&#160;in weight&#160;and&#160;in&#160;levels&#160;of&#160;blood&#160;lipids&#160;and glucose. This&#160;is&#160;</p>
<p style="position:absolute;top:783px;left:85px;white-space:nowrap" class="ft462">partly&#160;linked&#160;to restored health and&#160;lifestyle,&#160;and sometimes&#160;to&#160;the&#160;HIV&#160;medicines&#160;themselves. Your&#160;doctor&#160;</p>
<p style="position:absolute;top:802px;left:85px;white-space:nowrap" class="ft4633">will&#160;test&#160;for&#160;these&#160;changes.&#160;<br/>&#160;<br/><b>Reporting&#160;of&#160;side effects&#160;&#160;</b></p>
<p style="position:absolute;top:861px;left:85px;white-space:nowrap" class="ft462">If&#160;you get&#160;any&#160;side&#160;effects, talk&#160;to your&#160;doctor&#160;or&#160;pharmacist.&#160;This&#160;includes&#160;any&#160;possible&#160;side&#160;effects&#160;not listed&#160;</p>
<p style="position:absolute;top:880px;left:85px;white-space:nowrap" class="ft462">in&#160;this&#160;leaflet.&#160;You&#160;can&#160;also&#160;report&#160;side&#160;effects directly&#160;via&#160;the&#160;national reporting&#160;system&#160;listed&#160;in&#160;</p>
<p style="position:absolute;top:899px;left:85px;white-space:nowrap" class="ft4619"><a href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc">Appendix&#160;V.</a>&#160;By reporting side&#160;effects&#160;you&#160;can help provide&#160;more&#160;information on the&#160;safety of&#160;this&#160;medicine.&#160;</p>
<p style="position:absolute;top:918px;left:85px;white-space:nowrap" class="ft462">&#160;</p>
<p style="position:absolute;top:937px;left:85px;white-space:nowrap" class="ft461"><b>5.&#160;</b></p>
<p style="position:absolute;top:937px;left:127px;white-space:nowrap" class="ft461"><b>How&#160;to&#160;store&#160;Dovato&#160;</b></p>
<p style="position:absolute;top:956px;left:85px;white-space:nowrap" class="ft462">&#160;</p>
<p style="position:absolute;top:975px;left:85px;white-space:nowrap" class="ft462">Keep&#160;this&#160;medicine&#160;out&#160;of&#160;the&#160;sight&#160;and reach&#160;of&#160;children.&#160;</p>
<p style="position:absolute;top:994px;left:85px;white-space:nowrap" class="ft462">&#160;</p>
<p style="position:absolute;top:1013px;left:85px;white-space:nowrap" class="ft462">Do not&#160;use&#160;this&#160;medicine&#160;after&#160;the expiry&#160;date&#160;which&#160;is&#160;stated&#160;on&#160;the carton&#160;and&#160;bottle&#160;after&#160;EXP.&#160;The&#160;expiry&#160;</p>
<p style="position:absolute;top:1032px;left:85px;white-space:nowrap" class="ft462">date&#160;refers to&#160;the last&#160;day&#160;of&#160;that&#160;month.&#160;</p>
<p style="position:absolute;top:1051px;left:85px;white-space:nowrap" class="ft462">&#160;</p>
<p style="position:absolute;top:1070px;left:85px;white-space:nowrap" class="ft462">This&#160;medicine&#160;does&#160;not&#160;require&#160;any special&#160;storage&#160;conditions.&#160;</p>
<p style="position:absolute;top:1088px;left:85px;white-space:nowrap" class="ft462">&#160;</p>
<p style="position:absolute;top:1108px;left:85px;white-space:nowrap" class="ft462">Do not&#160;throw&#160;away any&#160;medicines&#160;via wastewater&#160;or&#160;household waste.&#160;Ask your&#160;pharmacist&#160;how&#160;to&#160;throw&#160;</p>
<p style="position:absolute;top:1126px;left:85px;white-space:nowrap" class="ft462">away&#160;medicines&#160;you&#160;no longer&#160;use.&#160;These&#160;measures will&#160;help&#160;protect&#160;the environment.<i>&#160;</i></p>
<p style="position:absolute;top:1145px;left:85px;white-space:nowrap" class="ft462">&#160;</p>
</div>
<!-- Page 47 -->
<a name="47"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft4736{font-size:17px;font-family:LHCQSS+TimesNewRomanPS;color:#000000;}
-->
</style>
<div id="page47-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1191px;left:436px;white-space:nowrap" class="ft470">47&#160;</p>
<p style="position:absolute;top:83px;left:85px;white-space:nowrap" class="ft471"><b>6.&#160;</b></p>
<p style="position:absolute;top:83px;left:127px;white-space:nowrap" class="ft471"><b>Contents&#160;of&#160;the&#160;pack&#160;and other&#160;information&#160;</b></p>
<p style="position:absolute;top:102px;left:85px;white-space:nowrap" class="ft472">&#160;</p>
<p style="position:absolute;top:121px;left:85px;white-space:nowrap" class="ft471"><b>What&#160;Dovato&#160;contains&#160;&#160;</b></p>
<p style="position:absolute;top:142px;left:85px;white-space:nowrap" class="ft479">•</p>
<p style="position:absolute;top:141px;left:93px;white-space:nowrap" class="ft4724">&#160;</p>
<p style="position:absolute;top:141px;left:127px;white-space:nowrap" class="ft472">The active substances are dolutegravir&#160;and&#160;lamivudine.&#160;Each&#160;tablet&#160;contains&#160;dolutegravir&#160;sodium&#160;</p>
<p style="position:absolute;top:160px;left:127px;white-space:nowrap" class="ft472">equivalent&#160;to&#160;50&#160;mg dolutegravir&#160;and&#160;300&#160;mg lamivudine.<i>&#160;</i></p>
<p style="position:absolute;top:181px;left:85px;white-space:nowrap" class="ft479">•</p>
<p style="position:absolute;top:180px;left:93px;white-space:nowrap" class="ft4724">&#160;</p>
<p style="position:absolute;top:180px;left:127px;white-space:nowrap" class="ft472">The other&#160;ingredients are&#160;microcrystalline cellulose,&#160;sodium&#160;starch&#160;glycolate,&#160;magnesium&#160;stearate,&#160;</p>
<p style="position:absolute;top:199px;left:127px;white-space:nowrap" class="ft472">mannitol&#160;(E421), povidone&#160;(K29/32),&#160;sodium&#160;stearyl fumarate, hypromellose&#160;(E464),&#160;macrogol,&#160;</p>
<p style="position:absolute;top:218px;left:127px;white-space:nowrap" class="ft472">titanium&#160;dioxide&#160;(E171).&#160;</p>
<p style="position:absolute;top:239px;left:85px;white-space:nowrap" class="ft479">•</p>
<p style="position:absolute;top:239px;left:93px;white-space:nowrap" class="ft4724">&#160;</p>
<p style="position:absolute;top:239px;left:128px;white-space:nowrap" class="ft472">This&#160;medicine&#160;contains less&#160;than&#160;1&#160;mmol&#160;sodium&#160;(23&#160;mg)&#160;per&#160;tablet,&#160;that&#160;is&#160;to say&#160;essentially ‘sodium-</p>
<p style="position:absolute;top:257px;left:127px;white-space:nowrap" class="ft472">free’.&#160;</p>
<p style="position:absolute;top:276px;left:85px;white-space:nowrap" class="ft472">&#160;</p>
<p style="position:absolute;top:295px;left:85px;white-space:nowrap" class="ft471"><b>What&#160;Dovato&#160;looks&#160;like and&#160;contents of&#160;the pack&#160;</b></p>
<p style="position:absolute;top:314px;left:85px;white-space:nowrap" class="ft472">&#160;</p>
<p style="position:absolute;top:333px;left:85px;white-space:nowrap" class="ft472">Dovato&#160;film-coated&#160;tablets&#160;are&#160;oval,&#160;biconvex, white&#160;tablets&#160;debossed with 'SV&#160;137'&#160;on one&#160;face.&#160;</p>
<p style="position:absolute;top:352px;left:85px;white-space:nowrap" class="ft472">&#160;</p>
<p style="position:absolute;top:371px;left:85px;white-space:nowrap" class="ft472">The&#160;film-coated tablets&#160;are&#160;provided in&#160;bottles&#160;closed&#160;with&#160;child-resistant&#160;closures.&#160;</p>
<p style="position:absolute;top:390px;left:85px;white-space:nowrap" class="ft472">&#160;</p>
<p style="position:absolute;top:409px;left:85px;white-space:nowrap" class="ft472">Each bottle&#160;contains&#160;30&#160;film-coated&#160;tablets.&#160;</p>
<p style="position:absolute;top:428px;left:85px;white-space:nowrap" class="ft472">&#160;</p>
<p style="position:absolute;top:447px;left:85px;white-space:nowrap" class="ft472">Multipacks&#160;containing 90&#160;film-coated&#160;tablets&#160;(3&#160;packs&#160;of&#160;30 film-coated&#160;tablets)&#160;are also&#160;available.&#160;</p>
<p style="position:absolute;top:466px;left:85px;white-space:nowrap" class="ft472">&#160;</p>
<p style="position:absolute;top:485px;left:85px;white-space:nowrap" class="ft472">Not&#160;all&#160;pack sizes&#160;may be&#160;available&#160;in your&#160;country.&#160;</p>
<p style="position:absolute;top:504px;left:85px;white-space:nowrap" class="ft472">&#160;</p>
<p style="position:absolute;top:523px;left:85px;white-space:nowrap" class="ft471"><b>Marketing&#160;Authorisation Holder&#160;&#160;</b></p>
<p style="position:absolute;top:542px;left:85px;white-space:nowrap" class="ft472">ViiV&#160;Healthcare BV&#160;</p>
<p style="position:absolute;top:561px;left:85px;white-space:nowrap" class="ft472">Van Asch van Wijckstraat&#160;55H&#160;</p>
<p style="position:absolute;top:580px;left:85px;white-space:nowrap" class="ft472">3811 LP&#160;Amersfoort&#160;</p>
<p style="position:absolute;top:599px;left:85px;white-space:nowrap" class="ft472">Netherlands&#160;</p>
<p style="position:absolute;top:618px;left:85px;white-space:nowrap" class="ft472">&#160;</p>
<p style="position:absolute;top:637px;left:85px;white-space:nowrap" class="ft471"><b>Manufacturer</b>&#160;</p>
<p style="position:absolute;top:656px;left:85px;white-space:nowrap" class="ft472">Glaxo&#160;Wellcome,&#160;S.A.&#160;&#160;</p>
<p style="position:absolute;top:676px;left:85px;white-space:nowrap" class="ft472">Avda.&#160;Extremadura, 3&#160;</p>
<p style="position:absolute;top:695px;left:85px;white-space:nowrap" class="ft472">09400 Aranda&#160;De&#160;Duero&#160;</p>
<p style="position:absolute;top:715px;left:85px;white-space:nowrap" class="ft472">Burgos&#160;</p>
<p style="position:absolute;top:734px;left:85px;white-space:nowrap" class="ft472">Spain&#160;</p>
<p style="position:absolute;top:753px;left:85px;white-space:nowrap" class="ft472">&#160;</p>
<p style="position:absolute;top:772px;left:85px;white-space:nowrap" class="ft472">For&#160;any&#160;information&#160;about&#160;this&#160;medicine,&#160;please&#160;contact&#160;the local&#160;representative of&#160;the&#160;Marketing&#160;</p>
<p style="position:absolute;top:791px;left:85px;white-space:nowrap" class="ft472">Authorisation Holder:&#160;</p>
<p style="position:absolute;top:810px;left:85px;white-space:nowrap" class="ft472">&#160;</p>
<p style="position:absolute;top:830px;left:93px;white-space:nowrap" class="ft471"><b>België/Belgique/Belgien&#160;</b></p>
<p style="position:absolute;top:849px;left:93px;white-space:nowrap" class="ft472">ViiV&#160;Healthcare&#160;srl/bv&#160;&#160;</p>
<p style="position:absolute;top:868px;left:93px;white-space:nowrap" class="ft472">Tél/Tel:&#160;+&#160;32&#160;(0)</p>
<p style="position:absolute;top:868px;left:204px;white-space:nowrap" class="ft471"><b>&#160;</b>10 85 65&#160;00&#160;</p>
<p style="position:absolute;top:830px;left:441px;white-space:nowrap" class="ft471"><b>Lietuva&#160;</b></p>
<p style="position:absolute;top:849px;left:441px;white-space:nowrap" class="ft472">ViiV&#160;Healthcare BV&#160;</p>
<p style="position:absolute;top:869px;left:441px;white-space:nowrap" class="ft472">Tel:&#160;+&#160;370&#160;80000334&#160;</p>
<p style="position:absolute;top:888px;left:441px;white-space:nowrap" class="ft472">&#160;</p>
<p style="position:absolute;top:907px;left:93px;white-space:nowrap" class="ft4736"><b>България&#160;</b></p>
<p style="position:absolute;top:927px;left:93px;white-space:nowrap" class="ft472">ViiV&#160;Healthcare BV&#160;</p>
<p style="position:absolute;top:947px;left:93px;white-space:nowrap" class="ft472">Teл.:&#160;+&#160;359&#160;80018205&#160;</p>
<p style="position:absolute;top:966px;left:93px;white-space:nowrap" class="ft472">&#160;</p>
<p style="position:absolute;top:907px;left:441px;white-space:nowrap" class="ft471"><b>Luxembourg/Luxemburg&#160;</b></p>
<p style="position:absolute;top:927px;left:441px;white-space:nowrap" class="ft472">ViiV&#160;Healthcare&#160;srl/bv&#160;&#160;</p>
<p style="position:absolute;top:947px;left:441px;white-space:nowrap" class="ft472">Belgique/Belgien&#160;</p>
<p style="position:absolute;top:966px;left:441px;white-space:nowrap" class="ft472">Tél/Tel:&#160;+&#160;32&#160;(0)&#160;10 85 65&#160;00</p>
<p style="position:absolute;top:966px;left:635px;white-space:nowrap" class="ft471"><b>&#160;</b></p>
<p style="position:absolute;top:985px;left:93px;white-space:nowrap" class="ft471"><b>&#160;</b></p>
<p style="position:absolute;top:1005px;left:93px;white-space:nowrap" class="ft4736"><b>Česká&#160;republika&#160;</b></p>
<p style="position:absolute;top:1025px;left:93px;white-space:nowrap" class="ft472">GlaxoSmithKline,&#160;s.r.o.&#160;</p>
<p style="position:absolute;top:1044px;left:93px;white-space:nowrap" class="ft472">Tel:&#160;+&#160;420&#160;222 001&#160;111&#160;</p>
<p style="position:absolute;top:1064px;left:93px;white-space:nowrap" class="ft472">cz.info@gsk.com&#160;</p>
<p style="position:absolute;top:985px;left:441px;white-space:nowrap" class="ft471"><b>&#160;</b></p>
<p style="position:absolute;top:1005px;left:441px;white-space:nowrap" class="ft4736"><b>Magyarország&#160;</b></p>
<p style="position:absolute;top:1025px;left:441px;white-space:nowrap" class="ft472">ViiV&#160;Healthcare BV&#160;</p>
<p style="position:absolute;top:1044px;left:441px;white-space:nowrap" class="ft472">Tel.:&#160;+&#160;36&#160;80088309</p>
<p style="position:absolute;top:1044px;left:576px;white-space:nowrap" class="ft471"><b>&#160;</b></p>
<p style="position:absolute;top:1083px;left:93px;white-space:nowrap" class="ft471"><b>&#160;</b></p>
<p style="position:absolute;top:1102px;left:93px;white-space:nowrap" class="ft471"><b>Danmark</b>&#160;</p>
<p style="position:absolute;top:1122px;left:93px;white-space:nowrap" class="ft472">GlaxoSmithKline&#160;Pharma&#160;A/S&#160;</p>
<p style="position:absolute;top:1142px;left:93px;white-space:nowrap" class="ft472">Tlf:&#160;+&#160;45&#160;36 35 91 00&#160;</p>
<p style="position:absolute;top:1083px;left:441px;white-space:nowrap" class="ft471"><b>&#160;</b></p>
<p style="position:absolute;top:1102px;left:441px;white-space:nowrap" class="ft471"><b>Malta&#160;</b></p>
<p style="position:absolute;top:1122px;left:441px;white-space:nowrap" class="ft472">ViiV&#160;Healthcare BV&#160;</p>
<p style="position:absolute;top:1142px;left:441px;white-space:nowrap" class="ft472">Tel:&#160;+&#160;356&#160;80065004&#160;</p>
</div>
<!-- Page 48 -->
<a name="48"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft4837{font-size:17px;font-family:DTAKKI+TimesNewRomanPSMT;color:#ff0000;}
	.ft4838{font-size:17px;font-family:MCGCGQ+Arial;color:#000000;}
-->
</style>
<div id="page48-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1191px;left:436px;white-space:nowrap" class="ft480">48&#160;</p>
<p style="position:absolute;top:83px;left:93px;white-space:nowrap" class="ft482">dk-info@gsk.com</p>
<p style="position:absolute;top:83px;left:212px;white-space:nowrap" class="ft481"><b>&#160;</b></p>
<p style="position:absolute;top:103px;left:93px;white-space:nowrap" class="ft481"><b>&#160;</b></p>
<p style="position:absolute;top:122px;left:93px;white-space:nowrap" class="ft481"><b>Deutschland</b>&#160;</p>
<p style="position:absolute;top:142px;left:93px;white-space:nowrap" class="ft482">ViiV Healthcare&#160;GmbH&#160;&#160;</p>
<p style="position:absolute;top:162px;left:93px;white-space:nowrap" class="ft482">Tel.:&#160;+&#160;49 (0)89&#160;203 0038-10&#160;&#160;</p>
<p style="position:absolute;top:181px;left:93px;white-space:nowrap" class="ft482">viiv.med.info@viivhealthcare.com&#160;</p>
<p style="position:absolute;top:181px;left:327px;white-space:nowrap" class="ft481"><b>&#160;</b></p>
<p style="position:absolute;top:103px;left:441px;white-space:nowrap" class="ft481"><b>&#160;</b></p>
<p style="position:absolute;top:122px;left:441px;white-space:nowrap" class="ft481"><b>Nederland&#160;</b></p>
<p style="position:absolute;top:142px;left:441px;white-space:nowrap" class="ft482">ViiV&#160;Healthcare BV&#160;&#160;</p>
<p style="position:absolute;top:162px;left:441px;white-space:nowrap" class="ft482">Tel:&#160;+&#160;31 (0)33&#160;2081199&#160;</p>
<p style="position:absolute;top:181px;left:441px;white-space:nowrap" class="ft481"><b>&#160;</b></p>
<p style="position:absolute;top:200px;left:93px;white-space:nowrap" class="ft481"><b>&#160;</b></p>
<p style="position:absolute;top:220px;left:93px;white-space:nowrap" class="ft481"><b>Eesti&#160;</b></p>
<p style="position:absolute;top:239px;left:93px;white-space:nowrap" class="ft482">ViiV&#160;Healthcare BV&#160;</p>
<p style="position:absolute;top:258px;left:93px;white-space:nowrap" class="ft482">Tel:&#160;+&#160;372&#160;8002640&#160;</p>
<p style="position:absolute;top:277px;left:93px;white-space:nowrap" class="ft482">&#160;</p>
<p style="position:absolute;top:200px;left:441px;white-space:nowrap" class="ft481"><b>&#160;</b></p>
<p style="position:absolute;top:220px;left:441px;white-space:nowrap" class="ft481"><b>Norge&#160;</b></p>
<p style="position:absolute;top:239px;left:441px;white-space:nowrap" class="ft482">GlaxoSmithKline&#160;AS&#160;</p>
<p style="position:absolute;top:259px;left:441px;white-space:nowrap" class="ft482">Tlf:&#160;+&#160;47&#160;22 70 20 00&#160;</p>
<p style="position:absolute;top:278px;left:441px;white-space:nowrap" class="ft482">&#160;</p>
<p style="position:absolute;top:297px;left:93px;white-space:nowrap" class="ft481"><b>&#160;</b></p>
<p style="position:absolute;top:317px;left:93px;white-space:nowrap" class="ft4836"><b>Ελλάδα&#160;</b></p>
<p style="position:absolute;top:336px;left:93px;white-space:nowrap" class="ft482">GlaxoSmithKline&#160;Μονοπρόσωπη&#160;A.E.B.E.&#160;</p>
<p style="position:absolute;top:356px;left:93px;white-space:nowrap" class="ft487">Τηλ:&#160;+&#160;30&#160;210 68 82&#160;100&#160;</p>
<p style="position:absolute;top:297px;left:441px;white-space:nowrap" class="ft481"><b>&#160;</b></p>
<p style="position:absolute;top:316px;left:441px;white-space:nowrap" class="ft481"><b>Österreich</b>&#160;</p>
<p style="position:absolute;top:335px;left:441px;white-space:nowrap" class="ft482">GlaxoSmithKline&#160;Pharma&#160;GmbH&#160;</p>
<p style="position:absolute;top:354px;left:441px;white-space:nowrap" class="ft482">Tel:&#160;+&#160;43 (0)1&#160;97075 0&#160;</p>
<p style="position:absolute;top:373px;left:441px;white-space:nowrap" class="ft482">at.info@gsk.com&#160;</p>
<p style="position:absolute;top:392px;left:93px;white-space:nowrap" class="ft481"><b>&#160;</b></p>
<p style="position:absolute;top:412px;left:93px;white-space:nowrap" class="ft481"><b>España</b>&#160;</p>
<p style="position:absolute;top:431px;left:93px;white-space:nowrap" class="ft482">Laboratorios&#160;ViiV&#160;Healthcare, S.L.&#160;&#160;</p>
<p style="position:absolute;top:450px;left:93px;white-space:nowrap" class="ft482">Tel:&#160;+&#160;34&#160;900&#160;923 501&#160;&#160;</p>
<p style="position:absolute;top:469px;left:93px;white-space:nowrap" class="ft482">es-ci@viivhealthcare.com</p>
<p style="position:absolute;top:469px;left:265px;white-space:nowrap" class="ft481"><b>&#160;</b></p>
<p style="position:absolute;top:392px;left:441px;white-space:nowrap" class="ft481"><b>&#160;</b></p>
<p style="position:absolute;top:412px;left:441px;white-space:nowrap" class="ft481"><b>Polska&#160;</b></p>
<p style="position:absolute;top:431px;left:441px;white-space:nowrap" class="ft482">GSK&#160;Services&#160;Sp.&#160;z&#160;o.o.&#160;</p>
<p style="position:absolute;top:451px;left:441px;white-space:nowrap" class="ft482">Tel.:&#160;+&#160;48&#160;(0)22 576&#160;9000&#160;</p>
<p style="position:absolute;top:470px;left:441px;white-space:nowrap" class="ft482">&#160;</p>
<p style="position:absolute;top:490px;left:93px;white-space:nowrap" class="ft481"><b>&#160;</b></p>
<p style="position:absolute;top:509px;left:93px;white-space:nowrap" class="ft481"><b>France</b>&#160;</p>
<p style="position:absolute;top:529px;left:93px;white-space:nowrap" class="ft482">ViiV Healthcare&#160;SAS&#160;&#160;</p>
<p style="position:absolute;top:548px;left:93px;white-space:nowrap" class="ft482">Tél.:&#160;+&#160;33&#160;(0)1 39 17&#160;69&#160;69&#160;</p>
<p style="position:absolute;top:568px;left:93px;white-space:nowrap" class="ft482">Infomed@viivhealthcare.com</p>
<p style="position:absolute;top:568px;left:290px;white-space:nowrap" class="ft481"><b>&#160;</b></p>
<p style="position:absolute;top:490px;left:441px;white-space:nowrap" class="ft481"><b>&#160;</b></p>
<p style="position:absolute;top:509px;left:441px;white-space:nowrap" class="ft481"><b>Portugal</b><i>&#160;</i></p>
<p style="position:absolute;top:529px;left:441px;white-space:nowrap" class="ft482">VIIVHIV&#160;HEALTHCARE,&#160;UNIPESSOAL,&#160;LDA&#160;&#160;</p>
<p style="position:absolute;top:548px;left:441px;white-space:nowrap" class="ft482">Tel:&#160;+&#160;351 21&#160;094 08&#160;01&#160;&#160;</p>
<p style="position:absolute;top:568px;left:441px;white-space:nowrap" class="ft482">viiv.fi.pt@viivhealthcare.com&#160;</p>
<p style="position:absolute;top:587px;left:93px;white-space:nowrap" class="ft481"><b>&#160;</b></p>
<p style="position:absolute;top:607px;left:93px;white-space:nowrap" class="ft481"><b>Hrvatska</b>&#160;</p>
<p style="position:absolute;top:626px;left:93px;white-space:nowrap" class="ft482">ViiV&#160;Healthcare BV&#160;</p>
<p style="position:absolute;top:646px;left:93px;white-space:nowrap" class="ft482">Tel:&#160;+&#160;385&#160;800787089</p>
<p style="position:absolute;top:646px;left:240px;white-space:nowrap" class="ft481"><b>&#160;</b></p>
<p style="position:absolute;top:587px;left:441px;white-space:nowrap" class="ft481"><b>&#160;</b></p>
<p style="position:absolute;top:607px;left:441px;white-space:nowrap" class="ft481"><b>România&#160;</b></p>
<p style="position:absolute;top:626px;left:441px;white-space:nowrap" class="ft482">ViiV&#160;Healthcare BV&#160;</p>
<p style="position:absolute;top:646px;left:441px;white-space:nowrap" class="ft482">Tel: +&#160;40800672524&#160;</p>
<p style="position:absolute;top:665px;left:93px;white-space:nowrap" class="ft481"><b>&#160;</b></p>
<p style="position:absolute;top:685px;left:93px;white-space:nowrap" class="ft481"><b>Ireland&#160;</b></p>
<p style="position:absolute;top:704px;left:93px;white-space:nowrap" class="ft482">GlaxoSmithKline&#160;(Ireland)&#160;Limited&#160;</p>
<p style="position:absolute;top:724px;left:93px;white-space:nowrap" class="ft482">Tel:&#160;+&#160;353 (0)1&#160;4955000</p>
<p style="position:absolute;top:724px;left:255px;white-space:nowrap" class="ft481"><b>&#160;</b></p>
<p style="position:absolute;top:665px;left:441px;white-space:nowrap" class="ft481"><b>&#160;</b></p>
<p style="position:absolute;top:685px;left:441px;white-space:nowrap" class="ft481"><b>Slovenija&#160;</b></p>
<p style="position:absolute;top:704px;left:441px;white-space:nowrap" class="ft482">ViiV&#160;Healthcare BV&#160;</p>
<p style="position:absolute;top:724px;left:441px;white-space:nowrap" class="ft482">Tel:&#160;+&#160;386&#160;80688869&#160;</p>
<p style="position:absolute;top:743px;left:441px;white-space:nowrap" class="ft482">&#160;</p>
<p style="position:absolute;top:762px;left:93px;white-space:nowrap" class="ft481"><b>&#160;</b></p>
<p style="position:absolute;top:781px;left:93px;white-space:nowrap" class="ft481"><b>Ísland</b>&#160;</p>
<p style="position:absolute;top:800px;left:93px;white-space:nowrap" class="ft482">Vistor&#160;hf.&#160;</p>
<p style="position:absolute;top:820px;left:93px;white-space:nowrap" class="ft482">Sími:&#160;+354 535 7000&#160;</p>
<p style="position:absolute;top:763px;left:441px;white-space:nowrap" class="ft481"><b>&#160;</b></p>
<p style="position:absolute;top:782px;left:441px;white-space:nowrap" class="ft4836"><b>Slovenská&#160;republika&#160;</b></p>
<p style="position:absolute;top:801px;left:441px;white-space:nowrap" class="ft482">ViiV&#160;Healthcare BV&#160;</p>
<p style="position:absolute;top:820px;left:441px;white-space:nowrap" class="ft482">Tel:&#160;+&#160;421&#160;800500589&#160;</p>
<p style="position:absolute;top:840px;left:441px;white-space:nowrap" class="ft481"><b>&#160;</b></p>
<p style="position:absolute;top:859px;left:93px;white-space:nowrap" class="ft481"><b>&#160;</b></p>
<p style="position:absolute;top:879px;left:93px;white-space:nowrap" class="ft481"><b>Italia&#160;</b></p>
<p style="position:absolute;top:898px;left:93px;white-space:nowrap" class="ft482">ViiV&#160;Healthcare S.r.l&#160;&#160;</p>
<p style="position:absolute;top:918px;left:93px;white-space:nowrap" class="ft482">Tel:&#160;+&#160;39 (0)45&#160;7741600&#160;</p>
<p style="position:absolute;top:859px;left:441px;white-space:nowrap" class="ft481"><b>&#160;</b></p>
<p style="position:absolute;top:879px;left:441px;white-space:nowrap" class="ft481"><b>Suomi/Finland&#160;</b></p>
<p style="position:absolute;top:898px;left:441px;white-space:nowrap" class="ft482">GlaxoSmithKline&#160;Oy&#160;</p>
<p style="position:absolute;top:918px;left:441px;white-space:nowrap" class="ft482">Puh/Tel:&#160;+&#160;358&#160;(0)10 30 30&#160;30&#160;</p>
<p style="position:absolute;top:937px;left:441px;white-space:nowrap" class="ft481"><b>&#160;</b></p>
<p style="position:absolute;top:957px;left:93px;white-space:nowrap" class="ft481"><b>&#160;</b></p>
<p style="position:absolute;top:976px;left:93px;white-space:nowrap" class="ft4836"><b>Κύπρος&#160;</b></p>
<p style="position:absolute;top:995px;left:93px;white-space:nowrap" class="ft482">ViiV&#160;Healthcare BV&#160;</p>
<p style="position:absolute;top:1015px;left:93px;white-space:nowrap" class="ft487">Τηλ:&#160;+&#160;357&#160;80070017&#160;</p>
<p style="position:absolute;top:1034px;left:93px;white-space:nowrap" class="ft482">&#160;</p>
<p style="position:absolute;top:957px;left:441px;white-space:nowrap" class="ft481"><b>&#160;</b></p>
<p style="position:absolute;top:976px;left:441px;white-space:nowrap" class="ft481"><b>Sverige&#160;</b></p>
<p style="position:absolute;top:996px;left:441px;white-space:nowrap" class="ft482">GlaxoSmithKline&#160;AB&#160;</p>
<p style="position:absolute;top:1015px;left:441px;white-space:nowrap" class="ft482">Tel:&#160;+&#160;46&#160;(0)8 638 93&#160;00&#160;</p>
<p style="position:absolute;top:1035px;left:441px;white-space:nowrap" class="ft482">info.produkt@gsk.com</p>
<p style="position:absolute;top:1035px;left:594px;white-space:nowrap" class="ft481"><b>&#160;</b></p>
<p style="position:absolute;top:1054px;left:93px;white-space:nowrap" class="ft481"><b>&#160;</b></p>
<p style="position:absolute;top:1074px;left:93px;white-space:nowrap" class="ft481"><b>Latvija&#160;</b></p>
<p style="position:absolute;top:1093px;left:93px;white-space:nowrap" class="ft482">ViiV&#160;Healthcare BV&#160;</p>
<p style="position:absolute;top:1113px;left:93px;white-space:nowrap" class="ft482">Tel:&#160;+&#160;371&#160;80205045</p>
<p style="position:absolute;top:1113px;left:232px;white-space:nowrap" class="ft4838"><b>&#160;</b></p>
<p style="position:absolute;top:1132px;left:93px;white-space:nowrap" class="ft481"><b>&#160;</b></p>
<p style="position:absolute;top:1054px;left:441px;white-space:nowrap" class="ft481"><b>&#160;</b></p>
<p style="position:absolute;top:1074px;left:441px;white-space:nowrap" class="ft481"><b>United Kingdom&#160;(Northern&#160;Ireland)&#160;</b></p>
<p style="position:absolute;top:1093px;left:441px;white-space:nowrap" class="ft482">ViiV&#160;Healthcare&#160;BV&#160;</p>
<p style="position:absolute;top:1113px;left:441px;white-space:nowrap" class="ft482">Tel:&#160;+&#160;44 (0)800&#160;221441&#160;</p>
<p style="position:absolute;top:1132px;left:441px;white-space:nowrap" class="ft482">customercontactuk@gsk.com&#160;</p>
<p style="position:absolute;top:1132px;left:641px;white-space:nowrap" class="ft481"><b>&#160;</b></p>
<p style="position:absolute;top:1151px;left:85px;white-space:nowrap" class="ft481"><b>&#160;</b></p>
</div>
<!-- Page 49 -->
<a name="49"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page49-div" style="position:relative;width:892px;height:1263px;">
<p style="position:absolute;top:1191px;left:436px;white-space:nowrap" class="ft490">49&#160;</p>
<p style="position:absolute;top:83px;left:85px;white-space:nowrap" class="ft491"><b>This&#160;leaflet&#160;was&#160;last&#160;revised&#160;in&#160;</b>{<b>month&#160;YYYY</b>}.&#160;&#160;</p>
<p style="position:absolute;top:102px;left:85px;white-space:nowrap" class="ft492">&#160;</p>
<p style="position:absolute;top:121px;left:85px;white-space:nowrap" class="ft492">&#160;</p>
<p style="position:absolute;top:140px;left:85px;white-space:nowrap" class="ft491"><b>Other&#160;sources&#160;of&#160;information&#160;</b></p>
<p style="position:absolute;top:159px;left:85px;white-space:nowrap" class="ft492">&#160;</p>
<p style="position:absolute;top:178px;left:85px;white-space:nowrap" class="ft492">Detailed&#160;information on&#160;this&#160;medicine&#160;is&#160;available&#160;on&#160;the&#160;European&#160;Medicines&#160;Agency web&#160;site:&#160;</p>
<p style="position:absolute;top:197px;left:85px;white-space:nowrap" class="ft4919"><a href="http://www.ema.europa.eu/">http://www.ema.europa.eu.</a></p>
<p style="position:absolute;top:197px;left:265px;white-space:nowrap" class="ft491"><b>&#160;</b></p>
<p style="position:absolute;top:216px;left:85px;white-space:nowrap" class="ft492">&#160;</p>
<p style="position:absolute;top:235px;left:446px;white-space:nowrap" class="ft492">&#160;</p>
<p style="position:absolute;top:254px;left:85px;white-space:nowrap" class="ft491"><b>&#160;</b></p>
<p style="position:absolute;top:273px;left:85px;white-space:nowrap" class="ft491"><b>&#160;</b></p>
<p style="position:absolute;top:292px;left:85px;white-space:nowrap" class="ft491"><b>&#160;</b></p>
<p style="position:absolute;top:311px;left:85px;white-space:nowrap" class="ft491"><b>&#160;</b></p>
<p style="position:absolute;top:330px;left:85px;white-space:nowrap" class="ft491"><b>&#160;</b></p>
<p style="position:absolute;top:349px;left:85px;white-space:nowrap" class="ft491"><b>&#160;</b></p>
<p style="position:absolute;top:368px;left:85px;white-space:nowrap" class="ft491"><b>&#160;</b></p>
<p style="position:absolute;top:386px;left:85px;white-space:nowrap" class="ft491"><b>&#160;</b></p>
<p style="position:absolute;top:405px;left:85px;white-space:nowrap" class="ft491"><b>&#160;</b></p>
<p style="position:absolute;top:424px;left:85px;white-space:nowrap" class="ft491"><b>&#160;</b></p>
<p style="position:absolute;top:443px;left:85px;white-space:nowrap" class="ft491"><b>&#160;</b></p>
<p style="position:absolute;top:462px;left:85px;white-space:nowrap" class="ft491"><b>&#160;</b></p>
<p style="position:absolute;top:481px;left:85px;white-space:nowrap" class="ft491"><b>&#160;</b></p>
<p style="position:absolute;top:500px;left:85px;white-space:nowrap" class="ft491"><b>&#160;</b></p>
<p style="position:absolute;top:519px;left:85px;white-space:nowrap" class="ft491"><b>&#160;</b></p>
<p style="position:absolute;top:538px;left:85px;white-space:nowrap" class="ft491"><b>&#160;</b></p>
<p style="position:absolute;top:557px;left:85px;white-space:nowrap" class="ft491"><b>&#160;</b></p>
<p style="position:absolute;top:576px;left:85px;white-space:nowrap" class="ft491"><b>&#160;</b></p>
<p style="position:absolute;top:595px;left:85px;white-space:nowrap" class="ft491"><b>&#160;</b></p>
<p style="position:absolute;top:614px;left:85px;white-space:nowrap" class="ft491"><b>&#160;</b></p>
<p style="position:absolute;top:633px;left:85px;white-space:nowrap" class="ft491"><b>&#160;</b></p>
<p style="position:absolute;top:652px;left:85px;white-space:nowrap" class="ft491"><b>&#160;</b></p>
<p style="position:absolute;top:671px;left:85px;white-space:nowrap" class="ft491"><b>&#160;</b></p>
<p style="position:absolute;top:690px;left:85px;white-space:nowrap" class="ft491"><b>&#160;</b></p>
<p style="position:absolute;top:709px;left:85px;white-space:nowrap" class="ft491"><b>&#160;</b></p>
<p style="position:absolute;top:728px;left:85px;white-space:nowrap" class="ft491"><b>&#160;</b></p>
<p style="position:absolute;top:747px;left:85px;white-space:nowrap" class="ft491"><b>&#160;</b></p>
<p style="position:absolute;top:766px;left:85px;white-space:nowrap" class="ft491"><b>&#160;</b></p>
<p style="position:absolute;top:785px;left:85px;white-space:nowrap" class="ft491"><b>&#160;</b></p>
<p style="position:absolute;top:804px;left:85px;white-space:nowrap" class="ft491"><b>&#160;</b></p>
<p style="position:absolute;top:823px;left:85px;white-space:nowrap" class="ft491"><b>&#160;</b></p>
<p style="position:absolute;top:842px;left:85px;white-space:nowrap" class="ft491"><b>&#160;</b></p>
<p style="position:absolute;top:861px;left:85px;white-space:nowrap" class="ft491"><b>&#160;</b></p>
<p style="position:absolute;top:880px;left:85px;white-space:nowrap" class="ft491"><b>&#160;</b></p>
<p style="position:absolute;top:899px;left:85px;white-space:nowrap" class="ft491"><b>&#160;</b></p>
<p style="position:absolute;top:918px;left:85px;white-space:nowrap" class="ft491"><b>&#160;</b></p>
<p style="position:absolute;top:937px;left:85px;white-space:nowrap" class="ft491"><b>&#160;</b></p>
<p style="position:absolute;top:956px;left:85px;white-space:nowrap" class="ft491"><b>&#160;</b></p>
</div>
<a name="outline"></a><h1>Document Outline</h1>
<ul>
<li><a href="dovato-epar-product-information_en.html#1">SUMMARY OF PRODUCT CHARACTERISTICS</a></li>
<li><a href="dovato-epar-product-information_en.html#29">A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE</a></li>
<li><a href="dovato-epar-product-information_en.html#29">B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE</a></li>
<li><a href="dovato-epar-product-information_en.html#29">C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION</a></li>
<li><a href="dovato-epar-product-information_en.html#29">D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</a></li>
<li><a href="dovato-epar-product-information_en.html#31">A. LABELLING</a></li>
<li><a href="dovato-epar-product-information_en.html#40">B. PACKAGE LEAFLET</a></li>
</ul>
<hr/>
</body>
</html>
